Decoding the ceRNA-Network Blueprint of Breast Cancer Metastasis via Molecular Cross-Talk in Motion from Silence to Signal: A Systematic Review and Bioinformatics Analysis

Decoding the ceRNA-Network Blueprint of Breast Cancer Metastasis via Molecular Cross-Talk in Motion from Silence to Signal: A Systematic Review and Bioinformatics Analysis | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Systematic Review Decoding the ceRNA-Network Blueprint of Breast Cancer Metastasis via Molecular Cross-Talk in Motion from Silence to Signal: A Systematic Review and Bioinformatics Analysis Anoosha Niazmand, Mansoor Salehi, Hamid Aria, Neda Hosseini, Seyed Reza Mousavi This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8119740/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background Breast cancer metastasis (BCM) remains the primary cause of breast cancer–related mortality. Despite advances in understanding breast cancer pathogenesis, the mechanisms driving metastasis are complex and therapeutically challenging. Recent progress in transcriptomics and bioinformatics has enabled deeper insights into the genomic and regulatory alterations underlying BCM. Aim This study aimed to construct and analyze a comprehensive competing endogenous RNA (ceRNA) network involving non-coding RNAs (lncRNAs, miRNAs, and circRNAs) associated with BCM to elucidate their molecular cross-talk and regulatory roles. Methods Interaction data were obtained through systematic literature review and bioinformatic predictions using the multiMiR R package, LncBase, and Circular RNA Interactome databases. A ceRNA network integrating mRNAs, miRNAs, lncRNAs, and circRNAs was visualized in Cytoscape, along with a protein–protein interaction (PPI) network. Network topology was analyzed with cytoHubba and MCODE, while functional enrichment was performed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Survival analysis was conducted to evaluate the prognostic relevance of hub ncRNAs. Results Network analysis identified 11 key hub nodes, including hsa-miR-1, hsa-miR-9, hsa-miR-27b, and MALAT1, which were significantly associated with poor prognosis. KEGG pathways were enriched in proteoglycans in cancer, microRNAs in cancer, and signaling pathways regulating stem cell pluripotency. GO terms highlighted regulation of transcription, cell differentiation, epithelial-to-mesenchymal transition (EMT), and cyclin-dependent kinase complexes. Conclusion This integrative ceRNA network analysis provides new insights into the molecular mechanisms driving BCM, offering potential biomarkers for improved diagnosis, prognosis, and therapeutic targeting. Cancer Biology breast cancer metastasis EMT invasion migration competitive endogenous RNA ceRNA ncRNA Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Figure 8 Figure 9 Figure 10 1. Introduction Breast cancer (BC) is the most common malignancy diagnosed among females and a growing concern globally ( 1 , 2 ). The major cause contributing to BC mortality is the metastasis of the primary tumor to distant organs ( 3 – 5 ). Metastasis contributes to the poor prognosis of BC and complicates the treatment of the disease ( 5 ). Nevertheless, the survival rate can be increased by anticipating the early stage of the BC before metastasis ( 6 – 8 ). Therefore, developing therapies that target metastasis can be easier by having a better understanding of the nature and process of breast cancer metastasis (BCM). Distant metastasis is a complex, multi-step process influenced by several genetic, epigenetic, and environmental variables ( 6 , 9 ). Consequently, even if the pathogenesis features of BCM have been better understood in recent years, its underlying molecular mechanisms remain an open question ( 10 , 11 ). Recent advances in transcriptome analysis and next-generation sequencing (NGS) have facilitated precision treatment in cancer metastasis ( 12 – 14 ). Extensive research has elucidated the regulatory mechanism of ncRNAs at both transcriptional and post-transcriptional levels, which can function as competing endogenous RNA (ceRNA) and are involved in various biological processes, including metastasis and disease progression ( 15 – 17 ). CeRNA is a recently identified mechanism in the RNA world that suggests regulatory interactions between various RNAs, such as pseudogenes, lncRNAs, miRNAs, and circRNAs ( 18 , 19 ). In this context, the ceRNA hypothesis postulates that counts in coding sequences (CDSs) for common regions in miRNAs, ncRNAs, and mRNAs can control the expression of downstream target genes ( 20 ). Subsequent research has shown that ncRNAs and mRNAs compete with the microRNA response element (MRE), a particular regulatory mechanism, to influence each other's expression, which in turn influences the process of BCM development ( 20 – 22 ). The discovery of ceRNA has also considerably aided in the creation of novel medications and the study of targeted therapy unique to BCM ( 16 , 23 , 24 ). Regarding typical examples within this concept, several ceRNAs, such as SNHG12 and ciRS-7, promote migration and invasion, possibly through MMP13 de-repression ( 25 ). The lncRNA HOST2 and circSEPT9 promote proliferation and migration in tumor cells and immune infiltrates, while STAT3 is upregulated in the ceRNA network ( 26 , 27 ). It has been identified that cadherin 5 ( CDH5 ), homeobox D1 ( HOXD1 ), and HOXD10 as STAR-related lipid transfer domain containing 13 ( STARD13 )-correlated ceRNAs and 3′ UTRs of these genes suppress BCM via inhibiting epithelial-mesenchymal transition (EMT) ( 28 ). RNA-binding region-containing protein 1 ( RNPC1 ) could inhibit BC cell metastasis by promoting a STARD13 -correlated ceRNA-network ( 29 ). A circRNA-associated ceRNA has been constructed by Sang et al. analyzed the regulatory network and realized that hsa_circRNA_002082 and hsa_circRNA_400031 may function as ceRNAs to serve key roles in BC-related EMT ( 30 ). Another study conducted a ceRNA-network analysis to investigate the connection between tumor-infiltrating immune cell analysis and BCM to bone. Their results revealed that plasma and follicular helper T cell proportions were considerably higher in BC bone metastasis Additionally, they suggest that DLX6-AS1, Wnt6, and GABBR2 expression may contribute to bone metastasis in patients with BC ( 31 ). Furthermore, a bioinformatics study on a ceRNA network identified three potential RNA regulators (hsa-miR-105-5p, BCAR1, and PANX2) associated with BCM ( 23 ). These findings suggest that targeting these networks may serve as a potent adjuvant strategy for eliminating residual metastases and potentially targeting other mediators of invasion, migration, and metastasis. Despite numerous studies that implicate the role of ceRNAs in BCM, our understanding of these processes remains limited, and more comprehensive research in this area is needed. We are all in step in the present study to construct a ceRNA-network for ncRNAs involved in BC metastasis using data from previous studies and bioinformatics predictions. To boost, bioinformatics tools were to analyze these ncRNAs and their interactions, providing deeper insights into their roles in BC metastasis and progression. 2. Materials and methods 2.1 Literature review 2.1.1 Study selection: The current systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) declaration ( 32 ). For the literature review, the search was accomplished using the following terms: “breast cancer” OR “breast malignancy” AND “metastasis” OR “metastases” OR “invasion” AND “ncRNA” OR “noncoding RNA” AND “lncRNA” OR “long noncoding RNA” AND “miRNA” OR “microRNA” AND “circRNA” OR “circular RNA”. The study selection process aimed to ensure high-quality and relevant research by applying specific inclusion criteria, such as language restrictions (English), publication timeframe, and study type (clinical and experimental research). Priority was given to studies presenting clinically significant findings, contributing valuable insights into the role of noncoding RNAs in breast cancer metastasis. The study has been registered with the International Prospective Register of Systematic Reviews (PROSPERO) under the registration CRD420251173359. 2.1.2 Eligibility criteria and study characteristics: According to PICO ( 33 ) criteria: Population : Breast cell lines, tissue/blood samples, or animal studies Intervention : Altering ncRNA expression or regulation (miRNAs, lncRNAs, circRNAs) Comparison : Human BC tissue/blood samples, cell lines, and animal models without metastasis or healthy control groups Outcome : Changes in ncRNA expression or regulation led to metastasis's progression or onset. Two researchers (A.N and H.A) independently gathered the results using a standardized abstraction form ( 34 ), and consensus was sought for all extracted items. Differences in data extraction were settled by a third reviewer (N.H), where consensus could not be reached. The following information was extracted from each study: 1) Study and sample characteristics 2) Details on miRNA, lncRNA, and circRNA expression, including techniques used for expression analysis and quantification in BCM development (see Supplementary Table. 1 ). 2.1.3 Quality assessment: Since the present study involves literature reviews and bioinformatics analysis, it requires flexibility in assessing diverse data types and sources. Additionally, it focuses on ncRNAs expression levels in metastatic BC, a combination of established appraisal tools was required. Therefore, we utilized a combination of three guidelines, including The Critical Appraisal Skills Program (CASP) checklist ( 35 ), Quadas-2 for Diagnostic Accuracy Studies (QUADAS-2) ( 36 ), and Joanna Briggs Institute (JBI) ( 37 ) critical appraisal tools ( 38 ). Table.1 demonstrates the customized scoring form. For detailed scoring of each included study see Supplementary Table. 2 . Table 1 The customized quality assessment's evaluation criteria and scoring system. Domain Max Score Scoring Criteria Study Design 10 Methodology, criteria, sample size, controls, etc. Data Quality 10 Expression quantification, bioinformatics validation, statistics. Relevance and Bias Assessment 10 Relevance to metastatic BC, bias reduction. Generalizability and Applicability 5 Clinical significance and biological insights. Reporting Quality 5 Completeness and adherence to guidelines. 2.1.4 Inclusion and Exclusion Criteria Inclusion Criteria: Studies investigating the role of miRNAs, lncRNAs, and circRNAs in BC metastasis. Studies have examined the expression of these three types of ncRNAs (lncRNAs, miRNAs, and circRNAs) in different types and stages of invasive and metastatic BC. Studies exploring the relationships between ncRNAs and BC metastasis/invasion in human samples, cell lines, and animal models. Studies written in English and published between 2007 and 2024. Exclusion Criteria: Studies that focus on the role of miRNAs, lncRNAs, or circRNAs in other aspects of BC development (excluding metastasis), such as Studies that were not open access or unavailable. Studies published in languages other than English. Book chapters and conference papers. Studies investigating the role of ncRNAs in the metastasis of other cancer types. Studies focus on other ncRNAs in BC metastasis, including piwiRNAs, snRNAs, and tRNAs. 2.2 Bioinformatics analysis 2.2.1 Bioinformatics target prediction: Bioinformatics target predictions were made using specialized techniques for studies that did not specify a target for the ncRNA under investigation. Using the multiMiR R-package ( 39 ) through filtering to access the three databases miRTarBase , TargetScan , and miRDB ( 40 – 42 ) with cut-off criteria selecting the top 25% of the most significant target mRNAs of miRNAs and target miRNAs of mRNAs. The LncBase database ( https://diana.e-ce.uth.gr/lncbasev3 ) ( 43 ) was then applied to identify miRNAs for lncRNAs’s targets. Additionally, the target miRNAs of the acquired circRNAs were extracted from the Circular RNA Interactome database ( https://circinteractome.nia.nih.gov/ ) ( 44 ). All bioinformatics target predictions were conducted computationally using specialized tools without experimental validation. These analyses relied on database filtering techniques to identify significant target interactions within the specified criteria, ensuring a data-driven approach to ncRNA target identification. 2.2.2 ceRNA-network construction and analysis: Based on the predicted interactions, a ceRNA-network consisting of mRNAs, miRNAs, lncRNAs, and circRNAs was constructed and visualized using Cytoscape software ( 45 ). To identify the key components of the constructed network, topological analyses of network features were performed using the cytoHubba plugin ( 46 ). First, the top 50 hub nodes were selected based on degree, closeness, and betweenness criteria, and then 11 shared nodes between these topological criteria were chosen for further analysis. 2.2.3 Protein-protein interaction (PPI) network construction and analysis: The Cytoscape CluePedia plugin v1.3.3 ( 47 ) was used to create PPI networks associated with mRNAs obtained from literature reviewing and bioinformatics predictions from databases. The STRING database ( https://string-db.org/ ) ( 48 ) was used to characterize the PPI network, and a confidence score of > 0.8 was established as the cut-off threshold to investigate the likely connection between these mRNAs further. The STRING v10 also yielded edges with experimental validation proof. The PPI network was visualized with Cytoscape v3.9.1. The Molecular Complex Detection ( MCODE ) plugin ( http://apps.cytoscape.org/apps/mcode ) ( 49 ) was employed to select significant modules from the PPI network by considering scores > 5 and number of nodes > 10 as the cut-off. Module 1, which had the highest score, has been chosen for the following pathway enrichment analysis. 2.2.4 Enrichment analysis Enrichment analysis of regulatory genes and miRNAs was done using the Enrichr tool ( https://maayanlab.cloud/Enrichr/ ) ( 50 , 51 ). The groups with an adj- p < 0.05 were chosen. The enrichment of GO biological pathways is supplied by Enrichr as well. ggplot2 R package ( 52 ) was employed to illustrates dot plots of pathway enrichment analysis. 2.2.5 Survival analysis Patients were divided into two groups based on the quantile expression levels of the proposed biomarkers. A Kaplan-Meier survival plot was used to compare the two patient cohorts, and the hazard ratio (HR) with 95% confidence intervals (CI) and the log-rank p -value were calculated. The association between the expression levels of the top 11 RNAs identified from the ceRNA network and breast cancer overall survival (OS) was analyzed using the Kaplan-Meier plotter ( https://kmplot.com/analysis/ ). The schematic process of our approach is depicted in Fig. 1 . 3. Results 3.1 Results of literature review 3.1.1 Literature search, characteristics of the eligible studies, and quality assessment A total of 3,025 publications were identified through the MEDLINE/PubMed, Web of Science, and Scopus databases. After removing duplicates, authors independently assessed 928 titles and abstracts. Access to around 60 full-text papers was unavailable due to journal copyrights and restrictions. Irrelevant papers were excluded based on the exclusion criteria, and finally, 288 studies met the eligibility criteria. The selection process is illustrated in Fig. 2. All studies were published in English between 2007 and 2024 and investigated various types and stages of metastatic breast cancer. All studies examined the effects of ncRNAs on BC metastasis and invasion. Among them: 347 studies used only cell lines to investigate their hypotheses Three studies utilized just the patient's blood/serum sample 158 studies included in vivo experiments in animal models 224 studies also included human tissue specimen These studies identified: 79 miRNAs and their target genes. 117 studies describing lncRNAs and their miRNAs/mRNAs targets 43 studies illustrating circRNAs and their targeted miRNAs/mRNAs. 50 studies introducing ncRNAs without specifying their targets. The details of the included studies are provided in the Supplementary Table. 1. 3.2 Results of bioinformatics investigations 3.2.1 Putative targets of miRNAs, lncRNAs, and circRNAs Bioinformatics target predictions were conducted using specific approaches for 50 of the studies that did not specify a target for the ncRNA. Targeted mRNAs of 10 miRNAs were identified by accessing the three validated databases MiRTarBase, Targets can, and miRDB via the multiMiR (R-package). To identify the miRNAs associated with 37 lncRNAs, we utilized the Encase database. In addition, the Circular RNA Interactome database was used to extract the target miRNAs of the acquired three circRNAs. Finally, a multiMiR R-package was utilized to identify mRNA targets for miRNAs. 3.2.2 Construction of ceRNA-network and PPInetwork; key hubs and module identification Using the Cytoscape software, we established an interaction network to identify the interrelationships between 2752 mRNAs extracted from the constructed ceRNA network. Afterward, the disconnected nodes were removed, and then the network included 2264 nodes and 6705 edges through the CytoHubba and MCODE plugins. After selecting the 50 most dysregulated factors among the three most important network characteristics (betweenness, closeness, and degree) using the cytoHubba plug-in for network visualization, 11 shared most significant dysregulated factors were identified by Venn diagram (https://bioinfogp.cnb.csic.es/tools/venny/) (Fig. 3A). They were hsa-miR-1, has-miR-9, has-miR-27 b, has-miR-20 b, has-miR-21, has-miR-335, has-miR-139, ITGB1, MALAT1, CXCR4, and TGFB1 (Fig. 4). Subsequently, the MCODE plugin was utilized to obtain the significant modules from the PPI-network. The significant module (module 1) contained 32 nodes and 507 edges (Fig. 3B). 3.2.3 Pathways retrieved by functional enrichment analysis The Enrichr database was used to undertake functional enrichment analysis of the mRNAs in module 1 attained from the PPI-network to better understand the underlying mechanisms of BCM. Proteoglycans in cancer, microRNAs in cancer, pathways in cancer, and signaling pathways governing the pluripotency of stem cells were among the biological pathways that were the focus of the KEGG pathway (Fig. 5A) study the pathways indicated above. Biological process (BP), molecular function (MF), and cellular component (CC) were identified by GO enrichment analysis. Positive and negative control of cell differentiation, control of pri-miRNA transcription by RNA polymerase II, control of the epithelial to mesenchymal transition, proliferation, angiogenesis, and the apoptotic process were the key topics of the BP enrichment process for GO analysis (Fig. 5B). Meanwhile, CC enrichment mainly consisted of cyclin-dependent protein kinase holoenzyme complex and serine/threonine protein kinase complex (Fig. 5C). MF enrichment mainly featured transcription cis-regulatory region binding and ubiquitin protein ligase binding (Fig. 5D). 3.2.4 Survival and expression analysis Using the Kaplan-Meier plotter, we investigated the relationship between the expression of 11 hub RNAs extracted from the ceRNA-network and the prognosis of BC patients. For this purpose, the BC samples were grouped based on the median expression of each gene, and these two groups were evaluated with the log-rank test. Our results showed that among 11 hubs, three miRNAs, hsa-miR-1 (p-value= 0.00012), hsa-miR-9 (p-value= 0.0016), and hsa-miR-27 b ( p- value= 0.027), in addition to one lncRNA, MALAT1 (p-value= 0.039) had a significant relationship with the overall survival of BC patients. The remaining hubs did not show significant connections with poor prognosis (p-value≥0.05) (Fig. 6). 3.3 Synthesis of results 3.3.1 Metastasis procedure in BC: Breast cancer metastasis (BCM) is the main cause of death for most patients and a significant therapeutic issue (53,54). It is a multi-step process by which tumor cells move from primary tumors to secondary sites, spreading to distant body organs, particularly the lung, liver, bone, and brain (6). Invasion, intravasation, circulation, extravasation, and metastatic outgrowth (or colonization) are some of the many steps in this highly complicated process (55). During invasion, the process by which disseminated tumor cells (DTCs) split off from their source, migrate to other places and transform localized cancer into a systemic disease is known as the metastatic cascade (4,56) (Fig. 7). EMT is a major driver of cancer metastasis, with the ability to enhance stem cell-like traits in tumor cells which acquire self-renewal abilities (57,58). By mimicking an embryonic transition, these cells detach from the primary tumor, enter the bloodstream, and spread, fueling disease progression (59,60). During this process, they gain the ability to move, invade, and separate from epithelial cell sheets (61,62). Breast cancer stem cells (BCSCs) contribute to organ-specific metastasis by interacting with distant organ environments and promoting pre-metastatic niches (63). They also provide high motility and resistance to apoptosis (4). Key signaling pathways, including Wnt, Notch, PI3K/Akt, and TGF-β, play crucial roles in EMT and cancer stemness, driving metastasis (64,65). Non-coding RNAs, particularly microRNAs, contribute to regulatory networks by targeting key regulators in metastatic cascade (66–68). Gaining insight into this crosstalk amongst networks may help identify which nodes of interaction to focus on to address several of the harmful phases of the metastatic pathways at once (69). Along with these, it has been discovered that the TWIST1, SLUG, SNAIL, ZEB1, ZEB2, and FOX families are transcriptional inhibitors of E-cadherin BCSCs also showed strong expression of these genes as EMT markers and a markedly enhanced potential for self-renewal and tumor initiation (70–72). By controlling different gene expression in different combinations, these EMT transcription factors (EMT-TFs) and CSC transcription factors (CSC-TFs) are closely linked to the development, spread, invasion, and metastasis of cancer as well as chemo-resistance (73–75). Detecting the disease early before metastasis can improve survival and allow the adoption of the best strategy for disease management, targeted therapy, and personalized medicine. Despite the numerous investigations in this context, understanding the spread of BC is still unclear, with major molecular regulators crucial for its development. Therefore, in light of the results mentioned above, we have attempted to conduct a more thorough investigation into BCM by evaluating prior research and building a ceRNA-network to help identify the underlying mechanism and pave the way for future investigations. 3.3.2 The role of miRNAs in Breast Cancer Metastasis: MicroRNAs (miRNAs) are small, ~21–25 nucleotide (nt), regulatory RNA molecules that have been demonstrated to post-transcriptionally modify gene expression in a variety of biological pathways through complex regulatory networks and highly precise interactions (76). By binding to one or more sites within the 3' untranslated region (UTR) of several target mRNAs, they control genes by degrading or repressing mRNAs' translation (76). Recent studies have elucidated miRNAs' critical role in cancer cell metastatic spread (77). These miRNAs are referred to as ‘’metastamiRs” (78). Based on their target genes, certain miRNAs can have tumor-suppressive qualities (tsmiR) because the majority of miRNAs function by inhibiting their target genes (79). If its target is an oncogene, it can promote carcinogenesis (oncomiR) (80). According to several recent research, miRNAs can be dysregulated in tumor tissues and are essential for the spread of BCM (77). In this manner, many studies demonstrated that the overexpression of miR-10b by transcription factor Twist can act as oncomiR and is directly associated with BCM by regulating HOXD10 as its target gene (81–83). Several studies revealed the upregulation of miR-21 as another oncomiR that may increase BCM by controlling TIMP3 translation, especially in HER-2+ BC (84–87). Besides, BCM is caused by uncontrolled Wnt/β-catenin signaling that results from inactivating GSK3β and miR-29 upregulates the N-Myc oncogene (88). Additionally, in ERα- BC and TNBC, miR-29a overexpression is associated with distant metastasis and poor survival through targeting PTEN and inducing EMT and metastasis via AKT signaling (89). Along with oncogenic ras signaling, miR-29a can also inhibit tristetraprolin (TTP), a protein that breaks down messenger RNAs with AU-rich 3′-untranslated regions, resulting in EMT, metastasis, and BCM (90). It has also been reported that overexpression of miR-9 contributes to BCM development (91–93). It increases BC cell motility and promotes invasion, metastasis, and angiogenesis by regulating FOXO1 and E-cadherin (94). Regarding the suppressive effects of miRNAs on BCM, research has shown that increases in miR-126 expression levels can function as a tsmiR to prevent BC invasion and metastasis by directly inhibiting a disintegrin and metalloprotease 9 (ADAM9) (95) or by targeting and modifying the gene expressions of VEGF/PI3K/AKT and MAPK signaling (96). Additionally, as a tumor suppressor, miR-145 directly targets mucin1 (MUC1) and Fascin-1 (FSCN1) (97), and through Fascin-1, c-Myc, SMAD2/3, IGF-1R indirectly down-regulates Wnt signaling pathway and suppress BC cell invasion and metastasis (98). Mohammadi-Yeganeh et al. introduced miR-340 as a tsmiR and reported that it targets Wnt signaling and that its expression significantly decreased in BC metastatic cells. They also asserted that miR-340 can bind to the 3′-UTRs of CTNNB1, c-MYC, and ROCK1 oncogenes, inhibiting its oncogenic effects in BC cells (99). In the other study, the c-Met oncogene was considered a direct target of miR-340 to indirectly downregulate MMP-2 and MMP-9 expression and inhibit BC invasion and metastasis (100). Besides, upregulation of miR-512-3p can directly target the 3’UTR of Livin and decrease its expression, inhibiting BC invasiveness and metastasis (101). Similarly, miR‐515‐5p can inhibit BC cell migration and metastasis by binding to 3′ UTR of MARK4 and inhibiting its expression (102). There is conflicting evidence about the involvement of certain miRNAs in the development of BCM. As a typical example, members of the miR-200 family have been shown to play a significant part in BCM to regulate the invasion and migration of BC cells. However, some studies uncover their promoting activities, others expose their inhibitory impacts (103). In this notion, it has been revealed that in TNBC cells, IMP2 and IMP3 increase EMT and metastasis by directly targeting miR-200a and repressing its transcription, which downregulates progesterone receptor (PR) via IMP2/3-miR-200a-PR negative feedback loop (104). According to Roy et al., PELP1 controls the expression and activities of the tumor metastasis suppressors miR-200a and miR-14, hence regulating BC tumor metastasis (105). Comparably, Li et al. discovered that the expression of miR-200b/200c/429 functional groups, but not miR-141/200a, in a xenograft orthotopic model of BC limits tumor cell invasion and metastasis (106). Likewise, miR-200a directly interacts with 3′UTR of the EPHA2 oncogene and inhibits BC cell migration dually; regulating the well-characterized E-cadherin pathway regulates the EPHA2 pathway (107). Furthermore, miR-200b was shown to target moesin directly and restore it in cells expressing miR-200b to reduce metastatic features (106). In TNBC cells, miR-200b targets PKCα and reduces Rac1 activity to suppress invasion and tumor metastasis (108). Zhang G et al. discovered in a study that when FOXP3-KAT2B regulates miR-200c/141, these miRNAs' plasma levels rise in metastasis compared to individuals with localized BC (109). It is also demonstrated that compared to matching primary tumors, distant metastasis exhibits increased levels of miR-200 and miR-9 (93). In addition, BC cell line overexpression of miR-200c in mice targets Zeb2 and inhibits its expression, leading to MET and macroscopic metastasis (110). Another significant and contradictory miRNA that is involved in BCM is miR-206. Accordingly, Zhou Y et al. found that overexpression of miR-206 in BC cell lines and tissues enhances invasion and migration through binding to the 3′-UTR of full-length neurokinin-1 mRNA and controlling its protein production (111). Further, it was discovered that overexpression of miR-206 in the transfected BC cell lines diminished Cdc42 in addition to MMP-2 and MMP-9, thereby suppressing invasion and migration (112). Nevertheless, Adorno-Cruz et al. identified that BC stemness and metastasis are linked to low levels of miR-206, which targets and upregulates ITGA2 as well as its downstream genes ACLY and CCND1 (113). Moreover, a study identified that when the expression of the miR-206 was significantly lower than that in the primary breast tumor, the expression of the Cx43 protein was significantly higher in the liver, and pulmonary metastasis, migration, and invasion capacities were improved (114). MiR-1, considered a crucial regulator of tumor metastasis, has been mentioned that it functioned as a time by targeting K-RAS oncogene and lncRNA MALAT1 inhibited BC cell motility and invasion (115). In a study, Peng et al. found that overexpressed miR-1 in BC cells, which can bind to 3′-UTR of the Bcl‑2, can prevent invasion, migration, and metastasis Through the downregulation of miR-1, MALAT1 has been shown to act as a ceRNA of cdc42' 3′-UTR or via MALAT1miR-1/slug axis, causing BC cells to migrate and invade(116,117). However, Minemura et al. demonstrated that miR-1 overexpression is associated with poor prognosis and distant metastasis of BC patients (118). Table. 2 thoroughly represent miRNAs regulate BCM. Table. 2. The list of miRNAs involved in BCM regulation. MiRNA Regulation Target Detection Method(s) Authors Year Title miR-10b Up NA qRT-PCR Alan Halim et al 2024 (83) miR-29a Up PTEN qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay Jinhui Lü et al 2023 (89) miR-5694 Up AF9/Snail qRT‐PCR, Dual‐luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Xin Tian et al 2021 (119) miR-26 and miR-101 Down COX-2 qRT‐PCR, Dual‐luciferase reporter assay, Trans-endothelial migration assay Rania Harati et al 2021 (120) miR-301 Up CPEB1/SIRT1/SOX2 qRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assay Yanjing Jia et al 2021 (121) miR-206 Down ITGA2/CD49b qRT-PCR, Luciferase reporter assay, Scratch wound assays of cell migration and invasion Valery Adorno-Cruz et al 2021 (113) miR-934 Up PTEN qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay Yexia Lu et al 2021 (122) miR-181b-3p - FTO/miR-181b-3p/ARL5B qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell assay Yuanyuan Xu et al 2020 (123) miR-512-3p Down Livin qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay W. J. Duan et al 2020 (101) miR-382-5p Up MXD1 qRT-PCR, Matrigel Invasion Assay Xiliang Zhang et al 2020 (124) miR-6744-5p Down NAT1 qRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell invasion assay Sharan Malagobadan et al 2020 (125) miR-1 Down Bcl‑2 qRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assay Jing Peng et al 2020 (126) miR-106a UP DAX-1 qRT-PCR, Transwell migration and invasion assay C. Liu et al 2019 (127) miR-3184-5p, miR-181c-3p miR-3184-5p Up miR-181c-3p Down FOXP4 for miR‐3184‐5p, PPARα for miR‐181c‐3p qRT‐PCR, Matrigel invasion assay, Scratch assay Dheeran Rajarajan et al 2019 (128) miR-155 UP MAPK7 qRT-PCR, Wound healing assay, Transwell invasion assay Jian-Hua Liu et al 2019 (129) miR-331, miR-195 mir-331 Up mir-195 Down NA qRT-PCR Peter McAnena et al 2019 (130) miR-206 UP NK1R-FL qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Yu Zhou et al 2019 (111) miR-454-3p Up RPRD1A, AXIN2, DKK3, SFRP1 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Liangliang Ren et al 2019 (131) miR‑133b Down TGFβR1 qRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assay Shengjie Wang et al 2019 (132) miR-638 Down CREB1/Lin28/miR-638/VASP qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay Peng-Chao Hu et al 2019 (133) miR-218 Up Col1a1/INHBB/YY1 qRT-PCR Xuxiang Liu et al 2018 (134) miR-130a Down FOSL1/ZO-1 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Xiaowei Chen et al 2018 (135) miR-200a Down IMP2/3-miR-200a-PR qRT‐PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay Hye-Youn Kim et al 2018 (104) miR-203 Up bach1/MMP-9/CXCR4 receptor qRT-PCR Reza Mohammadzadeh et al 2017 (136) miR-381 Down CXCR4 qRT-PCR, Luciferase reporter assay, Cell migration and invasion assay Yubao Xue et al 2017 (137) miR-130b-3p Down DLL1 qRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assay Yifang Shui et al 2017 (138) miR-19b Up PTENP1, PTEN qRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell invasion assay R-K Li et al 2017 (139) miR-125b - StarD13/miR-125b/TP53INP1 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay Lufeng Zheng et al 2017 (140) miR-200c - FOXP3/KAT2B TaqMan miR assay, Nest-qPCR Guangxin Zhang et al 2017 (109) miR‑206 Down Connexin 43 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Zi-Jing Lin et al 2016 (114) miR-340 Down CTNNB1, c-MYC, ROCK1 qRT‐PCR, Dual‐luciferase reporter assay, Transwell migration and invasion assay Samira Mohammadi-Yeganeh et al 2016 (99) miR-152 Down DNMT1/CDH1 qRT-PCR, Luciferase reporter assay, Wound healing assay Dipta Sengupta et al 2016 (141) miR-497 Down ERRα qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay Li Han et al 2016 (142) miR-448 Down MALAT1/KDM5B qRT-PCR, Transwell invasion assay Oluwaseun Adebayo Bamodu et al 2016 (143) miR-515-5p Down MARK4 qRT-PCR, Luciferase reporter assay, Cell tracking assay, Boyden chamber assay Olivier E Pardo et al 2016 (102) miR-548j Up Tensin1 qRT-PCR, Transwell invasion assay Yun Zhan et al 2016 (144) miR-490-3p Down TNKS2 qRT-PCR, Luciferase reporter assay, Transwell invasion assay Zhongming Jia et al 2016 (145) miR-126 Down VEGF/PI3K/AKT qRT-PCR, Wound healing assay, Transwell invasion assay D Turgut Cosan et al 2016 (96) miR-146a Down CXCR4, TRAF6, EGFR qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Tianjing Zheng et al 2015 (146) miR-126 Down ADAM9 qRT-PCR, Matrigel invasion assay Cheng-Zheng Wang et al 2015 (95) miR-1 Down K-RAS, MALAT1 qRT-PCR, Dual-luciferase reporter assay, Transwell invasion assay Ruilei Liu et al 2015 (115) miR-1 Up NA MicroRNA PCR array, IHC Hiroyuki Minemura et al 2015 (118) miR-20b UP NA qRT-PCR, Transwell invasion assay Aamir Ahmad et al 2015 (147) miR-21 Up NA qRT-PCR Eman A Toraih et al 2015 (86) miR-9 Down NOTCH1 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration assay Samira Mohammadi-Yeganeh et al 2015 (148) miR-509 Down RhoC, TNF-α qRT‐PCR, Dual‐luciferase reporter assay, Wound healing assay, Transmigration assays Fei Xing et al 2015 (149) miR-191 Up TGFβ2, HuR qRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell migration and invasion assays Neha Nagpal et al 2015 (150) miR-200a Down EPHA2 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration assay Efrosini Tsouko et al 2015 (107) miR-9 Up FOXO1, E-cadherin qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration assay, Adhesion assay Jue Yang et al 2014 (94) miR-10b Up HOXD10 qRT-PCR Paola Parrella et al 2014 (81) miR-106b Down MMP2 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Xiaojian Ni et al 2014 (151) miR-183, miR-494, miR-21 - NA qRT-PCR Augusto LF Marino et al 2014 (152) miR-29 Up NMI qRT-PCR, Luciferase reporter assay, Transwell invasion assay Jack W Rostas III et al 2014 (88) miR-720 Down TWIST1 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Lin-Zi Li et al 2014 (153) miR-429 Down ZEB1, CRKL qRT-PCR, Transwell invasion assay Zhi-bin Ye et al 2014 (154) miR-200b Down PKCα qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration assay Brock Humphries et al 2014 (108) miR-127 Down BCL6 qRT-PCR, Wound healing assay, Transwell invasion assay Xiujuan Zhao et al 2013 (155) miR-21 Up TIMP-3 qRT-PCR Jianyi Li et al 2013 (85) miR-200a, miR-141 Down ZEB1, ZEB2 qRT-PCR, Luciferase reporter assay, Cell Migration and Invasion Assays Sudipa Saha Roy et al 2013 (105) miR-200b Down moesin qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay X Li et al 2013 (106) miR-135a UP HOXA10 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Yating Chen et al 2012 (156) miR-151-5p, miR-9 miR-151-5p Down NA qRT-PCR Jonathan Krell et al 2012 (91) miR-21 Up NA qRT-PCR Shahram Savad et al 2012 (84) miR-224 UP RKIP qRT-PCR, Wound healing assay, Transwell invasion assay, 3D spheroid invasion assay Lin Huang et al 2012 (157) miR-200, miR-9 UP NA qRT-PCR, ISH Karina H. Gravgaard et al 2012 (93) miR-340 Down c-Met qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Zheng-sheng Wu et al 2011 (100) miR-145 Down Fascin-1, c-myc, SMAD2/3, IGF-1R qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Seok-Jun Kim et al 2011 (98) miR-1258 Down HPSE qRT-PCR, Luciferase reporter assay, Cell invasion assays Lixin Zhang et al 2011 (158) miR-183 - VIL2 qRT-PCR, Transwell migration assay Aoife J Lowery et al 2010 (159) miR-206 - Cdc42, MMP-2, MMP-9 qRT-PCR, Transwell migration and invasion assay Hao Liu et al 2010 (112) miR-103/107 Up Dicer/mir-200 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration assay Graziano Martello et al 2010 (160) miR-17-5p UP HBP1/β-catenin qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Hongling Li et al 2010 (161) miR-196s - HOXC8 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Yong Li et al 2010 (162) miR-17/20 Down IL-8 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration assay Zuoren Yu et al 2010 (163) miR-145 Down MUC1 qRT-PCR, Luciferase reporter assay, Transwell invasion assay Mohit Sachdeva et al 2010 (97) mir-520h up PP2A/C qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Jen-Liang Su et al 2010 (164) miR-21 Up TIMP3 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Bao Song et al 2010 (87) miR-205 Down ErbB3, VEGF-A qRT-PCR, Luciferase reporter assay, Transwell invasion assay Hailong Wu et al 2009 (165) miR-661 Down c,EBPα/ miR-661/MTA1 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Sirigiri Divijendra Natha Reddy et al 2009 (166) miR-17-92 UP NA qRT-PCR, Wound healing assay, Transwell migration assay Sijin Liu et al 2009 (167) miR-27b UP ST14 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Yanfang Wang et al 2009 (168) miR-29a UP TTP qRT-PCR Christoph A Gebeshuber et al 2009 (90) miR-193b Down uPA qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay X-F Li et al 2009 (169) miR-373 and miR-520c UP CD44 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Qihong Huang et al 2008 (170) miR-7 Down Pak1 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Sirigiri Divijendra Natha Reddy et al 2008 (171) miR-155 UP RhoA qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay William Kong et al 2008 (172) miR-335 Down SOX4, PTPRN2, TNC, MERTK qRT‐PCR, Dual‐luciferase reporter assay, Transwell migration and invasion assay Sohail F Tavazoie et al 2008 (173) miR-10b UP HOXD10, RHOC qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Li Ma et al 2007 (82) 3.3.3 The role of lncRNAs in Breast Cancer Metastasis: Long non-coding RNAs are a category of ncRNAs longer than 200 nucleotides (174). Chromosome rearrangement, histone modification, transcription, stabilizing mRNA, and altering alternative splicing sequences are just a few of the physiological processes regulated by lncRNAs. Consequently, they are accountable for a large number of diseases, including cancer (175). As competitive endogenous RNAs and sponging miRNAs, lncRNAs have been shown to influence multiple signaling pathways and regulate the synthesis of proteins associated with invasion, migration, EMT and metastasis (23,175,176). Accordingly, the spread of the malignant process of BC cell invasion and metastasis might result from modifications to the several signaling pathways that govern lncRNAs' regulation (176,177). As an illustration, the TGF-β signaling pathway is a key regulator of the EMT process by affecting the expression of EMT-associated factors, such as ZEB, E-cadherin, Vimentin, and SNAIL (178–180). In line with this, Li et al. indicated that following induction of lncATB by TGF-β treatment, EMT markers such as ZEB1, Twist1, N-Cadherin, and Vimentin are upregulated while E-Cadherin is downregulated. They discovered that lncATB, which acts as a sponge for the miR-200 family and restores Twist1 expression, can promote cell invasion and migration in vitro and in vivo and is linked to distant metastasis (181). Furthermore, TGF-β-induced migration, invasion, EMT, and metastasis were prevented by suppressing lncRNA-HIT (HOXA transcript produced by TGFβ), which has E-cadherin as one of its major targets. Nevertheless, metastatic cells exhibited a significant increase in lncRNA-HIT expression (182). In a study conducted by Li GY et al., UCA1 functions as a competitive endogenous RNA (ceRNA) in the cytoplasm, whereas AC026904.1 functions as an enhancer RNA in the nucleus. LncRNAs AC026904.1 and UCA1 are also overexpressed in both canonical and non-canonical TGF-β pathways. They target and activate SLUG in BC cells to promote EMT and metastasis (183). There are controversial studies around the role of CASC2 in BCM. Two investigations illustrated the upregulation of CASC2 contributes to BCM progression by targeting TGF-β signaling-associated genes such as TGFB1, SMAD2, and α-SMA (184). On the other hand, two different studies reported that CASC2 has an inhibitory effect on BCM through the miR-96-5p/SYVN1 axis (185), and inactivation of the TGF-β signaling pathway is involved in its function (186). ARHGAP5-AS1 inhibits BC invasion and metastasis by inhibiting SMAD7 and impeding the TGF-β signaling pathway (187). The Wnt signaling pathway is known to be essential for regulating the development of embryonic organs and the advancement of cancers, especially since it plays a crucial role during the BCM process (188). There is mounting evidence that lncRNAs control Wnt signaling, which either promotes or inhibits the growth of BCM (189). In light of this, lncRNAs DGCR5, EZR‑AS1, LINC01287, RUSC1‑AS‑N, and HOTTIP have been found to promote BC invasion, EMT, and metastasis through their modulation of the Wnt/β-catenin signaling pathway (190–194). Multiple studies demonstrated that H19 could promote BC invasion and metastasis (195). In a ceRNA-network, H19 can competitively bind miR-200b/c and let-7 to regulate Lin28, Git2, and Cyth3 and accelerate BCM (196,197), or it can sponges miR-340-3p and enhance BCM and EMT by regulating YWHAZ and potentiating the Wnt/β-catenin signaling (198). Tan et al. discovered that lncRNA LINC00511 encodes the small peptide LINC00511-133aa and by controlling the expression levels of proteins related to the Wnt/β-catenin pathway, such as Bax, c-myc, and CyclinD1, and facilitating β-catenin protein entry into the nucleus, increased the invasiveness and stemness of BC cells (199). Overexpression of LncCCAT1 influences BCSC stemness, migration, and invasion capabilities (200). It potentially enhances T-cell factor 4 and triggers Wnt signaling through interactions with miR-204/211, miR-148a/152, and ANXA2 (200). In terms of epigenetic regulation, by engaging DNA methyl transferase and triggering the Wnt signaling pathway, LINC00518 increases CDX2 methylation and facilitates the metastasis and development of BC (201). Additionally, LINC00922 controls BC invasion, migration, and EMT by promoting NKD2 methylation and activating the Wnt signaling pathway (202). In contrast, the Wnt/β-catenin signaling pathway in BC is inhibited by LINC01089, which also predicts the clinical prognosis. Zhang et al. further showed that by directly targeting SFRP1 and DKK2/3, miR-586 induced Wnt/β-catenin activation and acted as an oncogene to promote BC progression and invasion (203). LINC01189 functioned as a tumor suppressor and inhibited BC progression by inhibiting EMT-like phenotype by sponging miR-586 in the LINC01189/miR-586/ZEB1 feedback loop (204). Fig. 8 depicts the interactions of lncRNAs in the process of BCM via a crucial signaling pathway. Moreover, NEAT1, MALAT1, HOTAIR, and linc-ROR are well-known lncRNAs that promote BCM via ceRNA-networks, sponging miRNAs and regulating essential genes (205,206,215–217,207–214). There are three studies mentioned the role of AFAP1-AS1 in BCM (218–220). According to Chen C et al., TNBC primary cells with elevated AFAP1-AS1 levels expressed more downstream genes of the PLK1 pathway, including CDC25C, CDK1, BUB1, and TTK. More significantly, in a mouse metastatic model, AFAP1-AS1 boosted lung metastases (219). Zhang X et al. discovered in a different study that AFAP1-AS1 stimulates TNBC cell invasion via regulating MTH1 expression by targeting miR-145 (220). Table. 3 thoroughly illustrates the studies that investigated the function of lncRNAs in BCM. Table. 3. List of the research that examined the regulation of lncRNAs in BCM. LncRNA Regulation Target Detection Method(s) Authors Year Title LINC01569 Down miR-300/FILIP1L qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Xinyu Jiang et al 2024 (221) LYPLAL1-DT Down hnRNPK/β-Catenin qRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell assay Yuhui Tang et al 2023 (222) T376626 Up LAMC2 qRT-PCR, RNA pulldown assay, Wound healing assay, Transwell migration and invasion assay Yongyin He et al 2023 (223) TMEM105 Up miR-1208/LDHA qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay Jinzhu Han et al 2023 (224) MIR17HG Down miR-454-3p/FAM135A qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Jingjing Xu et al 2023 (225) LncRNA‑BC069792 Down miR-658, miR-4739/KCNQ4 qRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Yunxiang Zhang et al 2023 (226) LINC00511 Up NA qRT-PCR, Wound healing assay, Transwell invasion assay Zhongqiu Tan et al 2023 (199) OBSCN-AS1 Down OBSCN qRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell migration assay, 3D collagen invasion assay Talia Guardia et al 2023 (227) LINC00478 Down PHB2/c-Myc qRT-PCR, RIP, Wound healing assay, Transwell migration and invasion assay Rong Guo et al 2023 (228) AFAP1-AS1 Up PLK1, CDC25C, CDK1, BUB1, TTK qRT-PCR, Transwell migration and invasion assay Shuizhong Cen et al 2023 (218) LINC01559 Up miR-370-3p/miR-485-5p/miR-940 qRT-PCR, Luciferase reporter assay, Wound healing and Transwell assays Xue Yang et al 2022 (229) TCONS_00068220 Up CDH1 qRT-PCR, Transwell migration and invasion assay Xiao Liu et al 2021 (230) ENST00000508435 Up FXR1 qRT-PCR, RIP, Wound healing assay, Transwell migration assay Luying Li et al 2021 (231) LINC00483 Up IGF2BP1 qRT-PCR, RIP Y.-S. QIAO et al., 2021 (232) SPINT1-AS1 Up let-7a/b/i-5p qRT-PCR, Wound-healing assay, Transwell migration and invasion assay Tongzhou Zhou et al 2021 (233) LINC00472 Down MCM6 qRT-PCR, RIP, Wound healing assay, Transwell invasion assay Guoli Shao et al 2021 (234) DGUOK-AS1 Up miR-204-5p/IL-11 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration assay Yiran Liang et al 2021 (235) MALAT1 Up miR‑26a/26b/ST8SIA4 qRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Cell migration and invasion assays Nan Wang et al 2021 (213) RACGAP1P UP miR-345-5p/RACGAP1 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Danmei Zhou et al 2021 (236) SChLAP1 Up miR‑524‑5p/HMGA2 qRT-PCR, Luciferase reporter assay Xiangdong Bai et al 2021 (237) LINC01189 Down miR-586/ZEB1 qRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Matrigel Invasion Assay Di Zhang et al 2021 (203) DSCAM-AS1 Up NA qRT-PCR Mahsa Tarighi et al 2021 (238) LINC00922 Up NKD2 qRT-PCR, Wound healing assay, Transwell migration and invasion assay Yan Wang et al 2021 (202) LINC00926 Down PGK1 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay Zhong Chu et al 2021 (239) NEAT1 Up PGK1/PGAM1/ENO1 Complexes qRT-PCR, Transwell invasion assay Mi Kyung Park et al 2021 (209) ARHGAP5-AS1 Down SMAD7 qRT-PCR, Dual-luciferase reporter assay,Transwell assay, F-actin staining Chen‑Long Wang et al 2021 (187) SNHG1 UP STAT6 qRT-PCR, Transwell invasion assay Shoukai Zong et al 2021 (240) AC073352.1 Up YBX1 qRT-PCR, Wound-healing assay, Transwell migration and invasion assay Xue Kong et al 2021 (241) ZEB2NAT - ZEB2 Transwell invasion assay Canan Eroğlu Güneş et al 2021 (242) LncRNA-CCRR Up CX43 qRT-PCR, Transwell assay, Dye transfer assay Deheng Li et al 2020 (243) ZFPM2-AS1 Up JMJD6 qRT-PCR, Luciferase reporter Assay, Transwell Assay Y-F ZHAO et al 2020 (244) H19 Up Let‑7/Lin28 qRT-PCR,Wound healing assay, Migration and invasion assays Hanchu Xiong et al 2020 (197) HOST2 Up Let-7b qRT-PCR, Dual-luciferase reporter assay, Transwell assay Kaiyao Hua et al 2020 (26) LINC00689 Up miR-142-3p/USP6NL qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assays Teng ma et al 2020 (245) AFAP1-AS1 Up miR-145/MTH1 qRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell invasion assay Xiaohui Zhang et al 2020 (220) LINC00511 Up miR-150/MMP13 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay GuangHui Shi et al 2020 (246) SNHG3 Up miR-154-3p/Notch2 qRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assay Hongnan Jiang et al 2020 (247) TUSC8 Down miR-190b-5p/MYLIP qRT-PCR, Luciferase reporter assay, Transwell invasion assay Luqing Zhao et al 2020 (248) SNHG1 Up miR-193a-5p-HOXA1 qRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Jun Li et al 2020 (249) H19 Up miR-340-3p/YWHAZ qRT‐PCR, Dual‐luciferase reporter assay, Wound healing assay, Transwell invasion assay Lei Yan et al 2020 (198) PCNAP1 Up miR‑340‑5p/SOX4 qRT-PCR, Luciferase reporter assay, Scratch assays, Transwell assays Yang Yu et al 2020 (250) OIP5‑AS1 Up miR‑340‑5p/ZEB2 qRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell invasion assay Lingjun Meng et al 2020 (251) LINC02163 Up miR-511-3p/HMGA2 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Chenglin Qin et al 2020 (252) LINC00115 Up miR-7/KLF4 qRT-PCR, Dual-luciferase reporter assay, Transwell assay, Matrigel invasion assay Chunlei Yuan et al 2020 (253) DCST1-AS1 Up miR-873-5p qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell assay Li Tang et al 2020 (254) DANCR Up miR-874-3p/SOX2 qRT‐PCR, Dual‐luciferase reporter assay,Transwell Invasion Assay Guiyun Wu et al 2020 (255) TRHDE‑AS1 Down NA qRT-PCR, Wound healing assay, Transwell migration and invasion assay Shufang Hu et al 2020 (256) LINC00665 Up NA qRT-PCR, Wound healing assay, Transwell migration and invasion assay J-L Zhou et al 2020 (257) A2M-AS1 Up NA qRT-PCR, Wound-healing assay, Transwell migration and invasion assay Kai Fang et al 2020 (258) DGCR5 Up NA qRT-PCR, Transwell invasion assay Daqing Jiang et al 2020 (190) LINC00261 Down NME1 qRT-PCR, RNA pull-down assay, Transwell Migration Assay Guangxiu Guo et al 2020 (259) H19 Up p53/TNFAIP8 qRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assay Yang Li et al 2020 (195) Linc00514 Up STAT3 qRT-PCR, Luciferase reporter assay, Transwell invasion assay Sifeng Tao et al 2020 (260) PHACTR2-AS1 (PAS1) Down SUV39H1 qRT‐PCR, Dual‐luciferase reporter assay Wenhui Chu et al 2020 (261) LINC01271 UP Tensin1 qRT-PCR, Wound healing assay, Migration and invasion assay Kung-Chi Chang et al 2020 (262) RAB11B-AS1 Up VEGFA, ANGPTL4 qRT-PCR, Luciferase reporter assay, Boyden chamber migration and invasion assays, In vitro angiogenesis assay Yanling Niu et al 2020 (263) HUMT Up YBX1/FOXK1 qRT-PCR, Wound healing assay, Transwell migration and invasion assay Shaoquan Zheng et al 2020 (264) NNT-AS1 Up ZFP36 qRT-PCR, Wound healing assay, Transwell assay, Bioinformatics analysis Pan QH et al 2020 (265) LINC00518 Up CDX2 qRT-PCR, Dual-luciferase reporter assay, Transwell assay, Scratch test Hong-Bin Wang et al 2019 (201) Lnc-NLIPMT (RP11–115N4.1) Down GSK3β qRT-PCR, Wound healing assay, Transwell migration and invasion assay Yang Jiang et al 2019 (266) MIR503HG Down miR‐103/OLFM4 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Jia Fu et al 2019 (267) NEAT1 Up miR-107/CPT1A qRT-PCR, Luciferase reporter assay, Wound healing assay, Matrigel assay Yiquan Xiong et al 2019 (206) MIR210HG UP miR-1226-3p/mucin-1c qRT-PCR, Luciferase reporter assay, Transwell invasion assay Xiao-Yu Li et al 2019 (268) NEAT1 UP miR-133b/TIMM17A qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Xinping Li et al 2019 (207) AC073284.4 Down miR-18b‐5p/DOCK4 qRT‐PCR, Dual‐luciferase reporter assay, Wound healing assay, Transwell invasion assay Yue‐Yue Wang et al 2019 (269) LINC00641 Down miR‐194‐5p qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Qixin Mao et al 2019 (270) LncCCAT1 Up miR-204/211, miR-148a/152, ANXA2 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Tingting Tang et al 2019 (200) LncRNA-CDC6 Up miR‐215/CDC6 qRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell migration assay Xiaoli Kong et al 2019 (271) HCP5 UP miR‐219a‐5p/BIRC3 qRT‐PCR, Luciferase reporter assay, Transwell migration and invasion assay Lihong Wang et al 2019 (272) GAS6-AS2 Up miR-493/FUT4 qRT‐PCR, Luciferase reporter assay, Transwell migration and invasion assay Wanfeng Li et al 2019 (273) LINC00473 Up miR-497 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay J BAI et al 2019 (274) LOXL1-AS1 UP miR-708-5p qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay Hui-ting Dong et al 2019 (275) TFAP2A-AS1 Down miR-933/SMAD2 qRT‐PCR, Dual‐luciferase reporter assay, Transwell invasion assay Bin Zhou et al 2019 (276) LINC01287 Up NA qRT-PCR, Wound healing assay, Transwell invasion assay C. Song et al 2019 (192) AFAP1-AS1 Up NA qRT-PCR, Wound scratch assay Dachang Ma et al 2019 (219) LINC01089 Down NA qRT-PCR, Wound healing assay, Transwell migration and invasion assay Hongfan Yuan et al 2019 (204) RUSC1-AS-N UP NA qRT-PCR, Wound healing assay, Transwell assay Peng Zhou et al 2019 (193) CASC2 Down NA qRT-PCR, Transwell migration and invasion assay Yang Zhang et al 2019 (186) FOXD3‐AS1 Up NA qRT-PCR, Invasion and migration assay Yaoyao Guan et al 2019 (277) PANDAR UP NA qRT-PCR, Transwell invasion assay Yi Li et al 2019 (278) HIF1A‐AS2 Up NA qRT‐PCR, Transwell migration and invasion assay Yufei Wang et al et al 2019 (279) HOTTIP Up NA qRT-PCR, Wound healing assay, Transwell invasion assay Sijia Han et al 2019 (194) NAMPT-AS UP NAMP qRT‐PCR, Dual‐luciferase reporter assay, Transwell migration and invasion assay Hanwen Zhang et al 2019 (280) Lnc-SLC4A1-1 UP NF-kB/CXCL8 qRT-PCR, Transwell migration and invasion assay Tongbo Yi et al 2019 (281) ST8SIA6-AS1 UP p38 , AKT1 qRT-PCR, Wound healing assay, Transwell migration and invasion assay Kai Fang et al 2019 (282) FBXL19-AS1 Up WDR66 qRT‐PCR, RIP assay, Transwell migration and invasion assay Yayuan Zhang et al 2019 (283) ZEB2-AS1 Up ZEB2 qRT-PCR, Wound healing assay, Transwell assay, Cellular F‐actin measurement Guoxin Zhang et al 2019 (284) TROJAN UP ZMYND8 qRT-PCR, Transwell migration and invasion assay Xi Jin et al 2019 (285) LINC01638 Up DNMT1, DNMT3a, DNMT3b, BRCA1, PTEN qRT-PCR, Transwell invasion assay Peng Liu et al 2018 (286) ZFHX4-AS1 UP FAT4 qRT‐PCR, Dual‐luciferase reporter assay, Wound healing assay, Transwell invasion assay Shao-Ying Li et al 2018 (287) IRAIN Down IGF1R qRT-PCR, Transwell migration and invasion assay Lingling Pian et al 2018 (288) LncRNA-BCHE (p10247) UP ITGB1 qRT-PCR, Wound healing assay, Transwell migration and invasion assay Yu-Xia Yang et al 2018 (289) ITGB2-AS1 Up ITGB2 qRT-PCR, Wound healing assay, Transwell invasion assay Mengyao Liu et al 2018 (290) LncRNA-CTD-2108O9.1 Down LIFR qRT-PCR, Wound healing assay, Transwell assay, Matrigel invasion assay Mozhi Wang et al 2018 (291) NNT-AS1 Up miR-142-3p/ZEB1 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Yan Li et al 2018 (292) MALAT1 Up miR-145, VEGF qRT-PCR, Transwell migration assay Xiao-juan Huang et al 2018 (293) XIST Down miR-155/CDX1 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Ruinian Zheng et al 2018 (294) SNHG7 Up miR-186 qRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assay X Luo et al 2018 (295) GAS5 Down miR-196a-5p/FOXO1/PI3K/AKT qRT-PCR, Luciferase reporter assay, Transwell invasion assay Shuqin Li et al 2018 (296) LncATB Up miR-200c/Twist1 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Rong-Hui Li et al 2018 (181) ARNILA Up miR-204/Sox4 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay Fang Yang et al 2018 (297) Lnc015192 Up miR-34a/Adam12 qRT-PCR, Luciferase reporter assay, Transwell invasion assay Xiaojia Huang et al 2018 (298) LncRNA-PRLB UP miR-4766-5p/SIRT1 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Yiran Liang et al 2018 (299) XIST Down miR-503, MSN qRT-PCR Fei Xing et al 2018 (300) linc-ZNF469-3 Up miR-574-5p/ZEB1 qRT-PCR, Luciferase reporter assay, Migration and invasion assays Po-Shun Wang et al 2018 (301) CASC2 Down miR-96-5p/SYVN1 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Zejun Gao et al 2018 (185) BANCR Up NA qRT-PCR, Transwell migration and invasion assay Jing Jiang et al 2018 (302) BANCR Up NA qRT-PCR, Wound healing assay, Transwell migration and invasion assay K-X Lou et al 2018 (303) EZR-AS1 Up NA qRT‐PCR, Transwell migration and invasion assay Yu Bai et al 2018 (191) LINC01296 Up NA qRT-PCR, Wound healing assay, Transwell migration and invasion assay Min Jiang et al 2018 (304) AC026904.1, UCA1 Up Slug qRT-PCR, Luciferase reporter assay, Transwell migration assay Guo-Yin Li et al 2018 (183) MALAT1 Down TEAD qRT-PCR, Luciferase reporter assay Jongchan Kim et al 2018 (214) HOXA-AS2 Up miR-520c-3p /TGFBR2 and RELA qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Yu Fang et al 2017 (305) NEAT1 UP FOXN3-NEAT1-SIN3A qRT-PCR, Luciferase reporter assay, Transwell invasion assay Wanjin Li et al 2017 (205) Lnc-BM Up JAK2 qRT-PCR, Cell adhesion assay, Trans-BBB invasion assay, Macrophage Transwell migration assay Shouyu Wang et al 2017 (306) MALAT1 UP miR-129-5p qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay Yonggang Zuo et al 2017 (212) H19 Up miR-200b/c and let-7b,Git2,Cyth3 qRT‐PCR, Transwell invasion assay Wu Zhou et al 2017 (196) MALAT1 Up miR-204/ZEB2 qRT-PCR, Luciferase reporter assay, Transwell assays Yuzhou Wang et al 2017 (307) NEAT1 Up miR-211/HMGA2 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Xuerui Li et al 2017 (208) SNHG15 UP miR-211-3p qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Qingli Kong et al 2017 (308) MEG3 Down miR-421/E-cadherin qRT-PCR, Luciferase reporter assay, Transwell invasion assays Wei Zhang et al 2017 (309) MEG3 Down NA qRT-PCR, Transwell invasion assay Chen-yu Zhang et al 2017 (310) Linc-ITGB1 Down NA qRT-PCR W-X Li et al 2017 (311) LINC00628 Down NA qRT-PCR, Transwell migration and invasion assay D-Q Chen et al 2017 (312) OR3A4 Up NA qRT-PCR, Transwell migration and invasion assay Genxiang Liu et al 2017 (313) HOXA11‑AS Up NA qRT-PCR, Wound healing assay, Transwell invasion assay Jian-Chun Su et al 2017 (314) TUG1 Down NA qRT-PCR, Transwell migration and invasion assay Shulin Fan et al 2017 (315) HOXA11-AS Up NA qRT-PCR, Wound healing assay, Transwell invasion assay Wenlei Li et al 2017 (316) LincRNA-ROR Up NA qRT-PCR Kaijiong Zhang et al 2017 (317) LincIN Up NF90-p21 qRT-PCR, RIP, Wound healing assay, Transwell invasion assay Zhengyu Jiang et al 2017 (318) Linc00617 Up Sox2 qRT-PCR, RIP, Wound healing assay, Transwell invasion assay Hengyu Li et al 2017 (319) CCAT2 Up TGFB1,SMAD2,α-SMA qRT-PCR, transwell assay Z-J WU et al 2017 (184) LINP1 Up TP53 qRT-PCR, Wound healing assay, Transwell migration and invasion assay Yiran Liang et al 2017 (320) ROR1-HER3 MAYA (MNX1-AS1) Up YAP qRT-PCR, RIP, Transwell migration and invasion assay Chunlai Li et al 2017 (321) ANCR Down EZH2/CDK1 qRT-PCR, Wound healing assay, RIP assay, Transwell migration and invasion assay Zhongwei Li et al 2016 (322) LIMT (LINC01089) Down NA qRT-PCR, Transwell migration and invasion assay Aldema Sas-Chen et al 2016 (323) MALAT1 Up NA qRT-PCR, Transwell migration and invasion assay Mahdieh Jadaliha et al 2016 (300) MEG3 Down NA qRT-PCR J-J ZHANG et al 2016 (324) TUG1 Up NA qRT-PCR, Transwell migration and invasion assay Teng Li et al 2016 (300) MALAT1 Up NA qRT-PCR, Transwell assay Yufeng Miao et al 2016 (211) MALAT1 UP miR-1/cdc42 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay Jinjiang Chou et al 2016 (116) HIT Up E-cadherin qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Edward J Richards et al 2015 (182) NKILA Down IkB qRT-PCR, Luciferase reporter assay Bodu Liu et al 2015 (325) MALAT1 Up miR-1/Slug qRT-PCR, Dual-luciferase reporter assay, Transwell invasion assay Chuan Jin et al 2015 (117) LincRNA-ROR Up miR-145/Arf6 qRT-PCR, Luciferase reporter assay, Transwell invasion assay Gabriel Eades et al 2015 (215) H19 Up miR-675/c-Cbl, Cbl-b qRT‐PCR, Luciferase reporter assay, Wound healing assay, Transwell migration assay Constance Vennin et al 2015 (326) EGOT Down NA qRT-PCR Shou-ping Xu et al 2015 (327) MALAT1 Down NA qRT–PCR, Wound healing assay, Matrigel invasion assay Shouping Xu et al 2015 (210) NBAT1 Down PRC2, DKK1 qRT-PCR, RIP, Wound healing assay, Transwell migration and invasion assay Pengnan Hu et al 2015 (328) LINC-ROR Up miR-205 / ZEB2 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay P Hou et al 2014 (216) BCAR4 Up PNUTS, SNIP1 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay Zhen Xing et al 2014 (329) HOTAIR - NA qRT-PCR Cleidson Pádua Alves et al 2013 (217) CCAT2 Up NA qRT-PCR, Transwell migration assay Roxana S Redis et al 2013 (330) HOTAIR Up NA Breast Tissue Microarrays, ISH Karen M Chisholm et al 2012 (331) 3.3.4 The role of CircRNAs in Breast Cancer Metastasis: Circular RNAs, a unique category of long noncoding RNAs, have a covalently closed loop structure without a 5′-cap or 3′-polyadenylated tail (332). This special structure enables them to express themselves well and be more stable than their counterparts (333). According to research, the development of BCM may be aided by circRNAs competing with other endogenous RNAs to bind to MREs or miRNAs, RNA-binding proteins (RBPs), or regulating parental genes (333). As a result, they can control downstream gene expression and modulate the essential biological processes of tumor progression and metastasis (334). By controlling different genes or signaling networks, they can either prevent or promote BC migration, invasion, and metastasis (334,335). Fig. 9 depicts the mechanisms of circRNA-mediated regulation in BCM. The inhibitory effects of circRNAs on BC invasion and metastasis were shown in multiple investigations. For instance, circEHMT1 can act as a tumor suppressor in BC by targeting miR-1233-3p, modifying the transcription factor KLF4, and then MMP2; it may be able to prevent invasion, migration and metastasis in a particular axis of circEHMT1/miR-1233-3p/KLF4/MMP2 (336). In metastatic BC, circNR3C2 upregulates and sponges miR-513a-3p, which can enhance the tumor-suppressive effects of HRD1 that modulate vimentin, a vital regulator of EMT (337). CircRGPD6 can also inhibit metastatic BCSCs through the miR-26b/YAF2 axis, and TV-circRGPD6 nanoparticles, either alone or in combination with docetaxel, demonstrated notable therapeutic responses on metastatic BCSCs (338). Moreover, circNOL10 not only can bind multiple miRNAs such as miR-149-5p, miR-330-3p, and miR-452-5p to alleviate BC carcinogenesis by regulating PDCD4 but also can act as an RBP-noncoding RNA and CASC3 and MTDH proteins bind directly to it with characterized motifs and inhibit BCM (339). CircNOL10 was represented in another study as a suppressor of BCM via sponging miR-767-5p and up-regulating SOCS2, which inactivates the JAK2/STAT5 signaling pathway (340). According to Liang Y et al., circBMPR2 down regulated in BCM. Additionally, sponging miR-553 by this circRNA results in overexpression of USP4, a TSG, inhibiting the metastasis and tamoxifen resistance (341). Further, it is reported that the Yap protein, a vital Hippo pathway component, can be inhibited by its circular RNA (circYap) and attenuate BC migration and invasion (342). Regarding the upregulation of circRNAs in BCM, it has been revealed that overexpression of circ-UBR1 could lead to BCM via miR-1299/CCND1 axis (343). In TNBC, circRAD18 sponges miR-208a and miR-3164 and increased IGF1 and FGF2 expression were associated with poor prognosis and distant metastasis, as well as cell migration and invasion in BC cell lines (344). Furthermore, it has been demonstrated that TNBC metastasis and progression could be facilitated via circ-UBAP2/ miR-661/MTA1 (345), circSEPT9/miR-637/LIF (27) and circIFI30/miR-520b-3p/CD44 axis (346). In the positive feedback loop of circHIF1A/NFIB/FUS (347), circHIF1A can be overexpressed and accelerate TNBC metastasis and invasion (347). CircDNAJC11 can directly regulate TAF15/MAPK6 and activate the MAPK signaling pathway in TNBC (348). CircANKS1B through miR-148a-3p and miR-152-3p/ USF1/ TGF-β1 activates TGF-β1/Smad signaling and promotes EMT (349). Li Y et al. found that circ-EIF6, which encodes EIF6-224aa, may be responsible for TNBC invasion and progression by inhibiting the MYH9 oncogene degradation and activation of the Wnt/β-catenin pathway (350). Besides, CircHIPK3 can assist the progress of BCM by regulating miR-193a/HMGB1 and PI3K/AKT signaling pathways (351). With inhibition of miR-296-5p, hsa_circ_0000515 can overexpress CXCL10 and promote cell invasiveness in the MCF-7 cell line and nude mice (352). Gao D et al. indicate that circ_0006528 up-regulated in BCM and sponges miR-7-5p to overexpressed Raf1, ultimately in the way activated MAPK/ERK signaling pathway (353). Further, Ju CH et al. introduced a novel circRNA, circ_0042881, which in a ceRNA-network sponges' miR-217, affects SOS1 and activates MEK/ERK pathway and PI3K/AKT pathway (354). They also claim that EIF4A3 could facilitate circ_0042881 circularization in this axis (354). In addition, it has been shown that circMYBL2 upregulated in BC liver metastasis and sponging miR-1205, then complexing with eIF4A3 and promoting EMT, or it can directly target eIF4A3 through circMYBL2/eIF4A3/ E2F1 axes and leads to BC liver metastasis (355). Several other studies had been reported the upregulation of circRNAs and sponging miRNAs in a particular axis can enhance or facilitate BCM including CircKIF4A/ miR-152/ZEB1 (356), circFOXK2/ IGF2BP3/miR-370 (357), circ_0072995/ SHMT2/miR-149-5p (358), circFBXL5/miR‐660/ SRSF6 (359), circHMCU/ let-7/ MCY/HMGA2/CCND1 (360), circIRAK3/miR-3607/FOXC1 (361), circACAP2/ miR-29a/b-3p-COL5A1 (362), circ_0000291/miR-326/ETS1 axes (363). Table. 4 comprehensively represents circRNAs and their targets, which play a role in BCM progression. Table. 4. List of circRNAs and their targets, which are involved in the BCM. CircRNA Regulation Target Detection Method(s) Authors Year Title circKIF4A Up miR-637/STAT3 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration assay Song Wu et al 2024 (364) circRNF10 Down DHX15 qRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell assay Wenfang Zheng et al 2023 (365) circ_0060467 (circMYBL2) Up miR-1205/E2F1 and eIF4A3/E2F1 qRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell migration assay Yan Zeng et al 2023 (355) circ_0042881 Up miR-217/SOS1 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration assay Chenxi Ju et al 2023 (354) circDNAJC11 Up TAF15/MAPK6 qRT-PCR, RIP, Transwell migration and invasion assay Bin Wang et al 2023 (348) circ-EIF6 Up MYH9 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Yaming Li et al 2022 (350) circFOXK2 Up IGF2BP3/miR-370 qRT-PCR, Luciferase reporter assay, Migration and invasion assay Wei Zhang et al 2021 (357) circRASSF2 Up miR-1205/HOXA1 qRT-PCR, Dual-luciferase reporter assay, Transwell assay Wei Zhong et al 2021 (366) circ-ERBB2 Up miR-136-5p/TFAP2C or miR-198/TFAP2C qRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assays Jin-xiu Zhong 2021 (367) circHIF1A Up miR-149-5p/NFIB/FUS qRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell assay Tong Chen et al 2021 (347) circ_0000515 Up miR-296-5p/CXCL10 qRT-PCR, Dual-luciferase reporter assay, Transwell assay Fenglin Cai et al 2021 (352) circNR3C2 Down miR-513a-3p/HRD1/Vimentin qRT-PCR, Luciferase reporter assay, Wound healing assay, Matrigel invasion assay Ya Fan et al 2021 (337) circNOL10 Down miR-767-5p/SOCS2/JAK2/STAT5 qRT-PCR, Dual-luciferase reporter Assay, Transwell Assay Fang Wang et al 2021 (340) circHMCU Up let-7/MCY/HMGA2/CCND1 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Xiaojin Song et al 2020 (360) circEHMT1 Down miR-1233-3p/KLF4/MMP2 qRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Mengqi Lu et al 2020 (336) circ_0091074 Down miR-1297/TAZ/TEAD4 qRT-PCR, Dual-luciferase reporter assay, Wound healing assay Jiashu Hu et al 2020 (368) circ-UBR1 Up miR-1299/CCND1 qRT‐PCR, Dual‐luciferase reporter assay, Transwell migration and invasion assay Linfeng Zhang et al 2020 (343) circVAPA Up miR-130a-5p qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Si-ying Zhou et al 2020 (369) circ-NOL10 Down miR-149-5p/miR-330-3p/miR-452-5p/PDCD4 qRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Matrigel invasion assay Yujie Cai et al 2020 (339) circ_0072995 Up miR-149-5p/SHMT2 qRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assay, Cell adhesion assay Chuang Qi et al 2020 (358) circKIF4A Up miR-152/ZEB1 qRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assay Yongping Jin et al 2020 (356) circHIPK3 Up miR-193a/HMGB1/PI3K/AKT qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay Zhen-Gang Chen et al 2020 (351) circRGPD6 Down miR-26b-YAF2 qRT-PCR Xiaoti Lin et al 2020 (338) circACAP2 Up miR-29a/miR-29b-3p/COL5A1 qRT-PCR, Luciferase reporter assay, Transwell migration and invasion assays Beiyong Zhao et al 2020 (362) circ_0000291 Up miR‐326/ETS1 qRT-PCR, Dual-luciferase reporter assay, Transwell assay Jie Min et al 2020 (363) circIFI30 Up miR-520b-3p/CD44 qRT-PCR, Dual-luciferase reporter assay, Wound healing and invasion assays Lei Xing et al 2020 (346) circSEPT9 Up miR-637/LIF qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assays Xiaying Zheng et al 2020 (27) circFBXL5 Up miR‐660/SRSF6 Microarray, Luciferase reporter assay Huamao Zhou et al 2020 (359) circSCYL2 Down NA qRT-PCR, Transwell migration and invasion assay Chunlei Yuan et al 2020 (370) circRNA_0025202 Down miR-182-5p/FOXO3a qRT-PCR, Luciferase reporter assay, Transwell migration assay Yuting Sang et al 2019 (371) circDENND4C Up miR-200b/c qRT-PCR, Luciferase reporter assay,3D spheroid invasion assay, Transwell migration and invasion assay Shasha Ren et al 2019 (372) circRAD18 Up miR-208a/3164-IGF1/FGF2 qRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell assay Yutian Zou et al 2019 (344) circAHNAK1 Down miR-421/RASA1 qRT-PCR, Luciferase reporter assay,Transwell assay, Migration assay Weikai Xiao et al 2019 (373) circASS1 Down miR-4443 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Jun-chen Hou et al 2019 (374) circKDM4C Down miR-548p/PBLD qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Yiran Liang et al 2019 (375) circBMPR2 Down miR-553/USP4 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Yiran Liang et al 2019 (341) circ-21439, circ-11783 circ 21439 Up circ 11783 Down NA qRT-PCR Xiaorong Lin et al 2019 (376) circYap Down Yap qRT-PCR, RIP, Wound healing assay, Transwell invasion assay Nan Wu et al 2019 (342) CiRS-7 Up miR-1299/MMP qRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Meixiang Sang et al 2018 (25) circANKS1B Up miR-148a-3p/152-3p/USF1 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell assays Kaixuan Zeng et al 2018 (349) circ-0072995 Up miR-30c-2-3p qRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assays He-da Zhang et al 2018 (377) circIRAK3 Up miR-3607/FOXC1 qRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell assay Jie Wu et al 2018 (361) circ-UBAP2 Up miR-661/MTA1 qRT-PCR, Luciferase reporter assay, Transwell migration assay Shengting Wang et al 2018 (345) circRNA_0006528 Up miR-7-5p/Raf1/MEK/ERK qRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay Danfeng Gao et al 2018 (353) FECR1 Up TET1 and DNMT1 qRT-PCR, RNA reverse transcription-associated trap (RAT), Matrigel invasion assay Naifei Chen et al 2018 (378) circ_0001785 Up NA qRT-PCR Wei-Bing Yin et al 2017 (379) 3.3.5 CeRNA physiology and participation in BC metastasis regulation: The term "competing endogenous RNAs" (ceRNAs) describes RNA transcripts, including circular RNAs, ncRNAs such as circRNAs and lncRNAs, pseudogene transcripts, and mRNAs, that have the ability to control one another by engaging in competition for the binding to MicoRNA Response Elements (MREs) (20,380,381). Based on the ceRNA hypothesis, the miRNA Sponge is integrated into the RNA-induced silencing complex and binds to its target mRNAs to modify the expression of the target (382). RNA editing, RNA-binding proteins, miRNA/ceRNA abundance, and ceRNAs' affinity for miRNAs are some variables that affect ceRNA activity (382) (Fig. 10). Any of these changes could result in an imbalance in the ceRNA-network, which would aid in the development and metastasis of BC (16,22). Recent research on BC has shown that the characteristics of BCM development are largely determined by the dysregulation of many ceRNA-networks (383). Furthermore, it is believed that such a finding would provide a fresh perspective on the concealed facets. Despite the intricacy of the process, ceRNA regulatory networks that impact several metastasis parameters may be responsible for the frequent metastatic progression of BC (23). As a result, the study of ceRNA-networks in metastasis has gained a special interest because most ceRNAs, including lncRNAs and circRNAs, have been found to contribute negatively to BC by influencing EMT, migration, invasion, and metastasis (24,384,385). Other ceRNAs associated with EMT in BC include HOTAIR, HULC, and NEAT1, all promoting a mesenchymal phenotype (214,386,387). The miR-200 family and p53 gene regulation regulate EMT, controlling mesenchymal transcription factors (307,388). Other ceRNAs associated with EMT in BC include HOTAIR, HULC, and NEAT1, all promoting a mesenchymal phenotype (389). The miR-200 family and p53 gene regulation regulate EMT, controlling mesenchymal transcription factors (298,390). The ongoing validation of ceRNA theory has provided new insights into BCM and invasion, leading to the discovery of therapeutic targets and biomarkers and enhancing clinical efficacy and prognosis. Nevertheless, due to the great diversity of BCM-related ceRNAs and their intricate ceRNA networks and inadequate experimental validation, there is a lack of systematic organization and comprehensive assessment of BC-related ceRNAs. 4. Discussion Metastasis remains an important clinical challenge for managing BC, as it is the main cause of disease relapse and BC-related fatalities due to its spread to distant organs and resistance to both targeted and systemic therapies ( 391 ). Although our knowledge of BC pathogenesis has advanced significantly over the past decades, our understanding of metastasis is still incomplete due to its complexity, which makes it demanding to prevent or target ( 4 , 392 , 393 ). It has been demonstrated that through various processes, such as cell differentiation, stemness, epigenetic regulation, and EMT, metastatic BC cells pick up aggressive traits from the tumor microenvironment (TME) ( 394 ). In agreement, the result of pathway enrichment in the current study exhibited the regulation of stem cell pluripotency, EMT, and cell differentiation, all of which are intimately related in numerous studies ( 395 , 396 ) (Fig. 5). The particular set of regulatory alterations allows EMT to induce the normal process of increasing differentiation in developing cell populations within an organism ( 395 ). Because of their stem cell characteristics, tumor cells produced from EMT are resistant to treatment ( 397 ). Because of that, dozens of treatments that target EMT are now being researched for patients with metastasis ( 398 ). Another significant result of pathway enrichment analysis highlights that proteoglycans play a pivotal role in BCM. In the development of ECM and CSC, proteoglycans are essential, impacting several pathways ( 399 ). Therapeutic resistance and CSC phenotype are influenced by aberrant proteoglycans and glycosaminoglycan (GAG) functions ( 400 , 401 ). Stemness is preserved and treatment resistance is encouraged by hyaluronan and the modification of the Wnt, hedgehog, and notch signaling pathways ( 402 ). Versican, a tumor stroma-associated proteoglycan in BC, suppresses the transforming growth factor-beta (TGF-β)/Smad2 pathway, promoting EMT and lung metastasis. It also stimulates tumor necrosis factor-alpha (TNF-α) secretion and toll-like receptor 2 (TLR2)/TLR6 complexes, promoting lung metastases ( 403 , 404 ). Likewise, versican G3 modulates the signaling of the epidermal growth factor (EGF) receptor, promoting tumor development and metastasis ( 405 – 407 ). Protein kinase C epsilon (PKCε), which plays a significant role in BCM based on our pathway enrichment results, is another key inducer of EMT in BC cells. Although Jain et al. demonstrated that PKCε acts downstream of TGFβ ( 408 ), a previous study revealed PKCε's function in the synthesis of active TGFβ ( 409 ). Therefore, PKCε and TGFβ may increase EMT by creating a positive feedback loop. They have also demonstrated that SNAIL , a crucial mediator of EMT, is positively regulated by PKCε. PKC's downstream targets ras homolog family member C 5 (RhoC5) and signal transducers and activators of transcription 3 (STAT3), which have been found to modulate EMT. ( 410 – 412 ). recent study showed that PKC is involved in controlling the stem cell marker NANOG ( 413 ). EMT and the stem cell phenotype are closely related ( 414 , 415 ), so further investigation of PKC's function in stemness may be possible. The significance of PKCε in BC and its potential as a therapeutic target for cancer treatment is thus highlighted by the PKCε-mediated control of EMT. Numerous investigations conducted in the most recent BC research have demonstrated that the dysregulation of many ceRNA-networks between ncRNAs fundamentally establishes the characteristics of BCM development. In this context, the ceRNA hypothesis posits that ncRNAs and mRNAs can compete for common regions in miRNAs to control the expression of downstream target genes. In the process of tumor invasion and metastasis, these RNAs function as signaling pathway control molecules, tumor suppressors, and oncogenic driver genes ( 380 , 381 ). In addition, it has been shown that CSC-TFs and EMT-TFs are considered essential regulators in developing a metastatic niche, which involves interactions between terminal stromal components and tumor-derived factors ( 416 , 417 ). According to recent research, stem cell-like cells that can self-renew and differentiate into various cell types play a major role in tumor development, spread, and metastasis ( 418 ). BC stem cells showed considerable expression of EMT markers such as SNAIL , SLUG , TWIST1 , CXCR4 , and FOXF2 , as well as a markedly enhanced capacity for self-renewal and tumor initiation ( 5 ). This is consistent with our findings that indicate following the construction and analysis of the ceRNA-network, the hub regulatory ncRNAs, MALAT1, miR-1, and miR-9 target TWIST1, SNAIL , and CXCR4 and participate in BCM (Fig. 4 ). In 2014 Yang's group demonstrated that the FOXO1 protein-encoding gene suppresses metastasis of BC cells by inducing E-cadherin expression by playing as ceRNA for miR-9. These outcomes are consistent with our discovery when building and analyzing the ceRNA-network for BC metastasis. Gene expression patterns in BC cells were decreased in FOXO1 and E-cadherin, while an upregulated level of miR-9 was observed ( 94 ). This co-expression state of FOXO1 and E-cadherin mRNAs was due to their similar binding sites in their 3′ UTRs, which competed for binding to common regulator miR-9. The inhibition of EMT and metastasis of BC cells by FOXO1 is done by inhibiting miR-9 and upregulating E-cadherin, a cell-cell adhesion molecule whose lack of expression leads to EMT and metastasis ( 94 ). Moreover, we identified LIN28A and LIN28B among hubs in the ceRNA-network, which are targeted by miR-9 and miR-27b, respectively. Lin28 is an RNA-binding protein that is one of the master regulators of embryonic stem cell self-renewal that correlates with clinical tumor grade and the terminal metastasis of BC ( 419 , 420 ). According to Qi et al., Lin28B did not influence the growth of the original tumor in the MMTV-PyMT animal model, but it did encourage the formation of lung metastasis ( 419 ). This suggests that the capacity of cancer cells to self-renew can encourage distant metastases in BC. In a study by Petri et al., it has been found that dysregulated miRNAs are linked to metastasis. These included upregulated miR-9-5p, miR-10b-5p, miR-21-5p, and miR-29, and downregulated miR-141-3p, miR-200 family members, miR-31-5p, and miR-15b-5p. miR-31-5p suppresses the expression of integrins, including as ITGA2, ITGA5, ITGAV, ITGB1, ITGB3 , and ITGB5 , which mediates its anti-invasive phenotype ( 77 ). These results align with our findings, which indicate that ITGB1 is a target that miR-9 downregulates in metastatic BC. The result of ceRNA-network construction and investigation indicates that miR-1 targets TWIST1 and SNAIL , while miR-27 targets ZEB-1 in the ceRNA-network, and miR-9 mostly targets FOX families. ITGB4 overexpression, another hub gene in our regulator ceRNA-network, determines the hybrid EMT state in BC. E-cadherin expression inhibits the TWIST1/Mi2/NuRD protein complex, which promotes EMT to cause BCM. This indicates that TWIST1 knockdown is crucial for preventing metastatic BC ( 73 ). In addition, lncRNA ATB predicts a poor prognosis for BC and upregulates the miR-200c/ TWIST1 axis to enhance EMT ( 181 ). miR-720 also targets TWIST1 to prevent tumor invasion and migration in BC ( 153 ). SNAIL suppresses E-cadherin expression by attaching itself to its promoter, which raises vimentin expression and triggers the EMT process. It was discovered that lncRNAs AC026904.1 and UCA1 target the EMT and TGF-β-induced SNAI2 activation in BC ( 183 ). It has been reported that miR-1 acts as a tumor suppressor in BC ( 421 , 422 ). Overexpression of miR-1 can limit cell invasion and migration ( 115 ). The most differentially expressed miRNAs validate that miR-1-3p was down-regulated in BC patients with sentinel lymph node (SLN) metastasis ( 423 ). Besides, miR-1 was discovered to be downregulated in BC cells with high levels of metastasis, whereas it was increased in cancer cells with low levels of metastasis ( 126 ). BC cells with high and low metastatic potential migrated and invaded after miR-1 inhibition. In addition, vimentin and matrix metallopeptidase 9 (MMP-9) were suppressed by miR-1, but E-cadherin levels were increased ( 116 , 126 ). Based on our knowledge, identifying potential regulatory networks of miRNAs responsible for self-renewal and EMT can facilitate the detection of metastatic cells with the ability to seed and enable the discovery of therapeutic targets. However, based on the findings of earlier research and bioinformatics prediction, this is the first step in determining the underlying mechanism of BCM. Additional experimental validations are required to guarantee the regulatory effects of pivotal miRNAs and their interactions in BCM. 5. Conclusion A comprehensive literature review, bioinformatics prediction, and analysis was conducted in the presented study to examine the role of the ceRNA regulatory network in BCM and invasion. As major regulators of the BCM-related ceRNA-network, the final results identified hsa-miR-1, hsa-miR-9, hsa-miR-27b, and MALAT1 contributing to the poor prognosis of BC. Besides that, the functional enrichment analysis of BP enrichment for GO analysis focuses on controlling pri-miRNA transcription, cell differentiation, EMT, proliferation, angiogenesis, and apoptosis. MF enrichment is dominated by transcription cis-regulatory region binding and ubiquitin protein ligase binding. In contrast, the serine/threonine protein kinase complex and cyclin-dependent protein kinase holoenzyme complex dominate CC enrichment. KEGG analysis focuses on signaling pathways controlling stem cell pluripotency, proteoglycans, and microRNAs in cancer. The overall findings can help clarify the molecular mechanism of BCM and help medical professionals diagnose and treat BC patients with metastases more precisely, preventing the disease from reaching its final stages and choosing the most appropriate and focused course of treatment. Declarations Consent to Participate Declaration: Not applicable for this study Ethics Approval Declaration: Not applicable for this study Funding: No funding was received to conduct this study Data availability: All data supporting the findings of this study are available under request Conflict of interest: The authors declare no conflict of interest Acknowledgments We thank our colleagues for their association and helpful discussions in this study. Author contributions: A.N. Conceptualization, research and methodology performance, data analysis and wrote the paper H.A. Drafting the manuscript, investigation, visualizing N.H. Data collection and data curation and recheck R.M. Revising the manuscript and providing technical help R.M. Data collection, drafting manuscript M.A. Review & editing the manuscript M.E. Data analysis B.B. Data collection B.H. Data collection M.J.R. Data collection G.F. Review & revise the manuscript R.N. Editing the manuscript M.S. Validation, supervision, and conceptualization. References Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74(6):477–95. Liao L. Inequality in breast cancer: Global statistics from 2022 to 2050. The Breast. 2025;79:103851. Caswell-Jin JL, Sun LP, Munoz D, Lu Y, Li Y, Huang H, et al. Analysis of breast cancer mortality in the US—1975 to 2019. Jama. 2024;331(3):233–41. Chen W, Hoffmann AD, Liu H, Liu X. Organotropism: new insights into molecular mechanisms of breast cancer metastasis. npj Precis Oncol [Internet]. 2018;2(1):4. Available from: https://doi.org/10.1038/s41698-018-0047-0 Park M, Kim D, Ko S, Kim A, Mo K, Yoon H. Breast cancer metastasis: mechanisms and therapeutic implications. Int J Mol Sci. 2022;23(12):6806. de Azevedo ALK, Carvalho TM, Mara CS, Giner IS, de Oliveira JC, Gradia DF, et al. Major regulators of the multi-step metastatic process are potential therapeutic targets for breast cancer management. Funct Integr Genomics. 2023;23(2):171. Ginsburg O, Yip C, Brooks A, Cabanes A, Caleffi M, Dunstan Yataco JA, et al. Breast cancer early detection: A phased approach to implementation. Cancer. 2020;126:2379–93. Chen S, Navickas A, Goodarzi H. Translational adaptation in breast cancer maetastasis and emerging therapeutic opportunities. Trends Pharmacol Sci. 2024; Zhang T, Zhou H, Wang K, Wang X, Wang M, Zhao W, et al. Role, molecular mechanism and the potential target of breast cancer stem cells in breast cancer development. Biomed Pharmacother. 2022;147:112616. Rakha EA, Pareja FG. New advances in molecular breast cancer pathology. In: Seminars in cancer biology. Elsevier; 2021. p. 102–13. Rakha EA, Tse GM, Quinn CM. An update on the pathological classification of breast cancer. Histopathology. 2023;82(1):5–16. Bruzas S, Kuemmel S, Harrach H, Breit E, Ataseven B, Traut A, et al. Next-generation sequencing-directed therapy in patients with metastatic breast cancer in routine clinical practice. Cancers (Basel). 2021;13(18):4564. Suh KJ, Kim SH, Kim YJ, Shin H, Kang E, Kim EK, et al. Clinical application of next-generation sequencing in patients with breast cancer: real-world data. J Breast Cancer. 2022;25(5):366. van Geelen CT, Savas P, Teo ZL, Luen SJ, Weng CF, Ko YA, et al. Clinical implications of prospective genomic profiling of metastatic breast cancer patients. Breast Cancer Res. 2020;22:1–13. Micheel J, Safrastyan A, Wollny D. Advances in non-coding RNA sequencing. Non-coding RNA. 2021;7(4):70. Yang S, Wang X, Zhou X, Hou L, Wu J, Zhang W, et al. ncRNA-mediated ceRNA regulatory network: Transcriptomic insights into breast cancer progression and treatment strategies. Biomed Pharmacother. 2023;162:114698. Saranya I, Dharshini VS, Akshaya RL, Subhashini PS, Selvamurugan N. Regulatory and therapeutic implications of competing endogenous RNA network in breast cancer progression and metastasis: a review. Int J Biol Macromol. 2024;131075. Kartha R V, Subramanian S. Competing endogenous RNAs (ceRNAs): new entrants to the intricacies of gene regulation. Front Genet. 2014;5:8. Mondal P, Meeran SM. Long non-coding RNAs in breast cancer metastasis. Non-coding RNA Res. 2020 Dec;5(4):208–18. Lin W, Liu H, Tang Y, Wei Y, Wei W, Zhang L, et al. The development and controversy of competitive endogenous RNA hypothesis in non-coding genes. Mol Cell Biochem. 2021 Jan;476(1):109–23. Yang X, Li F, Ma J, Liu Y, Wang X, Wang R, et al. Study on the relationship between the miRNA-centered ceRNA regulatory network and fatigue. J Mol Neurosci. 2021;1–8. Abdollahzadeh R, Daraei A, Mansoori Y, Sepahvand M, Amoli MM, Tavakkoly‐Bazzaz J. Competing endogenous RNA (ceRNA) cross talk and language in ceRNA regulatory networks: a new look at hallmarks of breast cancer. J Cell Physiol. 2019;234(7):10080–100. Qian D, Zheng Q, Wu D, Ye B, Qian Y, Zhou T, et al. Integrated Analysis of ceRNA Network Reveals Prognostic and Metastasis Associated Biomarkers in Breast Cancer. Front Oncol. 2021;11:670138. Wu Y, Shao A, Wang L, Hu K, Yu C, Pan C, et al. The Role of lncRNAs in the Distant Metastasis of Breast Cancer. Front Oncol. 2019;9:407. Sang M, Meng L, Liu S, Ding P, Chang S, Ju Y, et al. Circular RNA ciRS-7 Maintains Metastatic Phenotypes as a ceRNA of miR-1299 to Target MMPs. Mol Cancer Res. 2018 Nov;16(11):1665–75. Hua K, Deng X, Hu J, Ji C, Yu Y, Li J, et al. Long noncoding RNA HOST2, working as a competitive endogenous RNA, promotes STAT3-mediated cell proliferation and migration via decoying of let-7b in triple-negative breast cancer. J Exp Clin Cancer Res. 2020 Apr;39(1):58. Zheng X, Huang M, Xing L, Yang R, Wang X, Jiang R, et al. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer. Mol Cancer. 2020 Apr;19(1):73. Li X, Zheng L, Zhang F, Hu J, Chou J, Liu Y, et al. STARD13-correlated ceRNA network inhibits EMT and metastasis of breast cancer. Oncotarget. 2016;7(17):23197. Zheng L, Zhang Z, Zhang S, Guo Q, Zhang F, Gao L, et al. RNA Binding Protein RNPC1 Inhibits Breast Cancer Cell Metastasis via Activating STARD13-Correlated ceRNA Network. Mol Pharm. 2018 Jun;15(6):2123–32. Sang M, Wu M, Meng L, Zheng Y, Gu L, Liu F, et al. Identification of epithelial-mesenchymal transition-related circRNA-miRNA-mRNA ceRNA regulatory network in breast cancer. Pathol - Res Pract [Internet]. 2020;216(9):153088. Available from: https://www.sciencedirect.com/science/article/pii/S0344033820314060 Liu S, Song A, Zhou X, Huo Z, Yao S, Yang B, et al. ceRNA network development and tumour-infiltrating immune cell analysis of metastatic breast cancer to bone. J bone Oncol. 2020 Oct;24:100304. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339. Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014;14(1):579. Sampson M, McGowan J, Cogo E, Grimshaw J, Moher D, Lefebvre C. An evidence-based practice guideline for the peer review of electronic search strategies. J Clin Epidemiol. 2009;62(9):944–52. CASP UK. CASP (Critical Appraisal Skills Program) Checklists. 2018. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011 Oct;155(8):529–36. Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18(10):2127–33. Munn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Heal policy Manag. 2014;3(3):123. Ru Y, Kechris KJ, Tabakoff B, Hoffman P, Radcliffe RA, Bowler R, et al. The multiMiR R package and database: integration of microRNA–target interactions along with their disease and drug associations. Nucleic Acids Res. 2014;42(17):e133–e133. Hsu SD, Lin FM, Wu WY, Liang C, Huang WC, Chan WL, et al. miRTarBase: a database curates experimentally validated microRNA–target interactions. Nucleic Acids Res. 2011;39(suppl_1):D163–9. Edris B. A comparison of the Oligomap and TargetScan algorithms for miRNA target analysis. Bmi231 stanford edu. 2011; Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 2020;48(D1):D127–31. Napoli S. LncRNAs and available databases. Long Non-Coding RNAs Cancer. 2021;3–26. Dudekula DB, Panda AC, Grammatikakis I, De S, Abdelmohsen K, Gorospe M. CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biol. 2016;13(1):34–42. Doncheva NT, Morris JH, Gorodkin J, Jensen LJ. Cytoscape StringApp: network analysis and visualization of proteomics data. J Proteome Res. 2018;18(2):623–32. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol [Internet]. 2014;8(4):S11. Available from: https://doi.org/10.1186/1752-0509-8-S4-S11 Bindea G, Galon J, Mlecnik B. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics. 2013;29(5):661–3. Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638–46. Kohl M, Wiese S, Warscheid B. Cytoscape: software for visualization and analysis of biological networks. In: Data mining in proteomics: from standards to applications. Springer; 2010. p. 291–303. Evangelista JE, Xie Z, Marino GB, Nguyen N, Clarke DJB, Ma’ayan A. Enrichr-KG: bridging enrichment analysis across multiple libraries. Nucleic Acids Res. 2023;51(W1):W168–79. Kuleshov M V, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1):W90–7. Wickham H, Chang W, Wickham MH. Package ‘ggplot2.’ Creat elegant data Vis using Gramm Graph Version. 2016;2(1):1–189. Yu J, Mu Q, Fung M, Xu X, Zhu L, Ho RJY. Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response. Pharmacol Ther. 2022;236:108108. McGee SF. Understanding metastasis: current paradigms and therapeutic challenges in breast cancer progression. 2023; Dujon AM, Capp JP, Brown JS, Pujol P, Gatenby RA, Ujvari B, et al. Is there one key step in the metastatic cascade? Cancers (Basel). 2021;13(15):3693. Ramamoorthi G, Kodumudi K, Gallen C, Zachariah NN, Basu A, Albert G, et al. Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities. In: Seminars in cancer biology. Elsevier; 2022. p. 78–89. Buyuk B, Jin S, Ye K. Epithelial-to-mesenchymal transition signaling pathways responsible for breast cancer metastasis. Cell Mol Bioeng. 2022;15(1):1–13. Mortezaee K, Majidpoor J, Kharazinejad E. Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated. Med Oncol. 2022;39(12):193. Lambert AW, Weinberg RA. Linking EMT programmes to normal and neoplastic epithelial stem cells. Nat Rev Cancer. 2021;21(5):325–38. Vardas V, Politaki E, Pantazaka E, Georgoulias V, Kallergi G. Epithelial-to-mesenchymal transition of tumor cells: cancer progression and metastasis. Int J Dev Biol. 2021;66(1-2–3):277–83. Noubissi Nzeteu GA, Geismann C, Arlt A, Hoogwater FJH, Nijkamp MW, Meyer NH, et al. Role of epithelial-to-mesenchymal transition for the generation of circulating tumors cells and cancer cell dissemination. Cancers (Basel). 2022;14(22):5483. Celià-Terrassa T, Jolly MK. Cancer stem cells and epithelial-to-mesenchymal transition in cancer metastasis. Cold Spring Harb Perspect Med. 2020;10(7):a036905. Kulus M, Farzaneh M, Bryja A, Zehtabi M, Azizidoost S, Abouali Gale Dari M, et al. Phenotypic Transitions the Processes Involved in Regulation of Growth and Proangiogenic Properties of Stem Cells, Cancer Stem Cells and Circulating Tumor Cells. Stem Cell Rev Reports. 2024;1–13. Mo S, Fang D, Zhao S, Hoa PTT, Zhou C, Liang T, et al. Down regulated oncogene KIF2C inhibits growth, invasion, and metastasis of hepatocellular carcinoma through the Ras/MAPK signaling pathway and epithelial-to-mesenchymal transition. Ann Transl Med. 2022;10(3). Maharati A, Moghbeli M. PI3K/AKT signaling pathway as a critical regulator of epithelial-mesenchymal transition in colorectal tumor cells. Cell Commun Signal. 2023;21(1):201. Lavin DP, Tiwari VK. Unresolved complexity in the gene regulatory network underlying EMT. Front Oncol. 2020;10:554. Khanbabaei H, Ebrahimi S, García-Rodríguez JL, Ghasemi Z, Pourghadamyari H, Mohammadi M, et al. Non-coding RNAs and epithelial mesenchymal transition in cancer: molecular mechanisms and clinical implications. J Exp Clin Cancer Res. 2022;41(1):278. Hussen BM, Shoorei H, Mohaqiq M, Dinger ME, Hidayat HJ, Taheri M, et al. The impact of non-coding RNAs in the epithelial to mesenchymal transition. Front Mol Biosci. 2021;8:665199. Yousefi M, Nosrati R, Salmaninejad A, Dehghani S, Shahryari A, Saberi A. Organ-specific metastasis of breast cancer: molecular and cellular mechanisms underlying lung metastasis. Cell Oncol [Internet]. 2018;41(2):123–40. Available from: https://doi.org/10.1007/s13402-018-0376-6 Xu Y, Qin L, Sun T, Wu H, He T, Yang Z, et al. Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression. Oncogene. 2017 Feb;36(8):1157–66. Olmeda D, Moreno-Bueno G, Flores JM, Fabra A, Portillo F, Cano A. SNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells. Cancer Res. 2007 Dec;67(24):11721–31. Lee HY, Cha J, Kim SK, Park JH, Song KH, Kim P, et al. c-MYC Drives Breast Cancer Metastasis to the Brain, but Promotes Synthetic Lethality with TRAIL. Mol Cancer Res. 2019 Feb;17(2):544–54. Imani S, Hosseinifard H, Cheng J, Wei C, Fu J. Prognostic Value of EMT-inducing Transcription Factors (EMT-TFs) in Metastatic Breast Cancer: A Systematic Review and Meta-analysis. Sci Rep. 2016 Jun;6:28587. Tania M, Khan MA, Fu J. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014 Aug;35(8):7335–42. Goossens S, Vandamme N, Van Vlierberghe P, Berx G. EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET. Biochim Biophys acta Rev cancer. 2017 Dec;1868(2):584–91. Ergin K, Çetinkaya R. Regulation of MicroRNAs BT - miRNomics: MicroRNA Biology and Computational Analysis. In: Allmer J, Yousef M, editors. New York, NY: Springer US; 2022. p. 1–32. Available from: https://doi.org/10.1007/978-1-0716-1170-8_1 Petri BJ, Klinge CM. Regulation of breast cancer metastasis signaling by miRNAs. Cancer metastasis Rev. 2020;39(3):837–86. Hashemi ZS, Moghadam MF, Khalili S, Hashemi SM, Sepehr KS, Sadroddiny E. Distinctive Expression of MetastamiRs in Breast Cancer Mesenchymal Stem Cells Isolated from Solid Tumor. Curr Stem Cell Res Ther. 2024;19(11):1525–34. Otmani K, Lewalle P. Tumor suppressor miRNA in cancer cells and the tumor microenvironment: mechanism of deregulation and clinical implications. Front Oncol. 2021;11:708765. Otmani K, Rouas R, Berehab M, Lewalle P. The regulatory mechanisms of oncomiRs in cancer. Biomed Pharmacother. 2024;171:116165. Parrella P, Barbano R, Pasculli B, Fontana A, Copetti M, Valori VM, et al. Evaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients. Mol Cancer. 2014 Jun;13:142. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449(7163):682–8. Halim A, Al-Qadi N, Kenyon E, Conner KN, Mondal SK, Medarova Z, et al. Inhibition of miR-10b treats metastatic breast cancer by targeting stem cell-like properties. Oncotarget; Vol 15 [Internet]. 2024; Available from: https://www.oncotarget.com/article/28641/text/ Savad S, Mehdipour P, Miryounesi M, Shirkoohi R, Fereidooni F, Mansouri F, et al. Expression analysis of MiR-21, MiR-205, and MiR-342 in breast cancer in Iran. Asian Pac J Cancer Prev. 2012;13(3):873–7. Li J, Zhang Y, Zhang W, Jia S, Tian R, Kang Y, et al. Genetic heterogeneity of breast cancer metastasis may be related to miR-21 regulation of TIMP-3 in translation. Int J Surg Oncol. 2013;2013:875078. Toraih EA, Mohammed EA, Farrag S, Ramsis N, Hosny S. Pilot Study of Serum MicroRNA-21 as a Diagnostic and Prognostic Biomarker in Egyptian Breast Cancer Patients. Mol Diagn Ther. 2015 Jun;19(3):179–90. Song B, Wang C, Liu J, Wang X, Lv L, Wei L, et al. MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res. 2010 Mar;29(1):29. Rostas JW 3rd, Pruitt HC, Metge BJ, Mitra A, Bailey SK, Bae S, et al. microRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancer. Mol Cancer. 2014 Aug;13:200. Lü J, Zhao Q, Guo Y, Li D, Xie H, Liu C, et al. Regulation of ERα-dependent breast cancer metastasis by a miR-29a signaling. J Exp Clin Cancer Res [Internet]. 2023;42(1):93. Available from: https://doi.org/10.1186/s13046-023-02665-6 Gebeshuber CA, Zatloukal K, Martinez J. miR‐29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep [Internet]. 2009 Apr 1;10(4):400–5. Available from: https://doi.org/10.1038/embor.2009.9 Krell J, Frampton AE, Jacob J, Pellegrino L, Roca-Alonso L, Zeloof D, et al. The clinico-pathologic role of microRNAs miR-9 and miR-151-5p in breast cancer metastasis. Mol Diagn Ther. 2012 Jun;16(3):167–72. D’Ippolito E, Plantamura I, Bongiovanni L, Casalini P, Baroni S, Piovan C, et al. miR-9 and miR-200 regulate PDGFRβ-mediated endothelial differentiation of tumor cells in triple-negative breast cancer. Cancer Res. 2016;76(18):5562–72. Gravgaard KH, Lyng MB, Laenkholm AV, Søkilde R, Nielsen BS, Litman T, et al. The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. Breast Cancer Res Treat. 2012;134:207–17. Yang J, Li T, Gao C, Lv X, Liu K, Song H, et al. FOXO1 3’UTR functions as a ceRNA in repressing the metastases of breast cancer cells via regulating miRNA activity. FEBS Lett. 2014 Aug;588(17):3218–24. Wang CZ, Yuan P, Li Y. MiR-126 regulated breast cancer cell invasion by targeting ADAM9. Int J Clin Exp Pathol. 2015;8(6):6547–53. Turgut Cosan D, Oner C, Mutlu Sahin F. Micro RNA-126 coordinates cell behavior and signaling cascades according to characteristics of breast cancer cells. Bratisl Lek Listy. 2016;117(11):639–47. Sachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 2010;70(1):378–87. Kim SJ, Oh JS, Shin JY, Lee KD, Sung KW, Nam SJ, et al. Development of microRNA-145 for therapeutic application in breast cancer. J Control Release [Internet]. 2011;155(3):427–34. Available from: https://www.sciencedirect.com/science/article/pii/S0168365911004408 Mohammadi-Yeganeh S, Paryan M, Arefian E, Vasei M, Ghanbarian H, Mahdian R, et al. MicroRNA-340 inhibits the migration, invasion, and metastasis of breast cancer cells by targeting Wnt pathway. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2016 Jul;37(7):8993–9000. Wu Z, Wu Q, Wang C, Wang X, Huang J, Zhao J, et al. miR‐340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c‐Met. Cancer. 2011;117(13):2842–52. Duan WJ, Bi PD, Ma Y, Liu NQ, Zhen X. MiR-512-3p regulates malignant tumor behavior and multi-drug resistance in breast cancer cells via targeting Livin. Neoplasma. 2020 Jan;67(1):102–10. Pardo OE, Castellano L, Munro CE, Hu Y, Mauri F, Krell J, et al. miR-515-5p controls cancer cell migration through MARK4 regulation. EMBO Rep. 2016 Apr;17(4):570–84. Duong TTC, Nguyen THN, Nguyen TTN, Huynh LH, Ngo HP, Nguyen HT. Diagnostic and prognostic value of miR-200 family in breast cancer: A meta-analysis and systematic review. Cancer Epidemiol. 2022;77:102097. Kim HY, Ha Thi HT, Hong S. IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor. Cancer Lett. 2018 Feb;415:30–9. Roy SS, Gonugunta VK, Bandyopadhyay A, Rao MK, Goodall GJ, Sun LZ, et al. Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer. Oncogene. 2014 Jul;33(28):3707–16. Li X, Roslan S, Johnstone CN, Wright JA, Bracken CP, Anderson M, et al. MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways. Oncogene [Internet]. 2014;33(31):4077–88. Available from: https://doi.org/10.1038/onc.2013.370 Tsouko E, Wang J, Frigo DE, Aydogdu E, Williams C. miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene. Carcinogenesis [Internet]. 2015;36(9):1051–60. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84940670729&doi=10.1093%2Fcarcin%2Fbgv087&partnerID=40&md5=e73c71d4df4f0c7c16568a59750db7b7 Humphries B, Wang Z, Oom AL, Fisher T, Tan D, Cui Y, et al. MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis. Carcinogenesis [Internet]. 2014 Oct 1;35(10):2254–63. Available from: https://doi.org/10.1093/carcin/bgu133 Zhang G, Zhang W, Li B, Stringer-Reasor E, Chu C, Sun L, et al. MicroRNA-200c and microRNA- 141 are regulated by a FOXP3-KAT2B axis and associated with tumor metastasis in breast cancer. Breast Cancer Res [Internet]. 2017;19(1):73. Available from: https://doi.org/10.1186/s13058-017-0858-x Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, et al. miR-200 Enhances Mouse Breast Cancer Cell Colonization to Form Distant Metastases. PLoS One [Internet]. 2009 Sep 29;4(9):e7181. Available from: https://doi.org/10.1371/journal.pone.0007181 Zhou Y, Wang M, Tong Y, Liu X, Zhang L, Dong D, et al. miR-206 Promotes Cancer Progression by Targeting Full-Length Neurokinin-1 Receptor in Breast Cancer. Technol Cancer Res Treat. 2019 Jan;18:1533033819875168–1533033819875168. Liu Hao, Cao You-De, Ye Wei-Xia, Sun Yang-Yang. Effect of microRNA-206 on Cytoskeleton Remodelling by Downregulating Cdc42 in MDA-MB-231 Cells. Tumori J [Internet]. 2010 Sep 1;96(5):751–5. Available from: https://doi.org/10.1177/030089161009600518 Adorno-Cruz V, Hoffmann AD, Liu X, Dashzeveg NK, Taftaf R, Wray B, et al. ITGA2 promotes expression of ACLY and CCND1 in enhancing breast cancer stemness and metastasis. Genes Dis [Internet]. 2021;8(4):493–508. Available from: https://www.sciencedirect.com/science/article/pii/S2352304220300234 Lin ZJ, Ming J, Yang L, Du JZ, Wang N, Luo HJ. Mechanism of Regulatory Effect of MicroRNA-206 on Connexin 43 in Distant Metastasis of Breast Cancer. Chin Med J (Engl). 2016 Feb;129(4):424–34. Liu R, Li J, Lai Y, Liao Y, Liu R, Qiu W. Hsa-miR-1 suppresses breast cancer development by down-regulating K-ras and long non-coding RNA MALAT1. Int J Biol Macromol. 2015 Nov;81:491–7. Chou J, Wang B, Zheng T, Li X, Zheng L, Hu J, et al. MALAT1 induced migration and invasion of human breast cancer cells by competitively binding miR-1 with cdc42. Biochem Biophys Res Commun. 2016;472(1):262–9. Jin C, Yan B, Lu Q, Lin Y, Ma L. Reciprocal regulation of Hsa-miR-1 and long noncoding RNA MALAT1 promotes triple-negative breast cancer development. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2016 Jun;37(6):7383–94. Minemura H, Takagi K, Miki Y, Shibahara Y, Nakagawa S, Ebata A, et al. Abnormal expression of miR-1 in breast carcinoma as a potent prognostic factor. Cancer Sci. 2015 Nov;106(11):1642–50. Tian X, Yu H, Li D, Jin G, Dai S, Gong P, et al. The miR-5694/AF9/Snail Axis Provides Metastatic Advantages and a Therapeutic Target in Basal-like Breast Cancer. Mol Ther [Internet]. 2021;29(3):1239–57. Available from: https://www.sciencedirect.com/science/article/pii/S1525001620306201 Harati R, Mabondzo A, Tlili A, Khoder G, Mahfood M, Hamoudi R. Combinatorial targeting of microRNA-26b and microRNA-101 exerts a synergistic inhibition on cyclooxygenase-2 in brain metastatic triple-negative breast cancer cells. Breast Cancer Res Treat. 2021 Jun;187(3):695–713. Jia Y, Zhao J, Yang J, Shao J, Cai Z. miR-301 regulates the SIRT1/SOX2 pathway via CPEB1 in the breast cancer progression. Mol Ther - Oncolytics [Internet]. 2021;22:13–26. Available from: https://www.sciencedirect.com/science/article/pii/S2372770521000401 Lu Y, Hu X, Yang X. miR-934 promotes breast cancer metastasis by regulation of PTEN and epithelial–mesenchymal transition. Tissue Cell [Internet]. 2021;71:101581. Available from: https://www.sciencedirect.com/science/article/pii/S0040816621000975 Xu Y, Ye S, Zhang N, Zheng S, Liu H, Zhou K, et al. The FTO/miR-181b-3p/ARL5B signaling pathway regulates cell migration and invasion in breast cancer. Cancer Commun (London, England). 2020 Oct;40(10):484–500. Zhang X, Zhao H, Zhang Y, Yang X, Zhang J, Yi M, et al. The MicroRNA-382-5p/MXD1 Axis Relates to Breast Cancer Progression and Promotes Cell Malignant Phenotypes. J Surg Res. 2020 Feb;246:442–9. Malagobadan S, Ho CS, Nagoor NH. MicroRNA-6744-5p promotes anoikis in breast cancer and directly targets NAT1 enzyme. Cancer Biol Med. 2020 Feb;17(1):101–11. Peng J, Yuan C, Wu Z, Wang Y, Yin W, Lin Y, et al. Upregulation of microRNA‑1 inhibits proliferation and metastasis of breast cancer. Mol Med Rep. 2020;22(1):454–64. Liu C, Song YH, Mao Y, Wang HB, Nie G. MiRNA-106a promotes breast cancer progression by regulating DAX-1. Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1574–83. Rajarajan D, Selvarajan S, Charan Raja MR, Kar Mahapatra S, Kasiappan R. Genome-wide analysis reveals miR-3184-5p and miR-181c-3p as a critical regulator for adipocytes-associated breast cancer. J Cell Physiol. 2019 Aug;234(10):17959–74. Liu JH, Yang Y, Song Q, Li JB. MicroRNA-155regulates the proliferation and metastasis of human breast cancers by targeting MAPK7. J BUON. 2019;24(3):1075–80. McAnena P, Tanriverdi K, Curran C, Gilligan K, Freedman JE, Brown JAL, et al. Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer. BMC Cancer. 2019 May;19(1):436. Ren L, Chen H, Song J, Chen X, Lin C, Zhang X, et al. MiR-454-3p-Mediated Wnt/β-catenin Signaling Antagonists Suppression Promotes Breast Cancer Metastasis. Theranostics. 2019;9(2):449–65. Wang S, Huang M, Wang Z, Wang W, Zhang Z, Qu S, et al. MicroRNA‑133b targets TGFβ receptor I to inhibit TGF‑β‑induced epithelial‑to‑mesenchymal transition and metastasis by suppressing the TGF‑β/SMAD pathway in breast cancer. Int J Oncol. 2019 Nov;55(5):1097–109. Hu PC, Li K, Tian YH, Pan WT, Wang Y, Xu XL, et al. CREB1/Lin28/miR-638/VASP Interactive Network Drives the Development of Breast Cancer. Int J Biol Sci. 2019;15(12):2733–49. Liu X, Cao M, Palomares M, Wu X, Li A, Yan W, et al. Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts. Breast Cancer Res. 2018 Oct;20(1):127. Chen X, Zhao M, Huang J, Li Y, Wang S, Harrington CA, et al. microRNA-130a suppresses breast cancer cell migration and invasion by targeting FOSL1 and upregulating ZO-1. J Cell Biochem. 2018 Jun;119(6):4945–56. Mohammadzadeh R, Saeid Harouyan M, Ale Taha SM. Silencing of bach1 gene by small interfering RNA-mediation regulates invasive and expression level of miR-203, miR-145, matrix metalloproteinase-9, and CXCR4 receptor in MDA-MB-468 breast cancer cells. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2017 Mar;39(3):1010428317695925–1010428317695925. Xue Y, Xu W, Zhao W, Wang W, Zhang D, Wu P. miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition afile:///C:/Users/CMGRC-2/Downloads/csp_39_.risnd metastasis by targeting CXCR4. Biomed Pharmacother. 2017 Feb;86:426–33. Shui Y, Yu X, Duan R, Bao Q, Wu J, Yuan H, et al. miR-130b-3p inhibits cell invasion and migration by targeting the Notch ligand Delta-like 1 in breast carcinoma. Gene. 2017 Apr;609:80–7. Li RK, Gao J, Guo LH, Huang GQ, Luo WH. PTENP1 acts as a ceRNA to regulate PTEN by sponging miR-19b and explores the biological role of PTENP1 in breast cancer. Cancer Gene Ther. 2017 Jul;24(7):309–15. Zheng L, Li X, Chou J, Xiang C, Guo Q, Zhang Z, et al. StarD13 3’-untranslated region functions as a ceRNA for TP53INP1 in prohibiting migration and invasion of breast cancer cells by regulating miR-125b activity. Eur J Cell Biol. 2018 Jan;97(1):23–31. Sengupta D, Deb M, Rath SK, Kar S, Parbin S, Pradhan N, et al. DNA methylation and not H3K4 trimethylation dictates the expression status of miR-152 gene which inhibits migration of breast cancer cells via DNMT1/CDH1 loop. Exp Cell Res [Internet]. 2016;346(2):176–87. Available from: https://www.sciencedirect.com/science/article/pii/S0014482716302117 Han L, Liu B, Jiang L, Liu J, Han S. MicroRNA-497 downregulation contributes to cell proliferation, migration, and invasion of estrogen receptor alpha negative breast cancer by targeting estrogen-related receptor alpha. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2016 Oct;37(10):13205–14. Bamodu OA, Huang WC, Lee WH, Wu A, Wang LS, Hsiao M, et al. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448. BMC Cancer. 2016 Feb;16:160. Zhan Y, Liang X, Li L, Wang B, Ding F, Li Y, et al. MicroRNA-548j functions as a metastasis promoter in human breast cancer by targeting Tensin1. Mol Oncol. 2016 Jun;10(6):838–49. Jia Z, Liu Y, Gao Q, Han Y, Zhang G, Xu S, et al. miR-490-3p inhibits the growth and invasiveness in triple-negative breast cancer by repressing the expression of TNKS2. Gene. 2016 Nov;593(1):41–7. Zheng T, Chou J, Zhang F, Liu Y, Ni H, Li X, et al. CXCR4 3’UTR functions as a ceRNA in promoting metastasis, proliferation and survival of MCF-7 cells by regulating miR-146a activity. Eur J Cell Biol. 2015 Oct;94(10):458–69. Ahmad A, Ginnebaugh KR, Sethi S, Chen W, Ali R, Mittal S, et al. miR-20b is up-regulated in brain metastases from primary breast cancers. Oncotarget. 2015 May;6(14):12188–95. Mohammadi‐Yeganeh S, Mansouri A, Paryan M. Targeting of miR9/NOTCH1 interaction reduces metastatic behavior in triple‐negative breast cancer. Chem Biol Drug Des. 2015;86(5):1185–91. Xing F, Sharma S, Liu Y, Mo YY, Wu K, Zhang YY, et al. miR-509 suppresses brain metastasis of breast cancer cells by modulating RhoC and TNF-α. Oncogene. 2015 Sep;34(37):4890–900. Nagpal N, Ahmad HM, Chameettachal S, Sundar D, Ghosh S, Kulshreshtha R. HIF-inducible miR-191 promotes migration in breast cancer through complex regulation of TGFβ-signaling in hypoxic microenvironment. Sci Rep. 2015 Apr;5:9650. Ni X, Xia T, Zhao Y, Zhou W, Wu N, Liu X, et al. Downregulation of miR-106b induced breast cancer cell invasion and motility in association with overexpression of matrix metalloproteinase 2. Cancer Sci. 2014 Jan;105(1):18–25. Marino ALF, Evangelista AF, Vieira RAC, Macedo T, Kerr LM, Abrahão-Machado LF, et al. MicroRNA expression as risk biomarker of breast cancer metastasis: a pilot retrospective case-cohort study. BMC Cancer. 2014 Oct;14:739. Li LZ, Zhang CZ, Liu LL, Yi C, Lu SX, Zhou X, et al. miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1. Carcinogenesis. 2014 Feb;35(2):469–78. Ye ZB, Ma G, Zhao YH, Xiao Y, Zhan Y, Jing C, et al. miR-429 inhibits migration and invasion of breast cancer cells in vitro. Int J Oncol. 2015 Feb;46(2):531–8. Zhao X, Duan Z, Liu X, Wang B, Wang X, He J, et al. MicroRNA-127 is downregulated by Tudor-SN protein and contributes to metastasis and proliferation in breast cancer cell line MDA-MB-231. Anat Rec (Hoboken). 2013 Dec;296(12):1842–9. Chen Y, Zhang J, Wang H, Zhao J, Xu C, Du Y, et al. miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10. BMC Cancer. 2012 Mar;12:111. Huang L, Dai T, Lin X, Zhao X, Chen X, Wang C, et al. MicroRNA-224 targets RKIP to control cell invasion and expression of metastasis genes in human breast cancer cells. Biochem Biophys Res Commun [Internet]. 2012;425(2):127–33. Available from: https://www.sciencedirect.com/science/article/pii/S0006291X12013083 Zhang L, Sullivan PS, Goodman JC, Gunaratne PH, Marchetti D. MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res. 2011 Feb;71(3):645–54. Lowery AJ, Miller N, Dwyer RM, Kerin MJ. Dysregulated miR-183 inhibits migration in breast cancer cells. BMC Cancer [Internet]. 2010;10(1):502. Available from: https://doi.org/10.1186/1471-2407-10-502 Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, et al. A MicroRNA Targeting Dicer for Metastasis Control. Cell [Internet]. 2010;141(7):1195–207. Available from: https://www.sciencedirect.com/science/article/pii/S0092867410005532 Li H, Bian C, Liao L, Li J, Zhao RC. miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1. Breast Cancer Res Treat [Internet]. 2011;126(3):565–75. Available from: https://doi.org/10.1007/s10549-010-0954-4 Li Y, Zhang M, Chen H, Dong Z, Ganapathy V, Thangaraju M, et al. Ratio of miR-196s to HOXC8 messenger RNA correlates with breast cancer cell migration and metastasis. Cancer Res. 2010 Oct;70(20):7894–904. Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y, et al. microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci [Internet]. 2010 May 4;107(18):8231–6. Available from: https://doi.org/10.1073/pnas.1002080107 Su JL, Chen PB, Chen YH, Chen SC, Chang YW, Jan YH, et al. Downregulation of microRNA miR-520h by E1A contributes to anticancer activity. Cancer Res. 2010 Jun;70(12):5096–108. Wu H, Zhu S, Mo YY. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res [Internet]. 2009;19(4):439–48. Available from: https://doi.org/10.1038/cr.2009.18 Reddy SDN, Pakala SB, Ohshiro K, Rayala SK, Kumar R. MicroRNA-661, ac/EBPα target, inhibits metastatic tumor antigen 1 and regulates its functions. Cancer Res. 2009;69(14):5639–42. Liu S, Goldstein RH, Scepansky EM, Rosenblatt M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res. 2009;69(22):8742–51. Wang Y, Rathinam R, Walch A, Alahari SK. ST14 (suppression of tumorigenicity 14) gene is a target for miR-27b, and the inhibitory effect of ST14 on cell growth is independent of miR-27b regulation. J Biol Chem. 2009;284(34):23094–106. Li XF, Yan PJ, Shao ZM. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene [Internet]. 2009;28(44):3937–48. Available from: https://doi.org/10.1038/onc.2009.245 Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol [Internet]. 2008;10(2):202–10. Available from: https://doi.org/10.1038/ncb1681 Reddy SDN, Ohshiro K, Rayala SK, Kumar R. MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res. 2008;68(20):8195–200. Kong W, Yang H, He L, Zhao J jun, Coppola D, Dalton WS, et al. MicroRNA-155 is regulated by the transforming growth factor β/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008;28(22):6773–84. Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature [Internet]. 2008;451(7175):147–52. Available from: https://doi.org/10.1038/nature06487 Mattick JS, Amaral PP, Carninci P, Carpenter S, Chang HY, Chen LL, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol [Internet]. 2023;24(6):430–47. Available from: https://doi.org/10.1038/s41580-022-00566-8 Liu SJ, Dang HX, Lim DA, Feng FY, Maher CA. Long noncoding RNAs in cancer metastasis. Nat Rev Cancer. 2021;21(7):446–60. Yousefi H, Maheronnaghsh M, Molaei F, Mashouri L, Reza Aref A, Momeny M, et al. Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance. Oncogene. 2020;39(5):953–74. Zhang H, Wang J, Yin Y, Meng Q, Lyu Y. The role of EMT-related lncRNA in the process of triple-negative breast cancer metastasis. Biosci Rep. 2021 Feb;41(2). Saitoh M. Transcriptional regulation of EMT transcription factors in cancer. In: Seminars in Cancer Biology. Elsevier; 2023. p. 21–9. Saitoh M. Epithelial–mesenchymal transition by synergy between transforming growth factor-β and growth factors in cancer progression. Diagnostics. 2022;12(9):2127. Bracken CP, Goodall GJ, Gregory PA. RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer. In: Seminars in cancer biology. Elsevier; 2024. Li RH, Chen M, Liu J, Shao CC, Guo CP, Wei XL, et al. Long noncoding RNA ATB promotes the epithelial-mesenchymal transition by upregulating the miR-200c/Twist1 axe and predicts poor prognosis in breast cancer. Cell Death Dis. 2018 Dec;9(12):1171. Richards EJ, Zhang G, Li ZP, Permuth-Wey J, Challa S, Li Y, et al. Long non-coding RNAs (LncRNA) regulated by transforming growth factor (TGF) β: LncRNA-hit-mediated TGFβ-induced epithelial to mesenchymal transition in mammary epithelia. J Biol Chem. 2015 Mar;290(11):6857–67. Li GY, Wang W, Sun JY, Xin B, Zhang X, Wang T, et al. Long non-coding RNAs AC026904.1 and UCA1: a “one-two punch” for TGF-β-induced SNAI2 activation and epithelial-mesenchymal transition in breast cancer. Theranostics. 2018;8(10):2846–61. Wu ZJ, Li Y, Wu YZ, Wang Y, Nian WQ, Wang LL, et al. Long non-coding RNA CCAT2 promotes the breast cancer growth and metastasis by regulating TGF-β signaling pathway. Eur Rev Med Pharmacol Sci. 2017 Feb;21(4):706–14. Gao Z, Wang H, Li H, Li M, Wang J, Zhang W, et al. Long non-coding RNA CASC2 inhibits breast cancer cell growth and metastasis through the regulation of the miR-96-5p/SYVN1 pathway. Int J Oncol. 2018 Nov;53(5):2081–90. Zhang Y, Zhu M, Sun Y, Li W, Wang Y, Yu W. Upregulation of lncRNA CASC2 Suppresses Cell Proliferation and Metastasis of Breast Cancer via Inactivation of the TGF-β Signaling Pathway. Oncol Res. 2019 Feb;27(3):379–87. Wang CL, Li JC, Zhou CX, Ma CN, Wang DF, Wo LL, et al. Long non-coding RNA ARHGAP5-AS1 inhibits migration of breast cancer cell via stabilizing SMAD7 protein. Breast Cancer Res Treat. 2021 Oct;189(3):607–19. Xu X, Zhang M, Xu F, Jiang S. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. Mol Cancer [Internet]. 2020;19(1):165. Available from: https://doi.org/10.1186/s12943-020-01276-5 Alsaab HO. Pathological role of long non-coding (lnc) RNA in the regulation of Wnt/β-catenin signaling pathway during epithelial-mesenchymal transition (EMT). Pathol Pract. 2023;248:154566. Jiang D, Wang C, He J. Long non-coding RNA DGCR5 incudes tumorigenesis of triple-negative breast cancer by affecting Wnt/β-catenin signaling pathway. J BUON. 2020;25(2):702–8. Bai Y, Zhou X, Huang L, Wan Y, Li X, Wang Y. Long noncoding RNA EZR‑AS1 promotes tumor growth and metastasis by modulating Wnt/β‑catenin pathway in breast cancer. Exp Ther Med [Internet]. 2018;16(3):2235–42. Available from: https://doi.org/10.3892/etm.2018.6461 Song C, Sun P, He Q, Liu LL, Cui J, Sun LM. Long non-coding RNA LINC01287 promotes breast cancer cells proliferation and metastasis by activating Wnt/ß-catenin signaling. Eur Rev Med Pharmacol Sci. 2019 May;23(10):4234–42. Zhou P, Liu P, Zhang J. Long noncoding RNA RUSC1‑AS‑N promotes cell proliferation and metastasis through Wnt/β‑catenin signaling in human breast cancer. Mol Med Rep. 2019 Feb;19(2):861–8. Han S, Jin X, Liu Z, Xing F, Han Y, Yu X, et al. The long noncoding RNA HOTTIP promotes breast cancer cell migration, invasiveness, and epithelial-mesenchymal transition via the Wnt-β-catenin signaling pathway. Biochem Cell Biol. 2019 Oct;97(5):655–64. Li Y, Ma HY, Hu XW, Qu YY, Wen X, Zhang Y, et al. LncRNA H19 promotes triple-negative breast cancer cells invasion and metastasis through the p53/TNFAIP8 pathway. Cancer Cell Int. 2020;20:1–14. Zhou W, Ye XL, Xu J, Cao MG, Fang ZY, Li LY, et al. The lncRNA H19 mediates breast cancer cell plasticity during EMT and MET plasticity by differentially sponging miR-200b/c and let-7b. Sci Signal. 2017 Jun;10(483). Xiong H, Shen J, Chen Z, Yang J, Xie B, Jia Y, et al. H19/let‑7/Lin28 ceRNA network mediates autophagy inhibiting epithelial‑mesenchymal transition in breast cancer. Int J Oncol. 2020 Mar;56(3):794–806. Yan L, Yang S, Yue CX, Wei XY, Peng W, Dong ZY, et al. Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells. Environ Toxicol. 2020 Sep;35(9):1015–28. Tan Z, Zhao L, Huang S, Jiang Q, Wei Y, Wu JL, et al. Small peptide LINC00511-133aa encoded by LINC00511 regulates breast cancer cell invasion and stemness through the Wnt/β-catenin pathway. Mol Cell Probes [Internet]. 2023;69:101913. Available from: https://www.sciencedirect.com/science/article/pii/S0890850823000221 Tang T, Guo C, Xia T, Zhang R, Zen K, Pan Y, et al. LncCCAT1 Promotes Breast Cancer Stem Cell Function through Activating WNT/β-catenin Signaling. Theranostics. 2019;9(24):7384–402. Wang HB, Wei H, Wang JS, Li L, Chen AY, Li ZG. Down-regulated expression of LINC00518 prevents epithelial cell growth and metastasis in breast cancer through the inhibition of CDX2 methylation and the Wnt signaling pathway. Biochim Biophys acta Mol basis Dis. 2019 Mar;1865(3):708–23. Wang Y, Dong T, Wang P, Li S, Wu G, Zhou J, et al. LINC00922 regulates epithelial-mesenchymal transition, invasive and migratory capacities in breast cancer through promoting NKD2 methylation. Cell Signal. 2021 Jan;77:109808. Zhang D, Liu X, Li Y, Sun L, Liu SS, Ma Y, et al. LINC01189-miR-586-ZEB1 feedback loop regulates breast cancer progression through Wnt/β-catenin signaling pathway. Mol Ther - Nucleic Acids [Internet]. 2021;25:455–67. Available from: https://www.sciencedirect.com/science/article/pii/S2162253121001487 Yuan H, Qin Y, Zeng B, Feng Y, Li Y, Xiang T, et al. Long noncoding RNA LINC01089 predicts clinical prognosis and inhibits cell proliferation and invasion through the Wnt/β-catenin signaling pathway in breast cancer. Onco Targets Ther. 2019;12:4883–95. Li W, Zhang Z, Liu X, Cheng X, Zhang Y, Han X, et al. The FOXN3-NEAT1-SIN3A repressor complex promotes progression of hormonally responsive breast cancer. J Clin Invest. 2017 Sep;127(9):3421–40. Xiong Y, Liu Z, Li Z, Wang S, Shen N, Xin Y, et al. Long non‑coding RNA nuclear paraspeckle assembly transcript 1 interacts with microRNA‑107 to modulate breast cancer growth and metastasis by targeting carnitine palmitoyltransferase‑1. Int J Oncol. 2019 Nov;55(5):1125–36. Li X, Deng S, Pang X, Song Y, Luo S, Jin L, et al. LncRNA NEAT1 Silenced miR-133b Promotes Migration and Invasion of Breast Cancer Cells. Int J Mol Sci. 2019 Jul;20(15). Li X, Wang S, Li Z, Long X, Guo Z, Zhang G, et al. The lncRNA NEAT1 facilitates cell growth and invasion via the miR-211/HMGA2 axis in breast cancer. Int J Biol Macromol [Internet]. 2017;105:346–53. Available from: https://www.sciencedirect.com/science/article/pii/S0141813017305871 Park MK, Zhang L, Min KW, Cho JH, Yeh CC, Moon H, et al. NEAT1 is essential for metabolic changes that promote breast cancer growth and metastasis. Cell Metab [Internet]. 2021;33(12):2380-2397.e9. Available from: https://www.sciencedirect.com/science/article/pii/S1550413121005398 Xu S, Sui S, Zhang J, Bai N, Shi Q, Zhang G, et al. Downregulation of long noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition via the PI3K-AKT pathway in breast cancer. Int J Clin Exp Pathol. 2015;8(5):4881–91. Miao Y, Fan R, Chen L, Qian H. Clinical Significance of Long Non-coding RNA MALAT1 Expression in Tissue and Serum of Breast Cancer. Ann Clin Lab Sci. 2016 Jul;46(4):418–24. Zuo Y, Li Y, Zhou Z, Ma M, Fu K. Long non-coding RNA MALAT1 promotes proliferation and invasion via targeting miR-129-5p in triple-negative breast cancer. Biomed Pharmacother. 2017 Nov;95:922–8. Wang N, Cao S, Wang X, Zhang L, Yuan H, Ma X. lncRNA MALAT1/miR‑26a/26b/ST8SIA4 axis mediates cell invasion and migration in breast cancer cell lines. Oncol Rep. 2021 Aug;46(2). Kim J, Piao HL, Kim BJ, Yao F, Han Z, Wang Y, et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet. 2018 Dec;50(12):1705–15. Eades G, Wolfson B, Zhang Y, Li Q, Yao Y, Zhou Q. lincRNA-RoR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6. Mol Cancer Res. 2015 Feb;13(2):330–8. Hou P, Zhao Y, Li Z, Yao R, Ma M, Gao Y, et al. LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis. Cell Death Dis. 2014 Jun;5(6):e1287–e1287. Pádua Alves C, Fonseca AS, Muys BR, de Barros E Lima Bueno R, Bürger MC, de Souza JES, et al. Brief report: The lincRNA Hotair is required for epithelial-to-mesenchymal transition and stemness maintenance of cancer cell lines. Stem Cells. 2013 Dec;31(12):2827–32. Cen S, Peng X, Deng J, Jin H, Deng Z, Lin X, et al. The role of AFAP1-AS1 in mitotic catastrophe and metastasis of triple-negative breast cancer cells by activating the PLK1 signaling pathway. Oncol Res. 2023;31(3):375–88. Ma D, Chen C, Wu J, Wang H, Wu D. Up-regulated lncRNA AFAP1-AS1 indicates a poor prognosis and promotes carcinogenesis of breast cancer. Breast Cancer. 2019 Jan;26(1):74–83. Zhang X, Zhou Y, Mao F, Lin Y, Shen S, Sun Q. lncRNA AFAP1-AS1 promotes triple negative breast cancer cell proliferation and invasion via targeting miR-145 to regulate MTH1 expression. Sci Rep. 2020 May;10(1):7662. Jiang Xinyu, Lin Juli, Zhu Zhanlin. Long-chain noncoding RNA LINC01569 upregulates filamin A-interacting protein 1-like to prevent metastasis of triple-negative breast cancer via sponging miR-300. Cancer Biomarkers [Internet]. 2024 Feb 1;39(2):79–94. Available from: https://doi.org/10.3233/CBM-230261 Tang Y, Tian W, Zheng S, Zou Y, Xie J, Zhang J, et al. Dissection of FOXO1-Induced LYPLAL1-DT Impeding Triple-Negative Breast Cancer Progression via Mediating hnRNPK/β-Catenin Complex. Research [Internet]. 2025 May 11;6:289. Available from: https://doi.org/10.34133/research.0289 He Y, Xiao B, Lei T, Xuan J, Zhu Y, Kuang Z, et al. LncRNA T376626 is a promising serum biomarker and promotes proliferation, file:///C:/Users/s.jazini/Downloads/S0378111923000689.rismigration, and invasion via binding to LAMC2 in triple-negative breast cancer. Gene [Internet]. 2023;860:147227. Available from: https://www.sciencedirect.com/science/article/pii/S0378111923000689 Han J, Chen X, Wang J, Liu B. Glycolysis-related lncRNA TMEM105 upregulates LDHA to facilitate breast cancer liver metastasis via sponging miR-1208. Cell Death Dis [Internet]. 2023;14(2):80. Available from: https://doi.org/10.1038/s41419-023-05628-z Xu J, Hu M, Gao Y, Wang Y, Yuan X, Yang Y, et al. LncRNA MIR17HG Suppresses Breast Cancer Proliferation and Migration as ceRNA to Target FAM135A by Sponging miR-454-3p. Mol Biotechnol [Internet]. 2023;65(12):2071–85. Available from: https://doi.org/10.1007/s12033-023-00706-1 Zhang Y, Dong X, Guo X, Li C, Fan Y, Liu P, et al. LncRNA-BC069792 suppresses tumor progression by targeting KCNQ4 in breast cancerfile:///C:/Users/s.jazini/Downloads/10.1186_s12943-023-01747-5-citation.ris. Mol Cancer [Internet]. 2023;22(1):41. Available from: https://doi.org/10.1186/s12943-023-01747-5 Guardia T, Zhang Y, Thompson KN, Lee SJ, Martin SS, Konstantopoulos K, et al. OBSCN restoration via OBSCN-AS1 long-noncoding RNA CRISPR-targeting suppresses metastasis in triple-negative breast cancer. Proc Natl Acad Sci [Internet]. 2023 Mar 14;120(11):e2215553120. Available from: https://doi.org/10.1073/pnas.2215553120 Guo R, Su Y, Zhang Q, Xiu B, Huang S, Chi W, et al. LINC00478-derived novel cytoplasmic lncRNA LacRNA stabilizes PHB2 and suppresses breast cancer metastasis via repressing MYC targets. J Transl Med [Internet]. 2023;21(1):120. Available from: https://doi.org/10.1186/s12967-023-03967-1 Yang X, Yang Y, Qian X, Xu X, Lv P. Long non-coding RNA LINC01559 serves as a competing endogenous RNA accelerating triple-negative breast cancer progression. Biomed J [Internet]. 2021; Available from: https://www.sciencedirect.com/science/article/pii/S2319417021000597 Liu X, Tian X. Long Noncoding RNA TCONS_00068220 Promotes Breast Cancer Progression by Regulating Epithelial-Mesenchymal Transition Marker E-Cadherin. Med Sci Monit Int Med J Exp Clin Res. 2021 Mar;27:e929832–e929832. Li L, Jin Y, Wang X, Wang L, Sun Y, Luo Y, et al. Long noncoding RNA ENST00000508435 promotes migration of breast cancer via FXR 1. Cell Adh Migr. 2021 Dec;15(1):140–51. Qiao YS, Zhou JH, Jin BH, Wu YQ, Zhao B. LINC00483 is regulated by IGF2BP1 and participates in the progression of breast cancer. Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1379–86. Zhou T, Lin K, Nie J, Pan B, He B, Pan Y, et al. LncRNA SPINT1-AS1 promotes breast cancer proliferation and metastasis by sponging let-7 a/b/i-5p. Pathol Res Pract. 2021 Jan;217:153268. Shao G, Fan X, Zhang P, Liu X, Huang L, Ji S. Methylation-dependent MCM6 repression induced by LINC00472 inhibits triple-negative breast cancer metastasis by disturbing the MEK/ERK signaling pathway. Aging (Albany NY). 2021 Feb;13(4):4962–75. Liang Y, Ye F, Wang Y, Li Y, Li Y, Song X, et al. DGUOK-AS1 acts as a tumor promoter through regulating miR-204-5p/IL-11 axis in breast cancer. Mol Ther - Nucleic Acids [Internet]. 2021;26:1079–91. Available from: https://www.sciencedirect.com/science/article/pii/S2162253121002614 Zhou D, Ren K, Wang M, Wang J, Li E, Hou C, et al. Long non-coding RNA RACGAP1P promotes breast cancer invasion and metastasis via miR-345-5p/RACGAP1-mediated mitochondrial fission. Mol Oncol. 2021 Feb;15(2):543–59. Bai X, Zhang S, Qiao J, Xing X, Li W, Zhang H, et al. Long non‑coding RNA SChLAP1 regulates the proliferation of triple negative breast cancer cells via the miR‑524‑5p/HMGA2 axis. Mol Med Rep. 2021 Jun;23(6). Tarighi M, Khalaj-Kondori M, Hosseinzadeh A, Abtin M. Long non-coding RNA (lncRNA) DSCAM-AS1 is upregulated in breast cancer. Breast Dis. 2021;40(2):63–8. Chu Z, Huo N, Zhu X, Liu H, Cong R, Ma L, et al. FOXO3A-induced LINC00926 suppresses breast tumor growth and metastasis through inhibition of PGK1-mediated Warburg effect. Mol Ther [Internet]. 2021;29(9):2737–53. Available from: https://www.sciencedirect.com/science/article/pii/S1525001621002501 Zong S, Dai W, Guo X, Wang K. LncRNA-SNHG1 promotes macrophage M2-like polarization and contributes to breast cancer growth and metastasis. Aging (Albany NY). 2021;13(19):23169. Kong X, Li J, Li Y, Duan W, Qi Q, Wang T, et al. A novel long non-coding RNA AC073352.1 promotes metastasis and angiogenesis via interacting with YBX1 in breast cancer. Cell Death Dis. 2021 Jul;12(7):670. Eroğlu Güneş C, Güçlü E, Vural H, Kurar E. Knockdown of lncRNA ZEB2NAT suppresses epithelial mesenchymal transition, metastasis and proliferation in breast cancer cells. Gene. 2021 Dec;805:145904. Li D, Li L, Chen X, Zhou C, Hao B, Cao Y. Dysregulation of lncRNA-CCRR contributes to brain metastasis of breast cancer by intercellular coupling via regulating connexin 43 expression. J Cell Mol Med. 2021 May;25(10):4826–34. Zhao YF, Li L, Li HJ, Yang FR, Liu ZK, Hu XW, et al. LncRNA ZFPM2-AS1 aggravates the malignant development of breast cancer via upregulating JMJD6. Eur Rev Med Pharmacol Sci. 2020 Nov;24(21):11139–47. Ma T, Liu H, Liu Y, Liu T, Wang H, Qiao F, et al. USP6NL mediated by LINC00689/miR-142-3p promotes the development of triple-negative breast cancer. BMC Cancer. 2020 Oct;20(1):998. Shi G, Cheng Y, Zhang Y, Guo R, Li S, Hong X. Long non-coding RNA LINC00511/miR-150/MMP13 axis promotes breast cancer proliferation, migration and invasion. Biochim Biophys acta Mol basis Dis. 2021 Mar;1867(3):165957. Jiang H, Li X, Wang W, Dong H. Long non-coding RNA SNHG3 promotes breast cancer cell proliferation and metastasis by binding to microRNA-154-3p and activating the notch signaling pathway. BMC Cancer. 2020 Sep;20(1):838. Zhao L, Zhou Y, Zhao Y, Li Q, Zhou J, Mao Y. Long non-coding RNA TUSC8 inhibits breast cancer growth and metastasis via miR-190b-5p/MYLIP axis. Aging (Albany NY). 2020 Feb;12(3):2974–91. Li J, Zeng T, Li W, Wu H, Sun C, Yang F, et al. Long non-coding RNA SNHG1 activates HOXA1 expression via sponging miR-193a-5p in breast cancer progression. Aging (Albany NY). 2020 Jun;12(11):10223–34. Yu Y, He Y, Shao Y, Chen Q, Liu H. lncRNA PCNAP1 predicts poor prognosis in breast cancer and promotes cancer metastasis via miR‑340‑5p‑dependent upregulation of SOX4. Oncol Rep. 2020 Oct;44(4):1511–23. Meng L, Yue X, Zhou D, Li H. Long non coding RNA OIP5‑AS1 promotes metastasis of breast cancer via miR‑340‑5p/ZEB2 axis. Oncol Rep. 2020 Oct;44(4):1662–70. Qin C, Jin L, Li J, Zha W, Ding H, Liu X, et al. Long Noncoding RNA LINC02163 Accelerates Malignant Tumor Behaviors in Breast Cancer by Regulating the MicroRNA-511-3p/HMGA2 Axis. Oncol Res. 2020 Dec;28(5):483–95. Yuan C, Luo X, Duan S, Guo L. Long noncoding RNA LINC00115 promotes breast cancer metastasis by inhibiting miR-7. FEBS Open Bio. 2020 Jul;10(7):1230–7. Tang L, Chen Y, Tang X, Wei D, Xu X, Yan F. Long Noncoding RNA DCST1-AS1 Promotes Cell Proliferation and Metastasis in Triple-negative Breast Cancer by Forming a Positive Regulatory Loop with miR-873-5p and MYC. J Cancer. 2020;11(2):311–23. Wu G, Zhou H, Li D, Zhi Y, Liu Y, Li J, et al. LncRNA DANCR upregulation induced by TUFT1 promotes malignant progression in triple negative breast cancer via miR-874-3p-SOX2 axis. Exp Cell Res. 2020 Nov;396(2):112331. Hu S, Zheng W, Jin L. Astragaloside IV inhibits cell proliferation and metastasis of breast cancer via promoting the long noncoding RNA TRHDE-AS1. J Nat Med. 2021 Jan;75(1):156–66. Zhou JL, Zou L, Zhu T. Long non-coding RNA c promotes metastasis of breast cancer cells by triggering EMT. Eur Rev Med Pharmacol Sci. 2020 Mar;24(6):3097–104. Fang K, Caixia H, Xiufen Z, Zijian G, Li L. Screening of a Novel Upregulated lncRNA, A2M-AS1, That Promotes Invasion and Migration and Signifies Poor Prognosis in Breast Cancer. Biomed Res Int. 2020;2020:9747826. Guo G, Dai S, Chen Q. Long Noncoding RNA LINC00261 Reduces Proliferation and Migration of Breast Cancer Cells via the NME1-EMT Pathway. Cancer Manag Res. 2020;12:3081–9. Tao S, Chen Q, Lin C, Dong H. Linc00514 promotes breast cancer metastasis and M2 polarization of tumor-associated macrophages via Jagged1-mediated notch signaling pathway. J Exp Clin Cancer Res. 2020 Sep;39(1):191. Chu W, Zhang X, Qi L, Fu Y, Wang P, Zhao W, et al. The EZH2-PHACTR2-AS1-Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer. Cancer Res. 2020 Jul;80(13):2737–50. Chang KC, Diermeier SD, Yu AT, Brine LD, Russo S, Bhatia S, et al. MaTAR25 lncRNA regulates the Tensin1 gene to impact breast cancer progression. Nat Commun. 2020 Dec;11(1):6438. Niu Y, Bao L, Chen Y, Wang C, Luo M, Zhang B, et al. HIF2-Induced Long Noncoding RNA RAB11B-AS1 Promotes Hypoxia-Mediated Angiogenesis and Breast Cancer Metastasis. Cancer Res. 2020 Mar;80(5):964–75. Zheng S, Yang L, Zou Y, Liang JY, Liu P, Gao G, et al. Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer. J Hematol Oncol. 2020 Mar;13(1):17. Pan QH, Fan YH, Wang YZ, Li DM, Hu CE, Li RX. Long noncoding RNA NNT-AS1 functions as an oncogene in breast cancer via repressing ZFP36 expression. J Biol Regul Homeost Agents. 2020;34(3):795–805. Jiang Y, Lin L, Zhong S, Cai Y, Zhang F, Wang X, et al. Overexpression of novel lncRNA NLIPMT inhibits metastasis by reducing phosphorylated glycogen synthase kinase 3β in breast cancer. J Cell Physiol. 2019 Jul;234(7):10698–708. Fu J, Dong G, Shi H, Zhang J, Ning Z, Bao X, et al. LncRNA MIR503HG inhibits cell migration and invasion via miR-103/OLFM4 axis in triple negative breast cancer. J Cell Mol Med. 2019 Jul;23(7):4738–45. Li XY, Zhou LY, Luo H, Zhu Q, Zuo L, Liu GY, et al. The long noncoding RNA MIR210HG promotes tumor metastasis by acting as a ceRNA of miR-1226-3p to regulate mucin-1c expression in invasive breast cancer. Aging (Albany NY). 2019 Aug;11(15):5646–65. Wang YY, Yan L, Yang S, Xu HN, Chen TT, Dong ZY, et al. Long noncoding RNA AC073284.4 suppresses epithelial-mesenchymal transition by sponging miR-18b-5p in paclitaxel-resistant breast cancer cells. J Cell Physiol. 2019 Dec;234(12):23202–15. Mao Q, Lv M, Li L, Sun Y, Liu S, Shen Y, et al. Long intergenic noncoding RNA 00641 inhibits breast cancer cell proliferation, migration, and invasion by sponging miR-194-5p. J Cell Physiol. 2020 Mar;235(3):2668–75. Kong X, Duan Y, Sang Y, Li Y, Zhang H, Liang Y, et al. LncRNA-CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA-215. J Cell Physiol. 2019 Jun;234(6):9105–17. Wang L, Luan T, Zhou S, Lin J, Yang Y, Liu W, et al. LncRNA HCP5 promotes triple negative breast cancer progression as a ceRNA to regulate BIRC3 by sponging miR-219a-5p. Cancer Med. 2019 Aug;8(9):4389–403. Li W, Jin X, Zhao Y, Dai J, Cai Y. Long noncoding RNA GAS6-AS2 sponges microRNA-493, thereby enhancing the malignant characteristics of breast cancer cells via upregulation of FUT4. Pathol Res Pract. 2020 Feb;216(2):152772. Bai J, Zhao WY, Li WJ, Ying ZW, Jiang DQ. Long noncoding RNA LINC00473 indicates a poor prognosis of breast cancer and accelerates tumor carcinogenesis by competing endogenous sponging miR-497. Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3410–20. Dong HT, Liu Q, Zhao T, Yao F, Xu Y, Chen B, et al. Long Non-coding RNA LOXL1-AS1 Drives Breast Cancer Invasion and Metastasis by Antagonizing miR-708-5p Expression and Activity. Mol Ther Nucleic Acids. 2020 Mar;19:696–705. Zhou B, Guo H, Tang J. Long Non-Coding RNA TFAP2A-AS1 Inhibits Cell Proliferation and Invasion in Breast Cancer via miR-933/SMAD2. Med Sci Monit Int Med J Exp Clin Res. 2019 Feb;25:1242–53. Guan Y, Bhandari A, Xia E, Yang F, Xiang J, Wang O. lncRNA FOXD3-AS1 is associated with clinical progression and regulates cell migration and invasion in breast cancer. Cell Biochem Funct. 2019 Jun;37(4):239–44. Li Y, Su X, Pan H. Inhibition of lncRNA PANDAR reduces cell proliferation, cell invasion and suppresses EMT pathway in breast cancer. Cancer Biomark. 2019;25(2):185–92. Wang Y, Zhang G, Han J. HIF1A-AS2 predicts poor prognosis and regulates cell migration and invasion in triple-negative breast cancer. J Cell Biochem. 2019 Jun;120(6):10513–8. Zhang H, Zhang N, Liu Y, Su P, Liang Y, Li Y, et al. Epigenetic Regulation of NAMPT by NAMPT-AS Drives Metastatic Progression in Triple-Negative Breast Cancer. Cancer Res. 2019 Jul;79(13):3347–59. Yi T, Zhou X, Sang K, Huang X, Zhou J, Ge L. Activation of lncRNA lnc-SLC4A1-1 induced by H3K27 acetylation promotes the development of breast cancer via activating CXCL8 and NF-kB pathway. Artif cells, nanomedicine, Biotechnol. 2019 Dec;47(1):3765–73. Fang K, Hu C, Zhang X, Hou Y, Gao D, Guo Z, et al. LncRNA ST8SIA6-AS1 promotes proliferation, migration and invasion in breast cancer through the p38 MAPK signalling pathway. Carcinogenesis. 2020 Sep;41(9):1273–81. Zhang Y, Xiao X, Zhou W, Hu J, Zhou D. LIN28A-stabilized FBXL19-AS1 promotes breast cancer migration, invasion and EMT by regulating WDR66. In Vitro Cell Dev Biol Anim. 2019 Jun;55(6):426–35. Zhang G, Li H, Sun R, Li P, Yang Z, Liu Y, et al. Long non-coding RNA ZEB2-AS1 promotes the proliferation, metastasis and epithelial mesenchymal transition in triple-negative breast cancer by epigenetically activating ZEB2. J Cell Mol Med. 2019 May;23(5):3271–9. Jin X, Xu XE, Jiang YZ, Liu YR, Sun W, Guo YJ, et al. The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation. Sci Adv. 2019 Mar;5(3):eaat9820–eaat9820. Liu P, Tang H, Wu J, Qiu X, Kong Y, Zhang L, et al. Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer. Curr Cancer Drug Targets. 2019;19(1):74–80. Li SY, Wang H, Mai HF, Li GF, Chen SJ, Li GS, et al. Down-regulated long non-coding RNA RNAZFHX4-AS1 suppresses invasion and migration of breast cancer cells via FAT4-dependent Hippo signaling pathway. Cancer Gene Ther. 2019 Nov;26(11–12):374–87. Pian L, Wen X, Kang L, Li Z, Nie Y, Du Z, et al. Targeting the IGF1R Pathway in Breast Cancer Using Antisense lncRNA-Mediated Promoter cis Competition. Mol Ther Nucleic Acids. 2018 Sep;12:105–17. Yang YX, Wei L, Zhang YJ, Hayano T, Piñeiro Pereda MDP, Nakaoka H, et al. Long non-coding RNA p10247, high expressed in breast cancer (lncRNA-BCHE), is correlated with metastasis. Clin Exp Metastasis. 2018 Mar;35(3):109–21. Liu M, Gou L, Xia J, Wan Q, Jiang Y, Sun S, et al. LncRNA ITGB2-AS1 Could Promote the Migration and Invasion of Breast Cancer Cells through Up-Regulating ITGB2. Vol. 19, International Journal of Molecular Sciences. 2018. Wang M, Wang M, Wang Z, Yu X, Song Y, Wang C, et al. Long non-coding RNA-CTD-2108O9.1 represses breast cancer metastasis by influencing leukemia inhibitory factor receptor. Cancer Sci. 2018 Jun;109(6):1764–74. Li Y, Lv M, Song Z, Lou Z, Wang R, Zhuang M. Long non-coding RNA NNT-AS1 affects progression of breast cancer through miR-142-3p/ZEB1 axis. Biomed Pharmacother. 2018 Jul;103:939–46. Huang XJ, Xia Y, He GF, Zheng LL, Cai YP, Yin Y, et al. MALAT1 promotes angiogenesis of breast cancer. Oncol Rep. 2018 Nov;40(5):2683–9. Zheng R, Lin S, Guan L, Yuan H, Liu K, Liu C, et al. Long non-coding RNA XIST inhibited breast cancer cell growth, migration, and invasion via miR-155/CDX1 axis. Biochem Biophys Res Commun [Internet]. 2018;498(4):1002–8. Available from: https://www.sciencedirect.com/science/article/pii/S0006291X18305965 Luo X, Song Y, Tang L, Sun DH, Ji DG. LncRNA SNHG7 promotes development of breast cancer by regulating microRNA-186. Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):7788–97. Li S, Zhou J, Wang Z, Wang P, Gao X, Wang Y. Long noncoding RNA GAS5 suppresses triple negative breast cancer progression through inhibition of proliferation and invasion by competitively binding miR-196a-5p. Biomed Pharmacother. 2018 Aug;104:451–7. Yang F, Shen Y, Zhang W, Jin J, Huang D, Fang H, et al. An androgen receptor negatively induced long non-coding RNA ARNILA binding to miR-204 promotes the invasion and metastasis of triple-negative breast cancer. Cell Death Differ. 2018 Dec;25(12):2209–20. Huang X, Xie X, Liu P, Yang L, Chen B, Song C, et al. Adam12 and lnc015192 act as ceRNAs in breast cancer by regulating miR-34a. Oncogene. 2018 Dec;37(49):6316–26. Liang Y, Song X, Li Y, Sang Y, Zhang N, Zhang H, et al. A novel long non-coding RNA-PRLB acts as a tumor promoter through regulating miR-4766-5p/SIRT1 axis in breast cancer. Cell Death Dis. 2018 May;9(5):563. Xing F, Liu Y, Wu SY, Wu K, Sharma S, Mo YY, et al. Loss of XIST in breast cancer activates MSN-c-Met and reprograms microglia via exosomal miRNA to promote brain metastasis. Cancer Res. 2018;78(15):4316–30. Wang PS, Chou CH, Lin CH, Yao YC, Cheng HC, Li HY, et al. A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer. Oncogene. 2018 Aug;37(34):4662–78. Jiang J, Shi S, Li X, Sun L, Ge Q, Li C, et al. Long non‑coding RNA BRAF‑regulated lncRNA 1 promotes lymph node invasion, metastasis and proliferation, and predicts poor prognosis in breast cancer. Oncol Lett [Internet]. 2018;15(6):9543–52. Available from: https://doi.org/10.3892/ol.2018.8513 Lou KX, Li ZH, Wang P, Liu Z, Chen Y, Wang XL, et al. Long non-coding RNA BANCR indicates poor prognosis for breast cancer and promotes cell proliferation and invasion. Eur Rev Med Pharmacol Sci. 2018 Mar;22(5):1358–65. Jiang M, Xiao Y, Liu D, Luo N, Gao Q, Guan Y. Overexpression of long noncoding RNA LINC01296 indicates an unfavorable prognosis and promotes tumorigenesis in breast cancer. Gene. 2018 Oct;675:217–24. Fang Y, Wang J, Wu F, Song Y, Zhao S, Zhang Q. Long non-coding RNA HOXA-AS2 promotes proliferation and invasion of breast cancer by acting as a miR-520c-3p sponge. Oncotarget. 2017 Jul;8(28):46090–103. Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, et al. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest. 2017 Dec;127(12):4498–515. Wang Y, Zhou Y, Yang Z, Chen B, Huang W, Liu Y, et al. MiR-204/ZEB2 axis functions as key mediator for MALAT1-induced epithelial-mesenchymal transition in breast cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2017 Jul;39(7):1010428317690998–1010428317690998. Kong Q, Qiu M. Long noncoding RNA SNHG15 promotes human breast cancer proliferation, migration and invasion by sponging miR-211-3p. Biochem Biophys Res Commun. 2018 Jan;495(2):1594–600. Zhang W, Shi S, Jiang J, Li X, Lu H, Ren F. LncRNA MEG3 inhibits cell epithelial-mesenchymal transition by sponging miR-421 targeting E-cadherin in breast cancer. Biomed Pharmacother. 2017 Jul;91:312–9. Zhang CY, Yu MS, Li X, Zhang Z, Han CR, Yan B. Overexpression of long non-coding RNA MEG3 suppresses breast cancer cell proliferation, invasion, and angiogenesis through AKT pathway. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2017 Jun;39(6):1010428317701311–1010428317701311. Li WX, Sha RL, Bao JQ, Luan W, Su RL, Sun SR. Expression of long non-coding RNA linc-ITGB1 in breast cancer and its influence on prognosis and survival. Eur Rev Med Pharmacol Sci. 2017 Aug;21(15):3397–401. Chen DQ, Zheng XD, Cao Y, He XD, Nian WQ, Zeng XH, et al. Long non-coding RNA LINC00628 suppresses the growth and metastasis and promotes cell apoptosis in breast cancer. Eur Rev Med Pharmacol Sci. 2017 Jan;21(2):275–83. Liu G, Hu X, Zhou G. Long non-coding RNA OR3A4 promotes proliferation and migration in breast cancer. Biomed Pharmacother. 2017 Dec;96:426–33. Su JC, Hu XF. Long non‑coding RNA HOXA11‑AS promotes cell proliferation and metastasis in human breast cancer. Mol Med Rep. 2017 Oct;16(4):4887–94. Fan S, Yang Z, Ke Z, Huang K, Liu N, Fang X, et al. Downregulation of the long non-coding RNA TUG1 is associated with cell proliferation, migration, and invasion in breast cancer. Biomed Pharmacother. 2017 Nov;95:1636–43. Li W, Jia G, Qu Y, Du Q, Liu B, Liu B. Long Non-Coding RNA (LncRNA) HOXA11-AS Promotes Breast Cancer Invasion and Metastasis by Regulating Epithelial-Mesenchymal Transition. Med Sci Monit Int Med J Exp Clin Res. 2017 Jul;23:3393–403. Zhang K, Luo Z, Zhang Y, Wang Y, Cui M, Liu L, et al. Detection and analysis of circulating large intergenic non-coding RNA regulator of reprogramming in plasma for breast cancer. Thorac cancer. 2018 Jan;9(1):66–74. Jiang Z, Slater CM, Zhou Y, Devarajan K, Ruth KJ, Li Y, et al. LincIN, a novel NF90-binding long non-coding RNA, is overexpressed in advanced breast tumors and involved in metastasis. Breast Cancer Res. 2017 May;19(1):62. Li H, Zhu L, Xu L, Qin K, Liu C, Yu Y, et al. Long noncoding RNA linc00617 exhibits oncogenic activity in breast cancer. Mol Carcinog. 2017 Jan;56(1):3–17. Liang Y, Li Y, Song X, Zhang N, Sang Y, Zhang H, et al. Long noncoding RNA LINP1 acts as an oncogene and promotes chemoresistance in breast cancer. Cancer Biol Ther. 2018 Feb;19(2):120–31. Li C, Wang S, Xing Z, Lin A, Liang K, Song J, et al. A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis. Nat Cell Biol. 2017 Feb;19(2):106–19. Li Z, Hou P, Fan D, Dong M, Ma M, Li H, et al. The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer. Cell Death Differ [Internet]. 2017;24(1):59–71. Available from: https://doi.org/10.1038/cdd.2016.95 Sas-Chen A, Aure MR, Leibovich L, Carvalho S, Enuka Y, Körner C, et al. LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer. EMBO Mol Med. 2016 Sep;8(9):1052–64. Zhang JJ, Guo SH, Jia BQ. Down-regulation of long non-coding RNA MEG3 serves as an unfavorable risk factor for survival of patients with breast cancer. Eur Rev Med Pharmacol Sci. 2016 Dec;20(24):5143–7. Liu B, Sun L, Liu Q, Gong C, Yao Y, Lv X, et al. A cytoplasmic NF-κB interacting long noncoding RNA blocks IκB phosphorylation and suppresses breast cancer metastasis. Cancer Cell. 2015 Mar;27(3):370–81. Vennin C, Spruyt N, Dahmani F, Julien S, Bertucci F, Finetti P, et al. H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. Oncotarget. 2015 Oct;6(30):29209–23. Xu SP, Zhang JF, Sui SY, Bai NX, Gao S, Zhang GW, et al. Downregulation of the long noncoding RNA EGOT correlates with malignant status and poor prognosis in breast cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2015 Dec;36(12):9807–12. Hu P, Chu J, Wu Y, Sun L, Lv X, Zhu Y, et al. NBAT1 suppresses breast cancer metastasis by regulating DKK1 via PRC2. Oncotarget. 2015 Oct;6(32):32410–25. Xing Z, Lin A, Li C, Liang K, Wang S, Liu Y, et al. LncRNA directs cooperative epigenetic regulation downstream of chemokine signals. Cell [Internet]. 2014;159(5):1110–25. Available from: http://dx.doi.org/10.1016/j.cell.2014.10.013 Redis RS, Sieuwerts AM, Look MP, Tudoran O, Ivan C, Spizzo R, et al. CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget. 2013 Oct;4(10):1748–62. Chisholm KM, Wan Y, Li R, Montgomery KD, Chang HY, West RB. Detection of long non-coding RNA in archival tissue: correlation with polycomb protein expression in primary and metastatic breast carcinoma. PLoS One. 2012;7(10):e47998–e47998. Liu CX, Chen LL. Circular RNAs: Characterization, cellular roles, and applications. Cell. 2022;185(12):2016–34. Kristensen LS, Jakobsen T, Hager H, Kjems J. The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol. 2022;19(3):188–206. Ghafouri-Fard S, Hussen BM, Taheri M, Ayatollahi SA. Emerging role of circular RNAs in breast cancer. Pathol Pract. 2021;223:153496. Zepeda-Enríquez P, Silva-Cázares MB, López-Camarillo C. Novel Insights into Circular RNAs in Metastasis in Breast Cancer: An Update. Non-coding RNA. 2023 Sep;9(5). Lu M, Wu Y, Zeng B, Sun J, Li Y, Luo J, et al. CircEHMT1 inhibits metastatic potential of breast cancer cells by modulating miR-1233-3p/KLF4/MMP2 axis. Biochem Biophys Res Commun. 2020 May;526(2):306–13. Fan Y, Wang J, Jin W, Sun Y, Xu Y, Wang Y, et al. CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer. Mol Cancer. 2021 Feb;20(1):25. Lin X, Chen W, Wei F, Xie X. TV-circRGPD6 Nanoparticle Suppresses Breast Cancer Stem Cell-Mediated Metastasis via the miR-26b/YAF2 Axis. Mol Ther. 2021 Jan;29(1):244–62. Cai Y, Zhao X, Chen D, Zhang F, Chen Q, Shao CC, et al. circ-NOL10 regulated by MTDH/CASC3 inhibits breast cancer progression and metastasis via multiple miRNAs and PDCD4. Mol Ther - Nucleic Acids [Internet]. 2021;26:773–86. Available from: https://www.sciencedirect.com/science/article/pii/S2162253121002420 Wang F, Wang X, Li J, Lv P, Han M, Li L, et al. CircNOL10 suppresses breast cancer progression by sponging miR-767-5p to regulate SOCS2/JAK/STAT signaling. J Biomed Sci. 2021 Jan;28(1):4. Liang Y, Song X, Li Y, Ma T, Su P, Guo R, et al. Targeting the circBMPR2/miR-553/USP4 Axis as a Potent Therapeutic Approach for Breast Cancer. Mol Ther - Nucleic Acids [Internet]. 2019;17:347–61. Available from: https://www.sciencedirect.com/science/article/pii/S2162253119301350 Wu N, Yuan Z, Du KY, Fang L, Lyu J, Zhang C, et al. Translation of yes-associated protein (YAP) was antagonized by its circular RNA via suppressing the assembly of the translation initiation machinery. Cell Death Differ. 2019 Dec;26(12):2758–73. Zhang L, Sun D, Zhang J, Tian Y. Circ-UBR1 facilitates proliferation, metastasis, and inhibits apoptosis in breast cancer by regulating the miR-1299/CCND1 axis. Life Sci. 2021 Feb;266:118829. Zou Y, Zheng S, Xiao W, Xie X, Yang A, Gao G, et al. circRAD18 sponges miR-208a/3164 to promote triple-negative breast cancer progression through regulating IGF1 and FGF2 expression. Carcinogenesis. 2019 Dec;40(12):1469–79. Wang S, Li Q, Wang Y, Li X, Wang R, Kang Y, et al. Upregulation of circ-UBAP2 predicts poor prognosis and promotes triple-negative breast cancer progression through the miR-661/MTA1 pathway. Biochem Biophys Res Commun. 2018 Nov;505(4):996–1002. Xing L, Yang R, Wang X, Zheng X, Yang X, Zhang L, et al. The circRNA circIFI30 promotes progression of triple-negative breast cancer and correlates with prognosis. Aging (Albany NY). 2020 Jun;12(11):10983–1003. Chen T, Wang X, Li C, Zhang H, Liu Y, Han D, et al. CircHIF1A regulated by FUS accelerates triple-negative breast cancer progression by modulating NFIB expression and translocation. Oncogene. 2021 Apr;40(15):2756–71. Wang B, Chen H, Deng Y, Chen H, Xing L, Guo Y, et al. CircDNAJC11 interacts with TAF15 to promote breast cancer progression via enhancing MAPK6 expression and activating the MAPK signaling pathway. J Transl Med [Internet]. 2023;21(1):186. Available from: https://doi.org/10.1186/s12967-023-04020-x Zeng K, He B, Yang BB, Xu T, Chen X, Xu M, et al. The pro-metastasis effect of circANKS1B in breast cancer. Mol Cancer. 2018 Nov;17(1):160. Li Y, Wang Z, Su P, Liang Y, Li Z, Zhang H, et al. circ-EIF6 encodes EIF6-224aa to promote TNBC progression via stabilizing MYH9 and activating the Wnt/beta-catenin pathway. Mol Ther. 2022 Jan;30(1):415–30. Chen ZG, Zhao HJ, Lin L, Liu JB, Bai JZ, Wang GS. Circular RNA CirCHIPK3 promotes cell proliferation and invasion of breast cancer by sponging miR-193a/HMGB1/PI3K/AKT axis. Thorac cancer. 2020 Sep;11(9):2660–71. Cai F, Fu W, Tang L, Tang J, Sun J, Fu G, et al. Hsa_circ_0000515 is a novel circular RNA implicated in the development of breast cancer through its regulation of the microRNA-296-5p/CXCL10 axis. FEBS J. 2021 Feb;288(3):861–83. Gao D, Qi X, Zhang X, Fang K, Guo Z, Li L. hsa_circRNA_0006528 as a competing endogenous RNA promotes human breast cancer progression by sponging miR-7-5p and activating the MAPK/ERK signaling pathway. Mol Carcinog. 2019 Apr;58(4):554–64. Ju C, Zhou M, Du D, Wang C, Yao J, Li H, et al. EIF4A3-mediated circ_0042881 activates the RAS pathway via miR-217/SOS1 axis to facilitate breast cancer progression. Cell Death Dis [Internet]. 2023;14(8):559. Available from: https://doi.org/10.1038/s41419-023-06085-4 Zeng Y, Du W, Huang Z, Wu S, Ou X, Zhang J, et al. Hsa_circ_0060467 promotes breast cancer liver metastasis by complexing with eIF4A3 and sponging miR-1205. Cell Death Discov [Internet]. 2023;9(1):153. Available from: https://doi.org/10.1038/s41420-023-01448-4 Jin Y, Yang L, Li X, Liu F. Circular RNA KIF4A promotes cell migration, invasion and inhibits apoptosis through miR-152/ZEB1 axis in breast cancer. Diagn Pathol. 2020 May;15(1):55. Zhang W, Liu H, Jiang J, Yang Y, Wang W, Jia Z. CircRNA circFOXK2 facilitates oncogenesis in breast cancer via IGF2BP3/miR-370 axis. Aging (Albany NY). 2021 Jul;13(14):18978–92. Qi C, Qin X, Zhou Z, Wang Y, Yang Q, Liao T. Circ_0072995 promotes cell carcinogenesis via up-regulating miR-149-5p-mediated SHMT2 in breast cancer. Cancer Manag Res. 2020;11169–81. Zhou H, Tang G, Zhao M, Xie L, Xie Y, Zhang Z, et al. circFBXL5 promotes breast cancer progression by sponging miR-660. J Cell Mol Med. 2020 Jan;24(1):356–61. Song X, Liang Y, Sang Y, Li Y, Zhang H, Chen B, et al. circHMCU Promotes Proliferation and Metastasis of Breast Cancer by Sponging the let-7 Family. Mol Ther Nucleic Acids. 2020 Jun;20:518–33. Wu J, Jiang Z, Chen C, Hu Q, Fu Z, Chen J, et al. CircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis. Cancer Lett. 2018 Aug;430:179–92. Zhao B, Song X, Guan H. CircACAP2 promotes breast cancer proliferation and metastasis by targeting miR-29a/b-3p-COL5A1 axis. Life Sci. 2020 Mar;244:117179. Min J, Pan X, Lv G. The circRNA circ_0000291 acts as a sponge of microRNA 326 to regulate E26 transformation-specific sequence-1 expression and promote breast cancer progression. Pathol Int. 2020 Sep; Wu S, Lu J, Zhu H, Wu F, Mo Y, Xie L, et al. A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer. Cancer Lett [Internet]. 2024;581:216508. Available from: https://www.sciencedirect.com/science/article/pii/S0304383523004597 Zheng W, Wang X, Yu Y, Ji C, Fang L. CircRNF10-DHX15 interaction suppressed breast cancer progression by antagonizing DHX15-NF-κB p65 positive feedback loop. Cell Mol Biol Lett [Internet]. 2023;28(1):34. Available from: https://doi.org/10.1186/s11658-023-00448-7 Zhong W, Bao L, Yuan Y, Meng Y. CircRASSF2 acts as a prognostic factor and promotes breast cancer progression by modulating miR-1205/HOXA1 axis. Bioengineered. 2021 Dec;12(1):3014–28. Zhong JX, Kong YY, Luo RG, Xia GJ, He WX, Chen XZ, et al. Circular RNA circ-ERBB2 promotes HER2-positive breast cancer progression and metastasis via sponging miR-136-5p and miR-198. J Transl Med. 2021 Nov;19(1):455. Hu J, Ji C, Hua K, Wang X, Deng X, Li J, et al. Hsa_circ_0091074 regulates TAZ expression via microRNA‑1297 in triple negative breast cancer cells. Int J Oncol. 2020 May;56(5):1314–26. Zhou SY, Chen W, Yang SJ, Li J, Zhang JY, Zhang H da, et al. Circular RNA circVAPA regulates breast cancer cell migration and invasion via sponging miR-130a-5p. Epigenomics. 2020 Feb;12(4):303–17. Yuan C, Luo X, Zhan X, Zeng H, Duan S. EMT related circular RNA expression profiles identify circSCYL2 as a novel molecule in breast tumor metastasis. Int J Mol Med. 2020 Jun;45(6):1697–710. Sang Y, Chen B, Song X, Li Y, Liang Y, Han D, et al. circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer. Mol Ther. 2019 Sep;27(9):1638–52. Ren S, Liu J, Feng Y, Li Z, He L, Li L, et al. Knockdown of circDENND4C inhibits glycolysis, migration and invasion by up-regulating miR-200b/c in breast cancer under hypoxia. J Exp Clin Cancer Res. 2019 Sep;38(1):388. Xiao W, Zheng S, Zou Y, Yang A, Xie X, Tang H, et al. CircAHNAK1 inhibits proliferation and metastasis of triple-negative breast cancer by modulating miR-421 and RASA1. Aging (Albany NY). 2019 Dec;11(24):12043–56. Hou JC, Xu Z, Zhong SL, Zhang H da, Jiang LH, Chen X, et al. Circular RNA circASS1 is downregulated in breast cancer cells MDA-MB-231 and suppressed invasion and migration. Epigenomics. 2019 Feb;11(2):199–213. Liang Y, Song X, Li Y, Su P, Han D, Ma T, et al. circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer. Oncogene. 2019 Oct;38(42):6850–66. Lin X, Hong S, Chen J, Chen W, Wu Z. The potential targets for metastases: a study on altered circular RNA profile in breast cancer liver metastases. Epigenomics. 2019 Aug;11(11):1237–50. Zhang HD, Jiang LH, Hou JC, Zhou SY, Zhong SL, Zhu LP, et al. Circular RNA hsa_circ_0072995 promotes breast cancer cell migration and invasion through sponge for miR-30c-2-3p. Epigenomics. 2018 Sep;10(9):1229–42. Chen N, Zhao G, Yan X, Lv Z, Yin H, Zhang S, et al. A novel FLI1 exonic circular RNA promotes metastasis in breast cancer by coordinately regulating TET1 and DNMT1. Genome Biol. 2018 Dec;19(1):218. Yin WB, Yan MG, Fang X, Guo JJ, Xiong W, Zhang RP. Circulating circular RNA hsa_circ_0001785 acts as a diagnostic biomarker for breast cancer detection. Clin Chim Acta. 2018 Dec;487:363–8. Ala U. Competing endogenous RNAs and cancer: How coding and non-coding molecules cross-talk can impinge on disease. Int J Biochem Cell Biol. 2021 Jan;130:105874. Marques TM, Gama-Carvalho M. Network Approaches to Study Endogenous RNA Competition and Its Impact on Tissue-Specific microRNA Functions. Biomolecules. 2022 Feb;12(2). Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet [Internet]. 2016;17(5):272–83. Available from: https://doi.org/10.1038/nrg.2016.20 Qattan A, Al-Tweigeri T, Suleman K, Alkhayal W, Tulbah A. Advanced Insights into Competitive Endogenous RNAs (ceRNAs) Regulated Pathogenic Mechanisms in Metastatic Triple-Negative Breast Cancer (mTNBC). Vol. 16, Cancers. 2024. Sideris N, Dama P, Bayraktar S, Stiff T, Castellano L. LncRNAs in breast cancer: a link to future approaches. Cancer Gene Ther [Internet]. 2022;29(12):1866–77. Available from: https://doi.org/10.1038/s41417-022-00487-w Liu L, Zhang Y, Lu J. The roles of long noncoding RNAs in breast cancer metastasis. Cell Death Dis [Internet]. 2020;11(9):749. Available from: https://doi.org/10.1038/s41419-020-02954-4 Jadaliha M, Zong X, Malakar P, Ray T, Singh DK, Freier SM, et al. Functional and prognostic significance of long non-coding RNA MALAT1 as a metastasis driver in ER negative lymph node negative breast cancer. Oncotarget. 2016 Jun;7(26):40418–36. Hussein MA, Valinezhad K, Adel E, Munirathinam G. MALAT-1 is a key regulator of epithelial–mesenchymal transition in cancer: a potential therapeutic target for metastasis. Cancers (Basel). 2024;16(1):234. Dong Y, Liang G, Yuan B, Yang C, Gao R, Zhou X. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2015 Mar;36(3):1477–86. Heery R, Finn SP, Cuffe S, Gray SG. Long non-coding RNAs: key regulators of epithelial-mesenchymal transition, tumour drug resistance and cancer stem cells. Cancers (Basel). 2017;9(4):38. Cavallari I, Ciccarese F, Sharova E, Urso L, Raimondi V, Silic-Benussi M, et al. The miR-200 family of microRNAs: fine tuners of epithelial-mesenchymal transition and circulating cancer biomarkers. Cancers (Basel). 2021;13(23):5874. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science (80- ). 2011;331(6024):1559–64. Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer [Internet]. 2021;124(1):13–26. Available from: https://doi.org/10.1038/s41416-020-01161-4 Gerstberger S, Jiang Q, Ganesh K. Metastasis. Cell. 2023;186(8):1564–79. Drak Alsibai K, Meseure D. Tumor microenvironment and noncoding RNAs as co‐drivers of epithelial–mesenchymal transition and cancer metastasis. Dev Dyn. 2018;247(3):405–31. Chen T, You Y, Jiang H, Wang ZZ. Epithelial–mesenchymal transition (EMT): A biological process in the development, stem cell differentiation, and tumorigenesis. J Cell Physiol. 2017;232(12):3261–72. Lei ZN, Teng QX, Koya J, Liu Y, Chen Z, Zeng L, et al. The correlation between cancer stem cells and epithelial-mesenchymal transition: molecular mechanisms and significance in cancer theragnosis. Front Immunol. 2024;15:1417201. Dart A. EMT in chemoresistance. Nat Rev Cancer. 2023;23(6):349. van Staalduinen J, Baker D, Ten Dijke P, van Dam H. Epithelial–mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer? Oncogene. 2018;37(48):6195–211. Ahrens TD, Bang-Christensen SR, Jørgensen AM, Løppke C, Spliid CB, Sand NT, et al. The role of proteoglycans in cancer metastasis and circulating tumor cell analysis. Front cell Dev Biol. 2020;8:749. Blackhall FH, Merry CLR, Davies EJ, Jayson GC. Heparan sulfate proteoglycans and cancer. Br J Cancer [Internet]. 2001;85(8):1094–8. Available from: https://doi.org/10.1054/bjoc.2001.2054 Wei J, Hu M, Huang K, Lin S, Du H. Roles of Proteoglycans and Glycosaminoglycans in Cancer Development and Progression. Vol. 21, International Journal of Molecular Sciences. 2020. Vitale D, Kumar Katakam S, Greve B, Jang B, Oh E, Alaniz L, et al. Proteoglycans and glycosaminoglycans as regulators of cancer stem cell function and therapeutic resistance. FEBS J. 2019;286(15):2870–82. Gao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R, et al. Myeloid Progenitor Cells in the Premetastatic Lung Promote Metastases by Inducing Mesenchymal to Epithelial Transition. Cancer Res. 2012 Mar;72(6):1384–94. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009;457(7225):102–6. Du WW, Yang BB, Shatseva TA, Yang BL, Deng Z, Shan SW, et al. Versican G3 Promotes Mouse Mammary Tumor Cell Growth, Migration, and Metastasis by Influencing EGF Receptor Signaling. PLoS One. 2010 Nov;5(11):e13828. Schaefer L, Beck KF, Raslik I, Walpen S, Mihalik D, Micegova M, et al. Biglycan, a Nitric Oxide-regulated Gene, Affects Adhesion, Growth, and Survival of Mesangial Cells *. J Biol Chem. 2003 Jul;278(28):26227–37. Mundhenke C, Meyer K, Drew S, Friedl A. Heparan Sulfate Proteoglycans as Regulators of Fibroblast Growth Factor-2 Receptor Binding in Breast Carcinomas. Am J Pathol. 2002;160(1):185–94. Jain K, Basu A. Protein Kinase C-ε Promotes EMT in Breast Cancer. Breast Cancer Basic Clin Res. 2014 Jan;8:BCBCR.S13640. Cacace AM, Ueffing M, Han EK, Marmè D, Weinstein IB. Overexpression of PKCε in R6 fibroblasts causes increased production of active TGFβ. J Cell Physiol. 1998;175(3):314–22. Aziz MH, Hafeez BB, Sand JM, Pierce DB, Aziz SW, Dreckschmidt NE, et al. Protein kinase Cɛ mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2). Oncogene. 2010;29(21):3100–9. Hutchison N, Hendry BM, Sharpe CC. Rho isoforms have distinct and specific functions in the process of epithelial to mesenchymal transition in renal proximal tubular cells. Cell Signal. 2009;21(10):1522–31. Cho KH, Jeong KJ, Shin SC, Kang J, Park CG, Lee HY. STAT3 mediates TGF-β1-induced TWIST1 expression and prostate cancer invasion. Cancer Lett. 2013;336(1):167–73. Bourguignon LYW, Spevak CC, Wong G, Xia W, Gilad E. Hyaluronan-CD44 interaction with protein kinase Cϵ promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance . J Biol Chem. 2009;284(39):26533–46. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15. Brabletz T. EMT and MET in metastasis: where are the cancer stem cells? Cancer Cell. 2012;22(6):699–701. Khan AQ, Hasan A, Mir SS, Rashid K, Uddin S, Stienhoff M. Exploiting Transcription Factors to Target EMT and Cancer Stem Cells for Tumor Modulation and Therapy. In: Seminars in Cancer Biology. Elsevier; 2024. Hasan A, Khan NA, Uddin S, Khan AQ, Steinhoff M. Deregulated transcription factors in the emerging cancer hallmarks. In: Seminars in Cancer Biology. Elsevier; 2023. He L, Wick N, Germans SK, Peng Y. The role of breast cancer stem cells in chemoresistance and metastasis in triple-negative breast cancer. Cancers (Basel). 2021;13(24):6209. Qi M, Xia Y, Wu Y, Zhang Z, Wang X, Lu L, et al. Lin28B-high breast cancer cells promote immune suppression in the lung pre-metastatic niche via exosomes and support cancer progression. Nat Commun. 2022 Feb;13(1):897. Lin Z, Radaeva M, Cherkasov A, Dong X. Lin28 regulates cancer cell stemness for tumour progression. Cancers (Basel). 2022;14(19):4640. Li D, Liu Y, Li H, Peng JJ, Tan Y, Zou Q, et al. MicroRNA-1 promotes apoptosis of hepatocarcinoma cells by targeting apoptosis inhibitor-5 (API-5). Febs Lett. 2015;589(1):68–76. Furukawa S, Kawasaki Y, Miyamoto M, Hiyoshi M, Kitayama J, Akiyama T. The miR-1-NOTCH3-Asef pathway is important for colorectal tumor cell migration. PLoS One. 2013;8(11):e80609. Sun D, Zhong J, Wei W, Chen X, Liu J, Hu Z. Identification of microRNA expression in sentinel lymph nodes from patients with breast cancer via RNA sequencing for diagnostic accuracy. J Gene Med. 2019 Apr;21(4):e3075–e3075. Additional Declarations The authors declare no competing interests. Supplementary Files Supplementarytable1.edited.xlsx Supplementarytable2.edited.xlsx GraphicalAbstract.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8119740","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Systematic Review","associatedPublications":[],"authors":[{"id":545408671,"identity":"41e99506-c156-41ec-9689-fbb4ae766fa5","order_by":0,"name":"Anoosha Niazmand","email":"","orcid":"https://orcid.org/0009-0002-8532-7530","institution":"Isfahan University of Medical Science","correspondingAuthor":false,"prefix":"","firstName":"Anoosha","middleName":"","lastName":"Niazmand","suffix":""},{"id":545412138,"identity":"8b244e7a-046c-4bd4-b18c-2665d0b5de06","order_by":1,"name":"Mansoor Salehi","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABAElEQVRIiWNgGAWjYCgAORBx4AEJOgyMwVoSSNGS2ACi8GmRd+89+OhGBUM+P/8Bxg8fd/xJnx92+CHQFjs53QbsWgzPnEs2zjnDYDlzRgKz5MwzBrkbb6cZALUkG5sdwKFlRo6ZdG4bg4HBDQY2Zt42oJbZCSAtBxK34dIy/w1Qyz8GA/vzB9iY/7YZpBvOTv+AV4u8BA9QSwPQFoYENmbGNoMEeekc/LYY8OQYG+cckzCQuJHYLNnbZmy4QTqn4ECCAW6/yLefMXycU2NjwN9/+OCHn21y8vKz0zd/+FBhJ4dLiwFEXAKIGRuQRAywKwfb0kBYZBSMglEwCkY6AAB9cFtO4oebsAAAAABJRU5ErkJggg==","orcid":"","institution":"Cellular, Molecular and Genetics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran","correspondingAuthor":true,"prefix":"","firstName":"Mansoor","middleName":"","lastName":"Salehi","suffix":""},{"id":545412216,"identity":"6112dd2e-f310-4ea6-8392-6ba9faf4a5be","order_by":2,"name":"Hamid Aria","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Hamid","middleName":"","lastName":"Aria","suffix":""},{"id":545412217,"identity":"0095545b-e4e4-4700-b593-866d2749975b","order_by":3,"name":"Neda Hosseini","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Neda","middleName":"","lastName":"Hosseini","suffix":""},{"id":545412218,"identity":"55070bd2-3857-41f4-b274-1cf5159069b0","order_by":4,"name":"Seyed Reza Mousavi","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Seyed","middleName":"Reza","lastName":"Mousavi","suffix":""}],"badges":[],"createdAt":"2025-11-15 06:09:54","currentVersionCode":1,"declarations":{"humanSubjects":false,"vertebrateSubjects":false,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":false,"humanSubjectConsent":false,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":false},"doi":"10.21203/rs.3.rs-8119740/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8119740/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":96251800,"identity":"c4e212db-0b15-4ab5-a705-2ed060d04fba","added_by":"auto","created_at":"2025-11-19 07:40:03","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":3532638,"visible":true,"origin":"","legend":"","description":"","filename":"Manuscript.systematic.bioinformatics.docx","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/45288b99ce3a3ad383d55c40.docx"},{"id":96250615,"identity":"d16cc1c1-d367-48d1-a2f0-f80463f3529e","added_by":"auto","created_at":"2025-11-19 07:38:47","extension":"json","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":342,"visible":true,"origin":"","legend":"","description":"","filename":"rs8119740.json","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/78514c73a635ac89bc88f1ab.json"},{"id":96250715,"identity":"e8231274-84d0-4280-9add-d8ffc878181b","added_by":"auto","created_at":"2025-11-19 07:38:54","extension":"xml","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":854795,"visible":true,"origin":"","legend":"","description":"","filename":"rs81197400enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/8ac3ca93c5775f56c62a966e.xml"},{"id":96154766,"identity":"8b368b63-715a-4fbd-b2ec-797f1497a3ff","added_by":"auto","created_at":"2025-11-18 08:09:48","extension":"png","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":215076,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/e071f15bffdb74228f528e35.png"},{"id":96154770,"identity":"f8fabaaf-12b4-434f-8202-02c2f4ca40c2","added_by":"auto","created_at":"2025-11-18 08:09:49","extension":"jpeg","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":156547,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage10.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/ae1cf50f01baeb941a6d7cbd.jpeg"},{"id":96251831,"identity":"37493b11-abb7-482e-ac70-c9e53d390379","added_by":"auto","created_at":"2025-11-19 07:40:06","extension":"jpeg","order_by":5,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":205736,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage11.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/5404ec30091fc913003a2101.jpeg"},{"id":96154773,"identity":"dc0741b2-c469-4bb4-aeff-6fc055a4e63c","added_by":"auto","created_at":"2025-11-18 08:09:50","extension":"jpeg","order_by":6,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":624329,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage2.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/c304559c839fb9c8ef59092c.jpeg"},{"id":96154775,"identity":"a84ee83e-13f7-4745-8796-67ffb6d32b2d","added_by":"auto","created_at":"2025-11-18 08:09:50","extension":"png","order_by":7,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":254888,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/3163b05fb88d4c32565fe785.png"},{"id":96154795,"identity":"eb9e8fdd-aa03-459b-b6c3-02ae101b248b","added_by":"auto","created_at":"2025-11-18 08:09:52","extension":"jpeg","order_by":8,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":712343,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage4.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/7c4a78867f3c9dfb3fa495a0.jpeg"},{"id":96154771,"identity":"5c428da6-ebe5-466e-955b-4644919324c5","added_by":"auto","created_at":"2025-11-18 08:09:50","extension":"jpeg","order_by":9,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1196044,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage5.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/d015a17d7b0d5083e6b87a37.jpeg"},{"id":96154783,"identity":"133654d0-fac6-4619-9736-34fecfc5a674","added_by":"auto","created_at":"2025-11-18 08:09:50","extension":"jpeg","order_by":10,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":341322,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage6.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/81ec2a7d93b516812ef4b08e.jpeg"},{"id":96154804,"identity":"2644d165-7058-437a-8d5b-85cacfa3130a","added_by":"auto","created_at":"2025-11-18 08:09:54","extension":"png","order_by":11,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":133432,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage7.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/c79d6c22101ee9a1ddac33a9.png"},{"id":96154793,"identity":"4856c4c3-9d22-4afb-8e19-642a143d4a47","added_by":"auto","created_at":"2025-11-18 08:09:51","extension":"jpeg","order_by":12,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":193843,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage8.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/2b3c06f660427ad3fef31800.jpeg"},{"id":96154782,"identity":"180a6cfd-7b52-44e5-b8b3-0b20712e605c","added_by":"auto","created_at":"2025-11-18 08:09:50","extension":"jpeg","order_by":13,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":548480,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage9.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/ac44759505c4d8520b90ba8a.jpeg"},{"id":96154799,"identity":"629775ce-4288-42f9-9976-fb33f5ca4ada","added_by":"auto","created_at":"2025-11-18 08:09:52","extension":"png","order_by":14,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":41106,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/87573a573c50587eb6112ec5.png"},{"id":96252042,"identity":"3af45b80-6a19-4571-b69c-98085ab7c898","added_by":"auto","created_at":"2025-11-19 07:40:22","extension":"png","order_by":15,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":45875,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage10.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/e4974803904edf3a4cd503d8.png"},{"id":96154772,"identity":"4886a9df-5c98-4ca6-b495-5652a3215e73","added_by":"auto","created_at":"2025-11-18 08:09:50","extension":"png","order_by":16,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":69227,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage11.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/433061790f82e3b074e4e4d6.png"},{"id":96251940,"identity":"ff5aa24d-0e99-4dd9-8f66-699f457a1a52","added_by":"auto","created_at":"2025-11-19 07:40:12","extension":"png","order_by":17,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":116963,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/ff852e658de91699fae395cf.png"},{"id":96154790,"identity":"6e1886a8-547d-4952-b823-a8a41ba817e9","added_by":"auto","created_at":"2025-11-18 08:09:51","extension":"png","order_by":18,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":64760,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/b5e32454dc407112a1c4666c.png"},{"id":96154792,"identity":"bab1b1f3-1f0b-4790-8850-c36bbc3767ab","added_by":"auto","created_at":"2025-11-18 08:09:51","extension":"png","order_by":19,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":185381,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage4.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/aab43f1f1d7e02fd52f9c55b.png"},{"id":96154781,"identity":"bbedc777-d997-41da-9186-271c6a030d93","added_by":"auto","created_at":"2025-11-18 08:09:50","extension":"png","order_by":20,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":258123,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage5.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/42a892afbcd71dcb8485dbff.png"},{"id":96154801,"identity":"baab02cb-2ece-4b9e-b0fb-06588328df57","added_by":"auto","created_at":"2025-11-18 08:09:53","extension":"png","order_by":21,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":60553,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage6.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/1f910c67c10bb7419cbb1b4f.png"},{"id":96251826,"identity":"754ffc44-cb34-4775-9462-d93cdb8108b9","added_by":"auto","created_at":"2025-11-19 07:40:06","extension":"png","order_by":22,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":33155,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage7.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/4050dd30baba03a34fb523ee.png"},{"id":96154774,"identity":"ed8df5a0-dd8d-4d6e-92db-18fe6df5ef22","added_by":"auto","created_at":"2025-11-18 08:09:50","extension":"png","order_by":23,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":151897,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage8.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/4e8b5ab0bb3dba444dd61689.png"},{"id":96154777,"identity":"a6711ce5-4544-4f7d-8728-ce145971175e","added_by":"auto","created_at":"2025-11-18 08:09:50","extension":"png","order_by":24,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":87494,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage9.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/78892b7f862fc8a771e0aad8.png"},{"id":96154789,"identity":"1d5069b1-8b11-4693-9d5d-98aed0d53fe2","added_by":"auto","created_at":"2025-11-18 08:09:51","extension":"xml","order_by":25,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":850822,"visible":true,"origin":"","legend":"","description":"","filename":"rs81197400structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/915ab5f4763527b60e011751.xml"},{"id":96154805,"identity":"895fe92c-a2e6-4086-a678-648276fcd235","added_by":"auto","created_at":"2025-11-18 08:09:54","extension":"html","order_by":26,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":881355,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/a381420646ea419e86ca7ac6.html"},{"id":96154791,"identity":"61d29fd6-4ab1-4d27-883c-3fc8fd4834f6","added_by":"auto","created_at":"2025-11-18 08:09:51","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":878083,"visible":true,"origin":"","legend":"\u003cp\u003eStudy workflow. First, a comprehensive search and assessment of previous research and ncRNAs involved in BCM were retrieved. Next, bioinformatics methods were used to anticipate unknown ncRNA targets. \u0026nbsp;After that, the ceRNA-network was constructed, and network analysis was done\u003cstrong\u003e.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"floatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/91a70cd277dcdcac2f3717f3.png"},{"id":96250609,"identity":"cd11192a-ad18-4f66-862e-aeebd0961e2d","added_by":"auto","created_at":"2025-11-19 07:38:45","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":254888,"visible":true,"origin":"","legend":"\u003cp\u003eThe remodeled flow chart of literature evaluation and selection criteria from PRISMA. In the end screening procedure, 288 studies met eligibility and inclusion criteria and were included for further investigations.\u003c/p\u003e","description":"","filename":"floatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/2027ec9c89b0174ac84d035c.png"},{"id":96154768,"identity":"733d0731-4a68-4eb9-bbe5-3c7e5d3e9309","added_by":"auto","created_at":"2025-11-18 08:09:49","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":748054,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eA:\u003c/strong\u003e Venn diagram of the top 50 significant hubs commonly dysregulated among three topological features of the ceRNA network (betweenness, closeness, and degree). \u003cstrong\u003eB:\u003c/strong\u003eModule 1 with highest score of 33 from PPI-network.\u003c/p\u003e","description":"","filename":"floatimage4.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/1ef3a8b6989d1e2e20148150.png"},{"id":96154803,"identity":"1a8a4245-d8ae-4c2d-9fcb-e66b92d40b86","added_by":"auto","created_at":"2025-11-18 08:09:53","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":1218156,"visible":true,"origin":"","legend":"\u003cp\u003eThe Hubs from the ceRNA network are associated with poor prognosis and overall survival (OS) for BC patients and their interactions. Nodes in pink represent mRNAs, while red nodes depict miRNAs and green nodes are related to lncRNAs.\u003c/p\u003e","description":"","filename":"floatimage5.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/2d01645c04cc63ed9e6f7bd8.png"},{"id":96252011,"identity":"7bc1e39c-1085-4d8f-8cf1-9b3f1931e520","added_by":"auto","created_at":"2025-11-19 07:40:19","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":545484,"visible":true,"origin":"","legend":"\u003cp\u003ePathway enrichment of module 1. A: pathway enrichment and annotation clustering by KEGG pathway analysis. Gene Ontology (GO) enrichment and functional enrichment plot based on the B: biological process (BP), C: cellular components (CC), and D: molecular function (MF). The Y-axis label indicates the pathway, and the X-axis indicates the gene term ratio (gene term ratio = all involved Hubs of module 1 in each pathway). The bubble size indicates the number of BCM-related hubs enriched in the pathway, and the color indicates the p-adjusted value of the enriched pathway.\u003c/p\u003e","description":"","filename":"floatimage6.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/21f8d54c674fdd02b6a2f95f.png"},{"id":96154798,"identity":"1dc7b84c-1872-44a8-ad52-f50f91d99e83","added_by":"auto","created_at":"2025-11-18 08:09:52","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":133432,"visible":true,"origin":"","legend":"\u003cp\u003eKaplan-Meier plot graphics of the miRNAs expression in BC patients that presented significant association with poor prognosis and overall survival of patients.\u003c/p\u003e","description":"","filename":"floatimage7.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/3b1e5decf9e8faeeafb32ff8.png"},{"id":96154769,"identity":"79b9be7f-b6ee-4b52-86ee-637c47c4e1bd","added_by":"auto","created_at":"2025-11-18 08:09:49","extension":"png","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":441199,"visible":true,"origin":"","legend":"\u003cp\u003eThe multi-step process of metastasis. The process initiates with primary BC cells' angiogenesis, transformation of normal epithelial cells to mesenchymal shape (EMT), and invasion. Eventually, BC cells spread through circulation and reach other body organs, such as the liver, lungs, and brain, where they proliferate.\u003c/p\u003e","description":"","filename":"floatimage8.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/146cb7ece7ca8c93cd119890.png"},{"id":96154796,"identity":"b0714603-5684-4d8e-8d65-fd20ec0f19ba","added_by":"auto","created_at":"2025-11-18 08:09:52","extension":"png","order_by":8,"title":"Figure 8","display":"","copyAsset":false,"role":"figure","size":476478,"visible":true,"origin":"","legend":"\u003cp\u003eLncRNAs interactions in Breast Cancer Metastasis (BCM) via regulation of TGF-β, Wnt/β-catenin, and other signaling pathways.\u003c/p\u003e","description":"","filename":"floatimage9.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/38e24e1506fb5a51e9a9c7ec.png"},{"id":96154784,"identity":"7505a2c2-3af1-4e3d-b2ef-c77dfc7e3c2f","added_by":"auto","created_at":"2025-11-18 08:09:51","extension":"png","order_by":9,"title":"Figure 9","display":"","copyAsset":false,"role":"figure","size":297680,"visible":true,"origin":"","legend":"\u003cp\u003eMechanisms of circRNA-mediated regulation in breast cancer metastasis (BCM) via miRNA sponging, transcriptional control, and mRNA processing.\u003c/p\u003e","description":"","filename":"floatimage10.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/77fc3d770bbab0f283d26f31.png"},{"id":96154797,"identity":"1031fb1c-38f7-4339-a39f-9541723ab123","added_by":"auto","created_at":"2025-11-18 08:09:52","extension":"png","order_by":10,"title":"Figure 10","display":"","copyAsset":false,"role":"figure","size":358324,"visible":true,"origin":"","legend":"\u003cp\u003eCeRNA-network: A very high percentage of transcribed RNAs are ncRNAs. In their normal condition, they inhibit the expression of the corresponding protein by binding to their targets. However, their binding is prevented by being placed in the ceRNA network, and the corresponding proteins can be expressed.\u003c/p\u003e","description":"","filename":"floatimage11.png","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/5392993e2ebea101891a212e.png"},{"id":96602754,"identity":"6d24b680-c73b-4de1-95a7-7034d2aa861c","added_by":"auto","created_at":"2025-11-24 09:00:38","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":8206267,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/f1a7d162-f6c8-44dc-b65e-599ad62d44bd.pdf"},{"id":96154778,"identity":"be58e4d3-dd2e-4992-8851-b7cc49b36d47","added_by":"auto","created_at":"2025-11-18 08:09:50","extension":"xlsx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":43585,"visible":true,"origin":"","legend":"","description":"","filename":"Supplementarytable1.edited.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/bbd56e7d4c0c7f87616e3efb.xlsx"},{"id":96154786,"identity":"5bd6f237-0c56-43e6-8048-95ab56ef9107","added_by":"auto","created_at":"2025-11-18 08:09:51","extension":"xlsx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":39224,"visible":true,"origin":"","legend":"","description":"","filename":"Supplementarytable2.edited.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/ed451030853ef8e95a56270c.xlsx"},{"id":96154787,"identity":"0dad2634-8ac1-4991-819f-f2c205aef365","added_by":"auto","created_at":"2025-11-18 08:09:51","extension":"docx","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":229999,"visible":true,"origin":"","legend":"","description":"","filename":"GraphicalAbstract.docx","url":"https://assets-eu.researchsquare.com/files/rs-8119740/v1/2821da9799072a5b95712633.docx"}],"financialInterests":"The authors declare no competing interests.","formattedTitle":"\u003cp\u003eDecoding the ceRNA-Network Blueprint of Breast Cancer Metastasis via Molecular Cross-Talk in Motion from Silence to Signal: A Systematic Review and Bioinformatics Analysis\u003c/p\u003e","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eBreast cancer (BC) is the most common malignancy diagnosed among females and a growing concern globally (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e). The major cause contributing to BC mortality is the metastasis of the primary tumor to distant organs (\u003cspan additionalcitationids=\"CR4\" citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e). Metastasis contributes to the poor prognosis of BC and complicates the treatment of the disease (\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e). Nevertheless, the survival rate can be increased by anticipating the early stage of the BC before metastasis (\u003cspan additionalcitationids=\"CR7\" citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e). Therefore, developing therapies that target metastasis can be easier by having a better understanding of the nature and process of breast cancer metastasis (BCM).\u003c/p\u003e\u003cp\u003eDistant metastasis is a complex, multi-step process influenced by several genetic, epigenetic, and environmental variables (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e). Consequently, even if the pathogenesis features of BCM have been better understood in recent years, its underlying molecular mechanisms remain an open question (\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e).\u003c/p\u003e\u003cp\u003eRecent advances in transcriptome analysis and next-generation sequencing (NGS) have facilitated precision treatment in cancer metastasis (\u003cspan additionalcitationids=\"CR13\" citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e). Extensive research has elucidated the regulatory mechanism of ncRNAs at both transcriptional and post-transcriptional levels, which can function as competing endogenous RNA (ceRNA) and are involved in various biological processes, including metastasis and disease progression (\u003cspan additionalcitationids=\"CR16\" citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e). CeRNA is a recently identified mechanism in the RNA world that suggests regulatory interactions between various RNAs, such as pseudogenes, lncRNAs, miRNAs, and circRNAs (\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e). In this context, the ceRNA hypothesis postulates that counts in coding sequences (CDSs) for common regions in miRNAs, ncRNAs, and mRNAs can control the expression of downstream target genes (\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e). Subsequent research has shown that ncRNAs and mRNAs compete with the microRNA response element (MRE), a particular regulatory mechanism, to influence each other's expression, which in turn influences the process of BCM development (\u003cspan additionalcitationids=\"CR21\" citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e). The discovery of ceRNA has also considerably aided in the creation of novel medications and the study of targeted therapy unique to BCM (\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e).\u003c/p\u003e\u003cp\u003eRegarding typical examples within this concept, several ceRNAs, such as SNHG12 and ciRS-7, promote migration and invasion, possibly through MMP13 de-repression (\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e). The lncRNA HOST2 and circSEPT9 promote proliferation and migration in tumor cells and immune infiltrates, while STAT3 is upregulated in the ceRNA network (\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e, \u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e).\u003c/p\u003e\u003cp\u003eIt has been identified that cadherin 5 (\u003cem\u003eCDH5\u003c/em\u003e), homeobox D1 (\u003cem\u003eHOXD1\u003c/em\u003e), and \u003cem\u003eHOXD10\u003c/em\u003e as STAR-related lipid transfer domain containing 13 (\u003cem\u003eSTARD13\u003c/em\u003e)-correlated ceRNAs and 3\u0026prime; UTRs of these genes suppress BCM via inhibiting epithelial-mesenchymal transition (EMT) (\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e). RNA-binding region-containing protein 1 (\u003cem\u003eRNPC1\u003c/em\u003e) could inhibit BC cell metastasis by promoting a \u003cem\u003eSTARD13\u003c/em\u003e-correlated ceRNA-network (\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e). A circRNA-associated ceRNA has been constructed by Sang et al. analyzed the regulatory network and realized that hsa_circRNA_002082 and hsa_circRNA_400031 may function as ceRNAs to serve key roles in BC-related EMT (\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e). Another study conducted a ceRNA-network analysis to investigate the connection between tumor-infiltrating immune cell analysis and BCM to bone. Their results revealed that plasma and follicular helper T cell proportions were considerably higher in BC bone metastasis Additionally, they suggest that DLX6-AS1, Wnt6, and GABBR2 expression may contribute to bone metastasis in patients with BC (\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e). Furthermore, a bioinformatics study on a ceRNA network identified three potential RNA regulators (hsa-miR-105-5p, BCAR1, and PANX2) associated with BCM (\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e). These findings suggest that targeting these networks may serve as a potent adjuvant strategy for eliminating residual metastases and potentially targeting other mediators of invasion, migration, and metastasis.\u003c/p\u003e\u003cp\u003eDespite numerous studies that implicate the role of ceRNAs in BCM, our understanding of these processes remains limited, and more comprehensive research in this area is needed. We are all in step in the present study to construct a ceRNA-network for ncRNAs involved in BC metastasis using data from previous studies and bioinformatics predictions. To boost, bioinformatics tools were to analyze these ncRNAs and their interactions, providing deeper insights into their roles in BC metastasis and progression.\u003c/p\u003e"},{"header":"2. Materials and methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e\n \u003ch2\u003e2.1 Literature review\u003c/h2\u003e\n \u003cdiv id=\"Sec4\" class=\"Section3\"\u003e\n \u003ch2\u003e2.1.1 Study selection:\u003c/h2\u003e\n \u003cp\u003eThe current systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) declaration (\u003cspan class=\"CitationRef\"\u003e32\u003c/span\u003e). For the literature review, the search was accomplished using the following terms: \u0026ldquo;breast cancer\u0026rdquo; OR \u0026ldquo;breast malignancy\u0026rdquo; AND \u0026ldquo;metastasis\u0026rdquo; OR \u0026ldquo;metastases\u0026rdquo; OR \u0026ldquo;invasion\u0026rdquo; AND \u0026ldquo;ncRNA\u0026rdquo; OR \u0026ldquo;noncoding RNA\u0026rdquo; AND \u0026ldquo;lncRNA\u0026rdquo; OR \u0026ldquo;long noncoding RNA\u0026rdquo; AND \u0026ldquo;miRNA\u0026rdquo; OR \u0026ldquo;microRNA\u0026rdquo; AND \u0026ldquo;circRNA\u0026rdquo; OR \u0026ldquo;circular RNA\u0026rdquo;. The study selection process aimed to ensure high-quality and relevant research by applying specific inclusion criteria, such as language restrictions (English), publication timeframe, and study type (clinical and experimental research). Priority was given to studies presenting clinically significant findings, contributing valuable insights into the role of noncoding RNAs in breast cancer metastasis. The study has been registered with the International Prospective Register of Systematic Reviews (PROSPERO) under the registration CRD420251173359.\u003c/p\u003e\n \u003c/div\u003e\n \u003cdiv id=\"Sec5\" class=\"Section3\"\u003e\n \u003ch2\u003e2.1.2 Eligibility criteria and study characteristics:\u003c/h2\u003e\n \u003cp\u003eAccording to PICO (\u003cspan class=\"CitationRef\"\u003e33\u003c/span\u003e) criteria:\u003c/p\u003e\n \u003cul\u003e\n \u003cli\u003e\n \u003cp\u003e\u003cstrong\u003ePopulation\u003c/strong\u003e: Breast cell lines, tissue/blood samples, or animal studies\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003e\u003cstrong\u003eIntervention\u003c/strong\u003e: Altering ncRNA expression or regulation (miRNAs, lncRNAs, circRNAs)\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003e\u003cstrong\u003eComparison\u003c/strong\u003e: Human BC tissue/blood samples, cell lines, and animal models without metastasis or healthy control groups\u003c/p\u003e\n \u003c/li\u003e\n \u003cli\u003e\n \u003cp\u003e\u003cstrong\u003eOutcome\u003c/strong\u003e: Changes in ncRNA expression or regulation led to metastasis\u0026apos;s progression or onset.\u003c/p\u003e\n \u003c/li\u003e\n \u003c/ul\u003e\n \u003cp\u003eTwo researchers (A.N and H.A) independently gathered the results using a standardized abstraction form (\u003cspan class=\"CitationRef\"\u003e34\u003c/span\u003e), and consensus was sought for all extracted items. Differences in data extraction were settled by a third reviewer (N.H), where consensus could not be reached. The following information was extracted from each study:\u003c/p\u003e\n \u003c/div\u003e\n\u003c/div\u003e\n\u003cp\u003e1) Study and sample characteristics\u003c/p\u003e\n\u003cp\u003e2) Details on miRNA, lncRNA, and circRNA expression, including techniques used for expression analysis and quantification in BCM development (see \u003cstrong\u003eSupplementary Table. 1\u003c/strong\u003e).\u003c/p\u003e\n\u003cdiv id=\"Sec7\" class=\"Section3\"\u003e\n \u003cdiv class=\"Heading\"\u003e2.1.3 Quality assessment:\u003c/div\u003e\n \u003cp\u003eSince the present study involves literature reviews and bioinformatics analysis, it requires flexibility in assessing diverse data types and sources. Additionally, it focuses on ncRNAs expression levels in metastatic BC, a combination of established appraisal tools was required. Therefore, we utilized a combination of three guidelines, including The Critical Appraisal Skills Program (CASP) checklist (\u003cspan class=\"CitationRef\"\u003e35\u003c/span\u003e), Quadas-2 for Diagnostic Accuracy Studies (QUADAS-2) (\u003cspan class=\"CitationRef\"\u003e36\u003c/span\u003e), and Joanna Briggs Institute (JBI) (\u003cspan class=\"CitationRef\"\u003e37\u003c/span\u003e) critical appraisal tools (\u003cspan class=\"CitationRef\"\u003e38\u003c/span\u003e). Table.1 demonstrates the customized scoring form. For detailed scoring of each included study see \u003cstrong\u003eSupplementary Table. 2\u003c/strong\u003e.\u003c/p\u003e\n \u003cp\u003e\u003c/p\u003e\n \u003ctable id=\"Tab1\" border=\"1\"\u003e\n \u003ccaption language=\"En\"\u003e\n \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e\n \u003cdiv class=\"CaptionContent\"\u003e\n \u003cp\u003eThe customized quality assessment\u0026apos;s evaluation criteria and scoring system.\u003c/p\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eDomain\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eMax Score\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eScoring Criteria\u003c/p\u003e\n \u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eStudy Design\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eMethodology, criteria, sample size, controls, etc.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eData Quality\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eExpression quantification, bioinformatics validation, statistics.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eRelevance and Bias Assessment\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eRelevance to metastatic BC, bias reduction.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eGeneralizability and Applicability\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eClinical significance and biological insights.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eReporting Quality\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eCompleteness and adherence to guidelines.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n \u003cp\u003e\u003c/p\u003e\n \u003cp\u003e\u003cbr\u003e\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec8\" class=\"Section3\"\u003e\n \u003cdiv class=\"Heading\"\u003e\u003cstrong\u003e2.1.4 Inclusion and Exclusion Criteria\u003c/strong\u003e\u003c/div\u003e\n \u003cdiv class=\"BlockQuote\"\u003e\n \u003cp\u003e\u003cstrong\u003eInclusion Criteria:\u003c/strong\u003e\u003c/p\u003e\n \u003col start=\"1\" type=\"1\"\u003e\n \u003cli\u003eStudies investigating the role of miRNAs, lncRNAs, and circRNAs in BC metastasis.\u003c/li\u003e\n \u003cli\u003eStudies have examined the expression of these three types of ncRNAs (lncRNAs, miRNAs, and circRNAs) in different types and stages of invasive and metastatic BC.\u003c/li\u003e\n \u003cli\u003eStudies exploring the relationships between ncRNAs and BC metastasis/invasion in human samples, cell lines, and animal models.\u003c/li\u003e\n \u003cli\u003eStudies written in English and published between 2007 and 2024.\u003c/li\u003e\n \u003c/ol\u003e\n \u003cp\u003e\u003cstrong\u003eExclusion Criteria:\u003c/strong\u003e\u003c/p\u003e\n \u003col start=\"1\" type=\"1\"\u003e\n \u003cli\u003eStudies that focus on the role of miRNAs, lncRNAs, or circRNAs in other aspects of BC development (excluding metastasis), such as\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eStudies that were not open access or unavailable.\u003c/li\u003e\n \u003cli\u003eStudies published in languages other than English.\u003c/li\u003e\n \u003cli\u003eBook chapters and conference papers.\u003c/li\u003e\n \u003cli\u003eStudies investigating the role of ncRNAs in the metastasis of other cancer types.\u003c/li\u003e\n \u003cli\u003eStudies focus on other ncRNAs in BC metastasis, including piwiRNAs, snRNAs, and tRNAs.\u003c/li\u003e\n \u003c/ol\u003e\n \u003c/div\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec9\" class=\"Section2\"\u003e\n \u003ch2\u003e2.2 Bioinformatics analysis\u003c/h2\u003e\n \u003cdiv id=\"Sec10\" class=\"Section3\"\u003e\n \u003ch2\u003e2.2.1 Bioinformatics target prediction:\u003c/h2\u003e\n \u003cp\u003eBioinformatics target predictions were made using specialized techniques for studies that did not specify a target for the ncRNA under investigation. Using the multiMiR R-package (\u003cspan class=\"CitationRef\"\u003e39\u003c/span\u003e) through filtering to access the three databases \u003cstrong\u003emiRTarBase\u003c/strong\u003e, \u003cstrong\u003eTargetScan\u003c/strong\u003e, and \u003cstrong\u003emiRDB\u003c/strong\u003e (\u003cspan class=\"CitationRef\"\u003e40\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e42\u003c/span\u003e) with cut-off criteria selecting the top 25% of the most significant target mRNAs of miRNAs and target miRNAs of mRNAs. The \u003cstrong\u003eLncBase\u003c/strong\u003e database (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://diana.e-ce.uth.gr/lncbasev3\u003c/span\u003e\u003c/span\u003e) (\u003cspan class=\"CitationRef\"\u003e43\u003c/span\u003e) was then applied to identify miRNAs for lncRNAs\u0026rsquo;s targets. Additionally, the target miRNAs of the acquired circRNAs were extracted from the \u003cstrong\u003eCircular RNA Interactome\u003c/strong\u003e database (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://circinteractome.nia.nih.gov/\u003c/span\u003e\u003c/span\u003e) (\u003cspan class=\"CitationRef\"\u003e44\u003c/span\u003e). All bioinformatics target predictions were conducted computationally using specialized tools without experimental validation. These analyses relied on database filtering techniques to identify significant target interactions within the specified criteria, ensuring a data-driven approach to ncRNA target identification.\u003c/p\u003e\n \u003c/div\u003e\n \u003cdiv id=\"Sec11\" class=\"Section3\"\u003e\n \u003ch2\u003e2.2.2 ceRNA-network construction and analysis:\u003c/h2\u003e\n \u003cp\u003eBased on the predicted interactions, a ceRNA-network consisting of mRNAs, miRNAs, lncRNAs, and circRNAs was constructed and visualized using \u003cstrong\u003eCytoscape\u003c/strong\u003e software (\u003cspan class=\"CitationRef\"\u003e45\u003c/span\u003e). To identify the key components of the constructed network, topological analyses of network features were performed using the \u003cstrong\u003ecytoHubba\u003c/strong\u003e plugin (\u003cspan class=\"CitationRef\"\u003e46\u003c/span\u003e). First, the top 50 hub nodes were selected based on degree, closeness, and betweenness criteria, and then 11 shared nodes between these topological criteria were chosen for further analysis.\u003c/p\u003e\n \u003c/div\u003e\n \u003cdiv id=\"Sec12\" class=\"Section3\"\u003e\n \u003ch2\u003e2.2.3 Protein-protein interaction (PPI) network construction and analysis:\u003c/h2\u003e\n \u003cp\u003eThe Cytoscape \u003cstrong\u003eCluePedia\u003c/strong\u003e plugin v1.3.3 (\u003cspan class=\"CitationRef\"\u003e47\u003c/span\u003e) was used to create PPI networks associated with mRNAs obtained from literature reviewing and bioinformatics predictions from databases. The \u003cstrong\u003eSTRING\u003c/strong\u003e database (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://string-db.org/\u003c/span\u003e\u003c/span\u003e) (\u003cspan class=\"CitationRef\"\u003e48\u003c/span\u003e) was used to characterize the PPI network, and a confidence score of \u0026gt;\u0026thinsp;0.8 was established as the cut-off threshold to investigate the likely connection between these mRNAs further. The STRING v10 also yielded edges with experimental validation proof. The PPI network was visualized with Cytoscape v3.9.1. The Molecular Complex Detection (\u003cstrong\u003eMCODE\u003c/strong\u003e) plugin (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://apps.cytoscape.org/apps/mcode\u003c/span\u003e\u003c/span\u003e) (\u003cspan class=\"CitationRef\"\u003e49\u003c/span\u003e) was employed to select significant modules from the PPI network by considering scores\u0026thinsp;\u0026gt;\u0026thinsp;5 and number of nodes\u0026thinsp;\u0026gt;\u0026thinsp;10 as the cut-off. Module 1, which had the highest score, has been chosen for the following pathway enrichment analysis.\u003c/p\u003e\n \u003c/div\u003e\n \u003cdiv id=\"Sec13\" class=\"Section3\"\u003e\n \u003ch2\u003e2.2.4 Enrichment analysis\u003c/h2\u003e\n \u003cp\u003eEnrichment analysis of regulatory genes and miRNAs was done using the \u003cstrong\u003eEnrichr\u003c/strong\u003e tool (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://maayanlab.cloud/Enrichr/\u003c/span\u003e\u003c/span\u003e) (\u003cspan class=\"CitationRef\"\u003e50\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e51\u003c/span\u003e). The groups with an adj-\u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05 were chosen. The enrichment of GO biological pathways is supplied by Enrichr as well. ggplot2 R package (\u003cspan class=\"CitationRef\"\u003e52\u003c/span\u003e) was employed to illustrates dot plots of pathway enrichment analysis.\u003c/p\u003e\n \u003c/div\u003e\n \u003cdiv id=\"Sec14\" class=\"Section3\"\u003e\n \u003ch2\u003e2.2.5 Survival analysis\u003c/h2\u003e\n \u003cp\u003ePatients were divided into two groups based on the quantile expression levels of the proposed biomarkers. A Kaplan-Meier survival plot was used to compare the two patient cohorts, and the hazard ratio (HR) with 95% confidence intervals (CI) and the log-rank \u003cem\u003ep\u003c/em\u003e-value were calculated. The association between the expression levels of the top 11 RNAs identified from the ceRNA network and breast cancer overall survival (OS) was analyzed using the Kaplan-Meier plotter (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://kmplot.com/analysis/\u003c/span\u003e\u003c/span\u003e).\u003c/p\u003e\n \u003cp\u003eThe schematic process of our approach is depicted in Fig. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e.\u003c/p\u003e\n \u003c/div\u003e\n\u003c/div\u003e"},{"header":"3. Results","content":"\u003cp\u003e\u003cstrong\u003e3.1 Results of literature review\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.1.1 Literature search, characteristics of the eligible studies, and quality assessment\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA total of 3,025 publications were identified through the MEDLINE/PubMed, Web of Science, and Scopus databases. After removing duplicates, authors independently assessed 928 titles and abstracts. Access to around 60 full-text papers was unavailable due to journal copyrights and restrictions. Irrelevant papers were excluded based on the exclusion criteria, and finally, 288 studies met the eligibility criteria. The selection process is illustrated in Fig. 2.\u003c/p\u003e\n\u003cp\u003eAll studies were published in English between 2007 and 2024 and investigated various types and stages of metastatic breast cancer. All studies examined the effects of ncRNAs on BC metastasis and invasion. Among them:\u003c/p\u003e\n\u003cul type=\"disc\"\u003e\n \u003cli\u003e347 studies used only cell lines to investigate their hypotheses\u003c/li\u003e\n \u003cli\u003eThree studies utilized just the patient\u0026apos;s blood/serum sample\u003c/li\u003e\n \u003cli\u003e158 studies included in vivo experiments in animal models\u003c/li\u003e\n \u003cli\u003e224 studies also included human tissue specimen \u0026nbsp;\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eThese studies identified:\u003c/p\u003e\n\u003cul type=\"disc\"\u003e\n \u003cli\u003e79 miRNAs and their target genes.\u003c/li\u003e\n \u003cli\u003e117 studies describing lncRNAs and their miRNAs/mRNAs targets\u003c/li\u003e\n \u003cli\u003e43 studies illustrating circRNAs and their targeted miRNAs/mRNAs.\u003c/li\u003e\n \u003cli\u003e50 studies introducing ncRNAs without specifying their targets.\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eThe details of the included studies are provided in the \u003cstrong\u003eSupplementary Table. 1.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.2 Results of bioinformatics investigations\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.2.1 Putative targets of miRNAs, lncRNAs, and circRNAs\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eBioinformatics target predictions were conducted using specific approaches for 50 of the studies that did not specify a target for the ncRNA. Targeted mRNAs of 10 miRNAs were identified by accessing the three validated databases MiRTarBase, Targets can, and miRDB via the multiMiR (R-package). To identify the miRNAs associated with 37 lncRNAs, we utilized the Encase database. In addition, the Circular RNA Interactome database was used to extract the target miRNAs of the acquired three circRNAs. Finally, a multiMiR R-package was utilized to identify mRNA targets for miRNAs.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.2.2 Construction of ceRNA-network and PPInetwork; key hubs and module identification\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eUsing the Cytoscape software, we established an interaction network to identify the interrelationships between 2752 mRNAs extracted from the constructed ceRNA network. Afterward, the disconnected nodes were removed, and then the network included 2264 nodes and 6705 edges through the CytoHubba and MCODE plugins. After selecting the 50 most dysregulated factors among the three most important network characteristics (betweenness, closeness, and degree) using the cytoHubba plug-in for network visualization, 11 shared most significant dysregulated factors were identified by Venn diagram (https://bioinfogp.cnb.csic.es/tools/venny/) (Fig. 3A). They were hsa-miR-1, has-miR-9, has-miR-27 b, has-miR-20 b, has-miR-21, has-miR-335, has-miR-139, ITGB1, MALAT1, CXCR4, and TGFB1 (Fig. 4). Subsequently, the MCODE plugin was utilized to obtain the significant modules from the PPI-network. The significant module (module 1) contained 32 nodes and 507 edges (Fig. 3B).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.2.3 Pathways retrieved by functional\u003c/strong\u003e\u003cem\u003e\u0026nbsp;\u003c/em\u003e\u003cstrong\u003eenrichment analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e The Enrichr database was used to undertake functional enrichment analysis of the mRNAs in module 1 attained from the PPI-network to better understand the underlying mechanisms of BCM.\u003c/p\u003e\n\u003cp\u003eProteoglycans in cancer, microRNAs in cancer, pathways in cancer, and signaling pathways governing the pluripotency of stem cells were among the biological pathways that were the focus of the KEGG pathway (Fig. 5A) study the pathways indicated above.\u003c/p\u003e\n\u003cp\u003eBiological process (BP), molecular function (MF), and cellular component (CC) were identified by GO enrichment analysis. Positive and negative control of cell differentiation, control of pri-miRNA transcription by RNA polymerase II, control of the epithelial to mesenchymal transition, proliferation, angiogenesis, and the apoptotic process were the key topics of the BP enrichment process for GO analysis (Fig. 5B). Meanwhile, CC enrichment mainly consisted of cyclin-dependent protein kinase holoenzyme complex and serine/threonine protein kinase complex (Fig. 5C). MF enrichment mainly featured transcription cis-regulatory region binding and ubiquitin protein ligase binding (Fig. 5D).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.2.4 Survival and expression analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eUsing the Kaplan-Meier plotter, we investigated the relationship between the expression of 11 hub RNAs extracted from the ceRNA-network and the prognosis of BC patients. For this purpose, the BC samples were grouped based on the median expression of each gene, and these two groups were evaluated with the log-rank test. Our results showed that among 11 hubs, three miRNAs, hsa-miR-1 (p-value= 0.00012), hsa-miR-9 (p-value= 0.0016), and hsa-miR-27 b (\u003cem\u003ep-\u003c/em\u003evalue= 0.027), in addition to one lncRNA, MALAT1 (p-value= 0.039) had a significant relationship with the overall survival of BC patients. The remaining hubs did not show significant connections with poor prognosis (p-value\u0026ge;0.05) (Fig. 6).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.3 Synthesis of results\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.3.1 Metastasis procedure in BC:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eBreast cancer metastasis (BCM) is the main cause of death for most patients and a significant therapeutic issue (53,54). It is a multi-step process by which tumor cells move from primary tumors to secondary sites,\u0026nbsp;spreading to distant body organs, particularly the lung, liver, bone, and brain\u0026nbsp;(6). Invasion, intravasation, circulation, extravasation, and metastatic outgrowth (or colonization) are some of the many steps in this highly complicated process\u0026nbsp;(55). During invasion, the process by which disseminated tumor cells (DTCs) split off from their source, migrate to other places and transform localized cancer into a systemic disease is known as the metastatic cascade\u0026nbsp;(4,56)\u0026nbsp;(Fig. 7).\u003c/p\u003e\n\u003cp\u003eEMT\u0026nbsp;is a major driver of cancer metastasis, with the ability to enhance stem cell-like traits in tumor cells which acquire self-renewal abilities (57,58). By mimicking an embryonic transition, these cells detach from the primary tumor, enter the bloodstream, and spread, fueling disease progression (59,60). During this process, they gain the ability to move, invade, and separate from epithelial cell sheets (61,62). Breast cancer stem cells (BCSCs) contribute to organ-specific metastasis by interacting with distant organ environments and promoting pre-metastatic niches (63). They also provide high motility and resistance to apoptosis\u0026nbsp;(4).\u0026nbsp;Key signaling pathways, including Wnt, Notch, PI3K/Akt, and TGF-\u0026beta;, play crucial roles in EMT and cancer stemness, driving metastasis\u0026nbsp;(64,65). Non-coding RNAs, particularly microRNAs, contribute to regulatory \u0026nbsp;networks by targeting key regulators in metastatic cascade\u0026nbsp;(66\u0026ndash;68). Gaining insight into this crosstalk amongst networks may help identify which nodes of interaction to focus on to address several of the harmful phases of the metastatic pathways at once\u0026nbsp;(69). Along with these, it has been discovered that the TWIST1, SLUG, SNAIL, ZEB1, ZEB2, and FOX families are transcriptional inhibitors of E-cadherin BCSCs also showed strong expression of these genes as EMT markers and a markedly enhanced potential for self-renewal and tumor initiation\u0026nbsp;(70\u0026ndash;72). By controlling different gene expression in different combinations, these EMT transcription factors (EMT-TFs) and CSC transcription factors (CSC-TFs) are closely linked to the development, spread, invasion, and metastasis of cancer as well as chemo-resistance\u0026nbsp;(73\u0026ndash;75).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eDetecting the disease early before metastasis can improve survival and allow the adoption of the best strategy for disease management, targeted therapy, and personalized medicine. Despite the numerous investigations in this context, understanding the spread of BC is still unclear, with major molecular regulators crucial for its development. Therefore, in light of the results mentioned above, we have attempted to conduct a more thorough investigation into BCM by evaluating prior research and building a ceRNA-network to help identify the underlying mechanism and pave the way for future investigations.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.3.2 The role of miRNAs in Breast Cancer Metastasis:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMicroRNAs (miRNAs) are small, ~21\u0026ndash;25 nucleotide (nt), regulatory RNA molecules that have been demonstrated to post-transcriptionally modify gene expression in a variety of biological pathways through complex regulatory networks and highly precise interactions (76). By binding to one or more sites within the 3\u0026apos; untranslated region (UTR) of several target mRNAs, they control genes by degrading or repressing mRNAs\u0026apos; translation \u0026nbsp;(76). Recent studies have elucidated miRNAs\u0026apos; critical role in cancer cell metastatic spread (77). These miRNAs are referred to as \u0026lsquo;\u0026rsquo;metastamiRs\u0026rdquo; (78). Based on their target genes, certain miRNAs can have tumor-suppressive qualities (tsmiR) because the majority of miRNAs function by inhibiting their target genes (79). If its target is an oncogene, it can promote carcinogenesis (oncomiR) (80). According to several recent research, miRNAs can be dysregulated in tumor tissues and are essential for the spread of BCM (77).\u003c/p\u003e\n\u003cp\u003eIn this manner, many studies demonstrated that the overexpression of miR-10b by transcription factor Twist can act as oncomiR and is directly associated with BCM by regulating HOXD10 as its target gene \u0026nbsp;(81\u0026ndash;83). Several studies revealed the upregulation of miR-21 as another oncomiR that may increase BCM by controlling TIMP3 translation, especially in HER-2+ BC (84\u0026ndash;87). Besides, BCM is caused by uncontrolled Wnt/\u0026beta;-catenin signaling that results from inactivating GSK3\u0026beta; and miR-29 upregulates the N-Myc oncogene (88). Additionally, in ER\u0026alpha;- BC and TNBC, miR-29a overexpression is associated with distant metastasis and poor survival through targeting PTEN and inducing EMT and metastasis via AKT signaling (89). Along with oncogenic ras signaling, miR-29a can also inhibit tristetraprolin (TTP), a protein that breaks down messenger RNAs with AU-rich 3\u0026prime;-untranslated regions, resulting in EMT, metastasis, and BCM (90). It has also been reported that overexpression of miR-9 contributes to BCM development (91\u0026ndash;93). It increases BC cell motility and promotes invasion, metastasis, and angiogenesis by regulating FOXO1 and E-cadherin (94).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eRegarding the suppressive effects of miRNAs on BCM, research has shown that increases in miR-126 expression levels can function as a tsmiR to prevent BC invasion and metastasis by directly inhibiting a disintegrin and metalloprotease 9 (ADAM9) (95) or by targeting and modifying the gene expressions of VEGF/PI3K/AKT and MAPK signaling (96). Additionally, as a tumor suppressor, miR-145 directly targets mucin1 (MUC1) and Fascin-1 (FSCN1) (97), and through Fascin-1, c-Myc, SMAD2/3, IGF-1R \u0026nbsp;indirectly down-regulates Wnt signaling pathway and suppress BC cell invasion and metastasis (98). Mohammadi-Yeganeh et al. introduced miR-340 as a tsmiR and reported that it targets Wnt signaling and that its expression significantly decreased in BC metastatic cells. They also asserted that miR-340 can bind to the 3\u0026prime;-UTRs of CTNNB1, c-MYC, and ROCK1 oncogenes, inhibiting its oncogenic effects in BC cells (99). In the other study, the c-Met oncogene was considered a direct target of miR-340 to indirectly downregulate MMP-2 and MMP-9 expression and inhibit BC invasion and metastasis (100). Besides, upregulation of miR-512-3p can directly target the 3\u0026rsquo;UTR of Livin and decrease its expression, inhibiting BC invasiveness and metastasis (101). Similarly, miR‐515‐5p can inhibit BC cell migration and metastasis by binding to 3\u0026prime; UTR of MARK4 and inhibiting its expression (102).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThere is conflicting evidence about the involvement of certain miRNAs in the development of BCM. As a typical example, members of the miR-200 family have been shown to play a significant part in BCM to regulate the invasion and migration of BC cells. However, some studies uncover their promoting activities, others expose their inhibitory impacts (103). In this notion, it has been revealed that in TNBC cells, IMP2 and IMP3 increase EMT and metastasis by directly targeting miR-200a and repressing its transcription, which downregulates progesterone receptor (PR) via IMP2/3-miR-200a-PR negative feedback loop (104). According to Roy et al., PELP1 controls the expression and activities of the tumor metastasis suppressors miR-200a and miR-14, hence regulating BC tumor metastasis (105). Comparably, Li et al. discovered that the expression of miR-200b/200c/429 functional groups, but not miR-141/200a, in a xenograft orthotopic model of BC limits tumor cell invasion and metastasis (106). Likewise, miR-200a directly interacts with 3\u0026prime;UTR of the EPHA2 oncogene and inhibits BC cell migration dually; regulating the well-characterized E-cadherin pathway regulates the EPHA2 pathway (107). Furthermore, miR-200b was shown to target moesin directly and restore it in cells expressing miR-200b to reduce metastatic features (106). In TNBC cells, miR-200b targets PKC\u0026alpha; and reduces Rac1 activity to suppress invasion and tumor metastasis (108). Zhang G et al. discovered in a study that when FOXP3-KAT2B regulates miR-200c/141, these miRNAs\u0026apos; plasma levels rise in metastasis compared to individuals with localized BC (109). It is also demonstrated that compared to matching primary tumors, distant metastasis exhibits increased levels of miR-200 and miR-9 (93). In addition, BC cell line overexpression of miR-200c in mice targets Zeb2 and inhibits its expression, leading to MET and macroscopic metastasis (110).\u003c/p\u003e\n\u003cp\u003eAnother significant and contradictory miRNA that is involved in BCM is miR-206. Accordingly, Zhou Y et al. found that overexpression of miR-206 in BC cell lines and tissues enhances invasion and migration through binding to the 3\u0026prime;-UTR of full-length neurokinin-1 mRNA and controlling its protein production (111). Further, it was discovered that overexpression of miR-206 in the transfected BC cell lines diminished Cdc42 in addition to MMP-2 and MMP-9, thereby suppressing invasion and migration (112). Nevertheless, Adorno-Cruz et al. identified that BC stemness and metastasis are linked to low levels of miR-206, which targets and upregulates ITGA2 as well as its downstream genes ACLY and CCND1 (113). Moreover, a study identified that when the expression of the miR-206 was significantly lower than that in the primary breast tumor, the expression of the Cx43 protein was significantly higher in the liver, and pulmonary metastasis, migration, and invasion capacities were improved (114). MiR-1, considered a crucial regulator of tumor metastasis, has been mentioned that it functioned as a time by targeting K-RAS oncogene and lncRNA MALAT1 inhibited BC cell motility and invasion (115). In a study, Peng et al. found that overexpressed miR-1 in BC cells, which can bind to 3\u0026prime;-UTR of the Bcl‑2, can prevent invasion, migration, and metastasis Through the downregulation of miR-1, MALAT1 has been shown to act as a ceRNA of cdc42\u0026apos; 3\u0026prime;-UTR or via MALAT1miR-1/slug axis, causing BC cells to migrate and invade(116,117). However, Minemura et al. demonstrated that miR-1 overexpression is associated with poor prognosis and distant metastasis of BC patients (118). Table. 2 thoroughly represent miRNAs regulate BCM.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable. 2.\u003c/strong\u003e The list of miRNAs involved in BCM regulation.\u0026nbsp;\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" align=\"\" width=\"784\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eMiRNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eRegulation\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eTarget\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eDetection Method(s)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eAuthors\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003eYear\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003eTitle\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-10b\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eAlan Halim et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2024\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(83)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-29a\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003ePTEN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eJinhui L\u0026uuml; et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2023\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(89)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-5694\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eAF9/Snail\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT‐PCR, Dual‐luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eXin Tian et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(119)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-26 and miR-101\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eCOX-2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT‐PCR, Dual‐luciferase reporter assay, Trans-endothelial migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eRania Harati et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(120)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-301\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eCPEB1/SIRT1/SOX2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eYanjing Jia et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(121)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-206\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eITGA2/CD49b\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Scratch wound assays of cell migration and invasion\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eValery Adorno-Cruz et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(113)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-934\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003ePTEN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eYexia Lu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(122)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-181b-3p\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eFTO/miR-181b-3p/ARL5B\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eYuanyuan Xu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(123)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-512-3p\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eLivin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eW. J. Duan et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(101)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-382-5p\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eMXD1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Matrigel Invasion Assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eXiliang Zhang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(124)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-6744-5p\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eNAT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eSharan Malagobadan et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(125)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eBcl‑2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eJing Peng et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(126)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-106a\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eDAX-1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eC. \u0026nbsp;Liu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(127)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-3184-5p, miR-181c-3p\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003emiR-3184-5p Up\u003cbr\u003e\u0026nbsp;miR-181c-3p Down\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eFOXP4 for miR‐3184‐5p, PPAR\u0026alpha; for miR‐181c‐3p\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT‐PCR, Matrigel invasion assay, Scratch assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eDheeran Rajarajan et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(128)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-155\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eMAPK7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eJian-Hua Liu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(129)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003emiR-331, miR-195\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003emir-331 Up\u003cbr\u003e\u0026nbsp;mir-195 Down\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ePeter McAnena et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(130)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e\u003cu\u003e\u0026nbsp;\u003c/u\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-206\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eNK1R-FL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eYu Zhou et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(111)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-454-3p\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eRPRD1A, AXIN2, DKK3, SFRP1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLiangliang Ren et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(131)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR‑133b\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eTGF\u0026beta;R1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eShengjie Wang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(132)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-638\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eCREB1/Lin28/miR-638/VASP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ePeng-Chao Hu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(133)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-218\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eCol1a1/INHBB/YY1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eXuxiang Liu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(134)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-130a\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eFOSL1/ZO-1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eXiaowei Chen et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(135)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-200a\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eIMP2/3-miR-200a-PR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT‐PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eHye-Youn Kim et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(104)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-203\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003ebach1/MMP-9/CXCR4 receptor\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eReza Mohammadzadeh et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(136)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-381\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eCXCR4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Cell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eYubao Xue et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(137)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-130b-3p\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eDLL1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eYifang Shui et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(138)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-19b\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003ePTENP1, PTEN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eR-K Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(139)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-125b\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eStarD13/miR-125b/TP53INP1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLufeng Zheng et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(140)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-200c\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eFOXP3/KAT2B\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eTaqMan miR assay, Nest-qPCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eGuangxin Zhang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(109)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR‑206\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eConnexin 43\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eZi-Jing Lin et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2016\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(114)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-340\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eCTNNB1, c-MYC, ROCK1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT‐PCR, Dual‐luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eSamira Mohammadi-Yeganeh et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2016\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(99)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-152\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eDNMT1/CDH1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eDipta Sengupta et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2016\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(141)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-497\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eERR\u0026alpha;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLi Han et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2016\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(142)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-448\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eMALAT1/KDM5B\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eOluwaseun Adebayo Bamodu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2016\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(143)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-515-5p\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eMARK4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Cell tracking assay, Boyden chamber assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eOlivier E Pardo et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2016\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(102)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-548j\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eTensin1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eYun Zhan et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2016\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(144)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-490-3p\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eTNKS2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eZhongming Jia et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2016\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(145)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-126\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eVEGF/PI3K/AKT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eD Turgut Cosan et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2016\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(96)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-146a\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eCXCR4, TRAF6, EGFR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eTianjing Zheng et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(146)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-126\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eADAM9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Matrigel invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eCheng-Zheng Wang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(95)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eK-RAS, MALAT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eRuilei Liu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(115)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eMicroRNA PCR array, IHC\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eHiroyuki Minemura et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(118)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-20b\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eAamir Ahmad et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(147)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eEman A Toraih et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(86)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eNOTCH1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eSamira Mohammadi-Yeganeh et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(148)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-509\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eRhoC, TNF-\u0026alpha;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT‐PCR, Dual‐luciferase reporter assay, Wound healing assay, Transmigration assays\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eFei Xing et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(149)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-191\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eTGF\u0026beta;2, HuR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell migration and invasion assays\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eNeha Nagpal et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(150)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-200a\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eEPHA2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eEfrosini Tsouko et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(107)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eFOXO1, E-cadherin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration assay, Adhesion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eJue Yang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2014\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(94)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-10b\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eHOXD10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ePaola Parrella et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2014\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(81)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-106b\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eMMP2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eXiaojian Ni et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2014\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(151)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-183, miR-494, miR-21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eAugusto LF Marino et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2014\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(152)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-29\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eNMI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eJack W Rostas III et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2014\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(88)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-720\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eTWIST1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLin-Zi Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2014\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(153)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-429\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eZEB1, CRKL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eZhi-bin Ye et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2014\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(154)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-200b\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003ePKC\u0026alpha;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eBrock Humphries et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2014\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(108)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-127\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eBCL6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eXiujuan Zhao et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2013\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(155)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eTIMP-3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eJianyi Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2013\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(85)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-200a, miR-141\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eZEB1, ZEB2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Cell Migration and Invasion Assays\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eSudipa Saha Roy et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2013\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(105)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-200b\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003emoesin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eX Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2013\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(106)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-135a\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eHOXA10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eYating Chen et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2012\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(156)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-151-5p, miR-9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003emiR-151-5p Down\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eJonathan Krell et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2012\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(91)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eShahram Savad et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2012\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(84)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-224\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eRKIP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell invasion assay, 3D spheroid invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLin Huang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2012\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(157)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-200, miR-9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, ISH\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eKarina H. Gravgaard et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2012\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(93)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-340\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003ec-Met\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eZheng-sheng Wu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2011\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(100)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-145\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eFascin-1, c-myc, SMAD2/3, IGF-1R\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eSeok-Jun Kim et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2011\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(98)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-1258\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eHPSE\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Cell invasion assays\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLixin Zhang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2011\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(158)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-183\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eVIL2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eAoife J Lowery et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2010\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(159)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-206\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eCdc42, MMP-2, MMP-9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eHao Liu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2010\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(112)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-103/107\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eDicer/mir-200\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eGraziano Martello et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2010\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(160)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-17-5p\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eHBP1/\u0026beta;-catenin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eHongling Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2010\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(161)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-196s\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eHOXC8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eYong Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2010\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(162)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-17/20\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eIL-8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eZuoren Yu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2010\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(163)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-145\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eMUC1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eMohit Sachdeva et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2010\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(97)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emir-520h\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eup\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003ePP2A/C\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eJen-Liang Su et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2010\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(164)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eTIMP3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eBao Song et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2010\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(87)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-205\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eErbB3, VEGF-A\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eHailong Wu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2009\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(165)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-661\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003ec,EBP\u0026alpha;/\u0026nbsp;miR-661/MTA1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eSirigiri Divijendra Natha Reddy et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2009\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(166)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-17-92\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eSijin Liu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2009\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(167)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-27b\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eST14\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eYanfang Wang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2009\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(168)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-29a\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eTTP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eChristoph A Gebeshuber et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2009\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(90)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-193b\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003euPA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eX-F Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2009\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(169)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-373 and miR-520c\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eCD44\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eQihong Huang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2008\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(170)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003ePak1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eSirigiri Divijendra Natha Reddy et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2008\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(171)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-155\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eRhoA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eWilliam Kong et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2008\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(172)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-335\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eSOX4, PTPRN2, TNC, MERTK\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT‐PCR, Dual‐luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eSohail F Tavazoie et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2008\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(173)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003emiR-10b\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 128px;\"\u003e\n \u003cp\u003eHOXD10, RHOC\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 269px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLi Ma et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2007\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(82)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003e3.3.3 The role of lncRNAs in Breast Cancer Metastasis:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eLong non-coding RNAs are a category of ncRNAs longer than 200 nucleotides (174). Chromosome rearrangement, histone modification, transcription, stabilizing mRNA, and altering alternative splicing sequences are just a few of the physiological processes regulated by lncRNAs. Consequently, they are accountable for a large number of diseases, including cancer (175). As competitive endogenous RNAs and sponging miRNAs, lncRNAs have been shown to influence multiple signaling pathways and regulate the synthesis of proteins associated with invasion, migration, EMT and metastasis (23,175,176). Accordingly, the spread of the malignant process of BC cell invasion and metastasis might result from modifications to the several signaling pathways that govern lncRNAs\u0026apos; regulation (176,177).\u003c/p\u003e\n\u003cp\u003eAs an illustration, the TGF-\u0026beta; signaling pathway is a key regulator of the EMT process by affecting the expression of EMT-associated factors, such as ZEB, E-cadherin, Vimentin, and SNAIL (178\u0026ndash;180). In line with this, Li et al. indicated that following induction of lncATB by TGF-\u0026beta; treatment, EMT markers such as ZEB1, Twist1, N-Cadherin, and Vimentin are upregulated while E-Cadherin is downregulated. They discovered that lncATB, which acts as a sponge for the miR-200 family and restores Twist1 expression, can promote cell invasion and migration in vitro and in vivo and is linked to distant metastasis (181). Furthermore, TGF-\u0026beta;-induced migration, invasion, EMT, and metastasis were prevented by suppressing lncRNA-HIT (HOXA transcript produced by TGF\u0026beta;), which has E-cadherin as one of its major targets. Nevertheless, metastatic cells exhibited a significant increase in lncRNA-HIT expression (182). In a study conducted by Li GY et al., UCA1 functions as a competitive endogenous RNA (ceRNA) in the cytoplasm, whereas AC026904.1 functions as an enhancer RNA in the nucleus. LncRNAs AC026904.1 and UCA1 are also overexpressed in both canonical and non-canonical TGF-\u0026beta; pathways. They target and activate SLUG in BC cells to promote EMT and metastasis (183). There are controversial studies around the role of CASC2 in BCM. Two investigations illustrated the upregulation of CASC2 contributes to BCM progression by targeting TGF-\u0026beta; signaling-associated genes such as TGFB1, SMAD2, and \u0026alpha;-SMA (184). \u0026nbsp;On the other hand, two different studies reported that CASC2 has an inhibitory effect on BCM through the miR-96-5p/SYVN1 axis (185), and inactivation of the TGF-\u0026beta; signaling pathway is involved in its function (186). ARHGAP5-AS1 inhibits BC invasion and metastasis by inhibiting SMAD7 and impeding the TGF-\u0026beta; signaling pathway (187).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe Wnt signaling pathway is known to be essential for regulating the development of embryonic organs and the advancement of cancers, especially since it plays a crucial role during the BCM process (188). There is mounting evidence that lncRNAs control Wnt signaling, which either promotes or inhibits the growth of BCM (189). In light of this, lncRNAs DGCR5, EZR‑AS1, LINC01287, RUSC1‑AS‑N, and HOTTIP have been found to promote BC invasion, EMT, and metastasis through their modulation of the Wnt/\u0026beta;-catenin signaling pathway (190\u0026ndash;194). Multiple studies demonstrated that H19 could promote BC invasion and metastasis (195). In a ceRNA-network, H19 can competitively bind miR-200b/c and let-7 to regulate Lin28, Git2, and Cyth3 and accelerate BCM (196,197), or it can sponges miR-340-3p and enhance BCM and EMT by regulating YWHAZ and potentiating the Wnt/\u0026beta;-catenin signaling (198). Tan et al. discovered that lncRNA LINC00511 encodes the small peptide LINC00511-133aa and by controlling the expression levels of proteins related to the Wnt/\u0026beta;-catenin pathway, such as Bax, c-myc, and CyclinD1, and facilitating \u0026beta;-catenin protein entry into the nucleus, increased the invasiveness and stemness of BC cells (199). Overexpression of LncCCAT1 influences BCSC stemness, migration, and invasion capabilities (200). It potentially enhances T-cell factor 4 and triggers Wnt signaling through interactions with miR-204/211, miR-148a/152, and ANXA2 (200).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eIn terms of epigenetic regulation, by engaging DNA methyl transferase and triggering the Wnt signaling pathway, LINC00518 increases CDX2 methylation and facilitates the metastasis and development of BC (201). Additionally, LINC00922 controls BC invasion, migration, and EMT by promoting NKD2 methylation and activating the Wnt signaling pathway (202). In contrast, the Wnt/\u0026beta;-catenin signaling pathway in BC is inhibited by LINC01089, which also predicts the clinical prognosis. Zhang et al. further showed that by directly targeting SFRP1 and DKK2/3, miR-586 induced Wnt/\u0026beta;-catenin activation and acted as an oncogene to promote BC progression and invasion (203). LINC01189 functioned as a tumor suppressor and inhibited BC progression by inhibiting EMT-like phenotype by sponging miR-586 in the LINC01189/miR-586/ZEB1 feedback loop (204). Fig. 8 depicts the interactions of lncRNAs in the process of BCM via a crucial signaling pathway.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eMoreover, NEAT1, MALAT1, HOTAIR, and linc-ROR are well-known lncRNAs that promote BCM via ceRNA-networks, sponging miRNAs and regulating essential genes (205,206,215\u0026ndash;217,207\u0026ndash;214). There are three studies mentioned the role of AFAP1-AS1 in BCM (218\u0026ndash;220). According to Chen C et al., TNBC primary cells with elevated AFAP1-AS1 levels expressed more downstream genes of the PLK1 pathway, including CDC25C, CDK1, BUB1, and TTK. \u0026nbsp;More significantly, in a mouse metastatic model, AFAP1-AS1 boosted lung metastases (219). Zhang X et al. discovered in a different study that AFAP1-AS1 stimulates TNBC cell invasion via regulating MTH1 expression by targeting miR-145 (220). Table. 3 thoroughly illustrates the studies that investigated the function of lncRNAs in BCM.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable. 3.\u003c/strong\u003e List of the research that examined the regulation of lncRNAs in BCM.\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" align=\"\" width=\"784\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eLncRNA\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eRegulation\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTarget\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eDetection Method(s)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAuthors\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eYear\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTitle\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC01569\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-300/FILIP1L\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eXinyu Jiang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2024\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(221)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLYPLAL1-DT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003ehnRNPK/\u0026beta;-Catenin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYuhui Tang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2023\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(222)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eT376626\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eLAMC2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, RNA pulldown assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYongyin He et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2023\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(223)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eTMEM105\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-1208/LDHA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eJinzhu Han et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2023\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(224)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eMIR17HG\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-454-3p/FAM135A\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eJingjing Xu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2023\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(225)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLncRNA‑BC069792\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-658, miR-4739/KCNQ4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYunxiang Zhang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2023\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(226)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC00511\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eZhongqiu Tan et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2023\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(199)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eOBSCN-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eOBSCN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell migration assay, 3D collagen invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eTalia Guardia et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2023\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(227)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC00478\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003ePHB2/c-Myc\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, RIP, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eRong Guo et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2023\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(228)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eAFAP1-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003ePLK1, CDC25C, CDK1, BUB1, TTK\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eShuizhong Cen et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2023\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(218)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC01559\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-370-3p/miR-485-5p/miR-940\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing and Transwell assays\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eXue Yang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2022\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(229)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eTCONS_00068220\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eCDH1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eXiao Liu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(230)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eENST00000508435\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eFXR1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, RIP, Wound healing assay, Transwell migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eLuying Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(231)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC00483\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eIGF2BP1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, RIP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eY.-S. QIAO et al.,\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(232)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eSPINT1-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003elet-7a/b/i-5p\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound-healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eTongzhou Zhou et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(233)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e\u003cu\u003e\u0026nbsp;\u003c/u\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC00472\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eMCM6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, RIP, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eGuoli Shao et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(234)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eDGUOK-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-204-5p/IL-11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYiran Liang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(235)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eMALAT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR‑26a/26b/ST8SIA4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Cell migration and invasion assays\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eNan Wang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(213)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eRACGAP1P\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-345-5p/RACGAP1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eDanmei Zhou et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(236)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eSChLAP1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR‑524‑5p/HMGA2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eXiangdong Bai et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(237)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC01189\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-586/ZEB1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Matrigel Invasion Assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eDi Zhang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(203)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eDSCAM-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eMahsa Tarighi et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(238)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC00922\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNKD2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYan Wang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(202)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC00926\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003ePGK1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eZhong Chu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(239)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eNEAT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003ePGK1/PGAM1/ENO1 Complexes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eMi Kyung Park et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(209)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eARHGAP5-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eSMAD7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay,Transwell assay, F-actin staining\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eChen‑Long Wang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(187)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eSNHG1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eSTAT6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eShoukai Zong et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(240)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eAC073352.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eYBX1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound-healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eXue Kong et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(241)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eZEB2NAT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eZEB2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eTranswell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eCanan Eroğlu G\u0026uuml;neş et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(242)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLncRNA-CCRR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eCX43\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell assay, Dye transfer assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eDeheng Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(243)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 95px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 265px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 94px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 57px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 66px;\"\u003e\n \u003cp\u003e\u003cu\u003e\u0026nbsp;\u003c/u\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eZFPM2-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eJMJD6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter Assay, Transwell Assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eY-F \u0026nbsp;ZHAO et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(244)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eH19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eLet‑7/Lin28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR,Wound healing assay, Migration and invasion assays\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eHanchu Xiong et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(197)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eHOST2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eLet-7b\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Transwell assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eKaiyao Hua et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(26)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC00689\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-142-3p/USP6NL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assays\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eTeng ma et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(245)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eAFAP1-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-145/MTH1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eXiaohui Zhang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(220)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC00511\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-150/MMP13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eGuangHui Shi et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(246)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eSNHG3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-154-3p/Notch2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eHongnan Jiang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(247)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eTUSC8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-190b-5p/MYLIP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eLuqing Zhao et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(248)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eSNHG1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-193a-5p-HOXA1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eJun Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(249)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eH19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-340-3p/YWHAZ\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT‐PCR, Dual‐luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eLei Yan et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(198)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ePCNAP1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR‑340‑5p/SOX4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Scratch assays, Transwell assays\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYang Yu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(250)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eOIP5‑AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR‑340‑5p/ZEB2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eLingjun Meng et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(251)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC02163\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-511-3p/HMGA2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell \u0026nbsp;migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eChenglin Qin et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(252)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC00115\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-7/KLF4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Transwell assay, Matrigel invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eChunlei Yuan et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(253)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eDCST1-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-873-5p\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eLi Tang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(254)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eDANCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-874-3p/SOX2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT‐PCR, Dual‐luciferase reporter assay,Transwell Invasion Assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eGuiyun Wu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(255)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e\u003cu\u003e\u0026nbsp;\u003c/u\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eTRHDE‑AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eShufang Hu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(256)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC00665\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eJ-L Zhou et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(257)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eA2M-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound-healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eKai Fang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(258)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eDGCR5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eDaqing Jiang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(190)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC00261\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNME1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, RNA pull-down assay, Transwell Migration Assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eGuangxiu Guo et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(259)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eH19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003ep53/TNFAIP8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYang Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(195)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLinc00514\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eSTAT3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eSifeng Tao et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(260)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ePHACTR2-AS1 (PAS1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eSUV39H1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT‐PCR, Dual‐luciferase reporter assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eWenhui Chu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(261)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC01271\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eTensin1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eKung-Chi Chang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(262)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eRAB11B-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eVEGFA, ANGPTL4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Boyden chamber migration and invasion assays, In vitro angiogenesis assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYanling Niu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(263)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eHUMT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eYBX1/FOXK1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eShaoquan Zheng et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(264)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eNNT-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eZFP36\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell assay, Bioinformatics analysis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003ePan QH et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(265)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC00518\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eCDX2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Transwell assay, Scratch test\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eHong-Bin Wang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(201)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLnc-NLIPMT (RP11\u0026ndash;115N4.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eGSK3\u0026beta;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYang Jiang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(266)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eMIR503HG\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR‐103/OLFM4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eJia Fu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(267)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eNEAT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-107/CPT1A\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Matrigel assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYiquan Xiong et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(206)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e\u003cu\u003e\u0026nbsp;\u003c/u\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eMIR210HG\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-1226-3p/mucin-1c\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eXiao-Yu Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(268)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eNEAT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-133b/TIMM17A\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eXinping Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(207)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eAC073284.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-18b‐5p/DOCK4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT‐PCR, Dual‐luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYue‐Yue Wang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(269)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC00641\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR‐194‐5p\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eQixin Mao et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(270)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLncCCAT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-204/211, miR-148a/152, ANXA2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eTingting Tang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(200)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLncRNA-CDC6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR‐215/CDC6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eXiaoli Kong et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(271)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eHCP5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR‐219a‐5p/BIRC3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT‐PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eLihong Wang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(272)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eGAS6-AS2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-493/FUT4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT‐PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eWanfeng Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(273)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC00473\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-497\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eJ \u0026nbsp;BAI et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(274)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLOXL1-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-708-5p\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eHui-ting Dong et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(275)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eTFAP2A-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-933/SMAD2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT‐PCR, Dual‐luciferase reporter assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eBin Zhou et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(276)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC01287\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eC. \u0026nbsp;Song et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(192)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eAFAP1-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound scratch assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eDachang Ma et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(219)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC01089\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eHongfan Yuan et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(204)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eRUSC1-AS-N\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003ePeng Zhou et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(193)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eCASC2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYang Zhang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(186)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e\u003cu\u003e\u0026nbsp;\u003c/u\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eFOXD3‐AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Invasion and migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYaoyao Guan et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(277)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ePANDAR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYi Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(278)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eHIF1A‐AS2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT‐PCR, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYufei Wang et al et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(279)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eHOTTIP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eSijia Han et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(194)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eNAMPT-AS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNAMP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT‐PCR, Dual‐luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eHanwen Zhang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(280)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLnc-SLC4A1-1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNF-kB/CXCL8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eTongbo Yi et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(281)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eST8SIA6-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003ep38 , AKT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eKai Fang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(282)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eFBXL19-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eWDR66\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT‐PCR, RIP assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYayuan Zhang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(283)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eZEB2-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eZEB2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell assay, Cellular F‐actin measurement\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eGuoxin Zhang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(284)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eTROJAN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eZMYND8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eXi Jin et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(285)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC01638\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eDNMT1, DNMT3a, DNMT3b, BRCA1, PTEN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003ePeng Liu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(286)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eZFHX4-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eFAT4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT‐PCR, Dual‐luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eShao-Ying Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(287)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eIRAIN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eIGF1R\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eLingling Pian et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(288)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLncRNA-BCHE (p10247)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eITGB1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYu-Xia Yang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(289)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eITGB2-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eITGB2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eMengyao Liu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(290)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLncRNA-CTD-2108O9.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eLIFR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell assay, Matrigel invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eMozhi Wang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(291)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e\u003cu\u003e\u0026nbsp;\u003c/u\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eNNT-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-142-3p/ZEB1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYan Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(292)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eMALAT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-145, VEGF\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eXiao-juan Huang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(293)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eXIST\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-155/CDX1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eRuinian Zheng et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(294)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eSNHG7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-186\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eX Luo et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(295)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eGAS5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-196a-5p/FOXO1/PI3K/AKT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eShuqin Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(296)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLncATB\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-200c/Twist1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eRong-Hui Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(181)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eARNILA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-204/Sox4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eFang Yang \u0026nbsp;et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(297)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLnc015192\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-34a/Adam12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eXiaojia Huang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(298)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLncRNA-PRLB\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-4766-5p/SIRT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYiran Liang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(299)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eXIST\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-503, MSN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eFei Xing et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(300)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003elinc-ZNF469-3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-574-5p/ZEB1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Migration and invasion assays\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003ePo-Shun Wang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(301)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eCASC2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-96-5p/SYVN1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eZejun Gao et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(185)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eBANCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eJing Jiang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(302)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eBANCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eK-X Lou et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(303)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eEZR-AS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT‐PCR, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYu Bai et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(191)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC01296\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eMin Jiang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(304)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e\u003cu\u003e\u0026nbsp;\u003c/u\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eAC026904.1, UCA1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eSlug\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eGuo-Yin Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(183)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eMALAT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eTEAD\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eJongchan Kim et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(214)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eHOXA-AS2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-520c-3p /TGFBR2 and RELA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYu Fang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(305)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eNEAT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eFOXN3-NEAT1-SIN3A\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eWanjin Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(205)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLnc-BM\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eJAK2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Cell adhesion assay, Trans-BBB invasion assay, Macrophage Transwell migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eShouyu Wang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(306)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eMALAT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-129-5p\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYonggang Zuo et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(212)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eH19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-200b/c and let-7b,Git2,Cyth3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT‐PCR, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eWu Zhou et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(196)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eMALAT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-204/ZEB2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell assays\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYuzhou Wang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(307)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eNEAT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-211/HMGA2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eXuerui Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(208)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eSNHG15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-211-3p\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eQingli Kong et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(308)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eMEG3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-421/E-cadherin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell invasion assays\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eWei Zhang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(309)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eMEG3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eChen-yu Zhang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(310)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLinc-ITGB1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eW-X Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(311)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC00628\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eD-Q Chen et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(312)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eOR3A4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eGenxiang Liu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(313)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eHOXA11‑AS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eJian-Chun Su et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(314)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e\u003cu\u003e\u0026nbsp;\u003c/u\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eTUG1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eShulin Fan et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(315)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eHOXA11-AS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eWenlei Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(316)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLincRNA-ROR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eKaijiong Zhang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(317)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLincIN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNF90-p21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, RIP, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eZhengyu Jiang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(318)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLinc00617\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eSox2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, RIP, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eHengyu Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(319)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eCCAT2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eTGFB1,SMAD2,\u0026alpha;-SMA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, transwell assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eZ-J WU et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(184)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINP1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eTP53\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYiran Liang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(320)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eROR1-HER3 MAYA (MNX1-AS1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eYAP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, RIP, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eChunlai Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(321)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eANCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eEZH2/CDK1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Wound healing assay, RIP assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eZhongwei Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2016\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(322)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLIMT (LINC01089)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eAldema Sas-Chen et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2016\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(323)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eMALAT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eMahdieh Jadaliha et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2016\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(300)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eMEG3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eJ-J \u0026nbsp;ZHANG et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2016\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(324)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eTUG1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eTeng Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2016\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(300)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eMALAT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eYufeng Miao et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2016\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(211)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eMALAT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-1/cdc42\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eJinjiang Chou et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2016\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(116)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eHIT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eE-cadherin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eEdward J Richards et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(182)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e\u003cu\u003e\u0026nbsp;\u003c/u\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eNKILA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eIkB\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eBodu Liu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(325)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eMALAT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-1/Slug\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eChuan Jin et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(117)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLincRNA-ROR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-145/Arf6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eGabriel Eades et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(215)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eH19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-675/c-Cbl, Cbl-b\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT‐PCR, Luciferase reporter assay,\u0026nbsp;Wound healing assay, Transwell migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eConstance Vennin et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(326)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eEGOT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eShou-ping Xu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(327)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eMALAT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT\u0026ndash;PCR, Wound healing assay, Matrigel invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eShouping Xu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(210)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eNBAT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003ePRC2, DKK1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, RIP, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003ePengnan Hu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(328)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eLINC-ROR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-205 / ZEB2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eP Hou et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2014\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(216)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eBCAR4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003ePNUTS, SNIP1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eZhen Xing et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2014\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(329)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eHOTAIR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eCleidson P\u0026aacute;dua Alves et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2013\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(217)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eCCAT2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eRoxana S Redis et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2013\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(330)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eHOTAIR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 265px;\"\u003e\n \u003cp\u003eBreast Tissue Microarrays, ISH\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 94px;\"\u003e\n \u003cp\u003eKaren M \u0026nbsp;Chisholm et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57px;\"\u003e\n \u003cp\u003e2012\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 66px;\"\u003e\n \u003cp\u003e(331)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003e3.3.4 The role of CircRNAs in Breast Cancer Metastasis:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eCircular RNAs, a unique category of long noncoding RNAs, have a covalently closed loop structure without a 5\u0026prime;-cap or 3\u0026prime;-polyadenylated tail (332). This special structure enables them to express themselves well and be more stable than their counterparts (333). According to research, the development of BCM may be aided by circRNAs competing with other endogenous RNAs to bind to MREs or miRNAs, RNA-binding proteins (RBPs), or regulating parental genes (333). As a result, they can control downstream gene expression and modulate the essential biological processes of tumor progression and metastasis (334). \u0026nbsp;By controlling different genes or signaling networks, they can either prevent or promote BC migration, invasion, and metastasis (334,335).\u0026nbsp;Fig. 9 depicts the mechanisms of circRNA-mediated regulation in BCM.\u003c/p\u003e\n\u003cp\u003eThe inhibitory effects of circRNAs on BC invasion and metastasis were shown in multiple investigations. \u0026nbsp;For instance, circEHMT1 can act as a tumor suppressor in BC by targeting miR-1233-3p, modifying the transcription factor KLF4, and then MMP2; it may be able to prevent invasion, migration and metastasis in a particular axis of circEHMT1/miR-1233-3p/KLF4/MMP2 (336). In metastatic BC, circNR3C2 upregulates and sponges miR-513a-3p, which can enhance the tumor-suppressive effects of HRD1 that modulate vimentin, a vital regulator of EMT (337). CircRGPD6 can also inhibit metastatic BCSCs through the miR-26b/YAF2 axis, and TV-circRGPD6 nanoparticles, either alone or in combination with docetaxel, demonstrated notable therapeutic responses on metastatic BCSCs (338). Moreover, circNOL10 not only can bind multiple miRNAs such as miR-149-5p, miR-330-3p, and miR-452-5p to alleviate BC carcinogenesis by regulating PDCD4 but also can act as an RBP-noncoding RNA and CASC3 and MTDH proteins bind directly to it with characterized motifs and inhibit BCM (339). CircNOL10 was represented in another study as a suppressor of BCM via sponging miR-767-5p and up-regulating SOCS2, which inactivates the JAK2/STAT5 signaling pathway (340). According to Liang Y et al., circBMPR2 down regulated in BCM. Additionally, sponging miR-553 by this circRNA results in overexpression of USP4, a TSG, inhibiting the metastasis and tamoxifen resistance (341). Further, it is reported that the Yap protein, a vital Hippo pathway component, can be inhibited by its circular RNA (circYap) and attenuate BC migration and invasion (342).\u003c/p\u003e\n\u003cp\u003eRegarding the upregulation of circRNAs in BCM, it has been revealed that overexpression of circ-UBR1 could lead to BCM via miR-1299/CCND1 axis (343). In TNBC, circRAD18 sponges miR-208a and miR-3164 and increased IGF1 and FGF2 expression were associated with poor prognosis and distant metastasis, as well as cell migration and invasion in BC cell lines (344). Furthermore, it has been demonstrated that TNBC metastasis and progression could be facilitated via circ-UBAP2/ miR-661/MTA1 (345), circSEPT9/miR-637/LIF (27) and circIFI30/miR-520b-3p/CD44 axis (346). In the positive feedback loop of circHIF1A/NFIB/FUS (347), circHIF1A can be overexpressed and accelerate TNBC metastasis and invasion (347). CircDNAJC11 can directly regulate TAF15/MAPK6 and activate the MAPK signaling pathway in TNBC (348). CircANKS1B through miR-148a-3p and miR-152-3p/ USF1/ TGF-\u0026beta;1 activates TGF-\u0026beta;1/Smad signaling and promotes EMT (349). Li Y et al. found that circ-EIF6, which encodes EIF6-224aa, may be responsible for TNBC invasion and progression by inhibiting the MYH9 oncogene degradation and activation of the Wnt/\u0026beta;-catenin pathway (350).\u003c/p\u003e\n\u003cp\u003eBesides, CircHIPK3 can assist the progress of BCM by regulating miR-193a/HMGB1 and PI3K/AKT signaling pathways (351). With inhibition of miR-296-5p, hsa_circ_0000515 can overexpress CXCL10 and promote cell invasiveness in the MCF-7 cell line and nude mice (352). Gao D et al. indicate that circ_0006528 up-regulated in BCM and sponges miR-7-5p to overexpressed Raf1, ultimately in the way activated MAPK/ERK signaling pathway (353). Further, Ju CH et al. introduced a novel circRNA, circ_0042881, which in a ceRNA-network sponges\u0026apos; miR-217, affects SOS1 and activates MEK/ERK pathway and PI3K/AKT pathway (354). They also claim that EIF4A3 could facilitate circ_0042881 circularization in this axis (354). In addition, it has been shown that circMYBL2 upregulated in BC liver metastasis and sponging miR-1205, then complexing with eIF4A3 and promoting EMT, or it can directly target eIF4A3 through circMYBL2/eIF4A3/ E2F1 axes and leads to BC liver metastasis (355). Several other studies had been reported the upregulation of circRNAs and sponging miRNAs in a particular axis can enhance or facilitate BCM including CircKIF4A/ miR-152/ZEB1 (356), circFOXK2/ IGF2BP3/miR-370 (357), circ_0072995/ SHMT2/miR-149-5p (358), circFBXL5/miR‐660/ SRSF6 (359), circHMCU/ let-7/ MCY/HMGA2/CCND1 (360), circIRAK3/miR-3607/FOXC1 (361), circACAP2/ miR-29a/b-3p-COL5A1 (362), circ_0000291/miR-326/ETS1 axes (363). Table. 4 comprehensively represents circRNAs and their targets, which play a role in BCM progression.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable. 4.\u003c/strong\u003e List of circRNAs and their targets, which are involved in the BCM.\u003c/p\u003e\n\u003cdiv align=\"\"\u003e\n \u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" align=\"\" width=\"784\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCircRNA\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eRegulation\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTarget\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eDetection Method(s)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAuthors\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eYear\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTitle\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircKIF4A\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-637/STAT3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eSong Wu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2024\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(364)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircRNF10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eDHX15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eWenfang Zheng et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2023\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(365)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecirc_0060467 (circMYBL2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-1205/E2F1 and eIF4A3/E2F1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eYan Zeng et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2023\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(355)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecirc_0042881\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-217/SOS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eChenxi Ju et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2023\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(354)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircDNAJC11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eTAF15/MAPK6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, RIP, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eBin Wang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2023\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(348)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecirc-EIF6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eMYH9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eYaming Li et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2022\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(350)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircFOXK2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eIGF2BP3/miR-370\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eWei Zhang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(357)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircRASSF2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-1205/HOXA1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Transwell assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eWei Zhong et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(366)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecirc-ERBB2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-136-5p/TFAP2C or miR-198/TFAP2C\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assays\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eJin-xiu Zhong\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(367)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircHIF1A\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-149-5p/NFIB/FUS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eTong Chen et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(347)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecirc_0000515\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-296-5p/CXCL10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Transwell assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eFenglin Cai et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(352)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircNR3C2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-513a-3p/HRD1/Vimentin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Matrigel invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eYa Fan et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(337)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircNOL10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-767-5p/SOCS2/JAK2/STAT5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter Assay, Transwell Assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eFang Wang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2021\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(340)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircHMCU\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003elet-7/MCY/HMGA2/CCND1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eXiaojin Song et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(360)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircEHMT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-1233-3p/KLF4/MMP2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eMengqi Lu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(336)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecirc_0091074\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-1297/TAZ/TEAD4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eJiashu Hu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(368)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecirc-UBR1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-1299/CCND1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT‐PCR, Dual‐luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eLinfeng Zhang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(343)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircVAPA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-130a-5p\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eSi-ying Zhou et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(369)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecirc-NOL10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-149-5p/miR-330-3p/miR-452-5p/PDCD4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Matrigel invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eYujie Cai et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(339)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecirc_0072995\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-149-5p/SHMT2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assay, Cell adhesion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eChuang Qi et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(358)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircKIF4A\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-152/ZEB1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eYongping Jin et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(356)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircHIPK3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-193a/HMGB1/PI3K/AKT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eZhen-Gang Chen et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(351)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircRGPD6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-26b-YAF2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eXiaoti Lin et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(338)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircACAP2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-29a/miR-29b-3p/COL5A1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration and invasion assays\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eBeiyong Zhao et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(362)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecirc_0000291\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR‐326/ETS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Transwell assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eJie Min et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(363)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircIFI30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-520b-3p/CD44\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing and invasion assays\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eLei Xing et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(346)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircSEPT9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-637/LIF\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assays\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eXiaying Zheng et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(27)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircFBXL5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR‐660/SRSF6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eMicroarray, Luciferase reporter assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eHuamao Zhou et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(359)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircSCYL2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eChunlei Yuan et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(370)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircRNA_0025202\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-182-5p/FOXO3a\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eYuting Sang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(371)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircDENND4C\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-200b/c\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay,3D spheroid invasion assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eShasha Ren et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(372)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircRAD18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-208a/3164-IGF1/FGF2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eYutian Zou et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(344)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircAHNAK1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-421/RASA1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay,Transwell assay, Migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eWeikai Xiao et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(373)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircASS1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-4443\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eJun-chen Hou et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(374)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircKDM4C\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-548p/PBLD\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eYiran Liang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(375)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircBMPR2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-553/USP4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eYiran Liang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(341)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecirc-21439, circ-11783\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003ecirc 21439 Up\u003cbr\u003e\u0026nbsp;circ 11783 Down\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eXiaorong Lin et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(376)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircYap\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eDown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eYap\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, RIP, Wound healing assay, \u0026nbsp;Transwell invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eNan Wu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(342)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eCiRS-7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-1299/MMP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eMeixiang Sang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(25)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircANKS1B\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-148a-3p/152-3p/USF1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell assays\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eKaixuan Zeng et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(349)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecirc-0072995\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-30c-2-3p\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Transwell migration and invasion assays\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eHe-da Zhang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(377)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircIRAK3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-3607/FOXC1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Wound healing assay, Transwell assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eJie Wu et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(361)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecirc-UBAP2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-661/MTA1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Luciferase reporter assay, Transwell migration assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eShengting Wang et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(345)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecircRNA_0006528\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003emiR-7-5p/Raf1/MEK/ERK\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, Dual-luciferase reporter assay, Wound healing assay, Transwell migration and invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eDanfeng Gao et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(353)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003eFECR1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eTET1 and DNMT1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR, RNA reverse transcription-associated trap (RAT), Matrigel invasion assay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eNaifei Chen et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(378)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 95px;\"\u003e\n \u003cp\u003ecirc_0001785\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76px;\"\u003e\n \u003cp\u003eUp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 132px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 276px;\"\u003e\n \u003cp\u003eqRT-PCR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 82px;\"\u003e\n \u003cp\u003eWei-Bing Yin et al\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 55px;\"\u003e\n \u003cp\u003e2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 69px;\"\u003e\n \u003cp\u003e(379)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n\u003c/div\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3.3.5 CeRNA physiology and participation in BC metastasis regulation: \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe term \u0026quot;competing endogenous RNAs\u0026quot; (ceRNAs) describes RNA transcripts, including circular RNAs, ncRNAs such as circRNAs and lncRNAs, pseudogene transcripts, and mRNAs, that have the ability to control one another by engaging in competition for the binding to MicoRNA Response Elements (MREs) (20,380,381). Based on the ceRNA hypothesis, the miRNA Sponge is integrated into the RNA-induced silencing complex and binds to its target mRNAs to modify the expression of the target (382). RNA editing, RNA-binding proteins, miRNA/ceRNA abundance, and ceRNAs\u0026apos; affinity for miRNAs are some variables that affect ceRNA activity (382) (Fig. 10). Any of these changes could result in an imbalance in the ceRNA-network, which would aid in the development and metastasis of BC (16,22). \u0026nbsp;Recent research on BC has shown that the characteristics of BCM development are largely determined by the dysregulation of many ceRNA-networks (383). Furthermore, it is believed that such a finding would provide a fresh perspective on the concealed facets. Despite the intricacy of the process, ceRNA regulatory networks that impact several metastasis parameters may be responsible for the frequent metastatic progression of BC (23).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAs a result, the study of ceRNA-networks in metastasis has gained a special interest because most ceRNAs, including lncRNAs and circRNAs, have been found to contribute negatively to BC by influencing EMT, migration, invasion, and metastasis (24,384,385). Other ceRNAs associated with EMT in BC include HOTAIR, HULC, and NEAT1, all promoting a mesenchymal phenotype (214,386,387). The miR-200 family and p53 gene regulation regulate EMT, controlling mesenchymal transcription factors (307,388). Other ceRNAs associated with EMT in BC include HOTAIR, HULC, and NEAT1, all promoting a mesenchymal phenotype (389). The miR-200 family and p53 gene regulation regulate EMT, controlling mesenchymal transcription factors (298,390).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe ongoing validation of ceRNA theory has provided new insights into BCM and invasion, leading to the discovery of therapeutic targets and biomarkers and enhancing clinical efficacy and prognosis. Nevertheless, due to the great diversity of BCM-related ceRNAs and their intricate ceRNA networks and inadequate experimental validation, there is a lack of systematic organization and comprehensive assessment of BC-related ceRNAs.\u003c/p\u003e"},{"header":"4. Discussion","content":"\u003cp\u003eMetastasis remains an important clinical challenge for managing BC, as it is the main cause of disease relapse and BC-related fatalities due to its spread to distant organs and resistance to both targeted and systemic therapies (\u003cspan citationid=\"CR391\" class=\"CitationRef\"\u003e391\u003c/span\u003e). Although our knowledge of BC pathogenesis has advanced significantly over the past decades, our understanding of metastasis is still incomplete due to its complexity, which makes it demanding to prevent or target (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR392\" class=\"CitationRef\"\u003e392\u003c/span\u003e, \u003cspan citationid=\"CR393\" class=\"CitationRef\"\u003e393\u003c/span\u003e).\u003c/p\u003e\u003cp\u003eIt has been demonstrated that through various processes, such as cell differentiation, stemness, epigenetic regulation, and EMT, metastatic BC cells pick up aggressive traits from the tumor microenvironment (TME) (\u003cspan citationid=\"CR394\" class=\"CitationRef\"\u003e394\u003c/span\u003e). In agreement, the result of pathway enrichment in the current study exhibited the regulation of stem cell pluripotency, EMT, and cell differentiation, all of which are intimately related in numerous studies (\u003cspan citationid=\"CR395\" class=\"CitationRef\"\u003e395\u003c/span\u003e, \u003cspan citationid=\"CR396\" class=\"CitationRef\"\u003e396\u003c/span\u003e) (Fig.\u0026nbsp;5).\u003c/p\u003e\u003cp\u003eThe particular set of regulatory alterations allows EMT to induce the normal process of increasing differentiation in developing cell populations within an organism (\u003cspan citationid=\"CR395\" class=\"CitationRef\"\u003e395\u003c/span\u003e). Because of their stem cell characteristics, tumor cells produced from EMT are resistant to treatment (\u003cspan citationid=\"CR397\" class=\"CitationRef\"\u003e397\u003c/span\u003e). Because of that, dozens of treatments that target EMT are now being researched for patients with metastasis (\u003cspan citationid=\"CR398\" class=\"CitationRef\"\u003e398\u003c/span\u003e).\u003c/p\u003e\u003cp\u003eAnother significant result of pathway enrichment analysis highlights that proteoglycans play a pivotal role in BCM. In the development of ECM and CSC, proteoglycans are essential, impacting several pathways (\u003cspan citationid=\"CR399\" class=\"CitationRef\"\u003e399\u003c/span\u003e). Therapeutic resistance and CSC phenotype are influenced by aberrant proteoglycans and glycosaminoglycan (GAG) functions (\u003cspan citationid=\"CR400\" class=\"CitationRef\"\u003e400\u003c/span\u003e, \u003cspan citationid=\"CR401\" class=\"CitationRef\"\u003e401\u003c/span\u003e). Stemness is preserved and treatment resistance is encouraged by hyaluronan and the modification of the Wnt, hedgehog, and notch signaling pathways (\u003cspan citationid=\"CR402\" class=\"CitationRef\"\u003e402\u003c/span\u003e). Versican, a tumor stroma-associated proteoglycan in BC, suppresses the transforming growth factor-beta (TGF-β)/Smad2 pathway, promoting EMT and lung metastasis. It also stimulates tumor necrosis factor-alpha (TNF-α) secretion and toll-like receptor 2 (TLR2)/TLR6 complexes, promoting lung metastases (\u003cspan citationid=\"CR403\" class=\"CitationRef\"\u003e403\u003c/span\u003e, \u003cspan citationid=\"CR404\" class=\"CitationRef\"\u003e404\u003c/span\u003e). Likewise, versican G3 modulates the signaling of the epidermal growth factor (EGF) receptor, promoting tumor development and metastasis (\u003cspan additionalcitationids=\"CR406\" citationid=\"CR405\" class=\"CitationRef\"\u003e405\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR407\" class=\"CitationRef\"\u003e407\u003c/span\u003e).\u003c/p\u003e\u003cp\u003eProtein kinase C epsilon (PKCε), which plays a significant role in BCM based on our pathway enrichment results, is another key inducer of EMT in BC cells. Although Jain et al. demonstrated that PKCε acts downstream of TGFβ (\u003cspan citationid=\"CR408\" class=\"CitationRef\"\u003e408\u003c/span\u003e), a previous study revealed PKCε's function in the synthesis of active TGFβ (\u003cspan citationid=\"CR409\" class=\"CitationRef\"\u003e409\u003c/span\u003e). Therefore, PKCε and TGFβ may increase EMT by creating a positive feedback loop. They have also demonstrated that \u003cem\u003eSNAIL\u003c/em\u003e, a crucial mediator of EMT, is positively regulated by PKCε. PKC's downstream targets ras homolog family member C 5 (RhoC5) and signal transducers and activators of transcription 3 (STAT3), which have been found to modulate EMT. (\u003cspan additionalcitationids=\"CR411\" citationid=\"CR410\" class=\"CitationRef\"\u003e410\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR412\" class=\"CitationRef\"\u003e412\u003c/span\u003e). recent study showed that PKC is involved in controlling the stem cell marker \u003cem\u003eNANOG\u003c/em\u003e (\u003cspan citationid=\"CR413\" class=\"CitationRef\"\u003e413\u003c/span\u003e). EMT and the stem cell phenotype are closely related (\u003cspan citationid=\"CR414\" class=\"CitationRef\"\u003e414\u003c/span\u003e, \u003cspan citationid=\"CR415\" class=\"CitationRef\"\u003e415\u003c/span\u003e), so further investigation of PKC's function in stemness may be possible. The significance of PKCε in BC and its potential as a therapeutic target for cancer treatment is thus highlighted by the PKCε-mediated control of EMT.\u003c/p\u003e\u003cp\u003eNumerous investigations conducted in the most recent BC research have demonstrated that the dysregulation of many ceRNA-networks between ncRNAs fundamentally establishes the characteristics of BCM development. In this context, the ceRNA hypothesis posits that ncRNAs and mRNAs can compete for common regions in miRNAs to control the expression of downstream target genes. In the process of tumor invasion and metastasis, these RNAs function as signaling pathway control molecules, tumor suppressors, and oncogenic driver genes (\u003cspan citationid=\"CR380\" class=\"CitationRef\"\u003e380\u003c/span\u003e, \u003cspan citationid=\"CR381\" class=\"CitationRef\"\u003e381\u003c/span\u003e). In addition, it has been shown that CSC-TFs and EMT-TFs are considered essential regulators in developing a metastatic niche, which involves interactions between terminal stromal components and tumor-derived factors (\u003cspan citationid=\"CR416\" class=\"CitationRef\"\u003e416\u003c/span\u003e, \u003cspan citationid=\"CR417\" class=\"CitationRef\"\u003e417\u003c/span\u003e).\u003c/p\u003e\u003cp\u003eAccording to recent research, stem cell-like cells that can self-renew and differentiate into various cell types play a major role in tumor development, spread, and metastasis (\u003cspan citationid=\"CR418\" class=\"CitationRef\"\u003e418\u003c/span\u003e). BC stem cells showed considerable expression of EMT markers such as \u003cem\u003eSNAIL\u003c/em\u003e, \u003cem\u003eSLUG\u003c/em\u003e, \u003cem\u003eTWIST1\u003c/em\u003e, \u003cem\u003eCXCR4\u003c/em\u003e, and \u003cem\u003eFOXF2\u003c/em\u003e, as well as a markedly enhanced capacity for self-renewal and tumor initiation (\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e). This is consistent with our findings that indicate following the construction and analysis of the ceRNA-network, the hub regulatory ncRNAs, MALAT1, miR-1, and miR-9 target \u003cem\u003eTWIST1, SNAIL\u003c/em\u003e, and \u003cem\u003eCXCR4\u003c/em\u003e and participate in BCM (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003e). In 2014 Yang's group demonstrated that the \u003cem\u003eFOXO1\u003c/em\u003e protein-encoding gene suppresses metastasis of BC cells by inducing E-cadherin expression by playing as ceRNA for miR-9. These outcomes are consistent with our discovery when building and analyzing the ceRNA-network for BC metastasis. Gene expression patterns in BC cells were decreased in \u003cem\u003eFOXO1\u003c/em\u003e and E-cadherin, while an upregulated level of miR-9 was observed (\u003cspan citationid=\"CR94\" class=\"CitationRef\"\u003e94\u003c/span\u003e). This co-expression state of \u003cem\u003eFOXO1\u003c/em\u003e and E-cadherin mRNAs was due to their similar binding sites in their 3\u0026prime; UTRs, which competed for binding to common regulator miR-9. The inhibition of EMT and metastasis of BC cells by \u003cem\u003eFOXO1\u003c/em\u003e is done by inhibiting miR-9 and upregulating E-cadherin, a cell-cell adhesion molecule whose lack of expression leads to EMT and metastasis (\u003cspan citationid=\"CR94\" class=\"CitationRef\"\u003e94\u003c/span\u003e).\u003c/p\u003e\u003cp\u003eMoreover, we identified \u003cem\u003eLIN28A\u003c/em\u003e and \u003cem\u003eLIN28B\u003c/em\u003e among hubs in the ceRNA-network, which are targeted by miR-9 and miR-27b, respectively. Lin28 is an RNA-binding protein that is one of the master regulators of embryonic stem cell self-renewal that correlates with clinical tumor grade and the terminal metastasis of BC (\u003cspan citationid=\"CR419\" class=\"CitationRef\"\u003e419\u003c/span\u003e, \u003cspan citationid=\"CR420\" class=\"CitationRef\"\u003e420\u003c/span\u003e). According to Qi et al., Lin28B did not influence the growth of the original tumor in the MMTV-PyMT animal model, but it did encourage the formation of lung metastasis (\u003cspan citationid=\"CR419\" class=\"CitationRef\"\u003e419\u003c/span\u003e). This suggests that the capacity of cancer cells to self-renew can encourage distant metastases in BC.\u003c/p\u003e\u003cp\u003eIn a study by Petri et al., it has been found that dysregulated miRNAs are linked to metastasis. These included upregulated miR-9-5p, miR-10b-5p, miR-21-5p, and miR-29, and downregulated miR-141-3p, miR-200 family members, miR-31-5p, and miR-15b-5p. miR-31-5p suppresses the expression of integrins, including as \u003cem\u003eITGA2, ITGA5, ITGAV, ITGB1, ITGB3\u003c/em\u003e, and \u003cem\u003eITGB5\u003c/em\u003e, which mediates its anti-invasive phenotype (\u003cspan citationid=\"CR77\" class=\"CitationRef\"\u003e77\u003c/span\u003e). These results align with our findings, which indicate that \u003cem\u003eITGB1\u003c/em\u003e is a target that miR-9 downregulates in metastatic BC.\u003c/p\u003e\u003cp\u003eThe result of ceRNA-network construction and investigation indicates that miR-1 targets \u003cem\u003eTWIST1\u003c/em\u003e and \u003cem\u003eSNAIL\u003c/em\u003e, while miR-27 targets ZEB-1 in the ceRNA-network, and miR-9 mostly targets FOX families. \u003cem\u003eITGB4\u003c/em\u003e overexpression, another hub gene in our regulator ceRNA-network, determines the hybrid EMT state in BC. E-cadherin expression inhibits the TWIST1/Mi2/NuRD protein complex, which promotes EMT to cause BCM. This indicates that \u003cem\u003eTWIST1\u003c/em\u003e knockdown is crucial for preventing metastatic BC (\u003cspan citationid=\"CR73\" class=\"CitationRef\"\u003e73\u003c/span\u003e). In addition, lncRNA ATB predicts a poor prognosis for BC and upregulates the miR-200c/\u003cem\u003eTWIST1\u003c/em\u003e axis to enhance EMT (\u003cspan citationid=\"CR181\" class=\"CitationRef\"\u003e181\u003c/span\u003e). miR-720 also targets \u003cem\u003eTWIST1\u003c/em\u003e to prevent tumor invasion and migration in BC (\u003cspan citationid=\"CR153\" class=\"CitationRef\"\u003e153\u003c/span\u003e). \u003cem\u003eSNAIL\u003c/em\u003e suppresses E-cadherin expression by attaching itself to its promoter, which raises vimentin expression and triggers the EMT process. It was discovered that lncRNAs AC026904.1 and UCA1 target the EMT and TGF-β-induced \u003cem\u003eSNAI2\u003c/em\u003e activation in BC (\u003cspan citationid=\"CR183\" class=\"CitationRef\"\u003e183\u003c/span\u003e).\u003c/p\u003e\u003cp\u003eIt has been reported that miR-1 acts as a tumor suppressor in BC (\u003cspan citationid=\"CR421\" class=\"CitationRef\"\u003e421\u003c/span\u003e, \u003cspan citationid=\"CR422\" class=\"CitationRef\"\u003e422\u003c/span\u003e). Overexpression of miR-1 can limit cell invasion and migration (\u003cspan citationid=\"CR115\" class=\"CitationRef\"\u003e115\u003c/span\u003e). The most differentially expressed miRNAs validate that miR-1-3p was down-regulated in BC patients with sentinel lymph node (SLN) metastasis (\u003cspan citationid=\"CR423\" class=\"CitationRef\"\u003e423\u003c/span\u003e). Besides, miR-1 was discovered to be downregulated in BC cells with high levels of metastasis, whereas it was increased in cancer cells with low levels of metastasis (\u003cspan citationid=\"CR126\" class=\"CitationRef\"\u003e126\u003c/span\u003e). BC cells with high and low metastatic potential migrated and invaded after miR-1 inhibition. In addition, vimentin and matrix metallopeptidase 9 (MMP-9) were suppressed by miR-1, but E-cadherin levels were increased (\u003cspan citationid=\"CR116\" class=\"CitationRef\"\u003e116\u003c/span\u003e, \u003cspan citationid=\"CR126\" class=\"CitationRef\"\u003e126\u003c/span\u003e).\u003c/p\u003e\u003cp\u003eBased on our knowledge, identifying potential regulatory networks of miRNAs responsible for self-renewal and EMT can facilitate the detection of metastatic cells with the ability to seed and enable the discovery of therapeutic targets. However, based on the findings of earlier research and bioinformatics prediction, this is the first step in determining the underlying mechanism of BCM. Additional experimental validations are required to guarantee the regulatory effects of pivotal miRNAs and their interactions in BCM.\u003c/p\u003e"},{"header":"5. Conclusion","content":"\u003cp\u003eA comprehensive literature review, bioinformatics prediction, and analysis was conducted in the presented study to examine the role of the ceRNA regulatory network in BCM and invasion. As major regulators of the BCM-related ceRNA-network, the final results identified hsa-miR-1, hsa-miR-9, hsa-miR-27b, and MALAT1 contributing to the poor prognosis of BC. Besides that, the functional enrichment analysis of BP enrichment for GO analysis focuses on controlling pri-miRNA transcription, cell differentiation, EMT, proliferation, angiogenesis, and apoptosis. MF enrichment is dominated by transcription cis-regulatory region binding and ubiquitin protein ligase binding. In contrast, the serine/threonine protein kinase complex and cyclin-dependent protein kinase holoenzyme complex dominate CC enrichment. KEGG analysis focuses on signaling pathways controlling stem cell pluripotency, proteoglycans, and microRNAs in cancer. The overall findings can help clarify the molecular mechanism of BCM and help medical professionals diagnose and treat BC patients with metastases more precisely, preventing the disease from reaching its final stages and choosing the most appropriate and focused course of treatment.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eConsent to Participate Declaration:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable for this study\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics Approval Declaration:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u0026nbsp;for this study\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNo funding was received to conduct this study\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData availability:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll data supporting the findings of this study are available under request\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflict of interest:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare no conflict of interest\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgments\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe thank our colleagues for their association and helpful discussions in this study.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor contributions:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA.N.\u0026nbsp;Conceptualization, research and methodology performance, data analysis and wrote the paper\u003c/p\u003e\n\u003cp\u003eH.A. Drafting the manuscript, investigation, visualizing\u003c/p\u003e\n\u003cp\u003eN.H. Data collection and data curation and recheck\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eR.M. Revising the manuscript and providing technical help\u003c/p\u003e\n\u003cp\u003eR.M. Data collection, drafting manuscript\u003c/p\u003e\n\u003cp\u003eM.A. Review \u0026amp; editing the manuscript\u003c/p\u003e\n\u003cp\u003eM.E. Data analysis\u003c/p\u003e\n\u003cp\u003eB.B. Data collection\u003c/p\u003e\n\u003cp\u003eB.H. Data collection\u003c/p\u003e\n\u003cp\u003eM.J.R. Data collection\u003c/p\u003e\n\u003cp\u003eG.F.\u0026nbsp;Review \u0026amp; revise the manuscript\u003c/p\u003e\n\u003cp\u003eR.N. Editing the manuscript\u003c/p\u003e\n\u003cp\u003eM.S. Validation, supervision, and conceptualization.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eGiaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74(6):477\u0026ndash;95. \u003c/li\u003e\n\u003cli\u003eLiao L. Inequality in breast cancer: Global statistics from 2022 to 2050. The Breast. 2025;79:103851. \u003c/li\u003e\n\u003cli\u003eCaswell-Jin JL, Sun LP, Munoz D, Lu Y, Li Y, Huang H, et al. Analysis of breast cancer mortality in the US\u0026mdash;1975 to 2019. Jama. 2024;331(3):233\u0026ndash;41. \u003c/li\u003e\n\u003cli\u003eChen W, Hoffmann AD, Liu H, Liu X. Organotropism: new insights into molecular mechanisms of breast cancer metastasis. npj Precis Oncol [Internet]. 2018;2(1):4. Available from: https://doi.org/10.1038/s41698-018-0047-0\u003c/li\u003e\n\u003cli\u003ePark M, Kim D, Ko S, Kim A, Mo K, Yoon H. Breast cancer metastasis: mechanisms and therapeutic implications. Int J Mol Sci. 2022;23(12):6806. \u003c/li\u003e\n\u003cli\u003ede Azevedo ALK, Carvalho TM, Mara CS, Giner IS, de Oliveira JC, Gradia DF, et al. Major regulators of the multi-step metastatic process are potential therapeutic targets for breast cancer management. Funct Integr Genomics. 2023;23(2):171. \u003c/li\u003e\n\u003cli\u003eGinsburg O, Yip C, Brooks A, Cabanes A, Caleffi M, Dunstan Yataco JA, et al. Breast cancer early detection: A phased approach to implementation. Cancer. 2020;126:2379\u0026ndash;93. \u003c/li\u003e\n\u003cli\u003eChen S, Navickas A, Goodarzi H. Translational adaptation in breast cancer maetastasis and emerging therapeutic opportunities. Trends Pharmacol Sci. 2024; \u003c/li\u003e\n\u003cli\u003eZhang T, Zhou H, Wang K, Wang X, Wang M, Zhao W, et al. Role, molecular mechanism and the potential target of breast cancer stem cells in breast cancer development. Biomed Pharmacother. 2022;147:112616. \u003c/li\u003e\n\u003cli\u003eRakha EA, Pareja FG. New advances in molecular breast cancer pathology. In: Seminars in cancer biology. Elsevier; 2021. p. 102\u0026ndash;13. \u003c/li\u003e\n\u003cli\u003eRakha EA, Tse GM, Quinn CM. An update on the pathological classification of breast cancer. Histopathology. 2023;82(1):5\u0026ndash;16. \u003c/li\u003e\n\u003cli\u003eBruzas S, Kuemmel S, Harrach H, Breit E, Ataseven B, Traut A, et al. Next-generation sequencing-directed therapy in patients with metastatic breast cancer in routine clinical practice. Cancers (Basel). 2021;13(18):4564. \u003c/li\u003e\n\u003cli\u003eSuh KJ, Kim SH, Kim YJ, Shin H, Kang E, Kim EK, et al. Clinical application of next-generation sequencing in patients with breast cancer: real-world data. J Breast Cancer. 2022;25(5):366. \u003c/li\u003e\n\u003cli\u003evan Geelen CT, Savas P, Teo ZL, Luen SJ, Weng CF, Ko YA, et al. Clinical implications of prospective genomic profiling of metastatic breast cancer patients. Breast Cancer Res. 2020;22:1\u0026ndash;13. \u003c/li\u003e\n\u003cli\u003eMicheel J, Safrastyan A, Wollny D. Advances in non-coding RNA sequencing. Non-coding RNA. 2021;7(4):70. \u003c/li\u003e\n\u003cli\u003eYang S, Wang X, Zhou X, Hou L, Wu J, Zhang W, et al. ncRNA-mediated ceRNA regulatory network: Transcriptomic insights into breast cancer progression and treatment strategies. Biomed Pharmacother. 2023;162:114698. \u003c/li\u003e\n\u003cli\u003eSaranya I, Dharshini VS, Akshaya RL, Subhashini PS, Selvamurugan N. Regulatory and therapeutic implications of competing endogenous RNA network in breast cancer progression and metastasis: a review. Int J Biol Macromol. 2024;131075. \u003c/li\u003e\n\u003cli\u003eKartha R V, Subramanian S. Competing endogenous RNAs (ceRNAs): new entrants to the intricacies of gene regulation. Front Genet. 2014;5:8. \u003c/li\u003e\n\u003cli\u003eMondal P, Meeran SM. Long non-coding RNAs in breast cancer metastasis. Non-coding RNA Res. 2020 Dec;5(4):208\u0026ndash;18. \u003c/li\u003e\n\u003cli\u003eLin W, Liu H, Tang Y, Wei Y, Wei W, Zhang L, et al. The development and controversy of competitive endogenous RNA hypothesis in non-coding genes. Mol Cell Biochem. 2021 Jan;476(1):109\u0026ndash;23. \u003c/li\u003e\n\u003cli\u003eYang X, Li F, Ma J, Liu Y, Wang X, Wang R, et al. Study on the relationship between the miRNA-centered ceRNA regulatory network and fatigue. J Mol Neurosci. 2021;1\u0026ndash;8. \u003c/li\u003e\n\u003cli\u003eAbdollahzadeh R, Daraei A, Mansoori Y, Sepahvand M, Amoli MM, Tavakkoly‐Bazzaz J. Competing endogenous RNA (ceRNA) cross talk and language in ceRNA regulatory networks: a new look at hallmarks of breast cancer. J Cell Physiol. 2019;234(7):10080\u0026ndash;100. \u003c/li\u003e\n\u003cli\u003eQian D, Zheng Q, Wu D, Ye B, Qian Y, Zhou T, et al. Integrated Analysis of ceRNA Network Reveals Prognostic and Metastasis Associated Biomarkers in Breast Cancer. Front Oncol. 2021;11:670138. \u003c/li\u003e\n\u003cli\u003eWu Y, Shao A, Wang L, Hu K, Yu C, Pan C, et al. The Role of lncRNAs in the Distant Metastasis of Breast Cancer. Front Oncol. 2019;9:407. \u003c/li\u003e\n\u003cli\u003eSang M, Meng L, Liu S, Ding P, Chang S, Ju Y, et al. Circular RNA ciRS-7 Maintains Metastatic Phenotypes as a ceRNA of miR-1299 to Target MMPs. Mol Cancer Res. 2018 Nov;16(11):1665\u0026ndash;75. \u003c/li\u003e\n\u003cli\u003eHua K, Deng X, Hu J, Ji C, Yu Y, Li J, et al. Long noncoding RNA HOST2, working as a competitive endogenous RNA, promotes STAT3-mediated cell proliferation and migration via decoying of let-7b in triple-negative breast cancer. J Exp Clin Cancer Res. 2020 Apr;39(1):58. \u003c/li\u003e\n\u003cli\u003eZheng X, Huang M, Xing L, Yang R, Wang X, Jiang R, et al. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer. Mol Cancer. 2020 Apr;19(1):73. \u003c/li\u003e\n\u003cli\u003eLi X, Zheng L, Zhang F, Hu J, Chou J, Liu Y, et al. STARD13-correlated ceRNA network inhibits EMT and metastasis of breast cancer. Oncotarget. 2016;7(17):23197. \u003c/li\u003e\n\u003cli\u003eZheng L, Zhang Z, Zhang S, Guo Q, Zhang F, Gao L, et al. RNA Binding Protein RNPC1 Inhibits Breast Cancer Cell Metastasis via Activating STARD13-Correlated ceRNA Network. Mol Pharm. 2018 Jun;15(6):2123\u0026ndash;32. \u003c/li\u003e\n\u003cli\u003eSang M, Wu M, Meng L, Zheng Y, Gu L, Liu F, et al. Identification of epithelial-mesenchymal transition-related circRNA-miRNA-mRNA ceRNA regulatory network in breast cancer. Pathol - Res Pract [Internet]. 2020;216(9):153088. Available from: https://www.sciencedirect.com/science/article/pii/S0344033820314060\u003c/li\u003e\n\u003cli\u003eLiu S, Song A, Zhou X, Huo Z, Yao S, Yang B, et al. ceRNA network development and tumour-infiltrating immune cell analysis of metastatic breast cancer to bone. J bone Oncol. 2020 Oct;24:100304. \u003c/li\u003e\n\u003cli\u003eLiberati A, Altman DG, Tetzlaff J, Mulrow C, G\u0026oslash;tzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339. \u003c/li\u003e\n\u003cli\u003eMethley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014;14(1):579. \u003c/li\u003e\n\u003cli\u003eSampson M, McGowan J, Cogo E, Grimshaw J, Moher D, Lefebvre C. An evidence-based practice guideline for the peer review of electronic search strategies. J Clin Epidemiol. 2009;62(9):944\u0026ndash;52. \u003c/li\u003e\n\u003cli\u003eCASP UK. CASP (Critical Appraisal Skills Program) Checklists. 2018. \u003c/li\u003e\n\u003cli\u003eWhiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011 Oct;155(8):529\u0026ndash;36. \u003c/li\u003e\n\u003cli\u003eMunn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18(10):2127\u0026ndash;33. \u003c/li\u003e\n\u003cli\u003eMunn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Heal policy Manag. 2014;3(3):123. \u003c/li\u003e\n\u003cli\u003eRu Y, Kechris KJ, Tabakoff B, Hoffman P, Radcliffe RA, Bowler R, et al. The multiMiR R package and database: integration of microRNA\u0026ndash;target interactions along with their disease and drug associations. Nucleic Acids Res. 2014;42(17):e133\u0026ndash;e133. \u003c/li\u003e\n\u003cli\u003eHsu SD, Lin FM, Wu WY, Liang C, Huang WC, Chan WL, et al. miRTarBase: a database curates experimentally validated microRNA\u0026ndash;target interactions. Nucleic Acids Res. 2011;39(suppl_1):D163\u0026ndash;9. \u003c/li\u003e\n\u003cli\u003eEdris B. A comparison of the Oligomap and TargetScan algorithms for miRNA target analysis. Bmi231 stanford edu. 2011; \u003c/li\u003e\n\u003cli\u003eChen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 2020;48(D1):D127\u0026ndash;31. \u003c/li\u003e\n\u003cli\u003eNapoli S. LncRNAs and available databases. Long Non-Coding RNAs Cancer. 2021;3\u0026ndash;26. \u003c/li\u003e\n\u003cli\u003eDudekula DB, Panda AC, Grammatikakis I, De S, Abdelmohsen K, Gorospe M. CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biol. 2016;13(1):34\u0026ndash;42. \u003c/li\u003e\n\u003cli\u003eDoncheva NT, Morris JH, Gorodkin J, Jensen LJ. Cytoscape StringApp: network analysis and visualization of proteomics data. J Proteome Res. 2018;18(2):623\u0026ndash;32. \u003c/li\u003e\n\u003cli\u003eChin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol [Internet]. 2014;8(4):S11. Available from: https://doi.org/10.1186/1752-0509-8-S4-S11\u003c/li\u003e\n\u003cli\u003eBindea G, Galon J, Mlecnik B. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics. 2013;29(5):661\u0026ndash;3. \u003c/li\u003e\n\u003cli\u003eSzklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein\u0026ndash;protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638\u0026ndash;46. \u003c/li\u003e\n\u003cli\u003eKohl M, Wiese S, Warscheid B. Cytoscape: software for visualization and analysis of biological networks. In: Data mining in proteomics: from standards to applications. Springer; 2010. p. 291\u0026ndash;303. \u003c/li\u003e\n\u003cli\u003eEvangelista JE, Xie Z, Marino GB, Nguyen N, Clarke DJB, Ma\u0026rsquo;ayan A. Enrichr-KG: bridging enrichment analysis across multiple libraries. Nucleic Acids Res. 2023;51(W1):W168\u0026ndash;79. \u003c/li\u003e\n\u003cli\u003eKuleshov M V, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1):W90\u0026ndash;7. \u003c/li\u003e\n\u003cli\u003eWickham H, Chang W, Wickham MH. Package \u0026lsquo;ggplot2.\u0026rsquo; Creat elegant data Vis using Gramm Graph Version. 2016;2(1):1\u0026ndash;189. \u003c/li\u003e\n\u003cli\u003eYu J, Mu Q, Fung M, Xu X, Zhu L, Ho RJY. Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response. Pharmacol Ther. 2022;236:108108. \u003c/li\u003e\n\u003cli\u003eMcGee SF. Understanding metastasis: current paradigms and therapeutic challenges in breast cancer progression. 2023; \u003c/li\u003e\n\u003cli\u003eDujon AM, Capp JP, Brown JS, Pujol P, Gatenby RA, Ujvari B, et al. Is there one key step in the metastatic cascade? Cancers (Basel). 2021;13(15):3693. \u003c/li\u003e\n\u003cli\u003eRamamoorthi G, Kodumudi K, Gallen C, Zachariah NN, Basu A, Albert G, et al. Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities. In: Seminars in cancer biology. Elsevier; 2022. p. 78\u0026ndash;89. \u003c/li\u003e\n\u003cli\u003eBuyuk B, Jin S, Ye K. Epithelial-to-mesenchymal transition signaling pathways responsible for breast cancer metastasis. Cell Mol Bioeng. 2022;15(1):1\u0026ndash;13. \u003c/li\u003e\n\u003cli\u003eMortezaee K, Majidpoor J, Kharazinejad E. Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated. Med Oncol. 2022;39(12):193. \u003c/li\u003e\n\u003cli\u003eLambert AW, Weinberg RA. Linking EMT programmes to normal and neoplastic epithelial stem cells. Nat Rev Cancer. 2021;21(5):325\u0026ndash;38. \u003c/li\u003e\n\u003cli\u003eVardas V, Politaki E, Pantazaka E, Georgoulias V, Kallergi G. Epithelial-to-mesenchymal transition of tumor cells: cancer progression and metastasis. Int J Dev Biol. 2021;66(1-2\u0026ndash;3):277\u0026ndash;83. \u003c/li\u003e\n\u003cli\u003eNoubissi Nzeteu GA, Geismann C, Arlt A, Hoogwater FJH, Nijkamp MW, Meyer NH, et al. Role of epithelial-to-mesenchymal transition for the generation of circulating tumors cells and cancer cell dissemination. Cancers (Basel). 2022;14(22):5483. \u003c/li\u003e\n\u003cli\u003eCeli\u0026agrave;-Terrassa T, Jolly MK. Cancer stem cells and epithelial-to-mesenchymal transition in cancer metastasis. Cold Spring Harb Perspect Med. 2020;10(7):a036905. \u003c/li\u003e\n\u003cli\u003eKulus M, Farzaneh M, Bryja A, Zehtabi M, Azizidoost S, Abouali Gale Dari M, et al. Phenotypic Transitions the Processes Involved in Regulation of Growth and Proangiogenic Properties of Stem Cells, Cancer Stem Cells and Circulating Tumor Cells. Stem Cell Rev Reports. 2024;1\u0026ndash;13. \u003c/li\u003e\n\u003cli\u003eMo S, Fang D, Zhao S, Hoa PTT, Zhou C, Liang T, et al. Down regulated oncogene KIF2C inhibits growth, invasion, and metastasis of hepatocellular carcinoma through the Ras/MAPK signaling pathway and epithelial-to-mesenchymal transition. Ann Transl Med. 2022;10(3). \u003c/li\u003e\n\u003cli\u003eMaharati A, Moghbeli M. PI3K/AKT signaling pathway as a critical regulator of epithelial-mesenchymal transition in colorectal tumor cells. Cell Commun Signal. 2023;21(1):201. \u003c/li\u003e\n\u003cli\u003eLavin DP, Tiwari VK. Unresolved complexity in the gene regulatory network underlying EMT. Front Oncol. 2020;10:554. \u003c/li\u003e\n\u003cli\u003eKhanbabaei H, Ebrahimi S, Garc\u0026iacute;a-Rodr\u0026iacute;guez JL, Ghasemi Z, Pourghadamyari H, Mohammadi M, et al. Non-coding RNAs and epithelial mesenchymal transition in cancer: molecular mechanisms and clinical implications. J Exp Clin Cancer Res. 2022;41(1):278. \u003c/li\u003e\n\u003cli\u003eHussen BM, Shoorei H, Mohaqiq M, Dinger ME, Hidayat HJ, Taheri M, et al. The impact of non-coding RNAs in the epithelial to mesenchymal transition. Front Mol Biosci. 2021;8:665199. \u003c/li\u003e\n\u003cli\u003eYousefi M, Nosrati R, Salmaninejad A, Dehghani S, Shahryari A, Saberi A. Organ-specific metastasis of breast cancer: molecular and cellular mechanisms underlying lung metastasis. Cell Oncol [Internet]. 2018;41(2):123\u0026ndash;40. Available from: https://doi.org/10.1007/s13402-018-0376-6\u003c/li\u003e\n\u003cli\u003eXu Y, Qin L, Sun T, Wu H, He T, Yang Z, et al. Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression. Oncogene. 2017 Feb;36(8):1157\u0026ndash;66. \u003c/li\u003e\n\u003cli\u003eOlmeda D, Moreno-Bueno G, Flores JM, Fabra A, Portillo F, Cano A. SNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells. Cancer Res. 2007 Dec;67(24):11721\u0026ndash;31. \u003c/li\u003e\n\u003cli\u003eLee HY, Cha J, Kim SK, Park JH, Song KH, Kim P, et al. c-MYC Drives Breast Cancer Metastasis to the Brain, but Promotes Synthetic Lethality with TRAIL. Mol Cancer Res. 2019 Feb;17(2):544\u0026ndash;54. \u003c/li\u003e\n\u003cli\u003eImani S, Hosseinifard H, Cheng J, Wei C, Fu J. Prognostic Value of EMT-inducing Transcription Factors (EMT-TFs) in Metastatic Breast Cancer: A Systematic Review and Meta-analysis. Sci Rep. 2016 Jun;6:28587. \u003c/li\u003e\n\u003cli\u003eTania M, Khan MA, Fu J. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014 Aug;35(8):7335\u0026ndash;42. \u003c/li\u003e\n\u003cli\u003eGoossens S, Vandamme N, Van Vlierberghe P, Berx G. EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET. Biochim Biophys acta Rev cancer. 2017 Dec;1868(2):584\u0026ndash;91. \u003c/li\u003e\n\u003cli\u003eErgin K, \u0026Ccedil;etinkaya R. Regulation of MicroRNAs BT - miRNomics: MicroRNA Biology and Computational Analysis. In: Allmer J, Yousef M, editors. New York, NY: Springer US; 2022. p. 1\u0026ndash;32. Available from: https://doi.org/10.1007/978-1-0716-1170-8_1\u003c/li\u003e\n\u003cli\u003ePetri BJ, Klinge CM. Regulation of breast cancer metastasis signaling by miRNAs. Cancer metastasis Rev. 2020;39(3):837\u0026ndash;86. \u003c/li\u003e\n\u003cli\u003eHashemi ZS, Moghadam MF, Khalili S, Hashemi SM, Sepehr KS, Sadroddiny E. Distinctive Expression of MetastamiRs in Breast Cancer Mesenchymal Stem Cells Isolated from Solid Tumor. Curr Stem Cell Res Ther. 2024;19(11):1525\u0026ndash;34. \u003c/li\u003e\n\u003cli\u003eOtmani K, Lewalle P. Tumor suppressor miRNA in cancer cells and the tumor microenvironment: mechanism of deregulation and clinical implications. Front Oncol. 2021;11:708765. \u003c/li\u003e\n\u003cli\u003eOtmani K, Rouas R, Berehab M, Lewalle P. The regulatory mechanisms of oncomiRs in cancer. Biomed Pharmacother. 2024;171:116165. \u003c/li\u003e\n\u003cli\u003eParrella P, Barbano R, Pasculli B, Fontana A, Copetti M, Valori VM, et al. Evaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients. Mol Cancer. 2014 Jun;13:142. \u003c/li\u003e\n\u003cli\u003eMa L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449(7163):682\u0026ndash;8. \u003c/li\u003e\n\u003cli\u003eHalim A, Al-Qadi N, Kenyon E, Conner KN, Mondal SK, Medarova Z, et al. Inhibition of miR-10b treats metastatic breast cancer by targeting stem cell-like properties. Oncotarget; Vol 15 [Internet]. 2024; Available from: https://www.oncotarget.com/article/28641/text/\u003c/li\u003e\n\u003cli\u003eSavad S, Mehdipour P, Miryounesi M, Shirkoohi R, Fereidooni F, Mansouri F, et al. Expression analysis of MiR-21, MiR-205, and MiR-342 in breast cancer in Iran. Asian Pac J Cancer Prev. 2012;13(3):873\u0026ndash;7. \u003c/li\u003e\n\u003cli\u003eLi J, Zhang Y, Zhang W, Jia S, Tian R, Kang Y, et al. Genetic heterogeneity of breast cancer metastasis may be related to miR-21 regulation of TIMP-3 in translation. Int J Surg Oncol. 2013;2013:875078. \u003c/li\u003e\n\u003cli\u003eToraih EA, Mohammed EA, Farrag S, Ramsis N, Hosny S. Pilot Study of Serum MicroRNA-21 as a Diagnostic and Prognostic Biomarker in Egyptian Breast Cancer Patients. Mol Diagn Ther. 2015 Jun;19(3):179\u0026ndash;90. \u003c/li\u003e\n\u003cli\u003eSong B, Wang C, Liu J, Wang X, Lv L, Wei L, et al. MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res. 2010 Mar;29(1):29. \u003c/li\u003e\n\u003cli\u003eRostas JW 3rd, Pruitt HC, Metge BJ, Mitra A, Bailey SK, Bae S, et al. microRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancer. Mol Cancer. 2014 Aug;13:200. \u003c/li\u003e\n\u003cli\u003eL\u0026uuml; J, Zhao Q, Guo Y, Li D, Xie H, Liu C, et al. Regulation of ER\u0026alpha;-dependent breast cancer metastasis by a miR-29a signaling. J Exp Clin Cancer Res [Internet]. 2023;42(1):93. Available from: https://doi.org/10.1186/s13046-023-02665-6\u003c/li\u003e\n\u003cli\u003eGebeshuber CA, Zatloukal K, Martinez J. miR‐29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep [Internet]. 2009 Apr 1;10(4):400\u0026ndash;5. Available from: https://doi.org/10.1038/embor.2009.9\u003c/li\u003e\n\u003cli\u003eKrell J, Frampton AE, Jacob J, Pellegrino L, Roca-Alonso L, Zeloof D, et al. The clinico-pathologic role of microRNAs miR-9 and miR-151-5p in breast cancer metastasis. Mol Diagn Ther. 2012 Jun;16(3):167\u0026ndash;72. \u003c/li\u003e\n\u003cli\u003eD\u0026rsquo;Ippolito E, Plantamura I, Bongiovanni L, Casalini P, Baroni S, Piovan C, et al. miR-9 and miR-200 regulate PDGFR\u0026beta;-mediated endothelial differentiation of tumor cells in triple-negative breast cancer. Cancer Res. 2016;76(18):5562\u0026ndash;72. \u003c/li\u003e\n\u003cli\u003eGravgaard KH, Lyng MB, Laenkholm AV, S\u0026oslash;kilde R, Nielsen BS, Litman T, et al. The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. Breast Cancer Res Treat. 2012;134:207\u0026ndash;17. \u003c/li\u003e\n\u003cli\u003eYang J, Li T, Gao C, Lv X, Liu K, Song H, et al. FOXO1 3\u0026rsquo;UTR functions as a ceRNA in repressing the metastases of breast cancer cells via regulating miRNA activity. FEBS Lett. 2014 Aug;588(17):3218\u0026ndash;24. \u003c/li\u003e\n\u003cli\u003eWang CZ, Yuan P, Li Y. MiR-126 regulated breast cancer cell invasion by targeting ADAM9. Int J Clin Exp Pathol. 2015;8(6):6547\u0026ndash;53. \u003c/li\u003e\n\u003cli\u003eTurgut Cosan D, Oner C, Mutlu Sahin F. Micro RNA-126 coordinates cell behavior and signaling cascades according to characteristics of breast cancer cells. Bratisl Lek Listy. 2016;117(11):639\u0026ndash;47. \u003c/li\u003e\n\u003cli\u003eSachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 2010;70(1):378\u0026ndash;87. \u003c/li\u003e\n\u003cli\u003eKim SJ, Oh JS, Shin JY, Lee KD, Sung KW, Nam SJ, et al. Development of microRNA-145 for therapeutic application in breast cancer. J Control Release [Internet]. 2011;155(3):427\u0026ndash;34. Available from: https://www.sciencedirect.com/science/article/pii/S0168365911004408\u003c/li\u003e\n\u003cli\u003eMohammadi-Yeganeh S, Paryan M, Arefian E, Vasei M, Ghanbarian H, Mahdian R, et al. MicroRNA-340 inhibits the migration, invasion, and metastasis of breast cancer cells by targeting Wnt pathway. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2016 Jul;37(7):8993\u0026ndash;9000. \u003c/li\u003e\n\u003cli\u003eWu Z, Wu Q, Wang C, Wang X, Huang J, Zhao J, et al. miR‐340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c‐Met. Cancer. 2011;117(13):2842\u0026ndash;52. \u003c/li\u003e\n\u003cli\u003eDuan WJ, Bi PD, Ma Y, Liu NQ, Zhen X. MiR-512-3p regulates malignant tumor behavior and multi-drug resistance in breast cancer cells via targeting Livin. Neoplasma. 2020 Jan;67(1):102\u0026ndash;10. \u003c/li\u003e\n\u003cli\u003ePardo OE, Castellano L, Munro CE, Hu Y, Mauri F, Krell J, et al. miR-515-5p controls cancer cell migration through MARK4 regulation. EMBO Rep. 2016 Apr;17(4):570\u0026ndash;84. \u003c/li\u003e\n\u003cli\u003eDuong TTC, Nguyen THN, Nguyen TTN, Huynh LH, Ngo HP, Nguyen HT. Diagnostic and prognostic value of miR-200 family in breast cancer: A meta-analysis and systematic review. Cancer Epidemiol. 2022;77:102097. \u003c/li\u003e\n\u003cli\u003eKim HY, Ha Thi HT, Hong S. IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor. Cancer Lett. 2018 Feb;415:30\u0026ndash;9. \u003c/li\u003e\n\u003cli\u003eRoy SS, Gonugunta VK, Bandyopadhyay A, Rao MK, Goodall GJ, Sun LZ, et al. Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer. Oncogene. 2014 Jul;33(28):3707\u0026ndash;16. \u003c/li\u003e\n\u003cli\u003eLi X, Roslan S, Johnstone CN, Wright JA, Bracken CP, Anderson M, et al. MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways. Oncogene [Internet]. 2014;33(31):4077\u0026ndash;88. Available from: https://doi.org/10.1038/onc.2013.370\u003c/li\u003e\n\u003cli\u003eTsouko E, Wang J, Frigo DE, Aydogdu E, Williams C. miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene. Carcinogenesis [Internet]. 2015;36(9):1051\u0026ndash;60. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84940670729\u0026amp;doi=10.1093%2Fcarcin%2Fbgv087\u0026amp;partnerID=40\u0026amp;md5=e73c71d4df4f0c7c16568a59750db7b7\u003c/li\u003e\n\u003cli\u003eHumphries B, Wang Z, Oom AL, Fisher T, Tan D, Cui Y, et al. MicroRNA-200b targets protein kinase C\u0026alpha; and suppresses triple-negative breast cancer metastasis. Carcinogenesis [Internet]. 2014 Oct 1;35(10):2254\u0026ndash;63. Available from: https://doi.org/10.1093/carcin/bgu133\u003c/li\u003e\n\u003cli\u003eZhang G, Zhang W, Li B, Stringer-Reasor E, Chu C, Sun L, et al. MicroRNA-200c and microRNA- 141 are regulated by a FOXP3-KAT2B axis and associated with tumor metastasis in breast cancer. Breast Cancer Res [Internet]. 2017;19(1):73. Available from: https://doi.org/10.1186/s13058-017-0858-x\u003c/li\u003e\n\u003cli\u003eDykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, et al. miR-200 Enhances Mouse Breast Cancer Cell Colonization to Form Distant Metastases. PLoS One [Internet]. 2009 Sep 29;4(9):e7181. Available from: https://doi.org/10.1371/journal.pone.0007181\u003c/li\u003e\n\u003cli\u003eZhou Y, Wang M, Tong Y, Liu X, Zhang L, Dong D, et al. miR-206 Promotes Cancer Progression by Targeting Full-Length Neurokinin-1 Receptor in Breast Cancer. Technol Cancer Res Treat. 2019 Jan;18:1533033819875168\u0026ndash;1533033819875168. \u003c/li\u003e\n\u003cli\u003eLiu Hao, Cao You-De, Ye Wei-Xia, Sun Yang-Yang. Effect of microRNA-206 on Cytoskeleton Remodelling by Downregulating Cdc42 in MDA-MB-231 Cells. Tumori J [Internet]. 2010 Sep 1;96(5):751\u0026ndash;5. Available from: https://doi.org/10.1177/030089161009600518\u003c/li\u003e\n\u003cli\u003eAdorno-Cruz V, Hoffmann AD, Liu X, Dashzeveg NK, Taftaf R, Wray B, et al. ITGA2 promotes expression of ACLY and CCND1 in enhancing breast cancer stemness and metastasis. Genes Dis [Internet]. 2021;8(4):493\u0026ndash;508. Available from: https://www.sciencedirect.com/science/article/pii/S2352304220300234\u003c/li\u003e\n\u003cli\u003eLin ZJ, Ming J, Yang L, Du JZ, Wang N, Luo HJ. Mechanism of Regulatory Effect of MicroRNA-206 on Connexin 43 in Distant Metastasis of Breast Cancer. Chin Med J (Engl). 2016 Feb;129(4):424\u0026ndash;34. \u003c/li\u003e\n\u003cli\u003eLiu R, Li J, Lai Y, Liao Y, Liu R, Qiu W. Hsa-miR-1 suppresses breast cancer development by down-regulating K-ras and long non-coding RNA MALAT1. Int J Biol Macromol. 2015 Nov;81:491\u0026ndash;7. \u003c/li\u003e\n\u003cli\u003eChou J, Wang B, Zheng T, Li X, Zheng L, Hu J, et al. MALAT1 induced migration and invasion of human breast cancer cells by competitively binding miR-1 with cdc42. Biochem Biophys Res Commun. 2016;472(1):262\u0026ndash;9. \u003c/li\u003e\n\u003cli\u003eJin C, Yan B, Lu Q, Lin Y, Ma L. Reciprocal regulation of Hsa-miR-1 and long noncoding RNA MALAT1 promotes triple-negative breast cancer development. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2016 Jun;37(6):7383\u0026ndash;94. \u003c/li\u003e\n\u003cli\u003eMinemura H, Takagi K, Miki Y, Shibahara Y, Nakagawa S, Ebata A, et al. Abnormal expression of miR-1 in breast carcinoma as a potent prognostic factor. Cancer Sci. 2015 Nov;106(11):1642\u0026ndash;50. \u003c/li\u003e\n\u003cli\u003eTian X, Yu H, Li D, Jin G, Dai S, Gong P, et al. The miR-5694/AF9/Snail Axis Provides Metastatic Advantages and a Therapeutic Target in Basal-like Breast Cancer. Mol Ther [Internet]. 2021;29(3):1239\u0026ndash;57. Available from: https://www.sciencedirect.com/science/article/pii/S1525001620306201\u003c/li\u003e\n\u003cli\u003eHarati R, Mabondzo A, Tlili A, Khoder G, Mahfood M, Hamoudi R. Combinatorial targeting of microRNA-26b and microRNA-101 exerts a synergistic inhibition on cyclooxygenase-2 in brain metastatic triple-negative breast cancer cells. Breast Cancer Res Treat. 2021 Jun;187(3):695\u0026ndash;713. \u003c/li\u003e\n\u003cli\u003eJia Y, Zhao J, Yang J, Shao J, Cai Z. miR-301 regulates the SIRT1/SOX2 pathway via CPEB1 in the breast cancer progression. Mol Ther - Oncolytics [Internet]. 2021;22:13\u0026ndash;26. Available from: https://www.sciencedirect.com/science/article/pii/S2372770521000401\u003c/li\u003e\n\u003cli\u003eLu Y, Hu X, Yang X. miR-934 promotes breast cancer metastasis by regulation of PTEN and epithelial\u0026ndash;mesenchymal transition. Tissue Cell [Internet]. 2021;71:101581. Available from: https://www.sciencedirect.com/science/article/pii/S0040816621000975\u003c/li\u003e\n\u003cli\u003eXu Y, Ye S, Zhang N, Zheng S, Liu H, Zhou K, et al. The FTO/miR-181b-3p/ARL5B signaling pathway regulates cell migration and invasion in breast cancer. Cancer Commun (London, England). 2020 Oct;40(10):484\u0026ndash;500. \u003c/li\u003e\n\u003cli\u003eZhang X, Zhao H, Zhang Y, Yang X, Zhang J, Yi M, et al. The MicroRNA-382-5p/MXD1 Axis Relates to Breast Cancer Progression and Promotes Cell Malignant Phenotypes. J Surg Res. 2020 Feb;246:442\u0026ndash;9. \u003c/li\u003e\n\u003cli\u003eMalagobadan S, Ho CS, Nagoor NH. MicroRNA-6744-5p promotes anoikis in breast cancer and directly targets NAT1 enzyme. Cancer Biol Med. 2020 Feb;17(1):101\u0026ndash;11. \u003c/li\u003e\n\u003cli\u003ePeng J, Yuan C, Wu Z, Wang Y, Yin W, Lin Y, et al. Upregulation of microRNA‑1 inhibits proliferation and metastasis of breast cancer. Mol Med Rep. 2020;22(1):454\u0026ndash;64. \u003c/li\u003e\n\u003cli\u003eLiu C, Song YH, Mao Y, Wang HB, Nie G. MiRNA-106a promotes breast cancer progression by regulating DAX-1. Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1574\u0026ndash;83. \u003c/li\u003e\n\u003cli\u003eRajarajan D, Selvarajan S, Charan Raja MR, Kar Mahapatra S, Kasiappan R. Genome-wide analysis reveals miR-3184-5p and miR-181c-3p as a critical regulator for adipocytes-associated breast cancer. J Cell Physiol. 2019 Aug;234(10):17959\u0026ndash;74. \u003c/li\u003e\n\u003cli\u003eLiu JH, Yang Y, Song Q, Li JB. MicroRNA-155regulates the proliferation and metastasis of human breast cancers by targeting MAPK7. J BUON. 2019;24(3):1075\u0026ndash;80. \u003c/li\u003e\n\u003cli\u003eMcAnena P, Tanriverdi K, Curran C, Gilligan K, Freedman JE, Brown JAL, et al. Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer. BMC Cancer. 2019 May;19(1):436. \u003c/li\u003e\n\u003cli\u003eRen L, Chen H, Song J, Chen X, Lin C, Zhang X, et al. MiR-454-3p-Mediated Wnt/\u0026beta;-catenin Signaling Antagonists Suppression Promotes Breast Cancer Metastasis. Theranostics. 2019;9(2):449\u0026ndash;65. \u003c/li\u003e\n\u003cli\u003eWang S, Huang M, Wang Z, Wang W, Zhang Z, Qu S, et al. MicroRNA‑133b targets TGF\u0026beta; receptor I to inhibit TGF‑\u0026beta;‑induced epithelial‑to‑mesenchymal transition and metastasis by suppressing the TGF‑\u0026beta;/SMAD pathway in breast cancer. Int J Oncol. 2019 Nov;55(5):1097\u0026ndash;109. \u003c/li\u003e\n\u003cli\u003eHu PC, Li K, Tian YH, Pan WT, Wang Y, Xu XL, et al. CREB1/Lin28/miR-638/VASP Interactive Network Drives the Development of Breast Cancer. Int J Biol Sci. 2019;15(12):2733\u0026ndash;49. \u003c/li\u003e\n\u003cli\u003eLiu X, Cao M, Palomares M, Wu X, Li A, Yan W, et al. Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts. Breast Cancer Res. 2018 Oct;20(1):127. \u003c/li\u003e\n\u003cli\u003eChen X, Zhao M, Huang J, Li Y, Wang S, Harrington CA, et al. microRNA-130a suppresses breast cancer cell migration and invasion by targeting FOSL1 and upregulating ZO-1. J Cell Biochem. 2018 Jun;119(6):4945\u0026ndash;56. \u003c/li\u003e\n\u003cli\u003eMohammadzadeh R, Saeid Harouyan M, Ale Taha SM. Silencing of bach1 gene by small interfering RNA-mediation regulates invasive and expression level of miR-203, miR-145, matrix metalloproteinase-9, and CXCR4 receptor in MDA-MB-468 breast cancer cells. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2017 Mar;39(3):1010428317695925\u0026ndash;1010428317695925. \u003c/li\u003e\n\u003cli\u003eXue Y, Xu W, Zhao W, Wang W, Zhang D, Wu P. miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition afile:///C:/Users/CMGRC-2/Downloads/csp_39_.risnd metastasis by targeting CXCR4. Biomed Pharmacother. 2017 Feb;86:426\u0026ndash;33. \u003c/li\u003e\n\u003cli\u003eShui Y, Yu X, Duan R, Bao Q, Wu J, Yuan H, et al. miR-130b-3p inhibits cell invasion and migration by targeting the Notch ligand Delta-like 1 in breast carcinoma. Gene. 2017 Apr;609:80\u0026ndash;7. \u003c/li\u003e\n\u003cli\u003eLi RK, Gao J, Guo LH, Huang GQ, Luo WH. PTENP1 acts as a ceRNA to regulate PTEN by sponging miR-19b and explores the biological role of PTENP1 in breast cancer. Cancer Gene Ther. 2017 Jul;24(7):309\u0026ndash;15. \u003c/li\u003e\n\u003cli\u003eZheng L, Li X, Chou J, Xiang C, Guo Q, Zhang Z, et al. StarD13 3\u0026rsquo;-untranslated region functions as a ceRNA for TP53INP1 in prohibiting migration and invasion of breast cancer cells by regulating miR-125b activity. Eur J Cell Biol. 2018 Jan;97(1):23\u0026ndash;31. \u003c/li\u003e\n\u003cli\u003eSengupta D, Deb M, Rath SK, Kar S, Parbin S, Pradhan N, et al. DNA methylation and not H3K4 trimethylation dictates the expression status of miR-152 gene which inhibits migration of breast cancer cells via DNMT1/CDH1 loop. Exp Cell Res [Internet]. 2016;346(2):176\u0026ndash;87. Available from: https://www.sciencedirect.com/science/article/pii/S0014482716302117\u003c/li\u003e\n\u003cli\u003eHan L, Liu B, Jiang L, Liu J, Han S. MicroRNA-497 downregulation contributes to cell proliferation, migration, and invasion of estrogen receptor alpha negative breast cancer by targeting estrogen-related receptor alpha. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2016 Oct;37(10):13205\u0026ndash;14. \u003c/li\u003e\n\u003cli\u003eBamodu OA, Huang WC, Lee WH, Wu A, Wang LS, Hsiao M, et al. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448. BMC Cancer. 2016 Feb;16:160. \u003c/li\u003e\n\u003cli\u003eZhan Y, Liang X, Li L, Wang B, Ding F, Li Y, et al. MicroRNA-548j functions as a metastasis promoter in human breast cancer by targeting Tensin1. Mol Oncol. 2016 Jun;10(6):838\u0026ndash;49. \u003c/li\u003e\n\u003cli\u003eJia Z, Liu Y, Gao Q, Han Y, Zhang G, Xu S, et al. miR-490-3p inhibits the growth and invasiveness in triple-negative breast cancer by repressing the expression of TNKS2. Gene. 2016 Nov;593(1):41\u0026ndash;7. \u003c/li\u003e\n\u003cli\u003eZheng T, Chou J, Zhang F, Liu Y, Ni H, Li X, et al. CXCR4 3\u0026rsquo;UTR functions as a ceRNA in promoting metastasis, proliferation and survival of MCF-7 cells by regulating miR-146a activity. Eur J Cell Biol. 2015 Oct;94(10):458\u0026ndash;69. \u003c/li\u003e\n\u003cli\u003eAhmad A, Ginnebaugh KR, Sethi S, Chen W, Ali R, Mittal S, et al. miR-20b is up-regulated in brain metastases from primary breast cancers. Oncotarget. 2015 May;6(14):12188\u0026ndash;95. \u003c/li\u003e\n\u003cli\u003eMohammadi‐Yeganeh S, Mansouri A, Paryan M. Targeting of miR9/NOTCH1 interaction reduces metastatic behavior in triple‐negative breast cancer. Chem Biol Drug Des. 2015;86(5):1185\u0026ndash;91. \u003c/li\u003e\n\u003cli\u003eXing F, Sharma S, Liu Y, Mo YY, Wu K, Zhang YY, et al. miR-509 suppresses brain metastasis of breast cancer cells by modulating RhoC and TNF-\u0026alpha;. Oncogene. 2015 Sep;34(37):4890\u0026ndash;900. \u003c/li\u003e\n\u003cli\u003eNagpal N, Ahmad HM, Chameettachal S, Sundar D, Ghosh S, Kulshreshtha R. HIF-inducible miR-191 promotes migration in breast cancer through complex regulation of TGF\u0026beta;-signaling in hypoxic microenvironment. Sci Rep. 2015 Apr;5:9650. \u003c/li\u003e\n\u003cli\u003eNi X, Xia T, Zhao Y, Zhou W, Wu N, Liu X, et al. Downregulation of miR-106b induced breast cancer cell invasion and motility in association with overexpression of matrix metalloproteinase 2. Cancer Sci. 2014 Jan;105(1):18\u0026ndash;25. \u003c/li\u003e\n\u003cli\u003eMarino ALF, Evangelista AF, Vieira RAC, Macedo T, Kerr LM, Abrah\u0026atilde;o-Machado LF, et al. MicroRNA expression as risk biomarker of breast cancer metastasis: a pilot retrospective case-cohort study. BMC Cancer. 2014 Oct;14:739. \u003c/li\u003e\n\u003cli\u003eLi LZ, Zhang CZ, Liu LL, Yi C, Lu SX, Zhou X, et al. miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1. Carcinogenesis. 2014 Feb;35(2):469\u0026ndash;78. \u003c/li\u003e\n\u003cli\u003eYe ZB, Ma G, Zhao YH, Xiao Y, Zhan Y, Jing C, et al. miR-429 inhibits migration and invasion of breast cancer cells in vitro. Int J Oncol. 2015 Feb;46(2):531\u0026ndash;8. \u003c/li\u003e\n\u003cli\u003eZhao X, Duan Z, Liu X, Wang B, Wang X, He J, et al. MicroRNA-127 is downregulated by Tudor-SN protein and contributes to metastasis and proliferation in breast cancer cell line MDA-MB-231. Anat Rec (Hoboken). 2013 Dec;296(12):1842\u0026ndash;9. \u003c/li\u003e\n\u003cli\u003eChen Y, Zhang J, Wang H, Zhao J, Xu C, Du Y, et al. miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10. BMC Cancer. 2012 Mar;12:111. \u003c/li\u003e\n\u003cli\u003eHuang L, Dai T, Lin X, Zhao X, Chen X, Wang C, et al. MicroRNA-224 targets RKIP to control cell invasion and expression of metastasis genes in human breast cancer cells. Biochem Biophys Res Commun [Internet]. 2012;425(2):127\u0026ndash;33. Available from: https://www.sciencedirect.com/science/article/pii/S0006291X12013083\u003c/li\u003e\n\u003cli\u003eZhang L, Sullivan PS, Goodman JC, Gunaratne PH, Marchetti D. MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res. 2011 Feb;71(3):645\u0026ndash;54. \u003c/li\u003e\n\u003cli\u003eLowery AJ, Miller N, Dwyer RM, Kerin MJ. Dysregulated miR-183 inhibits migration in breast cancer cells. BMC Cancer [Internet]. 2010;10(1):502. Available from: https://doi.org/10.1186/1471-2407-10-502\u003c/li\u003e\n\u003cli\u003eMartello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, et al. A MicroRNA Targeting Dicer for Metastasis Control. Cell [Internet]. 2010;141(7):1195\u0026ndash;207. Available from: https://www.sciencedirect.com/science/article/pii/S0092867410005532\u003c/li\u003e\n\u003cli\u003eLi H, Bian C, Liao L, Li J, Zhao RC. miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1. Breast Cancer Res Treat [Internet]. 2011;126(3):565\u0026ndash;75. Available from: https://doi.org/10.1007/s10549-010-0954-4\u003c/li\u003e\n\u003cli\u003eLi Y, Zhang M, Chen H, Dong Z, Ganapathy V, Thangaraju M, et al. Ratio of miR-196s to HOXC8 messenger RNA correlates with breast cancer cell migration and metastasis. Cancer Res. 2010 Oct;70(20):7894\u0026ndash;904. \u003c/li\u003e\n\u003cli\u003eYu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y, et al. microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci [Internet]. 2010 May 4;107(18):8231\u0026ndash;6. Available from: https://doi.org/10.1073/pnas.1002080107\u003c/li\u003e\n\u003cli\u003eSu JL, Chen PB, Chen YH, Chen SC, Chang YW, Jan YH, et al. Downregulation of microRNA miR-520h by E1A contributes to anticancer activity. Cancer Res. 2010 Jun;70(12):5096\u0026ndash;108. \u003c/li\u003e\n\u003cli\u003eWu H, Zhu S, Mo YY. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res [Internet]. 2009;19(4):439\u0026ndash;48. Available from: https://doi.org/10.1038/cr.2009.18\u003c/li\u003e\n\u003cli\u003eReddy SDN, Pakala SB, Ohshiro K, Rayala SK, Kumar R. MicroRNA-661, ac/EBP\u0026alpha; target, inhibits metastatic tumor antigen 1 and regulates its functions. Cancer Res. 2009;69(14):5639\u0026ndash;42. \u003c/li\u003e\n\u003cli\u003eLiu S, Goldstein RH, Scepansky EM, Rosenblatt M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res. 2009;69(22):8742\u0026ndash;51. \u003c/li\u003e\n\u003cli\u003eWang Y, Rathinam R, Walch A, Alahari SK. ST14 (suppression of tumorigenicity 14) gene is a target for miR-27b, and the inhibitory effect of ST14 on cell growth is independent of miR-27b regulation. J Biol Chem. 2009;284(34):23094\u0026ndash;106. \u003c/li\u003e\n\u003cli\u003eLi XF, Yan PJ, Shao ZM. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene [Internet]. 2009;28(44):3937\u0026ndash;48. Available from: https://doi.org/10.1038/onc.2009.245\u003c/li\u003e\n\u003cli\u003eHuang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol [Internet]. 2008;10(2):202\u0026ndash;10. Available from: https://doi.org/10.1038/ncb1681\u003c/li\u003e\n\u003cli\u003eReddy SDN, Ohshiro K, Rayala SK, Kumar R. MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res. 2008;68(20):8195\u0026ndash;200. \u003c/li\u003e\n\u003cli\u003eKong W, Yang H, He L, Zhao J jun, Coppola D, Dalton WS, et al. MicroRNA-155 is regulated by the transforming growth factor \u0026beta;/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008;28(22):6773\u0026ndash;84. \u003c/li\u003e\n\u003cli\u003eTavazoie SF, Alarc\u0026oacute;n C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature [Internet]. 2008;451(7175):147\u0026ndash;52. Available from: https://doi.org/10.1038/nature06487\u003c/li\u003e\n\u003cli\u003eMattick JS, Amaral PP, Carninci P, Carpenter S, Chang HY, Chen LL, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol [Internet]. 2023;24(6):430\u0026ndash;47. Available from: https://doi.org/10.1038/s41580-022-00566-8\u003c/li\u003e\n\u003cli\u003eLiu SJ, Dang HX, Lim DA, Feng FY, Maher CA. Long noncoding RNAs in cancer metastasis. Nat Rev Cancer. 2021;21(7):446\u0026ndash;60. \u003c/li\u003e\n\u003cli\u003eYousefi H, Maheronnaghsh M, Molaei F, Mashouri L, Reza Aref A, Momeny M, et al. Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance. Oncogene. 2020;39(5):953\u0026ndash;74. \u003c/li\u003e\n\u003cli\u003eZhang H, Wang J, Yin Y, Meng Q, Lyu Y. The role of EMT-related lncRNA in the process of triple-negative breast cancer metastasis. Biosci Rep. 2021 Feb;41(2). \u003c/li\u003e\n\u003cli\u003eSaitoh M. Transcriptional regulation of EMT transcription factors in cancer. In: Seminars in Cancer Biology. Elsevier; 2023. p. 21\u0026ndash;9. \u003c/li\u003e\n\u003cli\u003eSaitoh M. Epithelial\u0026ndash;mesenchymal transition by synergy between transforming growth factor-\u0026beta; and growth factors in cancer progression. Diagnostics. 2022;12(9):2127. \u003c/li\u003e\n\u003cli\u003eBracken CP, Goodall GJ, Gregory PA. RNA regulatory mechanisms controlling TGF-\u0026beta; signaling and EMT in cancer. In: Seminars in cancer biology. Elsevier; 2024. \u003c/li\u003e\n\u003cli\u003eLi RH, Chen M, Liu J, Shao CC, Guo CP, Wei XL, et al. Long noncoding RNA ATB promotes the epithelial-mesenchymal transition by upregulating the miR-200c/Twist1 axe and predicts poor prognosis in breast cancer. Cell Death Dis. 2018 Dec;9(12):1171. \u003c/li\u003e\n\u003cli\u003eRichards EJ, Zhang G, Li ZP, Permuth-Wey J, Challa S, Li Y, et al. Long non-coding RNAs (LncRNA) regulated by transforming growth factor (TGF) \u0026beta;: LncRNA-hit-mediated TGF\u0026beta;-induced epithelial to mesenchymal transition in mammary epithelia. J Biol Chem. 2015 Mar;290(11):6857\u0026ndash;67. \u003c/li\u003e\n\u003cli\u003eLi GY, Wang W, Sun JY, Xin B, Zhang X, Wang T, et al. Long non-coding RNAs AC026904.1 and UCA1: a \u0026ldquo;one-two punch\u0026rdquo; for TGF-\u0026beta;-induced SNAI2 activation and epithelial-mesenchymal transition in breast cancer. Theranostics. 2018;8(10):2846\u0026ndash;61. \u003c/li\u003e\n\u003cli\u003eWu ZJ, Li Y, Wu YZ, Wang Y, Nian WQ, Wang LL, et al. Long non-coding RNA CCAT2 promotes the breast cancer growth and metastasis by regulating TGF-\u0026beta; signaling pathway. Eur Rev Med Pharmacol Sci. 2017 Feb;21(4):706\u0026ndash;14. \u003c/li\u003e\n\u003cli\u003eGao Z, Wang H, Li H, Li M, Wang J, Zhang W, et al. Long non-coding RNA CASC2 inhibits breast cancer cell growth and metastasis through the regulation of the miR-96-5p/SYVN1 pathway. Int J Oncol. 2018 Nov;53(5):2081\u0026ndash;90. \u003c/li\u003e\n\u003cli\u003eZhang Y, Zhu M, Sun Y, Li W, Wang Y, Yu W. Upregulation of lncRNA CASC2 Suppresses Cell Proliferation and Metastasis of Breast Cancer via Inactivation of the TGF-\u0026beta; Signaling Pathway. Oncol Res. 2019 Feb;27(3):379\u0026ndash;87. \u003c/li\u003e\n\u003cli\u003eWang CL, Li JC, Zhou CX, Ma CN, Wang DF, Wo LL, et al. Long non-coding RNA ARHGAP5-AS1 inhibits migration of breast cancer cell via stabilizing SMAD7 protein. Breast Cancer Res Treat. 2021 Oct;189(3):607\u0026ndash;19. \u003c/li\u003e\n\u003cli\u003eXu X, Zhang M, Xu F, Jiang S. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. Mol Cancer [Internet]. 2020;19(1):165. Available from: https://doi.org/10.1186/s12943-020-01276-5\u003c/li\u003e\n\u003cli\u003eAlsaab HO. Pathological role of long non-coding (lnc) RNA in the regulation of Wnt/\u0026beta;-catenin signaling pathway during epithelial-mesenchymal transition (EMT). Pathol Pract. 2023;248:154566. \u003c/li\u003e\n\u003cli\u003eJiang D, Wang C, He J. Long non-coding RNA DGCR5 incudes tumorigenesis of triple-negative breast cancer by affecting Wnt/\u0026beta;-catenin signaling pathway. J BUON. 2020;25(2):702\u0026ndash;8. \u003c/li\u003e\n\u003cli\u003eBai Y, Zhou X, Huang L, Wan Y, Li X, Wang Y. Long noncoding RNA EZR‑AS1 promotes tumor growth and metastasis by modulating Wnt/\u0026beta;‑catenin pathway in breast cancer. Exp Ther Med [Internet]. 2018;16(3):2235\u0026ndash;42. Available from: https://doi.org/10.3892/etm.2018.6461\u003c/li\u003e\n\u003cli\u003eSong C, Sun P, He Q, Liu LL, Cui J, Sun LM. Long non-coding RNA LINC01287 promotes breast cancer cells proliferation and metastasis by activating Wnt/\u0026szlig;-catenin signaling. Eur Rev Med Pharmacol Sci. 2019 May;23(10):4234\u0026ndash;42. \u003c/li\u003e\n\u003cli\u003eZhou P, Liu P, Zhang J. Long noncoding RNA RUSC1‑AS‑N promotes cell proliferation and metastasis through Wnt/\u0026beta;‑catenin signaling in human breast cancer. Mol Med Rep. 2019 Feb;19(2):861\u0026ndash;8. \u003c/li\u003e\n\u003cli\u003eHan S, Jin X, Liu Z, Xing F, Han Y, Yu X, et al. The long noncoding RNA HOTTIP promotes breast cancer cell migration, invasiveness, and epithelial-mesenchymal transition via the Wnt-\u0026beta;-catenin signaling pathway. Biochem Cell Biol. 2019 Oct;97(5):655\u0026ndash;64. \u003c/li\u003e\n\u003cli\u003eLi Y, Ma HY, Hu XW, Qu YY, Wen X, Zhang Y, et al. LncRNA H19 promotes triple-negative breast cancer cells invasion and metastasis through the p53/TNFAIP8 pathway. Cancer Cell Int. 2020;20:1\u0026ndash;14. \u003c/li\u003e\n\u003cli\u003eZhou W, Ye XL, Xu J, Cao MG, Fang ZY, Li LY, et al. The lncRNA H19 mediates breast cancer cell plasticity during EMT and MET plasticity by differentially sponging miR-200b/c and let-7b. Sci Signal. 2017 Jun;10(483). \u003c/li\u003e\n\u003cli\u003eXiong H, Shen J, Chen Z, Yang J, Xie B, Jia Y, et al. H19/let‑7/Lin28 ceRNA network mediates autophagy inhibiting epithelial‑mesenchymal transition in breast cancer. Int J Oncol. 2020 Mar;56(3):794\u0026ndash;806. \u003c/li\u003e\n\u003cli\u003eYan L, Yang S, Yue CX, Wei XY, Peng W, Dong ZY, et al. Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells. Environ Toxicol. 2020 Sep;35(9):1015\u0026ndash;28. \u003c/li\u003e\n\u003cli\u003eTan Z, Zhao L, Huang S, Jiang Q, Wei Y, Wu JL, et al. Small peptide LINC00511-133aa encoded by LINC00511 regulates breast cancer cell invasion and stemness through the Wnt/\u0026beta;-catenin pathway. Mol Cell Probes [Internet]. 2023;69:101913. Available from: https://www.sciencedirect.com/science/article/pii/S0890850823000221\u003c/li\u003e\n\u003cli\u003eTang T, Guo C, Xia T, Zhang R, Zen K, Pan Y, et al. LncCCAT1 Promotes Breast Cancer Stem Cell Function through Activating WNT/\u0026beta;-catenin Signaling. Theranostics. 2019;9(24):7384\u0026ndash;402. \u003c/li\u003e\n\u003cli\u003eWang HB, Wei H, Wang JS, Li L, Chen AY, Li ZG. Down-regulated expression of LINC00518 prevents epithelial cell growth and metastasis in breast cancer through the inhibition of CDX2 methylation and the Wnt signaling pathway. Biochim Biophys acta Mol basis Dis. 2019 Mar;1865(3):708\u0026ndash;23. \u003c/li\u003e\n\u003cli\u003eWang Y, Dong T, Wang P, Li S, Wu G, Zhou J, et al. LINC00922 regulates epithelial-mesenchymal transition, invasive and migratory capacities in breast cancer through promoting NKD2 methylation. Cell Signal. 2021 Jan;77:109808. \u003c/li\u003e\n\u003cli\u003eZhang D, Liu X, Li Y, Sun L, Liu SS, Ma Y, et al. LINC01189-miR-586-ZEB1 feedback loop regulates breast cancer progression through Wnt/\u0026beta;-catenin signaling pathway. Mol Ther - Nucleic Acids [Internet]. 2021;25:455\u0026ndash;67. Available from: https://www.sciencedirect.com/science/article/pii/S2162253121001487\u003c/li\u003e\n\u003cli\u003eYuan H, Qin Y, Zeng B, Feng Y, Li Y, Xiang T, et al. Long noncoding RNA LINC01089 predicts clinical prognosis and inhibits cell proliferation and invasion through the Wnt/\u0026beta;-catenin signaling pathway in breast cancer. Onco Targets Ther. 2019;12:4883\u0026ndash;95. \u003c/li\u003e\n\u003cli\u003eLi W, Zhang Z, Liu X, Cheng X, Zhang Y, Han X, et al. The FOXN3-NEAT1-SIN3A repressor complex promotes progression of hormonally responsive breast cancer. J Clin Invest. 2017 Sep;127(9):3421\u0026ndash;40. \u003c/li\u003e\n\u003cli\u003eXiong Y, Liu Z, Li Z, Wang S, Shen N, Xin Y, et al. Long non‑coding RNA nuclear paraspeckle assembly transcript 1 interacts with microRNA‑107 to modulate breast cancer growth and metastasis by targeting carnitine palmitoyltransferase‑1. Int J Oncol. 2019 Nov;55(5):1125\u0026ndash;36. \u003c/li\u003e\n\u003cli\u003eLi X, Deng S, Pang X, Song Y, Luo S, Jin L, et al. LncRNA NEAT1 Silenced miR-133b Promotes Migration and Invasion of Breast Cancer Cells. Int J Mol Sci. 2019 Jul;20(15). \u003c/li\u003e\n\u003cli\u003eLi X, Wang S, Li Z, Long X, Guo Z, Zhang G, et al. The lncRNA NEAT1 facilitates cell growth and invasion via the miR-211/HMGA2 axis in breast cancer. Int J Biol Macromol [Internet]. 2017;105:346\u0026ndash;53. Available from: https://www.sciencedirect.com/science/article/pii/S0141813017305871\u003c/li\u003e\n\u003cli\u003ePark MK, Zhang L, Min KW, Cho JH, Yeh CC, Moon H, et al. NEAT1 is essential for metabolic changes that promote breast cancer growth and metastasis. Cell Metab [Internet]. 2021;33(12):2380-2397.e9. Available from: https://www.sciencedirect.com/science/article/pii/S1550413121005398\u003c/li\u003e\n\u003cli\u003eXu S, Sui S, Zhang J, Bai N, Shi Q, Zhang G, et al. Downregulation of long noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition via the PI3K-AKT pathway in breast cancer. Int J Clin Exp Pathol. 2015;8(5):4881\u0026ndash;91. \u003c/li\u003e\n\u003cli\u003eMiao Y, Fan R, Chen L, Qian H. Clinical Significance of Long Non-coding RNA MALAT1 Expression in Tissue and Serum of Breast Cancer. Ann Clin Lab Sci. 2016 Jul;46(4):418\u0026ndash;24. \u003c/li\u003e\n\u003cli\u003eZuo Y, Li Y, Zhou Z, Ma M, Fu K. Long non-coding RNA MALAT1 promotes proliferation and invasion via targeting miR-129-5p in triple-negative breast cancer. Biomed Pharmacother. 2017 Nov;95:922\u0026ndash;8. \u003c/li\u003e\n\u003cli\u003eWang N, Cao S, Wang X, Zhang L, Yuan H, Ma X. lncRNA MALAT1/miR‑26a/26b/ST8SIA4 axis mediates cell invasion and migration in breast cancer cell lines. Oncol Rep. 2021 Aug;46(2). \u003c/li\u003e\n\u003cli\u003eKim J, Piao HL, Kim BJ, Yao F, Han Z, Wang Y, et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet. 2018 Dec;50(12):1705\u0026ndash;15. \u003c/li\u003e\n\u003cli\u003eEades G, Wolfson B, Zhang Y, Li Q, Yao Y, Zhou Q. lincRNA-RoR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6. Mol Cancer Res. 2015 Feb;13(2):330\u0026ndash;8. \u003c/li\u003e\n\u003cli\u003eHou P, Zhao Y, Li Z, Yao R, Ma M, Gao Y, et al. LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis. Cell Death Dis. 2014 Jun;5(6):e1287\u0026ndash;e1287. \u003c/li\u003e\n\u003cli\u003eP\u0026aacute;dua Alves C, Fonseca AS, Muys BR, de Barros E Lima Bueno R, B\u0026uuml;rger MC, de Souza JES, et al. Brief report: The lincRNA Hotair is required for epithelial-to-mesenchymal transition and stemness maintenance of cancer cell lines. Stem Cells. 2013 Dec;31(12):2827\u0026ndash;32. \u003c/li\u003e\n\u003cli\u003eCen S, Peng X, Deng J, Jin H, Deng Z, Lin X, et al. The role of AFAP1-AS1 in mitotic catastrophe and metastasis of triple-negative breast cancer cells by activating the PLK1 signaling pathway. Oncol Res. 2023;31(3):375\u0026ndash;88. \u003c/li\u003e\n\u003cli\u003eMa D, Chen C, Wu J, Wang H, Wu D. Up-regulated lncRNA AFAP1-AS1 indicates a poor prognosis and promotes carcinogenesis of breast cancer. Breast Cancer. 2019 Jan;26(1):74\u0026ndash;83. \u003c/li\u003e\n\u003cli\u003eZhang X, Zhou Y, Mao F, Lin Y, Shen S, Sun Q. lncRNA AFAP1-AS1 promotes triple negative breast cancer cell proliferation and invasion via targeting miR-145 to regulate MTH1 expression. Sci Rep. 2020 May;10(1):7662. \u003c/li\u003e\n\u003cli\u003eJiang Xinyu, Lin Juli, Zhu Zhanlin. Long-chain noncoding RNA LINC01569 upregulates filamin A-interacting protein 1-like to prevent metastasis of triple-negative breast cancer via sponging miR-300. Cancer Biomarkers [Internet]. 2024 Feb 1;39(2):79\u0026ndash;94. Available from: https://doi.org/10.3233/CBM-230261\u003c/li\u003e\n\u003cli\u003eTang Y, Tian W, Zheng S, Zou Y, Xie J, Zhang J, et al. Dissection of FOXO1-Induced LYPLAL1-DT Impeding Triple-Negative Breast Cancer Progression via Mediating hnRNPK/\u0026beta;-Catenin Complex. Research [Internet]. 2025 May 11;6:289. Available from: https://doi.org/10.34133/research.0289\u003c/li\u003e\n\u003cli\u003eHe Y, Xiao B, Lei T, Xuan J, Zhu Y, Kuang Z, et al. LncRNA T376626 is a promising serum biomarker and promotes proliferation, file:///C:/Users/s.jazini/Downloads/S0378111923000689.rismigration, and invasion via binding to LAMC2 in triple-negative breast cancer. Gene [Internet]. 2023;860:147227. Available from: https://www.sciencedirect.com/science/article/pii/S0378111923000689\u003c/li\u003e\n\u003cli\u003eHan J, Chen X, Wang J, Liu B. Glycolysis-related lncRNA TMEM105 upregulates LDHA to facilitate breast cancer liver metastasis via sponging miR-1208. Cell Death Dis [Internet]. 2023;14(2):80. Available from: https://doi.org/10.1038/s41419-023-05628-z\u003c/li\u003e\n\u003cli\u003eXu J, Hu M, Gao Y, Wang Y, Yuan X, Yang Y, et al. LncRNA MIR17HG Suppresses Breast Cancer Proliferation and Migration as ceRNA to Target FAM135A by Sponging miR-454-3p. Mol Biotechnol [Internet]. 2023;65(12):2071\u0026ndash;85. Available from: https://doi.org/10.1007/s12033-023-00706-1\u003c/li\u003e\n\u003cli\u003eZhang Y, Dong X, Guo X, Li C, Fan Y, Liu P, et al. LncRNA-BC069792 suppresses tumor progression by targeting KCNQ4 in breast cancerfile:///C:/Users/s.jazini/Downloads/10.1186_s12943-023-01747-5-citation.ris. Mol Cancer [Internet]. 2023;22(1):41. Available from: https://doi.org/10.1186/s12943-023-01747-5\u003c/li\u003e\n\u003cli\u003eGuardia T, Zhang Y, Thompson KN, Lee SJ, Martin SS, Konstantopoulos K, et al. OBSCN restoration via OBSCN-AS1 long-noncoding RNA CRISPR-targeting suppresses metastasis in triple-negative breast cancer. Proc Natl Acad Sci [Internet]. 2023 Mar 14;120(11):e2215553120. Available from: https://doi.org/10.1073/pnas.2215553120\u003c/li\u003e\n\u003cli\u003eGuo R, Su Y, Zhang Q, Xiu B, Huang S, Chi W, et al. LINC00478-derived novel cytoplasmic lncRNA LacRNA stabilizes PHB2 and suppresses breast cancer metastasis via repressing MYC targets. J Transl Med [Internet]. 2023;21(1):120. Available from: https://doi.org/10.1186/s12967-023-03967-1\u003c/li\u003e\n\u003cli\u003eYang X, Yang Y, Qian X, Xu X, Lv P. Long non-coding RNA LINC01559 serves as a competing endogenous RNA accelerating triple-negative breast cancer progression. Biomed J [Internet]. 2021; Available from: https://www.sciencedirect.com/science/article/pii/S2319417021000597\u003c/li\u003e\n\u003cli\u003eLiu X, Tian X. Long Noncoding RNA TCONS_00068220 Promotes Breast Cancer Progression by Regulating Epithelial-Mesenchymal Transition Marker E-Cadherin. Med Sci Monit Int Med J Exp Clin Res. 2021 Mar;27:e929832\u0026ndash;e929832. \u003c/li\u003e\n\u003cli\u003eLi L, Jin Y, Wang X, Wang L, Sun Y, Luo Y, et al. Long noncoding RNA ENST00000508435 promotes migration of breast cancer via FXR 1. Cell Adh Migr. 2021 Dec;15(1):140\u0026ndash;51. \u003c/li\u003e\n\u003cli\u003eQiao YS, Zhou JH, Jin BH, Wu YQ, Zhao B. LINC00483 is regulated by IGF2BP1 and participates in the progression of breast cancer. Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1379\u0026ndash;86. \u003c/li\u003e\n\u003cli\u003eZhou T, Lin K, Nie J, Pan B, He B, Pan Y, et al. LncRNA SPINT1-AS1 promotes breast cancer proliferation and metastasis by sponging let-7 a/b/i-5p. Pathol Res Pract. 2021 Jan;217:153268. \u003c/li\u003e\n\u003cli\u003eShao G, Fan X, Zhang P, Liu X, Huang L, Ji S. Methylation-dependent MCM6 repression induced by LINC00472 inhibits triple-negative breast cancer metastasis by disturbing the MEK/ERK signaling pathway. Aging (Albany NY). 2021 Feb;13(4):4962\u0026ndash;75. \u003c/li\u003e\n\u003cli\u003eLiang Y, Ye F, Wang Y, Li Y, Li Y, Song X, et al. DGUOK-AS1 acts as a tumor promoter through regulating miR-204-5p/IL-11 axis in breast cancer. Mol Ther - Nucleic Acids [Internet]. 2021;26:1079\u0026ndash;91. Available from: https://www.sciencedirect.com/science/article/pii/S2162253121002614\u003c/li\u003e\n\u003cli\u003eZhou D, Ren K, Wang M, Wang J, Li E, Hou C, et al. Long non-coding RNA RACGAP1P promotes breast cancer invasion and metastasis via miR-345-5p/RACGAP1-mediated mitochondrial fission. Mol Oncol. 2021 Feb;15(2):543\u0026ndash;59. \u003c/li\u003e\n\u003cli\u003eBai X, Zhang S, Qiao J, Xing X, Li W, Zhang H, et al. Long non‑coding RNA SChLAP1 regulates the proliferation of triple negative breast cancer cells via the miR‑524‑5p/HMGA2 axis. Mol Med Rep. 2021 Jun;23(6). \u003c/li\u003e\n\u003cli\u003eTarighi M, Khalaj-Kondori M, Hosseinzadeh A, Abtin M. Long non-coding RNA (lncRNA) DSCAM-AS1 is upregulated in breast cancer. Breast Dis. 2021;40(2):63\u0026ndash;8. \u003c/li\u003e\n\u003cli\u003eChu Z, Huo N, Zhu X, Liu H, Cong R, Ma L, et al. FOXO3A-induced LINC00926 suppresses breast tumor growth and metastasis through inhibition of PGK1-mediated Warburg effect. Mol Ther [Internet]. 2021;29(9):2737\u0026ndash;53. Available from: https://www.sciencedirect.com/science/article/pii/S1525001621002501\u003c/li\u003e\n\u003cli\u003eZong S, Dai W, Guo X, Wang K. LncRNA-SNHG1 promotes macrophage M2-like polarization and contributes to breast cancer growth and metastasis. Aging (Albany NY). 2021;13(19):23169. \u003c/li\u003e\n\u003cli\u003eKong X, Li J, Li Y, Duan W, Qi Q, Wang T, et al. A novel long non-coding RNA AC073352.1 promotes metastasis and angiogenesis via interacting with YBX1 in breast cancer. Cell Death Dis. 2021 Jul;12(7):670. \u003c/li\u003e\n\u003cli\u003eEroğlu G\u0026uuml;neş C, G\u0026uuml;\u0026ccedil;l\u0026uuml; E, Vural H, Kurar E. Knockdown of lncRNA ZEB2NAT suppresses epithelial mesenchymal transition, metastasis and proliferation in breast cancer cells. Gene. 2021 Dec;805:145904. \u003c/li\u003e\n\u003cli\u003eLi D, Li L, Chen X, Zhou C, Hao B, Cao Y. Dysregulation of lncRNA-CCRR contributes to brain metastasis of breast cancer by intercellular coupling via regulating connexin 43 expression. J Cell Mol Med. 2021 May;25(10):4826\u0026ndash;34. \u003c/li\u003e\n\u003cli\u003eZhao YF, Li L, Li HJ, Yang FR, Liu ZK, Hu XW, et al. LncRNA ZFPM2-AS1 aggravates the malignant development of breast cancer via upregulating JMJD6. Eur Rev Med Pharmacol Sci. 2020 Nov;24(21):11139\u0026ndash;47. \u003c/li\u003e\n\u003cli\u003eMa T, Liu H, Liu Y, Liu T, Wang H, Qiao F, et al. USP6NL mediated by LINC00689/miR-142-3p promotes the development of triple-negative breast cancer. BMC Cancer. 2020 Oct;20(1):998. \u003c/li\u003e\n\u003cli\u003eShi G, Cheng Y, Zhang Y, Guo R, Li S, Hong X. Long non-coding RNA LINC00511/miR-150/MMP13 axis promotes breast cancer proliferation, migration and invasion. Biochim Biophys acta Mol basis Dis. 2021 Mar;1867(3):165957. \u003c/li\u003e\n\u003cli\u003eJiang H, Li X, Wang W, Dong H. Long non-coding RNA SNHG3 promotes breast cancer cell proliferation and metastasis by binding to microRNA-154-3p and activating the notch signaling pathway. BMC Cancer. 2020 Sep;20(1):838. \u003c/li\u003e\n\u003cli\u003eZhao L, Zhou Y, Zhao Y, Li Q, Zhou J, Mao Y. Long non-coding RNA TUSC8 inhibits breast cancer growth and metastasis via miR-190b-5p/MYLIP axis. Aging (Albany NY). 2020 Feb;12(3):2974\u0026ndash;91. \u003c/li\u003e\n\u003cli\u003eLi J, Zeng T, Li W, Wu H, Sun C, Yang F, et al. Long non-coding RNA SNHG1 activates HOXA1 expression via sponging miR-193a-5p in breast cancer progression. Aging (Albany NY). 2020 Jun;12(11):10223\u0026ndash;34. \u003c/li\u003e\n\u003cli\u003eYu Y, He Y, Shao Y, Chen Q, Liu H. lncRNA PCNAP1 predicts poor prognosis in breast cancer and promotes cancer metastasis via miR‑340‑5p‑dependent upregulation of SOX4. Oncol Rep. 2020 Oct;44(4):1511\u0026ndash;23. \u003c/li\u003e\n\u003cli\u003eMeng L, Yue X, Zhou D, Li H. Long non coding RNA OIP5‑AS1 promotes metastasis of breast cancer via miR‑340‑5p/ZEB2 axis. Oncol Rep. 2020 Oct;44(4):1662\u0026ndash;70. \u003c/li\u003e\n\u003cli\u003eQin C, Jin L, Li J, Zha W, Ding H, Liu X, et al. Long Noncoding RNA LINC02163 Accelerates Malignant Tumor Behaviors in Breast Cancer by Regulating the MicroRNA-511-3p/HMGA2 Axis. Oncol Res. 2020 Dec;28(5):483\u0026ndash;95. \u003c/li\u003e\n\u003cli\u003eYuan C, Luo X, Duan S, Guo L. Long noncoding RNA LINC00115 promotes breast cancer metastasis by inhibiting miR-7. FEBS Open Bio. 2020 Jul;10(7):1230\u0026ndash;7. \u003c/li\u003e\n\u003cli\u003eTang L, Chen Y, Tang X, Wei D, Xu X, Yan F. Long Noncoding RNA DCST1-AS1 Promotes Cell Proliferation and Metastasis in Triple-negative Breast Cancer by Forming a Positive Regulatory Loop with miR-873-5p and MYC. J Cancer. 2020;11(2):311\u0026ndash;23. \u003c/li\u003e\n\u003cli\u003eWu G, Zhou H, Li D, Zhi Y, Liu Y, Li J, et al. LncRNA DANCR upregulation induced by TUFT1 promotes malignant progression in triple negative breast cancer via miR-874-3p-SOX2 axis. Exp Cell Res. 2020 Nov;396(2):112331. \u003c/li\u003e\n\u003cli\u003eHu S, Zheng W, Jin L. Astragaloside IV inhibits cell proliferation and metastasis of breast cancer via promoting the long noncoding RNA TRHDE-AS1. J Nat Med. 2021 Jan;75(1):156\u0026ndash;66. \u003c/li\u003e\n\u003cli\u003eZhou JL, Zou L, Zhu T. Long non-coding RNA c promotes metastasis of breast cancer cells by triggering EMT. Eur Rev Med Pharmacol Sci. 2020 Mar;24(6):3097\u0026ndash;104. \u003c/li\u003e\n\u003cli\u003eFang K, Caixia H, Xiufen Z, Zijian G, Li L. Screening of a Novel Upregulated lncRNA, A2M-AS1, That Promotes Invasion and Migration and Signifies Poor Prognosis in Breast Cancer. Biomed Res Int. 2020;2020:9747826. \u003c/li\u003e\n\u003cli\u003eGuo G, Dai S, Chen Q. Long Noncoding RNA LINC00261 Reduces Proliferation and Migration of Breast Cancer Cells via the NME1-EMT Pathway. Cancer Manag Res. 2020;12:3081\u0026ndash;9. \u003c/li\u003e\n\u003cli\u003eTao S, Chen Q, Lin C, Dong H. Linc00514 promotes breast cancer metastasis and M2 polarization of tumor-associated macrophages via Jagged1-mediated notch signaling pathway. J Exp Clin Cancer Res. 2020 Sep;39(1):191. \u003c/li\u003e\n\u003cli\u003eChu W, Zhang X, Qi L, Fu Y, Wang P, Zhao W, et al. The EZH2-PHACTR2-AS1-Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer. Cancer Res. 2020 Jul;80(13):2737\u0026ndash;50. \u003c/li\u003e\n\u003cli\u003eChang KC, Diermeier SD, Yu AT, Brine LD, Russo S, Bhatia S, et al. MaTAR25 lncRNA regulates the Tensin1 gene to impact breast cancer progression. Nat Commun. 2020 Dec;11(1):6438. \u003c/li\u003e\n\u003cli\u003eNiu Y, Bao L, Chen Y, Wang C, Luo M, Zhang B, et al. HIF2-Induced Long Noncoding RNA RAB11B-AS1 Promotes Hypoxia-Mediated Angiogenesis and Breast Cancer Metastasis. Cancer Res. 2020 Mar;80(5):964\u0026ndash;75. \u003c/li\u003e\n\u003cli\u003eZheng S, Yang L, Zou Y, Liang JY, Liu P, Gao G, et al. Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer. J Hematol Oncol. 2020 Mar;13(1):17. \u003c/li\u003e\n\u003cli\u003ePan QH, Fan YH, Wang YZ, Li DM, Hu CE, Li RX. Long noncoding RNA NNT-AS1 functions as an oncogene in breast cancer via repressing ZFP36 expression. J Biol Regul Homeost Agents. 2020;34(3):795\u0026ndash;805. \u003c/li\u003e\n\u003cli\u003eJiang Y, Lin L, Zhong S, Cai Y, Zhang F, Wang X, et al. Overexpression of novel lncRNA NLIPMT inhibits metastasis by reducing phosphorylated glycogen synthase kinase 3\u0026beta; in breast cancer. J Cell Physiol. 2019 Jul;234(7):10698\u0026ndash;708. \u003c/li\u003e\n\u003cli\u003eFu J, Dong G, Shi H, Zhang J, Ning Z, Bao X, et al. LncRNA MIR503HG inhibits cell migration and invasion via miR-103/OLFM4 axis in triple negative breast cancer. J Cell Mol Med. 2019 Jul;23(7):4738\u0026ndash;45. \u003c/li\u003e\n\u003cli\u003eLi XY, Zhou LY, Luo H, Zhu Q, Zuo L, Liu GY, et al. The long noncoding RNA MIR210HG promotes tumor metastasis by acting as a ceRNA of miR-1226-3p to regulate mucin-1c expression in invasive breast cancer. Aging (Albany NY). 2019 Aug;11(15):5646\u0026ndash;65. \u003c/li\u003e\n\u003cli\u003eWang YY, Yan L, Yang S, Xu HN, Chen TT, Dong ZY, et al. Long noncoding RNA AC073284.4 suppresses epithelial-mesenchymal transition by sponging miR-18b-5p in paclitaxel-resistant breast cancer cells. J Cell Physiol. 2019 Dec;234(12):23202\u0026ndash;15. \u003c/li\u003e\n\u003cli\u003eMao Q, Lv M, Li L, Sun Y, Liu S, Shen Y, et al. Long intergenic noncoding RNA 00641 inhibits breast cancer cell proliferation, migration, and invasion by sponging miR-194-5p. J Cell Physiol. 2020 Mar;235(3):2668\u0026ndash;75. \u003c/li\u003e\n\u003cli\u003eKong X, Duan Y, Sang Y, Li Y, Zhang H, Liang Y, et al. LncRNA-CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA-215. J Cell Physiol. 2019 Jun;234(6):9105\u0026ndash;17. \u003c/li\u003e\n\u003cli\u003eWang L, Luan T, Zhou S, Lin J, Yang Y, Liu W, et al. LncRNA HCP5 promotes triple negative breast cancer progression as a ceRNA to regulate BIRC3 by sponging miR-219a-5p. Cancer Med. 2019 Aug;8(9):4389\u0026ndash;403. \u003c/li\u003e\n\u003cli\u003eLi W, Jin X, Zhao Y, Dai J, Cai Y. Long noncoding RNA GAS6-AS2 sponges microRNA-493, thereby enhancing the malignant characteristics of breast cancer cells via upregulation of FUT4. Pathol Res Pract. 2020 Feb;216(2):152772. \u003c/li\u003e\n\u003cli\u003eBai J, Zhao WY, Li WJ, Ying ZW, Jiang DQ. Long noncoding RNA LINC00473 indicates a poor prognosis of breast cancer and accelerates tumor carcinogenesis by competing endogenous sponging miR-497. Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3410\u0026ndash;20. \u003c/li\u003e\n\u003cli\u003eDong HT, Liu Q, Zhao T, Yao F, Xu Y, Chen B, et al. Long Non-coding RNA LOXL1-AS1 Drives Breast Cancer Invasion and Metastasis by Antagonizing miR-708-5p Expression and Activity. Mol Ther Nucleic Acids. 2020 Mar;19:696\u0026ndash;705. \u003c/li\u003e\n\u003cli\u003eZhou B, Guo H, Tang J. Long Non-Coding RNA TFAP2A-AS1 Inhibits Cell Proliferation and Invasion in Breast Cancer via miR-933/SMAD2. Med Sci Monit Int Med J Exp Clin Res. 2019 Feb;25:1242\u0026ndash;53. \u003c/li\u003e\n\u003cli\u003eGuan Y, Bhandari A, Xia E, Yang F, Xiang J, Wang O. lncRNA FOXD3-AS1 is associated with clinical progression and regulates cell migration and invasion in breast cancer. Cell Biochem Funct. 2019 Jun;37(4):239\u0026ndash;44. \u003c/li\u003e\n\u003cli\u003eLi Y, Su X, Pan H. Inhibition of lncRNA PANDAR reduces cell proliferation, cell invasion and suppresses EMT pathway in breast cancer. Cancer Biomark. 2019;25(2):185\u0026ndash;92. \u003c/li\u003e\n\u003cli\u003eWang Y, Zhang G, Han J. HIF1A-AS2 predicts poor prognosis and regulates cell migration and invasion in triple-negative breast cancer. J Cell Biochem. 2019 Jun;120(6):10513\u0026ndash;8. \u003c/li\u003e\n\u003cli\u003eZhang H, Zhang N, Liu Y, Su P, Liang Y, Li Y, et al. Epigenetic Regulation of NAMPT by NAMPT-AS Drives Metastatic Progression in Triple-Negative Breast Cancer. Cancer Res. 2019 Jul;79(13):3347\u0026ndash;59. \u003c/li\u003e\n\u003cli\u003eYi T, Zhou X, Sang K, Huang X, Zhou J, Ge L. Activation of lncRNA lnc-SLC4A1-1 induced by H3K27 acetylation promotes the development of breast cancer via activating CXCL8 and NF-kB pathway. Artif cells, nanomedicine, Biotechnol. 2019 Dec;47(1):3765\u0026ndash;73. \u003c/li\u003e\n\u003cli\u003eFang K, Hu C, Zhang X, Hou Y, Gao D, Guo Z, et al. LncRNA ST8SIA6-AS1 promotes proliferation, migration and invasion in breast cancer through the p38 MAPK signalling pathway. Carcinogenesis. 2020 Sep;41(9):1273\u0026ndash;81. \u003c/li\u003e\n\u003cli\u003eZhang Y, Xiao X, Zhou W, Hu J, Zhou D. LIN28A-stabilized FBXL19-AS1 promotes breast cancer migration, invasion and EMT by regulating WDR66. In Vitro Cell Dev Biol Anim. 2019 Jun;55(6):426\u0026ndash;35. \u003c/li\u003e\n\u003cli\u003eZhang G, Li H, Sun R, Li P, Yang Z, Liu Y, et al. Long non-coding RNA ZEB2-AS1 promotes the proliferation, metastasis and epithelial mesenchymal transition in triple-negative breast cancer by epigenetically activating ZEB2. J Cell Mol Med. 2019 May;23(5):3271\u0026ndash;9. \u003c/li\u003e\n\u003cli\u003eJin X, Xu XE, Jiang YZ, Liu YR, Sun W, Guo YJ, et al. The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation. Sci Adv. 2019 Mar;5(3):eaat9820\u0026ndash;eaat9820. \u003c/li\u003e\n\u003cli\u003eLiu P, Tang H, Wu J, Qiu X, Kong Y, Zhang L, et al. Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer. Curr Cancer Drug Targets. 2019;19(1):74\u0026ndash;80. \u003c/li\u003e\n\u003cli\u003eLi SY, Wang H, Mai HF, Li GF, Chen SJ, Li GS, et al. Down-regulated long non-coding RNA RNAZFHX4-AS1 suppresses invasion and migration of breast cancer cells via FAT4-dependent Hippo signaling pathway. Cancer Gene Ther. 2019 Nov;26(11\u0026ndash;12):374\u0026ndash;87. \u003c/li\u003e\n\u003cli\u003ePian L, Wen X, Kang L, Li Z, Nie Y, Du Z, et al. Targeting the IGF1R Pathway in Breast Cancer Using Antisense lncRNA-Mediated Promoter cis Competition. Mol Ther Nucleic Acids. 2018 Sep;12:105\u0026ndash;17. \u003c/li\u003e\n\u003cli\u003eYang YX, Wei L, Zhang YJ, Hayano T, Pi\u0026ntilde;eiro Pereda MDP, Nakaoka H, et al. Long non-coding RNA p10247, high expressed in breast cancer (lncRNA-BCHE), is correlated with metastasis. Clin Exp Metastasis. 2018 Mar;35(3):109\u0026ndash;21. \u003c/li\u003e\n\u003cli\u003eLiu M, Gou L, Xia J, Wan Q, Jiang Y, Sun S, et al. LncRNA ITGB2-AS1 Could Promote the Migration and Invasion of Breast Cancer Cells through Up-Regulating ITGB2. Vol. 19, International Journal of Molecular Sciences. 2018. \u003c/li\u003e\n\u003cli\u003eWang M, Wang M, Wang Z, Yu X, Song Y, Wang C, et al. Long non-coding RNA-CTD-2108O9.1 represses breast cancer metastasis by influencing leukemia inhibitory factor receptor. Cancer Sci. 2018 Jun;109(6):1764\u0026ndash;74. \u003c/li\u003e\n\u003cli\u003eLi Y, Lv M, Song Z, Lou Z, Wang R, Zhuang M. Long non-coding RNA NNT-AS1 affects progression of breast cancer through miR-142-3p/ZEB1 axis. Biomed Pharmacother. 2018 Jul;103:939\u0026ndash;46. \u003c/li\u003e\n\u003cli\u003eHuang XJ, Xia Y, He GF, Zheng LL, Cai YP, Yin Y, et al. MALAT1 promotes angiogenesis of breast cancer. Oncol Rep. 2018 Nov;40(5):2683\u0026ndash;9. \u003c/li\u003e\n\u003cli\u003eZheng R, Lin S, Guan L, Yuan H, Liu K, Liu C, et al. Long non-coding RNA XIST inhibited breast cancer cell growth, migration, and invasion via miR-155/CDX1 axis. Biochem Biophys Res Commun [Internet]. 2018;498(4):1002\u0026ndash;8. Available from: https://www.sciencedirect.com/science/article/pii/S0006291X18305965\u003c/li\u003e\n\u003cli\u003eLuo X, Song Y, Tang L, Sun DH, Ji DG. LncRNA SNHG7 promotes development of breast cancer by regulating microRNA-186. Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):7788\u0026ndash;97. \u003c/li\u003e\n\u003cli\u003eLi S, Zhou J, Wang Z, Wang P, Gao X, Wang Y. Long noncoding RNA GAS5 suppresses triple negative breast cancer progression through inhibition of proliferation and invasion by competitively binding miR-196a-5p. Biomed Pharmacother. 2018 Aug;104:451\u0026ndash;7. \u003c/li\u003e\n\u003cli\u003eYang F, Shen Y, Zhang W, Jin J, Huang D, Fang H, et al. An androgen receptor negatively induced long non-coding RNA ARNILA binding to miR-204 promotes the invasion and metastasis of triple-negative breast cancer. Cell Death Differ. 2018 Dec;25(12):2209\u0026ndash;20. \u003c/li\u003e\n\u003cli\u003eHuang X, Xie X, Liu P, Yang L, Chen B, Song C, et al. Adam12 and lnc015192 act as ceRNAs in breast cancer by regulating miR-34a. Oncogene. 2018 Dec;37(49):6316\u0026ndash;26. \u003c/li\u003e\n\u003cli\u003eLiang Y, Song X, Li Y, Sang Y, Zhang N, Zhang H, et al. A novel long non-coding RNA-PRLB acts as a tumor promoter through regulating miR-4766-5p/SIRT1 axis in breast cancer. Cell Death Dis. 2018 May;9(5):563. \u003c/li\u003e\n\u003cli\u003eXing F, Liu Y, Wu SY, Wu K, Sharma S, Mo YY, et al. Loss of XIST in breast cancer activates MSN-c-Met and reprograms microglia via exosomal miRNA to promote brain metastasis. Cancer Res. 2018;78(15):4316\u0026ndash;30. \u003c/li\u003e\n\u003cli\u003eWang PS, Chou CH, Lin CH, Yao YC, Cheng HC, Li HY, et al. A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer. Oncogene. 2018 Aug;37(34):4662\u0026ndash;78. \u003c/li\u003e\n\u003cli\u003eJiang J, Shi S, Li X, Sun L, Ge Q, Li C, et al. Long non‑coding RNA BRAF‑regulated lncRNA 1 promotes lymph node invasion, metastasis and proliferation, and predicts poor prognosis in breast cancer. Oncol Lett [Internet]. 2018;15(6):9543\u0026ndash;52. Available from: https://doi.org/10.3892/ol.2018.8513\u003c/li\u003e\n\u003cli\u003eLou KX, Li ZH, Wang P, Liu Z, Chen Y, Wang XL, et al. Long non-coding RNA BANCR indicates poor prognosis for breast cancer and promotes cell proliferation and invasion. Eur Rev Med Pharmacol Sci. 2018 Mar;22(5):1358\u0026ndash;65. \u003c/li\u003e\n\u003cli\u003eJiang M, Xiao Y, Liu D, Luo N, Gao Q, Guan Y. Overexpression of long noncoding RNA LINC01296 indicates an unfavorable prognosis and promotes tumorigenesis in breast cancer. Gene. 2018 Oct;675:217\u0026ndash;24. \u003c/li\u003e\n\u003cli\u003eFang Y, Wang J, Wu F, Song Y, Zhao S, Zhang Q. Long non-coding RNA HOXA-AS2 promotes proliferation and invasion of breast cancer by acting as a miR-520c-3p sponge. Oncotarget. 2017 Jul;8(28):46090\u0026ndash;103. \u003c/li\u003e\n\u003cli\u003eWang S, Liang K, Hu Q, Li P, Song J, Yang Y, et al. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest. 2017 Dec;127(12):4498\u0026ndash;515. \u003c/li\u003e\n\u003cli\u003eWang Y, Zhou Y, Yang Z, Chen B, Huang W, Liu Y, et al. MiR-204/ZEB2 axis functions as key mediator for MALAT1-induced epithelial-mesenchymal transition in breast cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2017 Jul;39(7):1010428317690998\u0026ndash;1010428317690998. \u003c/li\u003e\n\u003cli\u003eKong Q, Qiu M. Long noncoding RNA SNHG15 promotes human breast cancer proliferation, migration and invasion by sponging miR-211-3p. Biochem Biophys Res Commun. 2018 Jan;495(2):1594\u0026ndash;600. \u003c/li\u003e\n\u003cli\u003eZhang W, Shi S, Jiang J, Li X, Lu H, Ren F. LncRNA MEG3 inhibits cell epithelial-mesenchymal transition by sponging miR-421 targeting E-cadherin in breast cancer. Biomed Pharmacother. 2017 Jul;91:312\u0026ndash;9. \u003c/li\u003e\n\u003cli\u003eZhang CY, Yu MS, Li X, Zhang Z, Han CR, Yan B. Overexpression of long non-coding RNA MEG3 suppresses breast cancer cell proliferation, invasion, and angiogenesis through AKT pathway. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2017 Jun;39(6):1010428317701311\u0026ndash;1010428317701311. \u003c/li\u003e\n\u003cli\u003eLi WX, Sha RL, Bao JQ, Luan W, Su RL, Sun SR. Expression of long non-coding RNA linc-ITGB1 in breast cancer and its influence on prognosis and survival. Eur Rev Med Pharmacol Sci. 2017 Aug;21(15):3397\u0026ndash;401. \u003c/li\u003e\n\u003cli\u003eChen DQ, Zheng XD, Cao Y, He XD, Nian WQ, Zeng XH, et al. Long non-coding RNA LINC00628 suppresses the growth and metastasis and promotes cell apoptosis in breast cancer. Eur Rev Med Pharmacol Sci. 2017 Jan;21(2):275\u0026ndash;83. \u003c/li\u003e\n\u003cli\u003eLiu G, Hu X, Zhou G. Long non-coding RNA OR3A4 promotes proliferation and migration in breast cancer. Biomed Pharmacother. 2017 Dec;96:426\u0026ndash;33. \u003c/li\u003e\n\u003cli\u003eSu JC, Hu XF. Long non‑coding RNA HOXA11‑AS promotes cell proliferation and metastasis in human breast cancer. Mol Med Rep. 2017 Oct;16(4):4887\u0026ndash;94. \u003c/li\u003e\n\u003cli\u003eFan S, Yang Z, Ke Z, Huang K, Liu N, Fang X, et al. Downregulation of the long non-coding RNA TUG1 is associated with cell proliferation, migration, and invasion in breast cancer. Biomed Pharmacother. 2017 Nov;95:1636\u0026ndash;43. \u003c/li\u003e\n\u003cli\u003eLi W, Jia G, Qu Y, Du Q, Liu B, Liu B. Long Non-Coding RNA (LncRNA) HOXA11-AS Promotes Breast Cancer Invasion and Metastasis by Regulating Epithelial-Mesenchymal Transition. Med Sci Monit Int Med J Exp Clin Res. 2017 Jul;23:3393\u0026ndash;403. \u003c/li\u003e\n\u003cli\u003eZhang K, Luo Z, Zhang Y, Wang Y, Cui M, Liu L, et al. Detection and analysis of circulating large intergenic non-coding RNA regulator of reprogramming in plasma for breast cancer. Thorac cancer. 2018 Jan;9(1):66\u0026ndash;74. \u003c/li\u003e\n\u003cli\u003eJiang Z, Slater CM, Zhou Y, Devarajan K, Ruth KJ, Li Y, et al. LincIN, a novel NF90-binding long non-coding RNA, is overexpressed in advanced breast tumors and involved in metastasis. Breast Cancer Res. 2017 May;19(1):62. \u003c/li\u003e\n\u003cli\u003eLi H, Zhu L, Xu L, Qin K, Liu C, Yu Y, et al. Long noncoding RNA linc00617 exhibits oncogenic activity in breast cancer. Mol Carcinog. 2017 Jan;56(1):3\u0026ndash;17. \u003c/li\u003e\n\u003cli\u003eLiang Y, Li Y, Song X, Zhang N, Sang Y, Zhang H, et al. Long noncoding RNA LINP1 acts as an oncogene and promotes chemoresistance in breast cancer. Cancer Biol Ther. 2018 Feb;19(2):120\u0026ndash;31. \u003c/li\u003e\n\u003cli\u003eLi C, Wang S, Xing Z, Lin A, Liang K, Song J, et al. A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis. Nat Cell Biol. 2017 Feb;19(2):106\u0026ndash;19. \u003c/li\u003e\n\u003cli\u003eLi Z, Hou P, Fan D, Dong M, Ma M, Li H, et al. The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer. Cell Death Differ [Internet]. 2017;24(1):59\u0026ndash;71. Available from: https://doi.org/10.1038/cdd.2016.95\u003c/li\u003e\n\u003cli\u003eSas-Chen A, Aure MR, Leibovich L, Carvalho S, Enuka Y, K\u0026ouml;rner C, et al. LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer. EMBO Mol Med. 2016 Sep;8(9):1052\u0026ndash;64. \u003c/li\u003e\n\u003cli\u003eZhang JJ, Guo SH, Jia BQ. Down-regulation of long non-coding RNA MEG3 serves as an unfavorable risk factor for survival of patients with breast cancer. Eur Rev Med Pharmacol Sci. 2016 Dec;20(24):5143\u0026ndash;7. \u003c/li\u003e\n\u003cli\u003eLiu B, Sun L, Liu Q, Gong C, Yao Y, Lv X, et al. A cytoplasmic NF-\u0026kappa;B interacting long noncoding RNA blocks I\u0026kappa;B phosphorylation and suppresses breast cancer metastasis. Cancer Cell. 2015 Mar;27(3):370\u0026ndash;81. \u003c/li\u003e\n\u003cli\u003eVennin C, Spruyt N, Dahmani F, Julien S, Bertucci F, Finetti P, et al. H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. Oncotarget. 2015 Oct;6(30):29209\u0026ndash;23. \u003c/li\u003e\n\u003cli\u003eXu SP, Zhang JF, Sui SY, Bai NX, Gao S, Zhang GW, et al. Downregulation of the long noncoding RNA EGOT correlates with malignant status and poor prognosis in breast cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2015 Dec;36(12):9807\u0026ndash;12. \u003c/li\u003e\n\u003cli\u003eHu P, Chu J, Wu Y, Sun L, Lv X, Zhu Y, et al. NBAT1 suppresses breast cancer metastasis by regulating DKK1 via PRC2. Oncotarget. 2015 Oct;6(32):32410\u0026ndash;25. \u003c/li\u003e\n\u003cli\u003eXing Z, Lin A, Li C, Liang K, Wang S, Liu Y, et al. LncRNA directs cooperative epigenetic regulation downstream of chemokine signals. Cell [Internet]. 2014;159(5):1110\u0026ndash;25. Available from: http://dx.doi.org/10.1016/j.cell.2014.10.013\u003c/li\u003e\n\u003cli\u003eRedis RS, Sieuwerts AM, Look MP, Tudoran O, Ivan C, Spizzo R, et al. CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget. 2013 Oct;4(10):1748\u0026ndash;62. \u003c/li\u003e\n\u003cli\u003eChisholm KM, Wan Y, Li R, Montgomery KD, Chang HY, West RB. Detection of long non-coding RNA in archival tissue: correlation with polycomb protein expression in primary and metastatic breast carcinoma. PLoS One. 2012;7(10):e47998\u0026ndash;e47998. \u003c/li\u003e\n\u003cli\u003eLiu CX, Chen LL. Circular RNAs: Characterization, cellular roles, and applications. Cell. 2022;185(12):2016\u0026ndash;34. \u003c/li\u003e\n\u003cli\u003eKristensen LS, Jakobsen T, Hager H, Kjems J. The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol. 2022;19(3):188\u0026ndash;206. \u003c/li\u003e\n\u003cli\u003eGhafouri-Fard S, Hussen BM, Taheri M, Ayatollahi SA. Emerging role of circular RNAs in breast cancer. Pathol Pract. 2021;223:153496. \u003c/li\u003e\n\u003cli\u003eZepeda-Enr\u0026iacute;quez P, Silva-C\u0026aacute;zares MB, L\u0026oacute;pez-Camarillo C. Novel Insights into Circular RNAs in Metastasis in Breast Cancer: An Update. Non-coding RNA. 2023 Sep;9(5). \u003c/li\u003e\n\u003cli\u003eLu M, Wu Y, Zeng B, Sun J, Li Y, Luo J, et al. CircEHMT1 inhibits metastatic potential of breast cancer cells by modulating miR-1233-3p/KLF4/MMP2 axis. Biochem Biophys Res Commun. 2020 May;526(2):306\u0026ndash;13. \u003c/li\u003e\n\u003cli\u003eFan Y, Wang J, Jin W, Sun Y, Xu Y, Wang Y, et al. CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer. Mol Cancer. 2021 Feb;20(1):25. \u003c/li\u003e\n\u003cli\u003eLin X, Chen W, Wei F, Xie X. TV-circRGPD6 Nanoparticle Suppresses Breast Cancer Stem Cell-Mediated Metastasis via the miR-26b/YAF2 Axis. Mol Ther. 2021 Jan;29(1):244\u0026ndash;62. \u003c/li\u003e\n\u003cli\u003eCai Y, Zhao X, Chen D, Zhang F, Chen Q, Shao CC, et al. circ-NOL10 regulated by MTDH/CASC3 inhibits breast cancer progression and metastasis via multiple miRNAs and PDCD4. Mol Ther - Nucleic Acids [Internet]. 2021;26:773\u0026ndash;86. Available from: https://www.sciencedirect.com/science/article/pii/S2162253121002420\u003c/li\u003e\n\u003cli\u003eWang F, Wang X, Li J, Lv P, Han M, Li L, et al. CircNOL10 suppresses breast cancer progression by sponging miR-767-5p to regulate SOCS2/JAK/STAT signaling. J Biomed Sci. 2021 Jan;28(1):4. \u003c/li\u003e\n\u003cli\u003eLiang Y, Song X, Li Y, Ma T, Su P, Guo R, et al. Targeting the circBMPR2/miR-553/USP4 Axis as a Potent Therapeutic Approach for Breast Cancer. Mol Ther - Nucleic Acids [Internet]. 2019;17:347\u0026ndash;61. Available from: https://www.sciencedirect.com/science/article/pii/S2162253119301350\u003c/li\u003e\n\u003cli\u003eWu N, Yuan Z, Du KY, Fang L, Lyu J, Zhang C, et al. Translation of yes-associated protein (YAP) was antagonized by its circular RNA via suppressing the assembly of the translation initiation machinery. Cell Death Differ. 2019 Dec;26(12):2758\u0026ndash;73. \u003c/li\u003e\n\u003cli\u003eZhang L, Sun D, Zhang J, Tian Y. Circ-UBR1 facilitates proliferation, metastasis, and inhibits apoptosis in breast cancer by regulating the miR-1299/CCND1 axis. Life Sci. 2021 Feb;266:118829. \u003c/li\u003e\n\u003cli\u003eZou Y, Zheng S, Xiao W, Xie X, Yang A, Gao G, et al. circRAD18 sponges miR-208a/3164 to promote triple-negative breast cancer progression through regulating IGF1 and FGF2 expression. Carcinogenesis. 2019 Dec;40(12):1469\u0026ndash;79. \u003c/li\u003e\n\u003cli\u003eWang S, Li Q, Wang Y, Li X, Wang R, Kang Y, et al. Upregulation of circ-UBAP2 predicts poor prognosis and promotes triple-negative breast cancer progression through the miR-661/MTA1 pathway. Biochem Biophys Res Commun. 2018 Nov;505(4):996\u0026ndash;1002. \u003c/li\u003e\n\u003cli\u003eXing L, Yang R, Wang X, Zheng X, Yang X, Zhang L, et al. The circRNA circIFI30 promotes progression of triple-negative breast cancer and correlates with prognosis. Aging (Albany NY). 2020 Jun;12(11):10983\u0026ndash;1003. \u003c/li\u003e\n\u003cli\u003eChen T, Wang X, Li C, Zhang H, Liu Y, Han D, et al. CircHIF1A regulated by FUS accelerates triple-negative breast cancer progression by modulating NFIB expression and translocation. Oncogene. 2021 Apr;40(15):2756\u0026ndash;71. \u003c/li\u003e\n\u003cli\u003eWang B, Chen H, Deng Y, Chen H, Xing L, Guo Y, et al. CircDNAJC11 interacts with TAF15 to promote breast cancer progression via enhancing MAPK6 expression and activating the MAPK signaling pathway. J Transl Med [Internet]. 2023;21(1):186. Available from: https://doi.org/10.1186/s12967-023-04020-x\u003c/li\u003e\n\u003cli\u003eZeng K, He B, Yang BB, Xu T, Chen X, Xu M, et al. The pro-metastasis effect of circANKS1B in breast cancer. Mol Cancer. 2018 Nov;17(1):160. \u003c/li\u003e\n\u003cli\u003eLi Y, Wang Z, Su P, Liang Y, Li Z, Zhang H, et al. circ-EIF6 encodes EIF6-224aa to promote TNBC progression via stabilizing MYH9 and activating the Wnt/beta-catenin pathway. Mol Ther. 2022 Jan;30(1):415\u0026ndash;30. \u003c/li\u003e\n\u003cli\u003eChen ZG, Zhao HJ, Lin L, Liu JB, Bai JZ, Wang GS. Circular RNA CirCHIPK3 promotes cell proliferation and invasion of breast cancer by sponging miR-193a/HMGB1/PI3K/AKT axis. Thorac cancer. 2020 Sep;11(9):2660\u0026ndash;71. \u003c/li\u003e\n\u003cli\u003eCai F, Fu W, Tang L, Tang J, Sun J, Fu G, et al. Hsa_circ_0000515 is a novel circular RNA implicated in the development of breast cancer through its regulation of the microRNA-296-5p/CXCL10 axis. FEBS J. 2021 Feb;288(3):861\u0026ndash;83. \u003c/li\u003e\n\u003cli\u003eGao D, Qi X, Zhang X, Fang K, Guo Z, Li L. hsa_circRNA_0006528 as a competing endogenous RNA promotes human breast cancer progression by sponging miR-7-5p and activating the MAPK/ERK signaling pathway. Mol Carcinog. 2019 Apr;58(4):554\u0026ndash;64. \u003c/li\u003e\n\u003cli\u003eJu C, Zhou M, Du D, Wang C, Yao J, Li H, et al. EIF4A3-mediated circ_0042881 activates the RAS pathway via miR-217/SOS1 axis to facilitate breast cancer progression. Cell Death Dis [Internet]. 2023;14(8):559. Available from: https://doi.org/10.1038/s41419-023-06085-4\u003c/li\u003e\n\u003cli\u003eZeng Y, Du W, Huang Z, Wu S, Ou X, Zhang J, et al. Hsa_circ_0060467 promotes breast cancer liver metastasis by complexing with eIF4A3 and sponging miR-1205. Cell Death Discov [Internet]. 2023;9(1):153. Available from: https://doi.org/10.1038/s41420-023-01448-4\u003c/li\u003e\n\u003cli\u003eJin Y, Yang L, Li X, Liu F. Circular RNA KIF4A promotes cell migration, invasion and inhibits apoptosis through miR-152/ZEB1 axis in breast cancer. Diagn Pathol. 2020 May;15(1):55. \u003c/li\u003e\n\u003cli\u003eZhang W, Liu H, Jiang J, Yang Y, Wang W, Jia Z. CircRNA circFOXK2 facilitates oncogenesis in breast cancer via IGF2BP3/miR-370 axis. Aging (Albany NY). 2021 Jul;13(14):18978\u0026ndash;92. \u003c/li\u003e\n\u003cli\u003eQi C, Qin X, Zhou Z, Wang Y, Yang Q, Liao T. Circ_0072995 promotes cell carcinogenesis via up-regulating miR-149-5p-mediated SHMT2 in breast cancer. Cancer Manag Res. 2020;11169\u0026ndash;81. \u003c/li\u003e\n\u003cli\u003eZhou H, Tang G, Zhao M, Xie L, Xie Y, Zhang Z, et al. circFBXL5 promotes breast cancer progression by sponging miR-660. J Cell Mol Med. 2020 Jan;24(1):356\u0026ndash;61. \u003c/li\u003e\n\u003cli\u003eSong X, Liang Y, Sang Y, Li Y, Zhang H, Chen B, et al. circHMCU Promotes Proliferation and Metastasis of Breast Cancer by Sponging the let-7 Family. Mol Ther Nucleic Acids. 2020 Jun;20:518\u0026ndash;33. \u003c/li\u003e\n\u003cli\u003eWu J, Jiang Z, Chen C, Hu Q, Fu Z, Chen J, et al. CircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis. Cancer Lett. 2018 Aug;430:179\u0026ndash;92. \u003c/li\u003e\n\u003cli\u003eZhao B, Song X, Guan H. CircACAP2 promotes breast cancer proliferation and metastasis by targeting miR-29a/b-3p-COL5A1 axis. Life Sci. 2020 Mar;244:117179. \u003c/li\u003e\n\u003cli\u003eMin J, Pan X, Lv G. The circRNA circ_0000291 acts as a sponge of microRNA 326 to regulate E26 transformation-specific sequence-1 expression and promote breast cancer progression. Pathol Int. 2020 Sep; \u003c/li\u003e\n\u003cli\u003eWu S, Lu J, Zhu H, Wu F, Mo Y, Xie L, et al. A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer. Cancer Lett [Internet]. 2024;581:216508. Available from: https://www.sciencedirect.com/science/article/pii/S0304383523004597\u003c/li\u003e\n\u003cli\u003eZheng W, Wang X, Yu Y, Ji C, Fang L. CircRNF10-DHX15 interaction suppressed breast cancer progression by antagonizing DHX15-NF-\u0026kappa;B p65 positive feedback loop. Cell Mol Biol Lett [Internet]. 2023;28(1):34. Available from: https://doi.org/10.1186/s11658-023-00448-7\u003c/li\u003e\n\u003cli\u003eZhong W, Bao L, Yuan Y, Meng Y. CircRASSF2 acts as a prognostic factor and promotes breast cancer progression by modulating miR-1205/HOXA1 axis. Bioengineered. 2021 Dec;12(1):3014\u0026ndash;28. \u003c/li\u003e\n\u003cli\u003eZhong JX, Kong YY, Luo RG, Xia GJ, He WX, Chen XZ, et al. Circular RNA circ-ERBB2 promotes HER2-positive breast cancer progression and metastasis via sponging miR-136-5p and miR-198. J Transl Med. 2021 Nov;19(1):455. \u003c/li\u003e\n\u003cli\u003eHu J, Ji C, Hua K, Wang X, Deng X, Li J, et al. Hsa_circ_0091074 regulates TAZ expression via microRNA‑1297 in triple negative breast cancer cells. Int J Oncol. 2020 May;56(5):1314\u0026ndash;26. \u003c/li\u003e\n\u003cli\u003eZhou SY, Chen W, Yang SJ, Li J, Zhang JY, Zhang H da, et al. Circular RNA circVAPA regulates breast cancer cell migration and invasion via sponging miR-130a-5p. Epigenomics. 2020 Feb;12(4):303\u0026ndash;17. \u003c/li\u003e\n\u003cli\u003eYuan C, Luo X, Zhan X, Zeng H, Duan S. EMT related circular RNA expression profiles identify circSCYL2 as a novel molecule in breast tumor metastasis. Int J Mol Med. 2020 Jun;45(6):1697\u0026ndash;710. \u003c/li\u003e\n\u003cli\u003eSang Y, Chen B, Song X, Li Y, Liang Y, Han D, et al. circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer. Mol Ther. 2019 Sep;27(9):1638\u0026ndash;52. \u003c/li\u003e\n\u003cli\u003eRen S, Liu J, Feng Y, Li Z, He L, Li L, et al. Knockdown of circDENND4C inhibits glycolysis, migration and invasion by up-regulating miR-200b/c in breast cancer under hypoxia. J Exp Clin Cancer Res. 2019 Sep;38(1):388. \u003c/li\u003e\n\u003cli\u003eXiao W, Zheng S, Zou Y, Yang A, Xie X, Tang H, et al. CircAHNAK1 inhibits proliferation and metastasis of triple-negative breast cancer by modulating miR-421 and RASA1. Aging (Albany NY). 2019 Dec;11(24):12043\u0026ndash;56. \u003c/li\u003e\n\u003cli\u003eHou JC, Xu Z, Zhong SL, Zhang H da, Jiang LH, Chen X, et al. Circular RNA circASS1 is downregulated in breast cancer cells MDA-MB-231 and suppressed invasion and migration. Epigenomics. 2019 Feb;11(2):199\u0026ndash;213. \u003c/li\u003e\n\u003cli\u003eLiang Y, Song X, Li Y, Su P, Han D, Ma T, et al. circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer. Oncogene. 2019 Oct;38(42):6850\u0026ndash;66. \u003c/li\u003e\n\u003cli\u003eLin X, Hong S, Chen J, Chen W, Wu Z. The potential targets for metastases: a study on altered circular RNA profile in breast cancer liver metastases. Epigenomics. 2019 Aug;11(11):1237\u0026ndash;50. \u003c/li\u003e\n\u003cli\u003eZhang HD, Jiang LH, Hou JC, Zhou SY, Zhong SL, Zhu LP, et al. Circular RNA hsa_circ_0072995 promotes breast cancer cell migration and invasion through sponge for miR-30c-2-3p. Epigenomics. 2018 Sep;10(9):1229\u0026ndash;42. \u003c/li\u003e\n\u003cli\u003eChen N, Zhao G, Yan X, Lv Z, Yin H, Zhang S, et al. A novel FLI1 exonic circular RNA promotes metastasis in breast cancer by coordinately regulating TET1 and DNMT1. Genome Biol. 2018 Dec;19(1):218. \u003c/li\u003e\n\u003cli\u003eYin WB, Yan MG, Fang X, Guo JJ, Xiong W, Zhang RP. Circulating circular RNA hsa_circ_0001785 acts as a diagnostic biomarker for breast cancer detection. Clin Chim Acta. 2018 Dec;487:363\u0026ndash;8. \u003c/li\u003e\n\u003cli\u003eAla U. Competing endogenous RNAs and cancer: How coding and non-coding molecules cross-talk can impinge on disease. Int J Biochem Cell Biol. 2021 Jan;130:105874. \u003c/li\u003e\n\u003cli\u003eMarques TM, Gama-Carvalho M. Network Approaches to Study Endogenous RNA Competition and Its Impact on Tissue-Specific microRNA Functions. Biomolecules. 2022 Feb;12(2). \u003c/li\u003e\n\u003cli\u003eThomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet [Internet]. 2016;17(5):272\u0026ndash;83. Available from: https://doi.org/10.1038/nrg.2016.20\u003c/li\u003e\n\u003cli\u003eQattan A, Al-Tweigeri T, Suleman K, Alkhayal W, Tulbah A. Advanced Insights into Competitive Endogenous RNAs (ceRNAs) Regulated Pathogenic Mechanisms in Metastatic Triple-Negative Breast Cancer (mTNBC). Vol. 16, Cancers. 2024. \u003c/li\u003e\n\u003cli\u003eSideris N, Dama P, Bayraktar S, Stiff T, Castellano L. LncRNAs in breast cancer: a link to future approaches. Cancer Gene Ther [Internet]. 2022;29(12):1866\u0026ndash;77. Available from: https://doi.org/10.1038/s41417-022-00487-w\u003c/li\u003e\n\u003cli\u003eLiu L, Zhang Y, Lu J. The roles of long noncoding RNAs in breast cancer metastasis. Cell Death Dis [Internet]. 2020;11(9):749. Available from: https://doi.org/10.1038/s41419-020-02954-4\u003c/li\u003e\n\u003cli\u003eJadaliha M, Zong X, Malakar P, Ray T, Singh DK, Freier SM, et al. Functional and prognostic significance of long non-coding RNA MALAT1 as a metastasis driver in ER negative lymph node negative breast cancer. Oncotarget. 2016 Jun;7(26):40418\u0026ndash;36. \u003c/li\u003e\n\u003cli\u003eHussein MA, Valinezhad K, Adel E, Munirathinam G. MALAT-1 is a key regulator of epithelial\u0026ndash;mesenchymal transition in cancer: a potential therapeutic target for metastasis. Cancers (Basel). 2024;16(1):234. \u003c/li\u003e\n\u003cli\u003eDong Y, Liang G, Yuan B, Yang C, Gao R, Zhou X. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2015 Mar;36(3):1477\u0026ndash;86. \u003c/li\u003e\n\u003cli\u003eHeery R, Finn SP, Cuffe S, Gray SG. Long non-coding RNAs: key regulators of epithelial-mesenchymal transition, tumour drug resistance and cancer stem cells. Cancers (Basel). 2017;9(4):38. \u003c/li\u003e\n\u003cli\u003eCavallari I, Ciccarese F, Sharova E, Urso L, Raimondi V, Silic-Benussi M, et al. The miR-200 family of microRNAs: fine tuners of epithelial-mesenchymal transition and circulating cancer biomarkers. Cancers (Basel). 2021;13(23):5874. \u003c/li\u003e\n\u003cli\u003eChaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science (80- ). 2011;331(6024):1559\u0026ndash;64. \u003c/li\u003e\n\u003cli\u003eRiggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer [Internet]. 2021;124(1):13\u0026ndash;26. Available from: https://doi.org/10.1038/s41416-020-01161-4\u003c/li\u003e\n\u003cli\u003eGerstberger S, Jiang Q, Ganesh K. Metastasis. Cell. 2023;186(8):1564\u0026ndash;79. \u003c/li\u003e\n\u003cli\u003eDrak Alsibai K, Meseure D. Tumor microenvironment and noncoding RNAs as co‐drivers of epithelial\u0026ndash;mesenchymal transition and cancer metastasis. Dev Dyn. 2018;247(3):405\u0026ndash;31. \u003c/li\u003e\n\u003cli\u003eChen T, You Y, Jiang H, Wang ZZ. Epithelial\u0026ndash;mesenchymal transition (EMT): A biological process in the development, stem cell differentiation, and tumorigenesis. J Cell Physiol. 2017;232(12):3261\u0026ndash;72. \u003c/li\u003e\n\u003cli\u003eLei ZN, Teng QX, Koya J, Liu Y, Chen Z, Zeng L, et al. The correlation between cancer stem cells and epithelial-mesenchymal transition: molecular mechanisms and significance in cancer theragnosis. Front Immunol. 2024;15:1417201. \u003c/li\u003e\n\u003cli\u003eDart A. EMT in chemoresistance. Nat Rev Cancer. 2023;23(6):349. \u003c/li\u003e\n\u003cli\u003evan Staalduinen J, Baker D, Ten Dijke P, van Dam H. Epithelial\u0026ndash;mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer? Oncogene. 2018;37(48):6195\u0026ndash;211. \u003c/li\u003e\n\u003cli\u003eAhrens TD, Bang-Christensen SR, J\u0026oslash;rgensen AM, L\u0026oslash;ppke C, Spliid CB, Sand NT, et al. The role of proteoglycans in cancer metastasis and circulating tumor cell analysis. Front cell Dev Biol. 2020;8:749. \u003c/li\u003e\n\u003cli\u003eBlackhall FH, Merry CLR, Davies EJ, Jayson GC. Heparan sulfate proteoglycans and cancer. Br J Cancer [Internet]. 2001;85(8):1094\u0026ndash;8. Available from: https://doi.org/10.1054/bjoc.2001.2054\u003c/li\u003e\n\u003cli\u003eWei J, Hu M, Huang K, Lin S, Du H. Roles of Proteoglycans and Glycosaminoglycans in Cancer Development and Progression. Vol. 21, International Journal of Molecular Sciences. 2020. \u003c/li\u003e\n\u003cli\u003eVitale D, Kumar Katakam S, Greve B, Jang B, Oh E, Alaniz L, et al. Proteoglycans and glycosaminoglycans as regulators of cancer stem cell function and therapeutic resistance. FEBS J. 2019;286(15):2870\u0026ndash;82. \u003c/li\u003e\n\u003cli\u003eGao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R, et al. Myeloid Progenitor Cells in the Premetastatic Lung Promote Metastases by Inducing Mesenchymal to Epithelial Transition. Cancer Res. 2012 Mar;72(6):1384\u0026ndash;94. \u003c/li\u003e\n\u003cli\u003eKim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009;457(7225):102\u0026ndash;6. \u003c/li\u003e\n\u003cli\u003eDu WW, Yang BB, Shatseva TA, Yang BL, Deng Z, Shan SW, et al. Versican G3 Promotes Mouse Mammary Tumor Cell Growth, Migration, and Metastasis by Influencing EGF Receptor Signaling. PLoS One. 2010 Nov;5(11):e13828. \u003c/li\u003e\n\u003cli\u003eSchaefer L, Beck KF, Raslik I, Walpen S, Mihalik D, Micegova M, et al. Biglycan, a Nitric Oxide-regulated Gene, Affects Adhesion, Growth, and Survival of Mesangial Cells *. J Biol Chem. 2003 Jul;278(28):26227\u0026ndash;37. \u003c/li\u003e\n\u003cli\u003eMundhenke C, Meyer K, Drew S, Friedl A. Heparan Sulfate Proteoglycans as Regulators of Fibroblast Growth Factor-2 Receptor Binding in Breast Carcinomas. Am J Pathol. 2002;160(1):185\u0026ndash;94. \u003c/li\u003e\n\u003cli\u003eJain K, Basu A. Protein Kinase C-\u0026epsilon; Promotes EMT in Breast Cancer. Breast Cancer Basic Clin Res. 2014 Jan;8:BCBCR.S13640. \u003c/li\u003e\n\u003cli\u003eCacace AM, Ueffing M, Han EK, Marm\u0026egrave; D, Weinstein IB. Overexpression of PKC\u0026epsilon; in R6 fibroblasts causes increased production of active TGF\u0026beta;. J Cell Physiol. 1998;175(3):314\u0026ndash;22. \u003c/li\u003e\n\u003cli\u003eAziz MH, Hafeez BB, Sand JM, Pierce DB, Aziz SW, Dreckschmidt NE, et al. Protein kinase Cɛ mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2). Oncogene. 2010;29(21):3100\u0026ndash;9. \u003c/li\u003e\n\u003cli\u003eHutchison N, Hendry BM, Sharpe CC. Rho isoforms have distinct and specific functions in the process of epithelial to mesenchymal transition in renal proximal tubular cells. Cell Signal. 2009;21(10):1522\u0026ndash;31. \u003c/li\u003e\n\u003cli\u003eCho KH, Jeong KJ, Shin SC, Kang J, Park CG, Lee HY. STAT3 mediates TGF-\u0026beta;1-induced TWIST1 expression and prostate cancer invasion. Cancer Lett. 2013;336(1):167\u0026ndash;73. \u003c/li\u003e\n\u003cli\u003eBourguignon LYW, Spevak CC, Wong G, Xia W, Gilad E. Hyaluronan-CD44 interaction with protein kinase Cϵ promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance . J Biol Chem. 2009;284(39):26533\u0026ndash;46. \u003c/li\u003e\n\u003cli\u003eMani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704\u0026ndash;15. \u003c/li\u003e\n\u003cli\u003eBrabletz T. EMT and MET in metastasis: where are the cancer stem cells? Cancer Cell. 2012;22(6):699\u0026ndash;701. \u003c/li\u003e\n\u003cli\u003eKhan AQ, Hasan A, Mir SS, Rashid K, Uddin S, Stienhoff M. Exploiting Transcription Factors to Target EMT and Cancer Stem Cells for Tumor Modulation and Therapy. In: Seminars in Cancer Biology. Elsevier; 2024. \u003c/li\u003e\n\u003cli\u003eHasan A, Khan NA, Uddin S, Khan AQ, Steinhoff M. Deregulated transcription factors in the emerging cancer hallmarks. In: Seminars in Cancer Biology. Elsevier; 2023. \u003c/li\u003e\n\u003cli\u003eHe L, Wick N, Germans SK, Peng Y. The role of breast cancer stem cells in chemoresistance and metastasis in triple-negative breast cancer. Cancers (Basel). 2021;13(24):6209. \u003c/li\u003e\n\u003cli\u003eQi M, Xia Y, Wu Y, Zhang Z, Wang X, Lu L, et al. Lin28B-high breast cancer cells promote immune suppression in the lung pre-metastatic niche via exosomes and support cancer progression. Nat Commun. 2022 Feb;13(1):897. \u003c/li\u003e\n\u003cli\u003eLin Z, Radaeva M, Cherkasov A, Dong X. Lin28 regulates cancer cell stemness for tumour progression. Cancers (Basel). 2022;14(19):4640. \u003c/li\u003e\n\u003cli\u003eLi D, Liu Y, Li H, Peng JJ, Tan Y, Zou Q, et al. MicroRNA-1 promotes apoptosis of hepatocarcinoma cells by targeting apoptosis inhibitor-5 (API-5). Febs Lett. 2015;589(1):68\u0026ndash;76. \u003c/li\u003e\n\u003cli\u003eFurukawa S, Kawasaki Y, Miyamoto M, Hiyoshi M, Kitayama J, Akiyama T. The miR-1-NOTCH3-Asef pathway is important for colorectal tumor cell migration. PLoS One. 2013;8(11):e80609. \u003c/li\u003e\n\u003cli\u003eSun D, Zhong J, Wei W, Chen X, Liu J, Hu Z. Identification of microRNA expression in sentinel lymph nodes from patients with breast cancer via RNA sequencing for diagnostic accuracy. J Gene Med. 2019 Apr;21(4):e3075\u0026ndash;e3075. \u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"Isfahan University of Medical Sciences","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"breast cancer, metastasis, EMT, invasion, migration, competitive endogenous RNA, ceRNA, ncRNA","lastPublishedDoi":"10.21203/rs.3.rs-8119740/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8119740/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e\u003cp\u003eBreast cancer metastasis (BCM) remains the primary cause of breast cancer\u0026ndash;related mortality. Despite advances in understanding breast cancer pathogenesis, the mechanisms driving metastasis are complex and therapeutically challenging. Recent progress in transcriptomics and bioinformatics has enabled deeper insights into the genomic and regulatory alterations underlying BCM.\u003c/p\u003e\u003ch2\u003eAim\u003c/h2\u003e\u003cp\u003eThis study aimed to construct and analyze a comprehensive competing endogenous RNA (ceRNA) network involving non-coding RNAs (lncRNAs, miRNAs, and circRNAs) associated with BCM to elucidate their molecular cross-talk and regulatory roles.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e\u003cp\u003eInteraction data were obtained through systematic literature review and bioinformatic predictions using the multiMiR R package, LncBase, and Circular RNA Interactome databases. A ceRNA network integrating mRNAs, miRNAs, lncRNAs, and circRNAs was visualized in Cytoscape, along with a protein\u0026ndash;protein interaction (PPI) network. Network topology was analyzed with cytoHubba and MCODE, while functional enrichment was performed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Survival analysis was conducted to evaluate the prognostic relevance of hub ncRNAs.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e\u003cp\u003eNetwork analysis identified 11 key hub nodes, including hsa-miR-1, hsa-miR-9, hsa-miR-27b, and MALAT1, which were significantly associated with poor prognosis. KEGG pathways were enriched in proteoglycans in cancer, microRNAs in cancer, and signaling pathways regulating stem cell pluripotency. GO terms highlighted regulation of transcription, cell differentiation, epithelial-to-mesenchymal transition (EMT), and cyclin-dependent kinase complexes.\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e\u003cp\u003eThis integrative ceRNA network analysis provides new insights into the molecular mechanisms driving BCM, offering potential biomarkers for improved diagnosis, prognosis, and therapeutic targeting.\u003c/p\u003e","manuscriptTitle":"Decoding the ceRNA-Network Blueprint of Breast Cancer Metastasis via Molecular Cross-Talk in Motion from Silence to Signal: A Systematic Review and Bioinformatics Analysis","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-11-18 08:09:43","doi":"10.21203/rs.3.rs-8119740/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"c82217df-467c-487c-a409-cacc646a5171","owner":[],"postedDate":"November 18th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":58164489,"name":"Cancer Biology"}],"tags":[],"updatedAt":"2025-11-18T08:09:43+00:00","versionOfRecord":[],"versionCreatedAt":"2025-11-18 08:09:43","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8119740","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8119740","identity":"rs-8119740","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}